<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30326535</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1439-1058</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>16</Day>                    </PubDate>                </JournalIssue>                <Title>Psychotherapie, Psychosomatik, medizinische Psychologie</Title>                <ISOAbbreviation>Psychother Psychosom Med Psychol</ISOAbbreviation>            </Journal>            <ArticleTitle>[Psychosomatic Specialist Consultation in the General Practitioner's Office - A New Model of Integrated Care].</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1055/a-0668-1019</ELocationID>            <Abstract>                <AbstractText>A high number of patients with mental health disorders currently do not receive minimally adequate treatment, but remain solely in general practice. This is often due to long waiting times for psychotherapy, patient related barriers or diagnostic insecurity. For this reason, we have developed a care model that is applied directly in the general practitioner's (GP) office and is open to any form of psychosomatic disorder. The cornerstone of the model consists of a psychosomatic specialist consultation in the GP's office. Preliminary results concerning utilization and the target population show a high level of acceptance among patients, GPs, and psychosomatic specialists.</AbstractText>                <CopyrightInformation>© Georg Thieme Verlag KG Stuttgart · New York.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Hartmann</LastName>                    <ForeName>Mechthild</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Klinik für Allgemeine Innere Medizin und Psychosomatik, Universitätsklinikum Heidelberg.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Finkenzeller</LastName>                    <ForeName>Caroline</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Klinik für Allgemeine Innere Medizin und Psychosomatik, Universitätsklinikum Heidelberg.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Boehlen</LastName>                    <ForeName>Friederike Hildegard</ForeName>                    <Initials>FH</Initials>                    <AffiliationInfo>                        <Affiliation>Klinik für Allgemeine Innere Medizin und Psychosomatik, Universitätsklinikum Heidelberg.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Wagenlechner</LastName>                    <ForeName>Petra</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Klinik für Allgemeine Innere Medizin und Psychosomatik, Universitätsklinikum Heidelberg.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Peters-Klimm</LastName>                    <ForeName>Frank</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Abteilung Allgemeinmedizin und Versorgungsforschung, Universitätsklinikum Heidelberg, Heidelberg.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Herzog</LastName>                    <ForeName>Wolfgang</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Klinik für Allgemeine Innere Medizin und Psychosomatik, Universitätsklinikum Heidelberg.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>ger</Language>            <PublicationTypeList>                <PublicationType UI="D004740">English Abstract</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <VernacularTitle>Psychosomatische Sprechstunde in der Hausarztpraxis – ein neues Kooperationsmodell von Psychosomatik und Allgemeinmedizin.</VernacularTitle>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Psychother Psychosom Med Psychol</MedlineTA>            <NlmUniqueID>8002823</NlmUniqueID>            <ISSNLinking>0937-2032</ISSNLinking>        </MedlineJournalInfo>        <OtherAbstract Type="Publisher" Language="ger">            <AbstractText>Eine hohe Zahl an Patienten mit psychischen oder psychosomatischen Erkrankungen erhält derzeit keine adäquate fachärztliche bzw. fachpsychotherapeutische Behandlung, sondern verbleibt diesbezüglich alleinig beim Hausarzt. Ursachen sind häufig lange Wartezeiten auf Psychotherapie, patientenseitige Barrieren oder offene differenzialdiagnostische Fragen. Daher entwickelten wir ein Versorgungskonzept, das direkt in der Hausarztpraxis ansetzt und offen für jegliche psychosomatische Störung ist. Dieses Modell, das im Kern eine vor-Ort Sprechstunde durch einen Facharzt für Psychosomatische Medizin umfasst, wird im Folgenden vorgestellt. Erste Erfahrungen bezüglich Inanspruchnahme und Patientenklientel belegen eine hohe Akzeptanz seitens Patienten, Hausärzten und Fachärzten für Psychosomatische Medizin.</AbstractText>        </OtherAbstract>        <CoiStatement>Die Autoren geben an, dass kein Interessenkonflikt besteht.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30326535</ArticleId>            <ArticleId IdType="doi">10.1055/a-0668-1019</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30326358</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1532-8384</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>87</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>09</Day>                    </PubDate>                </JournalIssue>                <Title>Comprehensive psychiatry</Title>                <ISOAbbreviation>Compr Psychiatry</ISOAbbreviation>            </Journal>            <ArticleTitle>Neonatal outcomes in pregnant women with untreated and treated panic disorder.</ArticleTitle>            <Pagination>                <MedlinePgn>107-111</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0010-440X(18)30164-0</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.comppsych.2018.10.001</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of the present study was to compare neonatal outcomes including gestational age, birth weight and hospitalization of newborns of pregnant women with treated with antidepressants and untreated panic disorder.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">The study sample included 146 pregnant women (44 patients with panic disorder treated with antidepressants, 52 patients with untreated panic disorder, and 50 healthy controls). Panic disorder was diagnosed by means of the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The highest proportions of preterm birth (28.8%), low birth weight (34.6%) and requirement of neonatal care (25.0%) were observed in infants of untreated patients. Pharmacotherapy group and control subjects had similar neonatal outcomes. Compared with infants of healthy subjects and the pharmacotherapy group, infants of untreated patients had significantly lower birth weight and gestational age at delivery. In addition, newborns of untreated patients had higher rate of hospitalization at the neonatal care unit.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results suggest that treatment with pharmacotherapy of panic disorder during pregnancy may have beneficial effects on the risk of negative neonatal outcomes due to maternal panic disorder in the infants.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Inc. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Uguz</LastName>                    <ForeName>Faruk</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, University of Necmettin Erbakan, Meram Faculty of Medicine Konya, Turkey. Electronic address: farukuguz@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yuksel</LastName>                    <ForeName>Goksen</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Psychiatry Outpatient Clinic, Hospital of Acıbadem Altunizade, Istanbul, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Onur</LastName>                    <ForeName>Ozge Sahmelikoglu</ForeName>                    <Initials>OS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Karsidag</LastName>                    <ForeName>Cagatay</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Psychiatry Outpatient Clinic, Hospital of Acıbadem Altunizade, Istanbul, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gezginc</LastName>                    <ForeName>Kazim</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Obstetrics and Gynecology, University of Necmettin Erbakan, Meram Faculty of Medicine, Konya, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Arpaci</LastName>                    <ForeName>Nazile</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, University of Necmettin Erbakan, Meram Faculty of Medicine Konya, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>09</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Compr Psychiatry</MedlineTA>            <NlmUniqueID>0372612</NlmUniqueID>            <ISSNLinking>0010-440X</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30326358</ArticleId>            <ArticleId IdType="pii">S0010-440X(18)30164-0</ArticleId>            <ArticleId IdType="doi">10.1016/j.comppsych.2018.10.001</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30325700</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1556-3669</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>16</Day>                    </PubDate>                </JournalIssue>                <Title>Telemedicine journal and e-health : the official journal of the American Telemedicine Association</Title>                <ISOAbbreviation>Telemed J E Health</ISOAbbreviation>            </Journal>            <ArticleTitle>Mobile Self-Help Interventions as Augmentation Therapy for Patients with Anorexia Nervosa.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1089/tmj.2018.0180</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">It has been suggested that patients with anorexia nervosa (AN) who are resistant to first-line treatment would benefit from second-level interventions targeting specific features, an adaptive form of intervention. Guided self-help programs administered via mobile technology have the dual focus of instigating behavior change and managing anxiety associated with eating disorders in the moment and in users' naturalistic environments.</AbstractText>                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">We evaluated the feasibility, acceptability, and preliminary augmentative effects of mobile-based, guided self-help interventions (Recovery vodcasts) after initial unsuccessful first-line treatments for patients with AN.</AbstractText>                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Patients with AN who were unsuccessful in their treatments were recruited to access Recovery vodcasts as augmentation treatment for 3 weeks in Korea. Acceptability and feasibility of the intervention were evaluated, and qualitative feedback was collected. Preliminary treatment effects of adding the Recovery vodcasts were assessed, including eating disorder pathology, anxiety and depression symptoms, and body mass index.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The Recovery vodcasts were acceptable for patients with AN. The patients' psychopathologies of eating disorders improved with augmentation of the vodcasts in their first-line treatments. In addition, there was a tendency toward improvement of affective symptoms. The participants' feedback suggested that the intervention could be improved.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The study demonstrated that the Recovery vodcasts were well accepted by Korean patients with AN. Moreover, augmentation of the Recovery vodcasts could facilitate improvements in psychopathology of eating disorders, anxiety, and mood symptoms for patients with AN.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Youl-Ri</ForeName>                    <Initials>YR</Initials>                    <AffiliationInfo>                        <Affiliation>1 Department of Neuropsychiatry, Seoul Paik Hospital, Inje University , Seoul, South Korea .</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>2 Institute of Eating Disorders and Mental Health, Inje University , Seoul, South Korea .</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cardi</LastName>                    <ForeName>Valentina</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>3 Section of Eating Disorders, Department of Psychological Medicine, King's College London, Institute of Psychiatry , Psychology and Neuroscience, London, United Kingdom .</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lee</LastName>                    <ForeName>Gi Young</ForeName>                    <Initials>GY</Initials>                    <AffiliationInfo>                        <Affiliation>2 Institute of Eating Disorders and Mental Health, Inje University , Seoul, South Korea .</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>An</LastName>                    <ForeName>Sohyun</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>2 Institute of Eating Disorders and Mental Health, Inje University , Seoul, South Korea .</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Jione</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>2 Institute of Eating Disorders and Mental Health, Inje University , Seoul, South Korea .</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kwon</LastName>                    <ForeName>Gemma</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>2 Institute of Eating Disorders and Mental Health, Inje University , Seoul, South Korea .</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Jong Won</ForeName>                    <Initials>JW</Initials>                    <AffiliationInfo>                        <Affiliation>4 Department of Healthcare Information Technology, Inje University , Gimhae, South Korea .</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Eom</LastName>                    <ForeName>Jin-Sup</ForeName>                    <Initials>JS</Initials>                    <AffiliationInfo>                        <Affiliation>5 Department of Psychology, Chungbuk National University , Cheongju, South Korea .</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Treasure</LastName>                    <ForeName>Janet</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>3 Section of Eating Disorders, Department of Psychological Medicine, King's College London, Institute of Psychiatry , Psychology and Neuroscience, London, United Kingdom .</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Telemed J E Health</MedlineTA>            <NlmUniqueID>100959949</NlmUniqueID>            <ISSNLinking>1530-5627</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Recovery vodcast</Keyword>            <Keyword MajorTopicYN="N">acceptability</Keyword>            <Keyword MajorTopicYN="N">anorexia nervosa</Keyword>            <Keyword MajorTopicYN="N">feasibility</Keyword>            <Keyword MajorTopicYN="N">mobile technology</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30325700</ArticleId>            <ArticleId IdType="doi">10.1089/tmj.2018.0180</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30325063</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1098-1136</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>16</Day>                    </PubDate>                </JournalIssue>                <Title>Glia</Title>                <ISOAbbreviation>Glia</ISOAbbreviation>            </Journal>            <ArticleTitle>HIV Tat causes synapse loss in a mouse model of HIV-associated neurocognitive disorder that is independent of the classical complement cascade component C1q.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/glia.23511</ELocationID>            <Abstract>                <AbstractText>Microglial activation, increased proinflammatory cytokine production, and a reduction in synaptic density are key pathological features associated with HIV-associated neurocognitive disorders (HAND). Even with combination antiretroviral therapy (cART), more than 50% of HIV-positive individuals experience some type of cognitive impairment. Although viral replication is inhibited by cART, HIV proteins such as Tat are still produced within the nervous system that are neurotoxic, involved in synapse elimination, and provoke enduring neuroinflammation. As complement deposition on synapses followed by microglial engulfment has been shown during normal development and disease to be a mechanism for pruning synapses, we have tested whether complement is required for the loss of synapses that occurs after a cortical Tat injection mouse model of HAND. In Tat-injected animals evaluated 7 or 28 days after injection, levels of early complement pathway components, C1q and C3, are significantly elevated and associated with microgliosis and a loss of synapses. However, C1qa knockout mice have the same level of Tat-induced synapse loss as wild-type (WT) mice, showing that the C1q-initiated classical complement cascade is not driving synapse removal during HIV1 Tat-induced neuroinflammation.</AbstractText>                <CopyrightInformation>© 2018 Wiley Periodicals, Inc.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Hammond</LastName>                    <ForeName>Jennetta W</ForeName>                    <Initials>JW</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-3949-1594</Identifier>                    <AffiliationInfo>                        <Affiliation>Center for Neurotherapeutics Discovery, University of Rochester Medical Center, Rochester, New York.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Qiu</LastName>                    <ForeName>Wen Q</ForeName>                    <Initials>WQ</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Neurotherapeutics Discovery, University of Rochester Medical Center, Rochester, New York.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Marker</LastName>                    <ForeName>Daniel F</ForeName>                    <Initials>DF</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Neurotherapeutics Discovery, University of Rochester Medical Center, Rochester, New York.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chamberlain</LastName>                    <ForeName>Jeffrey M</ForeName>                    <Initials>JM</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Neurotherapeutics Discovery, University of Rochester Medical Center, Rochester, New York.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Greaves-Tunnell</LastName>                    <ForeName>Will</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Neurotherapeutics Discovery, University of Rochester Medical Center, Rochester, New York.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bellizzi</LastName>                    <ForeName>Matthew J</ForeName>                    <Initials>MJ</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Neurotherapeutics Discovery, University of Rochester Medical Center, Rochester, New York.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lu</LastName>                    <ForeName>Shao-Ming</ForeName>                    <Initials>SM</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Neurotherapeutics Discovery, University of Rochester Medical Center, Rochester, New York.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gelbard</LastName>                    <ForeName>Harris A</ForeName>                    <Initials>HA</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Neurotherapeutics Discovery, University of Rochester Medical Center, Rochester, New York.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>P30 AI078498</GrantID>                    <Agency>National Institute of Allergy and Infectious Diseases</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>F32 MH105288</GrantID>                    <Agency>National Institute of Mental Health</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>P01 MH064570</GrantID>                    <Agency>National Institute of Mental Health</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>R01 MH104147</GrantID>                    <Agency>National Institute of Mental Health</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Glia</MedlineTA>            <NlmUniqueID>8806785</NlmUniqueID>            <ISSNLinking>0894-1491</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">C1q</Keyword>            <Keyword MajorTopicYN="N">HIV</Keyword>            <Keyword MajorTopicYN="N">Tat</Keyword>            <Keyword MajorTopicYN="N">complement</Keyword>            <Keyword MajorTopicYN="N">synapse</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30325063</ArticleId>            <ArticleId IdType="doi">10.1002/glia.23511</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30324639</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1445-5994</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>15</Day>                    </PubDate>                </JournalIssue>                <Title>Internal medicine journal</Title>                <ISOAbbreviation>Intern Med J</ISOAbbreviation>            </Journal>            <ArticleTitle>MEDICAL COMPLICATIONS OF HOMELESSNESS: A NEGLECTED SIDE OF MEN'S HEALTH.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/imj.14139</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Homelessness is an increasing societal and health issue associated with high rates of substance abuse and mental health disorders. Homeless people die more often and younger than others.</AbstractText>                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To identify health needs and improve healthcare for homeless men.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">A physician-led clinic was established on-site at the Mission Australia Centre (MAC) in Sydney, incorporating a) liver screening, including portable fibroscan testing, and on-site treatment of Hepatitis C, b) a mental health clinic, staffed by a psychiatrist, and c) a nurse led clinic to follow up medical issues and deliver vaccinations. Patient data were recorded prospectively to determine what medical problems were encountered so as to drive future health care planning.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">257 men have been assessed between November 2011 and December 2017. In that time 561 men resided at the Centre. Of these 257 men who attended the clinic, 61% were &lt;45 years old, 69% were current and 8% former smokers, 62% had a history of chronic alcoholic abuse and 66% other substance abuse. 64% had one or more of depression, anxiety, psychosis or another mental health disorder. 44% had metabolic syndrome features, 38% cardiovascular disease, 29% hepatitis C and 21% a respiratory disorder.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The main health needs of homeless men fall into the categories of mental health, cardiovascular, respiratory, and metabolic disorders, as well as addictions and Hepatitis C. Establishing on-site clinics at homeless shelters with expertise to address these issues will likely improve the well-being of these men, reduce hospital admissions and prolong their lives. This article is protected by copyright. All rights reserved.</AbstractText>                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Brown</LastName>                    <ForeName>Mark A</ForeName>                    <Initials>MA</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-4759-9407</Identifier>                    <AffiliationInfo>                        <Affiliation>St. George Hospital &amp; University of NSW.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gellatley</LastName>                    <ForeName>Wendy</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Optimus Clinical Research, Kogarah, NSW.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hoffman</LastName>                    <ForeName>Anna</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>St. George Hospital.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dowdell</LastName>                    <ForeName>Lisa</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>St George Hospital.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Camac</LastName>                    <ForeName>Anne</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>St. George Hospital.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Francois</LastName>                    <ForeName>Rachel</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Mission Australia Centre.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Boston</LastName>                    <ForeName>Belinda</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Nurse Consultant Infection Control Department, St. George Hospital.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zekry</LastName>                    <ForeName>Amany</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Dept Gastroenterology, St. George hospital &amp; University of NSW.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Australia</Country>            <MedlineTA>Intern Med J</MedlineTA>            <NlmUniqueID>101092952</NlmUniqueID>            <ISSNLinking>1444-0903</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">addiction</Keyword>            <Keyword MajorTopicYN="N">cardiovascular disease</Keyword>            <Keyword MajorTopicYN="N">hepatitis C</Keyword>            <Keyword MajorTopicYN="N">homelessness</Keyword>            <Keyword MajorTopicYN="N">mental health</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>29</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>11</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30324639</ArticleId>            <ArticleId IdType="doi">10.1111/imj.14139</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30324556</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1433-0458</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>15</Day>                    </PubDate>                </JournalIssue>                <Title>HNO</Title>                <ISOAbbreviation>HNO</ISOAbbreviation>            </Journal>            <ArticleTitle>[Quality of life and depression in hearing-impairment : A German survey].</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00106-018-0576-4</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hearing-impairment can lead to a reduced quality of life and thus represents a vulnerability factor for mental disorders.</AbstractText>                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study represents the first psychiatric analysis of subjective quality of life and depression in people with hearing-impairment in Germany.</AbstractText>                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The patient group included 30 hearing-impaired participants (27 women, 3 men) with a current or previous mental disorder and/or psychiatric/psychotherapeutic treatment (age: mean, M = 49.67 years; standard deviation, SD = 13.54 years). The control group consisted of 22 hearing-impaired participants (16 women, 6 men) without mental disorders or treatment (age: M = 52.41 years, SD = 17.30 years). Besides sociodemographic variables, we registered onset/extent of the various hearing-impairments and hearing aid provision. Both groups underwent extensive diagnostic assessment comprising subjective functional impairment (Sheehan Disability Scale, SDS), health-related quality of life (SF-36 Health Survey), and depressive symptoms (Beck Depression Inventory, BDI-II).</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Groups did not differ significantly in terms of sociodemographic variables such as age, gender, or intelligence. Participants of the patient group had a significantly greater subjective impairment, a lower quality of life, and more pronounced symptoms of depression. The invasiveness of the hearing aid (i. e., cochlear implant) as well as the timepoint of hearing-impairment onset (postlingually) appear to serve as vulnerability factors for mental health problems in this group.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results indicate that besides delivering high-quality acoustic care, practitioners should continuously check patients' requirements for psychosocial treatment due to a loss of quality of life. The development of a specific psychotherapeutic treatment for hearing-impaired clients requires additional research focused on protective and vulnerability factors which may influence the emergence of mental disorders in these patients.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Tretbar</LastName>                    <ForeName>K</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Cochlea-Implantat-Zentrum Leipzig, Universitätsklinikum Leipzig AöR, Leipzig, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Basilowski</LastName>                    <ForeName>M</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>LVR-Klinikum Essen, Klinik für Psychiatrie und Psychotherapie, Medizinische Fakultät, Universität Duisburg-Essen, Essen, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wiedmann</LastName>                    <ForeName>K</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Klinik für Psychiatrie und Psychotherapie, Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bartels</LastName>                    <ForeName>C</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Klinik für Psychiatrie und Psychotherapie, Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Heßmann</LastName>                    <ForeName>P</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Klinik für Psychiatrie und Psychotherapie, Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kownatka</LastName>                    <ForeName>M</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>LVR-Klinikum Essen, Klinik für Psychiatrie und Psychotherapie, Medizinische Fakultät, Universität Duisburg-Essen, Essen, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Signerski-Krieger</LastName>                    <ForeName>J</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Klinik für Psychiatrie und Psychotherapie, Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Scherbaum</LastName>                    <ForeName>N</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>LVR-Klinikum Essen, Klinik für Psychiatrie und Psychotherapie, Medizinische Fakultät, Universität Duisburg-Essen, Essen, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Meuret</LastName>                    <ForeName>S</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Cochlea-Implantat-Zentrum Leipzig, Universitätsklinikum Leipzig AöR, Leipzig, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fuchs</LastName>                    <ForeName>M</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Cochlea-Implantat-Zentrum Leipzig, Universitätsklinikum Leipzig AöR, Leipzig, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wiltfang</LastName>                    <ForeName>J</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Klinik für Psychiatrie und Psychotherapie, Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kis</LastName>                    <ForeName>B</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Klinik für Psychiatrie und Psychotherapie, Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Abdel-Hamid</LastName>                    <ForeName>M</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Klinik für Psychiatrie und Psychotherapie, Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen, Deutschland. Mona.Abdel-Hamid@med.uni-goettingen.de.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>ger</Language>            <PublicationTypeList>                <PublicationType UI="D004740">English Abstract</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <VernacularTitle>Lebensqualität und Depression bei Hörminderung : Eine deutsche Bedarfsanalyse.</VernacularTitle>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>HNO</MedlineTA>            <NlmUniqueID>2985099R</NlmUniqueID>            <ISSNLinking>0017-6192</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Cochlear-implant</Keyword>            <Keyword MajorTopicYN="N">Depression</Keyword>            <Keyword MajorTopicYN="N">Hearing-impairment</Keyword>            <Keyword MajorTopicYN="N">Postlingual hearing-impairment</Keyword>            <Keyword MajorTopicYN="N">Quality of life</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30324556</ArticleId>            <ArticleId IdType="doi">10.1007/s00106-018-0576-4</ArticleId>            <ArticleId IdType="pii">10.1007/s00106-018-0576-4</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30324539</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1573-3610</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>15</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of community health</Title>                <ISOAbbreviation>J Community Health</ISOAbbreviation>            </Journal>            <ArticleTitle>Chronic Disease Burden of the Homeless: A Descriptive Study of Student-Run Free Clinics in Tampa, Florida.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10900-018-0580-3</ELocationID>            <Abstract>                <AbstractText>Variation between homeless populations due to socioeconomic and environmental factors necessitates tailoring medical, health policy, and public health interventions to the unique needs of the homeless population served. Despite the relatively large size of the homeless population in Florida, there is a paucity of research that characterizes the homeless population who frequent homeless clinics within the state. This project describes the demographics, disease prevalence, and other risk factors among homeless individuals in Tampa, Florida. We conducted a retrospective chart review on adult homeless patients seen in 2015 and 2016 at two free clinic sites operated by Tampa Bay Street Medicine, a medical student-run organization from the University of South Florida in Tampa, Florida. Rates of diseases and substance use were recorded and Charlson Comorbidity Index (CCI) was calculated to assess mortality risk. Of the 183 homeless patients in this study, 34.4% reported hypertension, 13.7% reported diabetes, 27.1% reported a respiratory disease, 5.6% reported hyperlipidemia, and 32.8% reported a psychiatric disorder. Tobacco use was reported by 65.6% of patients, 32.2% reported alcohol use, and 17.5% reported illicit drug use. CCI was positively associated with age. Females reported higher rates of anemia, anxiety, chronic obstructive pulmonary disease, and psychiatric disorders. Hypertension, diabetes, certain respiratory diseases, and mental health disorders were more prevalent in the homeless population than in the general population in Tampa, Florida. Homeless women appeared to have higher morbidity than homeless men. Rates of tobacco and illicit drug use were significantly higher whereas alcohol use was lower in the study population than the general population. This study underscores the critical need for mental health initiatives, substance abuse treatment programs, and women's health programs that are accessible to the homeless in Tampa.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Pribish</LastName>                    <ForeName>Abby</ForeName>                    <Initials>A</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-2229-7960</Identifier>                    <AffiliationInfo>                        <Affiliation>Morsani College of Medicine, University of South Florida, 12901 Bruce B Downs Blvd, Tampa, FL, 33612, USA. apribish@health.usf.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Khalil</LastName>                    <ForeName>Nadia</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Morsani College of Medicine, University of South Florida, 12901 Bruce B Downs Blvd, Tampa, FL, 33612, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mhaskar</LastName>                    <ForeName>Rahul</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, University of South Florida, Tampa, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Woodard</LastName>                    <ForeName>Laurie</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Family Medicine, University of South Florida, Tampa, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mirza</LastName>                    <ForeName>Abu-Sayeef</ForeName>                    <Initials>AS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, University of South Florida, Tampa, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>J Community Health</MedlineTA>            <NlmUniqueID>7600747</NlmUniqueID>            <ISSNLinking>0094-5145</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Chronic disease</Keyword>            <Keyword MajorTopicYN="N">Homeless</Keyword>            <Keyword MajorTopicYN="N">Morbidity</Keyword>            <Keyword MajorTopicYN="N">Substance use</Keyword>            <Keyword MajorTopicYN="N">Uninsured</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30324539</ArticleId>            <ArticleId IdType="doi">10.1007/s10900-018-0580-3</ArticleId>            <ArticleId IdType="pii">10.1007/s10900-018-0580-3</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30323776</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1664-0640</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>9</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Frontiers in psychiatry</Title>                <ISOAbbreviation>Front Psychiatry</ISOAbbreviation>            </Journal>            <ArticleTitle>New Perspectives in Phenomenological Psychopathology: Its Use in Psychiatric Treatment.</ArticleTitle>            <Pagination>                <MedlinePgn>466</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fpsyt.2018.00466</ELocationID>            <Abstract>                <AbstractText>Phenomenological psychopathology is a body of scientific knowledge on which the clinical practice of psychiatry is based since the first decades of the twentieth century, a method to assess the patient's abnormal experiences from their own perspective, and more importantly, a science responsible for delimiting the object of psychiatry. Recently, the frontiers of phenomenological psychopathology have expanded to the productive development of therapeutic strategies that target the whole of existence in their actions. In this article, we present an overview of the current state of this discipline, summing up some of its key concepts, and highlighting its importance to clinical psychiatry today. Phenomenological psychopathology understands mental disorders as modifications of the main dimensions of the life-world: lived time, lived space, lived body, intersubjectivity, and selfhood. Psychopathological symptoms are the expression of a dialectical modification of the proportions of certain domains of the life-world or of the lived experience. The far-reaching relevance of the concepts of proportion and dialectics for the clinical agenda is explored. The article presents two contemporary models for clinical practice based on phenomenological psychopathology: Dialectical-proportional oriented approach and Person-centered dialectic approach (P.H.D. method). The main characteristics of these approaches are considered, as well as the new perspectives they bring to the challenges of psychiatric care in the twentieth-first century.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Messas</LastName>                    <ForeName>Guilherme</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Mental Health, Santa Casa de Sao Paulo School of Medical Sciences, São Paulo, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tamelini</LastName>                    <ForeName>Melissa</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Psychiatry- Hospital das Clínicas de São Paulo, São Paulo, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mancini</LastName>                    <ForeName>Milena</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychological Sciences Humanities and Territory, University of Chieti, Chieti, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Stanghellini</LastName>                    <ForeName>Giovanni</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychological Sciences Humanities and Territory, University of Chieti, Chieti, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Diego Portales University, Santiago, Chile.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>28</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Front Psychiatry</MedlineTA>            <NlmUniqueID>101545006</NlmUniqueID>            <ISSNLinking>1664-0640</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">anthropological proportion</Keyword>            <Keyword MajorTopicYN="N">dialectics</Keyword>            <Keyword MajorTopicYN="N">life-world</Keyword>            <Keyword MajorTopicYN="N">person-centered approach</Keyword>            <Keyword MajorTopicYN="N">phenomenological approaches</Keyword>            <Keyword MajorTopicYN="N">phenomenological psychopathology</Keyword>            <Keyword MajorTopicYN="N">psychiatric care</Keyword>            <Keyword MajorTopicYN="N">psychotherapy</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30323776</ArticleId>            <ArticleId IdType="doi">10.3389/fpsyt.2018.00466</ArticleId>            <ArticleId IdType="pmc">PMC6172298</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30323774</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1664-0640</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>9</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Frontiers in psychiatry</Title>                <ISOAbbreviation>Front Psychiatry</ISOAbbreviation>            </Journal>            <ArticleTitle>Baclofen in the Treatment of Patients With Alcohol Use Disorder and Other Mental Health Disorders.</ArticleTitle>            <Pagination>                <MedlinePgn>464</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fpsyt.2018.00464</ELocationID>            <Abstract>                <AbstractText>A limited number of medications are approved to treat Alcohol Use Disorder (AUD). Furthermore, the magnitude of their therapeutic effect is relatively modest, suggesting the potential for subtypes of patients who respond to a specific medication. The use of these medications is also limited in clinical practice by a series of contraindications such as medical comorbidities and/or concurrent use of other medications. In recent years, animal and human studies have been conducted to evaluate the efficacy of baclofen, a GABA<sub>B</sub> receptor agonist approved for clinical use as a muscle relaxant, in the treatment of AUD. However, these studies have yielded contrasting results. Despite this discrepancy, baclofen is often used off-label to treat AUD, especially in some European countries and Australia. Recently, several factors have been considered to try to shed light on the potential reasons and mechanisms underlying the inconsistent results obtained until now. The presence of a psychiatric comorbidity may be amongst the abovementioned factors playing a role in explaining different responses to baclofen treatment in terms of alcohol drinking outcomes. Therefore, the aim here was to conduct a narrative review of the scientific literature related to the use of baclofen in AUD, both in patients with and without concomitant psychiatric disorders. All clinical studies (randomized and controlled, open-label, retrospective, human laboratory studies, and case reports) were analyzed and discussed, bearing in mind other potential factors that may have influenced baclofen response, including dose administered, severity of AUD, use of other psychosocial therapies, and the presence of physical disorders. This review indicates that the most frequent psychiatric comorbidities in patients affected by AUD undergoing baclofen treatment are anxiety and mood disorders. Unfortunately, no definitive conclusions can be drawn due to the lack of specific analyses on whether baclofen efficacy is different in AUD patients with comorbid psychiatric disorders vs. those without. Therefore, it will be critical that psychiatric comorbidities are considered in the planning of future studies and in the analysis of the data, with the ultimate goal of understanding whether subtypes of AUD patients may respond best to baclofen.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Agabio</LastName>                    <ForeName>Roberta</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Section of Neuroscience and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari, Monserrato, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Leggio</LastName>                    <ForeName>Lorenzo</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Basic Research and National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Bethesda, MD, United States.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Medication Development Program, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, United States.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Center for Alcohol and Addiction Studies, Brown University, Providence, RI, United States.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>28</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Front Psychiatry</MedlineTA>            <NlmUniqueID>101545006</NlmUniqueID>            <ISSNLinking>1664-0640</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">GABAB</Keyword>            <Keyword MajorTopicYN="N">alcohol use disorder</Keyword>            <Keyword MajorTopicYN="N">anxiety</Keyword>            <Keyword MajorTopicYN="N">baclofen</Keyword>            <Keyword MajorTopicYN="N">mental health disorders</Keyword>            <Keyword MajorTopicYN="N">mood disorders</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30323774</ArticleId>            <ArticleId IdType="doi">10.3389/fpsyt.2018.00464</ArticleId>            <ArticleId IdType="pmc">PMC6172346</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30323635</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1178-6981</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>10</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>ClinicoEconomics and outcomes research : CEOR</Title>                <ISOAbbreviation>Clinicoecon Outcomes Res</ISOAbbreviation>            </Journal>            <ArticleTitle>Does knowledge of patient non-compliance change prescribing behavior in the real world? A claims-based analysis of patients with serious mental illness.</ArticleTitle>            <Pagination>                <MedlinePgn>573-585</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.2147/CEOR.S175877</ELocationID>            <Abstract>                <AbstractText Label="Background" NlmCategory="UNASSIGNED">New digital technologies offer providers the promise of more accurately tracking patients' medication adherence. It is unclear, however, whether access to such information will affect provider treatment decisions in the real world.</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">Using prescriber-reported information on patient non-compliance from health insurance claims data between 2008 and 2014, we examined whether prescribers' knowledge of non-compliance was associated with different prescribing patterns for patients with serious mental illness (SMI). We examined patients who initiated an oral atypical antipsychotic, but were later objectively non-adherent to this treatment, defined as proportion of days covered (PDC) &lt;0.8. We examined how a physician's awareness of patient non-compliance (ICD-9 diagnosis code: V15.81) was correlated with the physician's real-world treatment decisions for that patient. Treatment decisions studied included the share of patients who increased antipsychotic dose, augmented treatment, switched their antipsychotic, or used a long-acting injectable (LAI).</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Among the 286,249 patients with SMI who initiated an antipsychotic and had PDC &lt;0.8, 4,033 (1.4%) had documented non-compliance. When prescribers documented non-compliance, patients were more likely to be switched to another antipsychotic (32.8% vs 24.7%, <i>P</i>&lt;0.001), have their dose increased (24.4% vs 22.1%, <i>P</i>=0.004), or receive an LAI (0.09% vs 0.04%, <i>P</i>=0.008), but were less likely to have augmented therapy with another antipsychotic (1.1% vs 1.3%, <i>P</i>=0.035) than patients without documented non-compliance.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Among SMI patients with documented non-compliance, the frequency of dose, medication switches, and LAI use were higher and augmentation was lower compared to patients without documented non-compliance. Access to adherence information may help prescribers more rapidly switch ineffective medications as well as avoid unnecessary medication augmentation.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Shafrin</LastName>                    <ForeName>Jason</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Policy and Economics, Precision Health Economics, Los Angeles, CA, USA, jason.shafrin@precisionhealtheconomics.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bognar</LastName>                    <ForeName>Katalin</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Policy and Economics, Precision Health Economics, Los Angeles, CA, USA, jason.shafrin@precisionhealtheconomics.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Everson</LastName>                    <ForeName>Katie</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Policy and Economics, Precision Health Economics, Los Angeles, CA, USA, jason.shafrin@precisionhealtheconomics.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Brauer</LastName>                    <ForeName>Michelle</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Policy and Economics, Precision Health Economics, Boston, MA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lakdawalla</LastName>                    <ForeName>Darius N</ForeName>                    <Initials>DN</Initials>                    <AffiliationInfo>                        <Affiliation>School of Pharmacy, Sol Price School of Public Policy, Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Forma</LastName>                    <ForeName>Felicia M</ForeName>                    <Initials>FM</Initials>                    <AffiliationInfo>                        <Affiliation>Health Economics and Outcomes Management, Otsuka Pharmaceutical Development &amp; Commercialization, Inc., Princeton, NJ, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>02</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>New Zealand</Country>            <MedlineTA>Clinicoecon Outcomes Res</MedlineTA>            <NlmUniqueID>101560564</NlmUniqueID>            <ISSNLinking>1178-6981</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">adherence</Keyword>            <Keyword MajorTopicYN="N">prescribing patterns</Keyword>            <Keyword MajorTopicYN="N">serious mental illness</Keyword>        </KeywordList>        <CoiStatement>Disclosure JS, KB, KE, and MB are employees of Precision Health Economics, a health care consulting firm that received funding for this study from Otsuka Pharmaceutical Development &amp; Commercialization, Inc. DNL is a consulting Scientific Advisor at Precision Health Economics. DNL and JS are investors in Precision Health Economics’ parent company, Precision Medicine Group. FMF is an employee of Otsuka Pharmaceutical Development &amp; Commercialization, Inc. The authors report no other conflicts of interest in this work.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30323635</ArticleId>            <ArticleId IdType="doi">10.2147/CEOR.S175877</ArticleId>            <ArticleId IdType="pii">ceor-10-573</ArticleId>            <ArticleId IdType="pmc">PMC6173173</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30323576</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1178-1998</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>13</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Clinical interventions in aging</Title>                <ISOAbbreviation>Clin Interv Aging</ISOAbbreviation>            </Journal>            <ArticleTitle>Frequency and coincidence of geriatric syndromes according to age groups: single-center experience in Turkey between 2013 and 2017.</ArticleTitle>            <Pagination>                <MedlinePgn>1899-1905</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.2147/CIA.S180281</ELocationID>            <Abstract>                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Geriatric syndromes are complex clinical manifestations that are not an isolated disease in older adults and have common risk factors within themselves. The syndromes are significant causes of mortality, morbidity, and increased health care costs.</AbstractText>                <AbstractText Label="Objective" NlmCategory="UNASSIGNED">To determine the frequency of geriatric syndromes such as malnutrition, dementia, depression, falls, polypharmacy, urinary incontinence, pressure ulcer, sarcopenia, and frailty in community-dwelling older adults.</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">A total of 2,816 patients, who applied to geriatric outpatient clinic and were evaluated by comprehensive geriatric assessment, were included in this cross-sectional retrospective study. Falls in the last year and urinary incontinence were recorded. Polypharmacy was accepted as concurrent use of more than four drugs. Diagnosis of dementia and depression was defined according to Diagnostic and Statistical Manual of Mental Disorders Fifth Edition diagnostic criteria. In addition, frailty and sarcopenia were evaluated according to Fried's physical frailty scale and European Working Group on Sarcopenia criteria, respectively.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">The frequency of polypharmacy was 54.5%, urinary incontinence 47.6%, malnutrition 9.6%, depression 35.1%, dementia 21.6%, falls 33.6%, sarcopenia 31.7%, and frailty 28.3%. When all the participants were divided into three groups (60-69, 70-79, ≥80 years), all syndromes were significantly increased with age, except for depression. While 20% of cases in 60-69 years age group did not have any syndromes, 48% of cases in ≥80 years had more than four syndromes simultaneously.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">The frequency and coincidence of geriatric syndromes, except for depression, increases with age. Therefore, clinicians other than geriatricians taking care of older people should be aware of these syndromes as well as their treatment mechanisms.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Bulut</LastName>                    <ForeName>Esra Ates</ForeName>                    <Initials>EA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Geriatric Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey, atisik@yahoo.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Soysal</LastName>                    <ForeName>Pinar</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Geriatric Medicine, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Isik</LastName>                    <ForeName>Ahmet Turan</ForeName>                    <Initials>AT</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Geriatric Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey, atisik@yahoo.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>04</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>New Zealand</Country>            <MedlineTA>Clin Interv Aging</MedlineTA>            <NlmUniqueID>101273480</NlmUniqueID>            <ISSNLinking>1176-9092</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">dementia</Keyword>            <Keyword MajorTopicYN="N">frailty</Keyword>            <Keyword MajorTopicYN="N">geriatric syndromes</Keyword>            <Keyword MajorTopicYN="N">malnutrition</Keyword>            <Keyword MajorTopicYN="N">sarcopenia</Keyword>        </KeywordList>        <CoiStatement>Disclosure The authors report no conflicts of interest in this work.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30323576</ArticleId>            <ArticleId IdType="doi">10.2147/CIA.S180281</ArticleId>            <ArticleId IdType="pii">cia-13-1899</ArticleId>            <ArticleId IdType="pmc">PMC6174888</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30323122</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Print">1673-5374</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>13</Volume>                    <Issue>12</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Dec</Month>                    </PubDate>                </JournalIssue>                <Title>Neural regeneration research</Title>                <ISOAbbreviation>Neural Regen Res</ISOAbbreviation>            </Journal>            <ArticleTitle>Apomorphine effects on the hippocampus.</ArticleTitle>            <Pagination>                <MedlinePgn>2064-2066</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.4103/1673-5374.241443</ELocationID>            <Abstract>                <AbstractText>Apomorphine is a non-specific dopamine receptor agonist that has been used in the treatment of some diseases and mental disorders. Its use has particularly well documented in Parkinson's disease (PD). The dopaminergic agonists like apomorphine are related to oxidative processes that could induce cell damage and the functional impairment of some structures in the brain. However, most information about apomorphine in literature is focused on the improvement of the motor problems characteristic of PD, but little is known about the effects on cognitive behaviors and brain structures indirectly related to motor function. The presence of dopaminergic receptors in the hippocampus has recently been discovered, in connection with cognitive behaviors like learning and memory, these receptors are needed in neuronal plasticity. There has been a growing interest to know if this structure could be compromised by the effect of apomorphine and elucidate if part of the cognitive impairment present in the PD is due to the effect of apomorphine. In this mini-review, we summarized how apomorphine has been used since its creation, we discuss the latest information about its effect on the hippocampus and also the future perspectives to fully understand the effects of this compound.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Arroyo-Garcia</LastName>                    <ForeName>Luis Enrique</ForeName>                    <Initials>LE</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratorio de Neuropsiquiatría, Instituto de Fisiología, Benemérita Universidad Autónoma de Puebla, Puebla, México.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rodríguez-Moreno</LastName>                    <ForeName>Antonio</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratorio de Neurociencia Celular y Plasticidad, Universidad Pablo de Olavide, Sevilla, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Flores</LastName>                    <ForeName>Gonzalo</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratorio de Neuropsiquiatría, Instituto de Fisiología, Benemérita Universidad Autónoma de Puebla, Puebla, México.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>India</Country>            <MedlineTA>Neural Regen Res</MedlineTA>            <NlmUniqueID>101316351</NlmUniqueID>            <ISSNLinking>1673-5374</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Parkinson's disease</Keyword>            <Keyword MajorTopicYN="N">apomorphine</Keyword>            <Keyword MajorTopicYN="N">dendritic length</Keyword>            <Keyword MajorTopicYN="N">dopamine receptor</Keyword>            <Keyword MajorTopicYN="N">hippocampus</Keyword>            <Keyword MajorTopicYN="N">learning and memory</Keyword>            <Keyword MajorTopicYN="N">oxidative stress</Keyword>            <Keyword MajorTopicYN="N">plasticity</Keyword>        </KeywordList>        <CoiStatement>None</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30323122</ArticleId>            <ArticleId IdType="pii">NeuralRegenRes_2018_13_12_2064_241443</ArticleId>            <ArticleId IdType="doi">10.4103/1673-5374.241443</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30322824</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2215-0374</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>12</Day>                    </PubDate>                </JournalIssue>                <Title>The lancet. Psychiatry</Title>                <ISOAbbreviation>Lancet Psychiatry</ISOAbbreviation>            </Journal>            <ArticleTitle>The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">S2215-0366(18)30345-6</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S2215-0366(18)30345-6</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The antibiotic minocycline has neuroprotective and anti-inflammatory properties that could prevent or reverse progressive neuropathic changes implicated in recent-onset schizophrenia. In the BeneMin study, we aimed to replicate the benefit of minocycline on negative symptoms reported in previous pilot studies, and to understand the mechanisms involved.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">In this randomised, double-blind, placebo-controlled trial, we recruited people with a schizophrenia-spectrum disorder that had begun within the past 5 years with continuing positive symptoms from 12 National Health Service (NHS) trusts. Participants were randomly assigned according to an automated permuted blocks algorithm, stratified by pharmacy, to receive minocycline (200 mg per day for 2 weeks, then 300 mg per day for the remainder of the 12-month study period) or matching placebo, which were added to their continuing treatment. The primary clinical outcome was the negative symptom subscale score of the Positive and Negative Syndrome Scales (PANSS) across follow-ups at months 2, 6, 9, and 12. The primary biomarker outcomes were medial prefrontal grey-matter volume, dorsolateral prefrontal cortex activation during a working memory task, and plasma concentration of interleukin 6. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN49141214, and the EU Clinical Trials register (EudraCT) number is 2010-022463-35I.</AbstractText>                <AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between April 16, 2013, and April 30, 2015, we recruited 207 people and randomly assigned them to receive minocycline (n=104) or placebo (n=103). Compared with placebo, the addition of minocycline had no effect on ratings of negative symptoms (treatment effect difference -0·19, 95% CI -1·23 to 0·85; p=0·73). The primary biomarker outcomes did not change over time and were not affected by minocycline. The groups did not differ in the rate of serious adverse events (n=11 in placebo group and n=18 in the minocycline group), which were mostly due to admissions for worsening psychiatric state (n=10 in the placebo group and n=15 in the minocycline group). The most common adverse events were gastrointestinal (n=12 in the placebo group, n=19 in the minocycline group), psychiatric (n=16 in placebo group, n=8 in minocycline group), nervous system (n=8 in the placebo group, n=12 in the minocycline group), and dermatological (n=10 in the placebo group, n=8 in the minocycline group).</AbstractText>                <AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Minocycline does not benefit negative or other symptoms of schizophrenia over and above adherence to routine clinical care in first-episode psychosis. There was no evidence of a persistent progressive neuropathic or inflammatory process underpinning negative symptoms. Further trials of minocycline in early psychosis are not warranted until there is clear evidence of an inflammatory process, such as microgliosis, against which minocycline has known efficacy.</AbstractText>                <AbstractText Label="FUNDING" NlmCategory="BACKGROUND">National Institute for Health Research Efficacy and Mechanism Evaluation (EME) programme, an MRC and NIHR partnership.</AbstractText>                <CopyrightInformation>Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Deakin</LastName>                    <ForeName>Bill</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Neuroscience and Psychiatry Unit, The University of Manchester, Manchester, UK; MAHSC, The University of Manchester, Manchester, UK; Greater Manchester Mental Health NHS Foundation Trust, Prestwich, Manchester, UK. Electronic address: bill.deakin@manchester.ac.uk.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Suckling</LastName>                    <ForeName>John</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Brain Mapping Unit, Department of Psychiatry, Herchel Smith Building for Brain and Mind Sciences, University of Cambridge, Cambridge, UK; Cambridgeshire &amp; Peterborough NHS Foundation Trust, Cambridge, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Barnes</LastName>                    <ForeName>Thomas R E</ForeName>                    <Initials>TRE</Initials>                    <AffiliationInfo>                        <Affiliation>Centre for Psychiatry, Imperial College London, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Byrne</LastName>                    <ForeName>Kelly</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Neuroscience and Psychiatry Unit, The University of Manchester, Manchester, UK; Tropical Clinical Trials Unit, Liverpool School of Tropical Medicine, Liverpool, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chaudhry</LastName>                    <ForeName>Imran B</ForeName>                    <Initials>IB</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Neuroscience and Experimental Psychology, The University of Manchester, Manchester, UK; Lancashire Care Early Intervention Service, Accrington, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dazzan</LastName>                    <ForeName>Paola</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Drake</LastName>                    <ForeName>Richard J</ForeName>                    <Initials>RJ</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Psychology and Mental Health, The University of Manchester, Manchester, UK; Greater Manchester Mental Health NHS Foundation Trust, Prestwich, Manchester, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Giordano</LastName>                    <ForeName>Annalisa</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Husain</LastName>                    <ForeName>Nusrat</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Psychology and Mental Health, The University of Manchester, Manchester, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jones</LastName>                    <ForeName>Peter B</ForeName>                    <Initials>PB</Initials>                    <AffiliationInfo>                        <Affiliation>Brain Mapping Unit, Department of Psychiatry, Herchel Smith Building for Brain and Mind Sciences, University of Cambridge, Cambridge, UK; Cambridgeshire &amp; Peterborough NHS Foundation Trust, Cambridge, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Joyce</LastName>                    <ForeName>Eileen</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Sobell Department of Motor Neurosciences and Movement Disorders, UCL Institute of Neurology, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Knox</LastName>                    <ForeName>Emma</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Neuroscience and Psychiatry Unit, The University of Manchester, Manchester, UK; Institute for Applied Clinical Sciences, Keele University, Guy Hilton Research Centre, Stoke-on-Trent, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Krynicki</LastName>                    <ForeName>Carl</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Institute for Mental Health, University of Birmingham, Birmingham, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lawrie</LastName>                    <ForeName>Stephen M</ForeName>                    <Initials>SM</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lewis</LastName>                    <ForeName>Shôn</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>MAHSC, The University of Manchester, Manchester, UK; Greater Manchester Mental Health NHS Foundation Trust, Prestwich, Manchester, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lisiecka-Ford</LastName>                    <ForeName>Danuta M</ForeName>                    <Initials>DM</Initials>                    <AffiliationInfo>                        <Affiliation>Neurology Unit, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nikkheslat</LastName>                    <ForeName>Naghmeh</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Stress, Psychiatry and Immunology Lab &amp; Perinatal Psychiatry, The Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pariante</LastName>                    <ForeName>Carmine M</ForeName>                    <Initials>CM</Initials>                    <AffiliationInfo>                        <Affiliation>Stress, Psychiatry and Immunology Lab &amp; Perinatal Psychiatry, The Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Smallman</LastName>                    <ForeName>Richard</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Neuroscience and Psychiatry Unit, The University of Manchester, Manchester, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Watson</LastName>                    <ForeName>Andrew</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Sobell Department of Motor Neurosciences and Movement Disorders, UCL Institute of Neurology, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Williams</LastName>                    <ForeName>Steven C R</ForeName>                    <Initials>SCR</Initials>                    <AffiliationInfo>                        <Affiliation>Department for Neuroimaging, King's College London, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Upthegrove</LastName>                    <ForeName>Rachel</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Institute for Mental Health, University of Birmingham, Birmingham, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dunn</LastName>                    <ForeName>Graham</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Population Health, Health Services Research and Primary Care, The University of Manchester, Manchester, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <CollectiveName>BeneMin Study team</CollectiveName>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Lancet Psychiatry</MedlineTA>            <NlmUniqueID>101638123</NlmUniqueID>            <ISSNLinking>2215-0366</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>20</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>31</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30322824</ArticleId>            <ArticleId IdType="pii">S2215-0366(18)30345-6</ArticleId>            <ArticleId IdType="doi">10.1016/S2215-0366(18)30345-6</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30322503</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1532-2122</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>36</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>European journal of oncology nursing : the official journal of European Oncology Nursing Society</Title>                <ISOAbbreviation>Eur J Oncol Nurs</ISOAbbreviation>            </Journal>            <ArticleTitle>Difficulties faced by long-term childhood cancer survivors: A qualitative study.</ArticleTitle>            <Pagination>                <MedlinePgn>129-134</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S1462-3889(18)30101-7</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejon.2018.08.003</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Due to improved survival rates of childhood cancer, there has been growing attention to survivors. In addition, experiences of illness in youth, during growth and development, affect the lives of these individuals in numerous ways. With a sample of long-term survivors of childhood cancer, this study investigated their difficult experiences after treatment completion and provided fundamental data for intervention programs that can assist growth.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Data from 15 survivors aged 15-28 years old were collected through face-to-face interviews; analysis used Giorgi's phenomenological method.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The long-term survivors' lives involved a process of struggle to overcome the difficulties. Survivors had physical vestiges of cancer treatments, such as physical strength limitations, appearance changes, and sexual problems. Additionally, they experienced social withdrawal and awkwardness due to adaptation difficulties caused by social life interruption, family issues, social prejudice, and discrimination. These physical and social struggles led to experiences of mental stress and psychological withdrawal, but were followed by rebound.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Long-term survivors of childhood cancer experienced physical, social, and emotional struggles following treatment completion. These results can yield improved understanding of this population, facilitate attention to their challenges, and contribute to their more effective integration into society, helping them live healthy and positive lives.</AbstractText>                <CopyrightInformation>Copyright © 2018. Published by Elsevier Ltd.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Yoonjung</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Red Cross College of Nursing, Chung-Ang University, 84 Heukseok-Ro, Dongjack-Gu, Seoul 156-756, Republic of Korea. Electronic address: yoonjung@cau.ac.kr.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lee</LastName>                    <ForeName>Kyoung-Sook</ForeName>                    <Initials>KS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Nursing, Korean Bible University, 32 Dongil-ro 214-gil, Nowon-gu, Seoul, 139-791, Republic of Korea. Electronic address: dhsvnd75@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Koh</LastName>                    <ForeName>Kyung-Nam</ForeName>                    <Initials>KN</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Olympic Road 43 Road 88, Seoul 05505, Republic of Korea. Electronic address: pedkkn@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>22</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Scotland</Country>            <MedlineTA>Eur J Oncol Nurs</MedlineTA>            <NlmUniqueID>100885136</NlmUniqueID>            <ISSNLinking>1462-3889</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Childhood cancer</Keyword>            <Keyword MajorTopicYN="N">Difficulty</Keyword>            <Keyword MajorTopicYN="N">Long-term survivors</Keyword>            <Keyword MajorTopicYN="N">Qualitative research</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>08</Month>                <Day>21</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30322503</ArticleId>            <ArticleId IdType="pii">S1462-3889(18)30101-7</ArticleId>            <ArticleId IdType="doi">10.1016/j.ejon.2018.08.003</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30322334</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1360-0567</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>15</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of mental health (Abingdon, England)</Title>                <ISOAbbreviation>J Ment Health</ISOAbbreviation>            </Journal>            <ArticleTitle>Self-reported physical activity levels of the 2017 Royal Australian and New Zealand College of Psychiatrists (RANZCP) conference delegates and their exercise referral practices.</ArticleTitle>            <Pagination>                <MedlinePgn>1-8</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1080/09638237.2018.1521935</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Physical activity (PA) significantly improves physical health and clinical symptoms across mental disorders. Accredited Exercise Physiologists (AEPs) are trained to lead PA interventions for people with mental illness, but referrals to AEPs are low.</AbstractText>                <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To determine the knowledge and attitudes of delegates attending the 2017 Royal Australian and New Zealand College of Psychiatrists (RANZCP) conference toward physical health monitoring and exercise interventions for people with mental illness.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">A cross-sectional survey of RANZCP delegates investigated knowledge and attitudes toward PA for people with mental illness, self-reported PA, and their understanding of AEP's role within mental health settings. A subgroup of delegates underwent fitness assessments.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Seventy-three delegates completed surveys and 24 underwent fitness assessments. Delegates demonstrated good knowledge regarding associations between PA and cardiovascular disease risk. Delegates were less knowledgeable of AEP's role within mental health settings. Forty-six participants (63%) did not meet the Australian recommended guidelines for PA. No association between referrals to AEPs and self-reported PA or fitness measures were evident.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Promoting PA participation for mental health professionals, coupled with education on the important role AEPs play in the multidisciplinary treatment of mental health consumers is vital to improve health outcomes for this vulnerable group.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Fibbins</LastName>                    <ForeName>Hamish</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>a Keeping the Body in Mind Program, South Eastern Sydney Local Health District , Sydney , Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>b School of Psychiatry , UNSW Sydney , Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Czosnek</LastName>                    <ForeName>Louise</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>c Exercise and Sports Science Australia , Brisbane , Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>d Mary Mackillop Institute for Health Research , Australian Catholic University , Melbourne , Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Stanton</LastName>                    <ForeName>Robert</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>e School of Health, Medical and Applied Sciences , Central Queensland University , Rockhampton , Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Davison</LastName>                    <ForeName>Kade</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>f School of Health Sciences , University of South Australia , Adelaide , Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lederman</LastName>                    <ForeName>Oscar</ForeName>                    <Initials>O</Initials>                    <AffiliationInfo>                        <Affiliation>a Keeping the Body in Mind Program, South Eastern Sydney Local Health District , Sydney , Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>g School of Medical Science , UNSW Sydney , Sydney , Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Morell</LastName>                    <ForeName>Rachel</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>a Keeping the Body in Mind Program, South Eastern Sydney Local Health District , Sydney , Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>b School of Psychiatry , UNSW Sydney , Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ward</LastName>                    <ForeName>Philip</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>b School of Psychiatry , UNSW Sydney , Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>h Schizophrenia Research Unit , Liverpool Hospital and Ingham Institute of Applied Medical Research , Sydney , Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rosenbaum</LastName>                    <ForeName>Simon</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>b School of Psychiatry , UNSW Sydney , Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>i The Black Dog Institute, Prince of Wales Hospital , Randwick , Australia.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>J Ment Health</MedlineTA>            <NlmUniqueID>9212352</NlmUniqueID>            <ISSNLinking>0963-8237</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Mental health</Keyword>            <Keyword MajorTopicYN="N">clinician health</Keyword>            <Keyword MajorTopicYN="N">exercise physiologist</Keyword>            <Keyword MajorTopicYN="N">physical activity</Keyword>            <Keyword MajorTopicYN="N">psychiatrist</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30322334</ArticleId>            <ArticleId IdType="doi">10.1080/09638237.2018.1521935</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30322314</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1360-0567</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>15</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of mental health (Abingdon, England)</Title>                <ISOAbbreviation>J Ment Health</ISOAbbreviation>            </Journal>            <ArticleTitle>Early intervention with cognitive behavioral therapy reduces sick leave duration in people with adjustment, anxiety and depressive disorders.</ArticleTitle>            <Pagination>                <MedlinePgn>1-9</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1080/09638237.2018.1521937</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Early intervention in workers diagnosed with mental disorders is associated with a lower incidence of relapse and shorter sick leave. However, no studies have been carried out on the effect of early intervention using an evidence-based therapy, Cognitive Behavioral Therapy (CBT), on people with sick leave.</AbstractText>                <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The objectives of the present study are to study whether the type of intervention (early or late) will affect the total duration of the sick leave, the partial duration of the sick leave, the duration of the psychotherapy and the time until return to work after the psychotherapy ends. The sample was composed of 167 participants who were on sick leave for adjustment disorders, anxiety disorders or depressive disorder.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The participants who had early intervention with CBT had a significantly shorter duration of total sick leave and partial sick leave, and a shorter time until returning to work after the psychotherapy ended than those who had late intervention. There were no statistically differences in the duration or efficacy of the psychotherapy.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We can suggest that providing early access to CBT significantly reduces the length of sick leave in patients with mental disorders.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Marco</LastName>                    <ForeName>José H</ForeName>                    <Initials>JH</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-1545-6452</Identifier>                    <AffiliationInfo>                        <Affiliation>a Department of Personality, Assessment, and Psychological Treatments, University of Valencia, Valencia, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Alonso</LastName>                    <ForeName>Sandra</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>b Doctoral School of Catholic University of Valencia, Saint Vincent Martyr, Valencia, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>c Cathedra UMIVALE Innovation and Research in Pathology Work, Valencia, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Andani</LastName>                    <ForeName>Joaquín</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>c Cathedra UMIVALE Innovation and Research in Pathology Work, Valencia, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>d Catholic University of Valencia, Saint Vincent Martyr, Valencia, Spain.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>J Ment Health</MedlineTA>            <NlmUniqueID>9212352</NlmUniqueID>            <ISSNLinking>0963-8237</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Sick leave</Keyword>            <Keyword MajorTopicYN="N">adjustment disorders</Keyword>            <Keyword MajorTopicYN="N">anxiety disorders</Keyword>            <Keyword MajorTopicYN="N">cognitive behavioral therapy</Keyword>            <Keyword MajorTopicYN="N">depressive disorders</Keyword>            <Keyword MajorTopicYN="N">return to work</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30322314</ArticleId>            <ArticleId IdType="doi">10.1080/09638237.2018.1521937</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30321873</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>15</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1439-4421</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>15</Day>                    </PubDate>                </JournalIssue>                <Title>Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))</Title>                <ISOAbbreviation>Gesundheitswesen</ISOAbbreviation>            </Journal>            <ArticleTitle>[Importance of Psychiatric Outpatient Clinics in Primary Care of Somatic Disorders].</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1055/a-0668-5891</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVE OF THE STUDY" NlmCategory="OBJECTIVE">General practitioners are mainly responsible for primary health care. Patients with mental disorders, in particular patients with complex or multiple needs, use these services infrequently in case of somatic complaints. Psychiatric outpatient clinics have to deal with these patients and have perhaps an additional role in diagnosing and treating somatic co-morbidities. This should be evaluated.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Physicians in outpatient clinics of the Centre of Psychiatry Suedwuerttemberg were asked about their attitude towards somatic co-morbidities, somatic co-treatment and prescribing somatic drugs. In addition, data of the outpatient clinic documentation were evaluated with respect to the treatment by general practitioners and somatic diagnosis.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">72% of all patients said that they have a general practitioner. Physicians in outpatient clinics said that they had a high responsibility for somatic co-treatment especially for those patients who did not have a general practitioner. The frequency and type of a somatic co-morbidity was different in patients from general psychiatric, geriatric psychiatry and addiction outpatient clinics.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results demonstrate that psychiatric outpatient clinics play a crucial role in diagnosing and treating somatic disorders. Their extent depends on the type of the psychiatric and the somatic disorder but also on the financing of the outpatient clinic.</AbstractText>                <CopyrightInformation>© Georg Thieme Verlag KG Stuttgart · New York.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Borbé</LastName>                    <ForeName>Raoul</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Klinik für Psychiatrie und Psychotherapie I der Universität Ulm.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>ZfP Südwürttemberg.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Pfäffle</LastName>                    <ForeName>Christine</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>ZfP Südwürttemberg.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Versorgungsforschung Zwiefalten/Reutlingen.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Eisele</LastName>                    <ForeName>Frank</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Versorgungsforschung Zwiefalten/Reutlingen.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Versorgungsforschung Zwiefalten/Reutlingen.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Längle</LastName>                    <ForeName>Gerhard</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Versorgungsforschung Zwiefalten/Reutlingen.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Versorgungsforschung Zwiefalten/Reutlingen.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>ger</Language>            <PublicationTypeList>                <PublicationType UI="D004740">English Abstract</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <VernacularTitle>Die Bedeutung Psychiatrischer Institutsambulanzen in der somatischen Grundversorgung.</VernacularTitle>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Gesundheitswesen</MedlineTA>            <NlmUniqueID>9204210</NlmUniqueID>            <ISSNLinking>0941-3790</ISSNLinking>        </MedlineJournalInfo>        <OtherAbstract Type="Publisher" Language="ger">            <AbstractText Label="ZIEL DER STUDIE" NlmCategory="UNASSIGNED">Die somatische Grundversorgung ist primär Aufgabe des Allgemein-/Hausärztlichen Sektors. Menschen mit psychischen Störungen, insbesondere die mit komplexem Hilfebedarf, nehmen dessen Leistungen bei somatischen Beschwerden seltener wahr. Sie stellen aber die Kernklientel Psychiatrischer Institutsambulanzen (PIA) dar, denen daher möglicherweise auch eine Aufgabe in der somatischen Versorgung dieser Patientengruppe zufällt. Der Stellenwert Psychiatrischer Institutsambulanzen in der somatischen Grundversorgung sollte daher untersucht werden.</AbstractText>            <AbstractText Label="METHODIK" NlmCategory="UNASSIGNED">Ärztinnen und Ärzte in Psychiatrischen Institutsambulanzen des ZfP Südwürttemberg wurden hinsichtlich ihrer Einstellung bezüglich der Bedeutung somatischer Komorbiditäten, der somatischen Mitbehandlung und dem Verschreibungsverhalten von somatischen Medikamenten befragt. Ergänzend wurden Daten der PIA-BADO ausgewertet hinsichtlich der Behandlung durch Hausärzte sowie der dokumentierten somatischen Nebendiagnosen.</AbstractText>            <AbstractText Label="ERGEBNISSE" NlmCategory="UNASSIGNED">72% aller Patienten gaben an, einen Hausarzt zu haben. Seitens der PIA-Ärzte wurde besonders bei den Patienten, die nicht hausärztlich versorgt waren, eine hohe eigene Verantwortung bei der Mitbehandlung somatischer Erkrankungen gesehen. Die Häufigkeit und die Art somatischer Nebendiagnosen unterschieden sich zwischen allgemeinpsychiatrischen, gerontopsychiatrischen und abhängigkeitskranken Patienten teils deutlich.</AbstractText>            <AbstractText Label="SCHLUSSFOLGERUNG" NlmCategory="UNASSIGNED">Die Ergebnisse zeigen, dass Psychiatrische Institutsambulanzen in der Erkennung und Mitbehandlung somatischer Erkrankungen eine wichtige Rolle spielen. Diese ist abhängig von der psychischen Störung und der Art der somatischen Erkrankung aber auch von der Form der PIA-Finanzierung.</AbstractText>        </OtherAbstract>        <CoiStatement>Die Autoren geben an, dass kein Interessenkonflikt besteht.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30321873</ArticleId>            <ArticleId IdType="doi">10.1055/a-0668-5891</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30320964</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>15</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2151-4658</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>15</Day>                    </PubDate>                </JournalIssue>                <Title>Arthritis care &amp; research</Title>                <ISOAbbreviation>Arthritis Care Res (Hoboken)</ISOAbbreviation>            </Journal>            <ArticleTitle>Long-term impact of belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: 6 years of treatment.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/acr.23788</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To report long-term health-related quality of life (HRQoL) and fatigue outcomes in patients with systemic lupus erythematosus (SLE) receiving belimumab.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Patients with SLE who completed the BLISS-76 trial were enrolled into this continuation study (BEL112233, NCT00724867). The belimumab groups continued to receive the same dose (1 mg/kg or 10 mg/kg intravenously; post-March 2011 all patients received 10 mg/kg) every 28 days, plus standard of care (SoC). The placebo group switched to belimumab 10 mg/kg. HRQoL and fatigue assessments included the Short Form-36 (SF-36) Health Survey and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale. Post hoc subgroup analyses (BEL206350) assessed clinical characteristics associated with improved HRQoL and fatigue.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">268 patients enrolled; 140 completed the study. Patients receiving long-term belimumab reported continued improvements in HRQoL and fatigue. At Study Year 6, mean (standard deviation [SD]) Physical Component Summary (PCS) and Mental Component Summary (MCS) SF-36 scores increased from baseline 37.0 (9.9) to 41.7 (10.0; mean change, 4.8 [9.4]) for PCS and from 44.3 (11.3) to 47.0 (11.6; mean change, 2.7 [11.3]) for MCS, exceeding the minimum clinically important difference (MCID) for improvement (2.5 units). Mean (SD) FACIT-Fatigue score exceeded the MCID of 4 at Study Years 1-5; at Study Year 6 the mean change was 3.7 (11.8). Statistically significant associations were observed between parent trial treatment groups and change from baseline in PCS, MCS, and FACIT-Fatigue scores (p&lt;0.01).</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Long-term control of disease activity with belimumab plus SoC translates into meaningful improvements in patient-reported fatigue and HRQoL.</AbstractText>                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Strand</LastName>                    <ForeName>Vibeke</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Stanford University School of Medicine, Palo Alto, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Berry</LastName>                    <ForeName>Pamela</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>GSK, Philadelphia, PA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lin</LastName>                    <ForeName>Xiwu</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>GSK, Philadelphia, PA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Asukai</LastName>                    <ForeName>Yumi</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>GSK, Uxbridge, Middlesex, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Punwaney</LastName>                    <ForeName>Rajesh</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>GSK, King of Prussia, PA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ramachandran</LastName>                    <ForeName>Sulabha</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>GSK, Philadelphia, PA, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Arthritis Care Res (Hoboken)</MedlineTA>            <NlmUniqueID>101518086</NlmUniqueID>            <ISSNLinking>2151-464X</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30320964</ArticleId>            <ArticleId IdType="doi">10.1002/acr.23788</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30320438</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>15</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1469-493X</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>10</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>15</Day>                    </PubDate>                </JournalIssue>                <Title>The Cochrane database of systematic reviews</Title>                <ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation>            </Journal>            <ArticleTitle>Family therapy approaches for anorexia nervosa.</ArticleTitle>            <Pagination>                <MedlinePgn>CD004780</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD004780.pub3</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Anorexia nervosa (AN) is characterised by a failure to maintain a normal body weight due to a paucity of nutrition, an intense fear of gaining weight or behaviour that prevents the individual from gaining weight, or both. The long-term prognosis is often poor, with severe developmental, medical and psychosocial complications, high rates of relapse and mortality. 'Family therapy approaches' indicate a range of approaches, derived from different theories, that involve the family in treatment. We have included therapies developed on the basis of dominant family systems theories, approaches that are based on or broadly similar to the family-based therapy derived from the Maudsley model, approaches that incorporate a focus on cognitive restructuring, as well as approaches that involve the family without articulation of a theoretical approach.This is an update of a Cochrane Review first published in 2010.</AbstractText>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the efficacy of family therapy approaches compared with standard treatment and other treatments for AN.</AbstractText>                <AbstractText Label="SEARCH METHODS" NlmCategory="METHODS">We searched the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR) and PsycINFO (OVID) (all years to April 2016). We ran additional searches directly on Cochrane Central Register for Controlled Trials (CENTRAL), MEDLINE, Ovid Embase, and PsycINFO (to 2008 and 2016 to 2018). We searched the World Health Organization (WHO) trials portal (ICTRP) and ClinicalTrials.gov, together with four theses databases (all years to 2018). We checked the reference lists of all included studies and relevant systematic reviews. We have included in the analyses only studies from searches conducted to April 2016.</AbstractText>                <AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Randomised controlled trials (RCTs) of family therapy approaches compared to any other intervention or other types of family therapy approaches were eligible for inclusion. We included participants of any age or gender with a primary clinical diagnosis of anorexia nervosa.</AbstractText>                <AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Four review authors selected the studies, assessed quality and extracted data. We used a random-effects meta-analysis. We used the risk ratio (with a 95% confidence interval) to summarise dichotomous outcomes and both the standardised mean difference and the mean difference to summarise continuous measures.</AbstractText>                <AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">We included 25 trials in this version of the review (13 from the original 2010 review and 12 newly-included studies). Sixteen trials were of adolescents, eight trials of adults (seven of these in young adults aged up to 26 years) and one trial included three age groups: one adolescent, one young adult and one adult. Most investigated family-based therapy or variants. Reporting of trial conduct was generally inadequate, so that in a large number of studies we rated the risk of bias as unclear for many of the domains. Selective reporting bias was particularly problematic, with 68% of studies rated at high risk of bias in this area, followed by incomplete outcome data, with 44% of studies rated at high risk of bias in this area. For the main outcome measure of remission there was some low-quality evidence (from only two studies, 81 participants) suggesting that family therapy approaches might offer some advantage over treatment as usual on rates of remission, post intervention (risk ratio (RR) 3.50, 95% confidence interval (CI) 1.49 to 8.23; I<sup>2</sup> = 0%). However, at follow-up, low-quality evidence from only one study suggested this effect was not maintained. There was very low-quality evidence from only one trial, which means it is difficult to determine whether family therapy approaches offer any advantage over educational interventions for remission (RR 9.00, 95% CI 0.53 to 153.79; 1 study, N = 30). Similarly, there was very low-quality evidence from only five trials for remission post-intervention, again meaning that it is difficult to determine whether there is any advantage of family therapy approaches over psychological interventions (RR 1.22, 95% CI 0.89 to 1.67; participants = 252; studies = 5; I<sup>2</sup> = 37%) and at long-term follow-up (RR 1.08, 95% CI 0.91 to 1.28; participants = 200; studies = 4 with 1 of these contributing 3 pairwise comparisons for different age groups; I<sup>2</sup> = 0%). There was no indication that the age group had any impact on the overall treatment effect; however, it should be noted that there were very few trials undertaken in adults, with the age range of adult studies included in this analysis from 20 to 27. There was some evidence of a small effect favouring family based therapy compared with other psychological interventions in terms of weight gain post-intervention (standardised mean difference (SMD) 0.32, 95% CI 0.01 to 0.63; participants = 210; studies = 4 with 1 of these contributing 3 pairwise comparisons for different age groups; I<sup>2</sup> = 11%) . Overall, there was insufficient evidence to determine whether there were any differences between groups across all comparisons for most of the secondary outcomes (weight, eating disorder psychopathology, dropouts, relapse, or family functioning measures), either at post-intervention or at follow-up.</AbstractText>                <AbstractText Label="AUTHORS' CONCLUSIONS" NlmCategory="CONCLUSIONS">There is a limited amount of low-quality evidence to suggest that family therapy approaches may be effective compared to treatment as usual in the short term. This finding is based on two trials that included only a small number of participants, and both had issues about potential bias. There is insufficient evidence to determine whether there is an advantage of family therapy approaches in people of any age compared to educational interventions (one study, very low quality) or psychological therapies (five studies, very low quality). Most studies contributing to this finding were undertaken in adolescents and youth. There are clear potential impacts on how family therapy approaches might be delivered to different age groups and further work is required to understand what the resulting effects on treatment efficacy might be. There is insufficient evidence to determine whether one type of family therapy approach is more effective than another. The field would benefit from further large, well-conducted trials.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Fisher</LastName>                    <ForeName>Caroline A</ForeName>                    <Initials>CA</Initials>                    <AffiliationInfo>                        <Affiliation>Allied Health - Psychology, Royal Melbourne Hospital, Melbourne Health, Parkville, Victoria, Australia, 3050.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Skocic</LastName>                    <ForeName>Sonja</ForeName>                    <Initials>S</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Rutherford</LastName>                    <ForeName>Kathleen A</ForeName>                    <Initials>KA</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Hetrick</LastName>                    <ForeName>Sarah E</ForeName>                    <Initials>SE</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Cochrane Database Syst Rev</MedlineTA>            <NlmUniqueID>100909747</NlmUniqueID>            <ISSNLinking>1361-6137</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30320438</ArticleId>            <ArticleId IdType="doi">10.1002/14651858.CD004780.pub3</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30319709</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>15</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Print">1750-9467</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>51</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Jul</Month>                    </PubDate>                </JournalIssue>                <Title>Research in autism spectrum disorders</Title>                <ISOAbbreviation>Res Autism Spectr Disord</ISOAbbreviation>            </Journal>            <ArticleTitle>Treatment Utilization by Adults with Autism and Co-Occurring Anxiety or Depression.</ArticleTitle>            <Pagination>                <MedlinePgn>32-37</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rasd.2018.03.009</ELocationID>            <Abstract>                <AbstractText Label="Background" NlmCategory="UNASSIGNED">While a growing body of research suggests that talk therapies can reduce anxiety and depression in adults with autism spectrum disorder (ASD), we know little about what community treatment for these disorders looks like for them. The present study investigated whether treatment utilization differs between adults with and without ASD who have anxiety or depression.</AbstractText>                <AbstractText Label="Method" NlmCategory="UNASSIGNED">Using Pennsylvania Medicaid claims data, adults aged 18-65 years diagnosed with ASD and depression or anxiety (n = 268) were matched 1:4 to adults with depression or anxiety disorder without ASD (n = 1,072). Chi-square tests and generalized linear models were used to estimate differences in diagnoses and psychiatric treatment between groups.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">While the proportion of people prescribed benzodiazepine and antidepressants did not differ between groups, the ASD group had more days per month prescribed for all medications. Adults with ASD also were more likely to be prescribed multiple medications concurrently and to use case management. Adults without ASD were more likely to receive talk therapy for anxiety/depression. Among those receiving talk therapy, adults with ASD averaged more individual visits per month.</AbstractText>                <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Findings suggest that therapists may need more session time for adults with ASD, although it is unclear if this time is dedicated to anxiety or depression treatment. The greater use of psychotropic medications among adults with ASD may suggest unresponsiveness to the talk therapy they receive or greater clinical complexity.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Maddox</LastName>                    <ForeName>Brenna B</ForeName>                    <Initials>BB</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Mental Health Policy and Services Research, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kang-Yi</LastName>                    <ForeName>Christina D</ForeName>                    <Initials>CD</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Mental Health Policy and Services Research, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Brodkin</LastName>                    <ForeName>Edward S</ForeName>                    <Initials>ES</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Neurobiology and Behavior, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mandell</LastName>                    <ForeName>David S</ForeName>                    <Initials>DS</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Mental Health Policy and Services Research, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>04</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Res Autism Spectr Disord</MedlineTA>            <NlmUniqueID>101300021</NlmUniqueID>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Autism spectrum disorder</Keyword>            <Keyword MajorTopicYN="N">adults</Keyword>            <Keyword MajorTopicYN="N">anxiety</Keyword>            <Keyword MajorTopicYN="N">depression</Keyword>            <Keyword MajorTopicYN="N">therapy</Keyword>            <Keyword MajorTopicYN="N">treatment</Keyword>        </KeywordList>        <CoiStatement>Conflict of Interest: The authors declare that they have no conflict of interest.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pmc-release">                <Year>2019</Year>                <Month>07</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30319709</ArticleId>            <ArticleId IdType="doi">10.1016/j.rasd.2018.03.009</ArticleId>            <ArticleId IdType="pmc">PMC6181232</ArticleId>        </ArticleIdList>        <?nihms?>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30319459</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>15</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1664-0640</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>9</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Frontiers in psychiatry</Title>                <ISOAbbreviation>Front Psychiatry</ISOAbbreviation>            </Journal>            <ArticleTitle>Mapping Systematic Reviews on Forensic Psychiatric Care: A Systematic Review Identifying Knowledge Gaps.</ArticleTitle>            <Pagination>                <MedlinePgn>452</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fpsyt.2018.00452</ELocationID>            <Abstract>                <AbstractText><b>Background:</b> Forensic psychiatric care treats mentally disordered offenders who suffer mainly from psychotic disorders, although comorbidities such as personality disorders, neurodevelopmental disorders, and substance abuse are common. A large proportion of these patients have committed violent crimes. Their care is involuntary, and their caregivers' mission is complex: not only to rehabilitate the patient, but also to consider their risk for reoffending and their risk to society. The objective of this overview of systematic reviews is to identify, appraise, and summarize the existing knowledge in forensic psychiatric care and identify knowledge gaps that require further research. <b>Methods:</b> We undertook a systematic literature search for systematic reviews in five defined domains considered important in daily clinical practice within the forensic psychiatric care: (1) diagnostic assessment and risk assessments; (2) pharmacological treatment; (3) psychological interventions; (4) psychosocial interventions, rehabilitation, and habilitation; and (5) restraint interventions. The target population was mentally disordered offenders (forensic psychiatric patients aged &gt;15 years). Each abstract and full text review was assessed by two of the authors. Relevant reviews then were assessed for bias, and those with moderate or low risk of bias were included. <b>Results:</b> Of 38 systematic reviews meeting the inclusion criteria, only four had a moderate risk of bias. Two aimed to incorporate as many aspects of forensic psychiatric care as possible, one investigated non-pharmacological interventions to reduce aggression in forensic psychiatric care, and one focused on women with intellectual disabilities in forensic care. However, most of the primary studies included in these reviews had high risks of bias, and therefore, no conclusions could be drawn. All of our identified domains must be considered knowledge gaps. <b>Conclusion:</b> We could not answer any of our research questions within the five domains because of the high risk of bias in the primary studies in the included systematic reviews. There is an urgent need for more research on forensic psychiatric care since all of our studied domains were considered knowledge gaps.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Howner</LastName>                    <ForeName>Katarina</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Neuroscience, Centre of Psychiatry Research, Karolinska Institutet, Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Division for Forensic Psychiatry in Stockholm, Department for Forensic Psychiatry, National Board of Forensic Medicine, Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Andiné</LastName>                    <ForeName>Peter</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Division for Forensic Psychiatry in Gothenburg, Department for Forensic Psychiatry, National Board of Forensic Medicine, Gothenburg, Sweden.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry and Neurochemistry, Centre for Ethics, Law and Mental Health, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Forensic Psychiatric Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bertilsson</LastName>                    <ForeName>Göran</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hultcrantz</LastName>                    <ForeName>Monica</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lindström</LastName>                    <ForeName>Eva</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mowafi</LastName>                    <ForeName>Frida</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Snellman</LastName>                    <ForeName>Alexandra</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hofvander</LastName>                    <ForeName>Björn</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Sciences, Lund, Child and Adolescent Psychiatry, Lund University, Lund, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>25</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Front Psychiatry</MedlineTA>            <NlmUniqueID>101545006</NlmUniqueID>            <ISSNLinking>1664-0640</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">forensic psychiatric care</Keyword>            <Keyword MajorTopicYN="N">mentally disordered offenders</Keyword>            <Keyword MajorTopicYN="N">pharmacological treatment</Keyword>            <Keyword MajorTopicYN="N">psychological interventions</Keyword>            <Keyword MajorTopicYN="N">psychosocial interventions</Keyword>            <Keyword MajorTopicYN="N">restraint interventions</Keyword>            <Keyword MajorTopicYN="N">risk assessments</Keyword>            <Keyword MajorTopicYN="N">systematic review</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>31</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30319459</ArticleId>            <ArticleId IdType="doi">10.3389/fpsyt.2018.00452</ArticleId>            <ArticleId IdType="pmc">PMC6167556</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30319341</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>15</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1662-4548</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>12</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Frontiers in neuroscience</Title>                <ISOAbbreviation>Front Neurosci</ISOAbbreviation>            </Journal>            <ArticleTitle>The Changes of Functional Connectivity Strength in Electroconvulsive Therapy for Depression: A Longitudinal Study.</ArticleTitle>            <Pagination>                <MedlinePgn>661</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fnins.2018.00661</ELocationID>            <Abstract>                <AbstractText>Electroconvulsive therapy (ECT) is an effective treatment for depression, but the mechanism of ECT for depression is still unclear. Recently, neuroimaging studies have reported that the prefrontal cortex, hippocampus, angular gyrus, insular and other brain regions are involved in the mechanism of ECT for depression, and these regions are highly overlapped with the location of brain hubs. Here, we try to explore the effects of ECT on the functional connectivity of brain hubs in depression patients. In current study, depression patients were assessed at three time points: prior to ECT, at the completion of ECT and about 1 month after the completion of ECT. At each time point, resting-state functional magnetic resonance imaging, assessment of clinical symptoms and cognition function were performed respectively, which was compared with 20 normal controls. Functional connectivity strength (FCS) was used to identify brain hubs. The results showed that FCS of left angular gyrus in depression patients significantly increased after ECT, accompanied by improved mood. The changed FCS in depression patients recovered obviously at 1 month after the completion of ECT. It suggested that ECT could modulate functional connectivity of left angular gyrus in depression patients.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Wei</LastName>                    <ForeName>Qiang</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Collaborative Innovation Centre of Neuropsychiatric Disorders and Mental Health, Hefei, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bai</LastName>                    <ForeName>Tongjian</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Collaborative Innovation Centre of Neuropsychiatric Disorders and Mental Health, Hefei, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Yang</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Anhui Mental Health Center, Hefei, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ji</LastName>                    <ForeName>Gongjun</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Collaborative Innovation Centre of Neuropsychiatric Disorders and Mental Health, Hefei, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hu</LastName>                    <ForeName>Xiaopeng</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xie</LastName>                    <ForeName>Wen</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Anhui Mental Health Center, Hefei, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xiong</LastName>                    <ForeName>Zulun</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Anhui Mental Health Center, Hefei, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhu</LastName>                    <ForeName>Daomin</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Anhui Mental Health Center, Hefei, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wei</LastName>                    <ForeName>Lin</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Collaborative Innovation Centre of Neuropsychiatric Disorders and Mental Health, Hefei, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hu</LastName>                    <ForeName>Panpan</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Collaborative Innovation Centre of Neuropsychiatric Disorders and Mental Health, Hefei, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yu</LastName>                    <ForeName>Yongqiang</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Kai</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Collaborative Innovation Centre of Neuropsychiatric Disorders and Mental Health, Hefei, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tian</LastName>                    <ForeName>Yanghua</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Collaborative Innovation Centre of Neuropsychiatric Disorders and Mental Health, Hefei, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>25</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Front Neurosci</MedlineTA>            <NlmUniqueID>101478481</NlmUniqueID>            <ISSNLinking>1662-453X</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">brain hub</Keyword>            <Keyword MajorTopicYN="N">depression</Keyword>            <Keyword MajorTopicYN="N">electroconvulsive therapy</Keyword>            <Keyword MajorTopicYN="N">fMRI</Keyword>            <Keyword MajorTopicYN="N">treatment</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>16</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30319341</ArticleId>            <ArticleId IdType="doi">10.3389/fnins.2018.00661</ArticleId>            <ArticleId IdType="pmc">PMC6167462</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30318942</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>15</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1748-3115</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>14</Day>                    </PubDate>                </JournalIssue>                <Title>Disability and rehabilitation. Assistive technology</Title>                <ISOAbbreviation>Disabil Rehabil Assist Technol</ISOAbbreviation>            </Journal>            <ArticleTitle>How college students diagnosed with anxiety disorders and/or depression use everyday technology.</ArticleTitle>            <Pagination>                <MedlinePgn>1-8</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1080/17483107.2018.1499143</ELocationID>            <Abstract>                <AbstractText>Anxiety disorders and/or depression are the most frequently diagnosed mental health problems (MHP) among American college students. Everyday technology (EDT) is being used with those who have MHP to help them cope with the mental/cognitive disabilities arising from having anxiety and/or depression. Deveau investigated the types of EDT students with MHP use to manage their roles as college students. While this research indicated that individuals with MHP were open to learning about EDT they can use, the author recommended further investigation of the topic. This qualitative study further investigated what types of EDT college students use to manage their anxiety disorder and/or depression. Our research found that while college students with anxiety and depression are familiar with and willing to use EDT to help compensate for some of the issues they have resulting from their anxiety and depression, some reported that the use of EDT contributes to their problems. Implications for further investigation include continuing to examine the use of EDT amongst a larger group of college students. Future research should also investigate creating a peer run technology group, taught by interested student such as occupational therapy, psychology or computer science students to name a few, to inform students about apps to manage scheduling, routines, medication management and symptoms management. Additionally, the positive and negative aspects of social media and how to manage ones use of it use would be a relevant topic for group discussion. Implications for rehabilitation While most college students currently use everyday technology as a part of their lives, it has positive and negative meanings to college students who have anxiety and/or depression. Finding out what a user wants to do with technology and the meaning it has for them is a critical part of insuring the right match between a person and an assistive technology intervention. Consider a full range of no to high technology options when working with college students who experience the mental/cognitive disabilities resulting from mental health problems to identify assistive technology solutions.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Gitlow</LastName>                    <ForeName>Lynn</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Occupational Therapy , Ithaca College , Ithaca , NY , USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Janney</LastName>                    <ForeName>Blaire</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Occupational Therapy , Ithaca College , Ithaca , NY , USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lemery</LastName>                    <ForeName>Caitlyn</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Occupational Therapy , Ithaca College , Ithaca , NY , USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>McDonald</LastName>                    <ForeName>Julianne</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Occupational Therapy , Ithaca College , Ithaca , NY , USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>McGinley</LastName>                    <ForeName>Bethany</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Occupational Therapy , Ithaca College , Ithaca , NY , USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rabideau</LastName>                    <ForeName>Kristin</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>a Department of Occupational Therapy , Ithaca College , Ithaca , NY , USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Disabil Rehabil Assist Technol</MedlineTA>            <NlmUniqueID>101255937</NlmUniqueID>            <ISSNLinking>1748-3107</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Everyday technology</Keyword>            <Keyword MajorTopicYN="N">assistive technology</Keyword>            <Keyword MajorTopicYN="N">mental illness</Keyword>            <Keyword MajorTopicYN="N">mental/cognitive disability</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30318942</ArticleId>            <ArticleId IdType="doi">10.1080/17483107.2018.1499143</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30318722</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>15</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1552-485X</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>14</Day>                    </PubDate>                </JournalIssue>                <Title>American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</Title>                <ISOAbbreviation>Am. J. Med. Genet. B Neuropsychiatr. Genet.</ISOAbbreviation>            </Journal>            <ArticleTitle>Convergent analysis of genome-wide genotyping and transcriptomic data suggests association of zinc finger genes with lithium response in bipolar disorder.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/ajmg.b.32663</ELocationID>            <Abstract>                <AbstractText>Lithium is the mainstay treatment in bipolar disorder (BD) for its effectiveness in the acute phases of illness and in prevention of recurrences. Lithium's mechanism of action is complex, and while it modulates the function of hundreds of molecular targets, most of these effects could be unspecific and not relevant for its clinical efficacy. In this study, we applied an integrated analytical approach using genome-wide expression and genotyping data from BD patients to identify lithium-responsive genes that may serve as biomarkers of its efficacy. To this purpose, we tested the effect of treatment with lithium chloride 1 mM on the transcriptome of lymphoblasts from 10 lithium responders (LR) and 10 nonresponders (NR) patients and identified genes significantly influenced by the treatment exclusively in LR. These findings were integrated with gene-based analysis on genome-wide genotyping data from an extended sample of 205 BD patients characterized for lithium response. The expression of 29 genes was significantly changed by lithium exclusively in LR. Gene-based analysis showed that two of these genes, zinc finger protein 429 (ZNF429) and zinc finger protein 493 (ZNF493), were also significantly associated with lithium response. Validation with quantitative real-time polymerase chain reaction confirmed the lithium-induced downregulation of ZNF493 in LR (p = .036). Using convergent analyses of genome-wide expression and genotyping data, we identified ZNF493 as a potential lithium-responsive target that may be involved in modulating lithium efficacy in BD. To our knowledge, this is the first evidence supporting the involvement of zinc finger proteins in lithium response.</AbstractText>                <CopyrightInformation>© 2018 Wiley Periodicals, Inc.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Pisanu</LastName>                    <ForeName>Claudia</ForeName>                    <Initials>C</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-9151-4319</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Congiu</LastName>                    <ForeName>Donatella</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Costa</LastName>                    <ForeName>Marta</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Advanced Sequencing Facility, the Francis Crick Institute, London NW1 1AT, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chillotti</LastName>                    <ForeName>Caterina</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Unit of Clinical Pharmacology, University Hospital of Cagliari, Cagliari, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ardau</LastName>                    <ForeName>Raffaella</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Unit of Clinical Pharmacology, University Hospital of Cagliari, Cagliari, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Severino</LastName>                    <ForeName>Giovanni</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Angius</LastName>                    <ForeName>Andrea</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche (CNR), Cagliari, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Heilbronner</LastName>                    <ForeName>Urs</ForeName>                    <Initials>U</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-7135-762X</Identifier>                    <AffiliationInfo>                        <Affiliation>Institute of Psychiatric Phenomics and Genomics (IPPG), Medical Center of the University of Munich, Campus Innenstadt, Munich, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hou</LastName>                    <ForeName>Liping</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>U.S. Department of Health &amp; Human Services, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>McMahon</LastName>                    <ForeName>Francis J</ForeName>                    <Initials>FJ</Initials>                    <AffiliationInfo>                        <Affiliation>U.S. Department of Health &amp; Human Services, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Schulze</LastName>                    <ForeName>Thomas G</ForeName>                    <Initials>TG</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Psychiatric Phenomics and Genomics (IPPG), Medical Center of the University of Munich, Campus Innenstadt, Munich, Germany.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>U.S. Department of Health &amp; Human Services, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Del Zompo</LastName>                    <ForeName>Maria</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Unit of Clinical Pharmacology, University Hospital of Cagliari, Cagliari, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Squassina</LastName>                    <ForeName>Alessio</ForeName>                    <Initials>A</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-7415-7607</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <Agency>Dr-Lisa-Oehler-Foundation</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>NCT00001174ZIA-MH00284311</GrantID>                    <Agency>Intramural Research Program of the National Institute of Mental Health</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>P.O.R. Sardegna F.S.E. Operational Program</GrantID>                    <Agency>Sardinia Regional Government</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>NCT00001174</GrantID>                    <Agency>National Institute of Mental Health</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>ZIA-MH00284311</GrantID>                    <Agency>National Institute of Mental Health</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Am J Med Genet B Neuropsychiatr Genet</MedlineTA>            <NlmUniqueID>101235742</NlmUniqueID>            <ISSNLinking>1552-4841</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">ZNF493</Keyword>            <Keyword MajorTopicYN="N">biomarker</Keyword>            <Keyword MajorTopicYN="N">bipolar disorder</Keyword>            <Keyword MajorTopicYN="N">lithium</Keyword>            <Keyword MajorTopicYN="N">pharmacogenomics</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>09</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>02</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30318722</ArticleId>            <ArticleId IdType="doi">10.1002/ajmg.b.32663</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30317688</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1744-6171</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>14</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of child and adolescent psychiatric nursing : official publication of the Association of Child and Adolescent Psychiatric Nurses, Inc</Title>                <ISOAbbreviation>J Child Adolesc Psychiatr Nurs</ISOAbbreviation>            </Journal>            <ArticleTitle>Novel four-session treatment intervention for anxiety and high-functioning autism: A single case report for Externalizing Metaphors Therapy.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jcap.12213</ELocationID>            <Abstract>                <AbstractText Label="TOPIC" NlmCategory="OBJECTIVE">The Brief Services psychotherapy paradigm has evolved to produce cost-effective and clinically significant outcomes in children's mental health. Though its clinical evaluation is still in its infancy, it has been utilized to a much lesser degree with autism spectrum disorders, which typically require a longer-term approach to psychotherapy treatment.</AbstractText>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The current paper introduces a novel, four-session intervention that aims to decrease anxiety experienced by clients presenting with high-functioning autism. Externalizing Metaphors Therapy is based upon the externalization of problems, transformation of metaphoric imagery, shifting of maladaptive emotional schemas, and the generalization of problems. A case study is utilized to visually aid in the understanding of this new treatment intervention.</AbstractText>                <AbstractText Label="SOURCE" NlmCategory="METHODS">A composite session-by-session case study was conducted with regard to significant works within Narrative Therapy, treatment interventions for anxiety and high-functioning autism, evidence-based treatments for anxiety, and practice-based approaches in psychotherapy. Works were selected based on their relevance to the research field of anxiety and autism.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This clinical research challenges the children's mental health field in addressing anxiety and high-functioning autism from a brief framework. Further clinical research is needed to clinically evaluate the current model.</AbstractText>                <CopyrightInformation>© 2018 Wiley Periodicals, Inc.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>McGuinty</LastName>                    <ForeName>Everett F</ForeName>                    <Initials>EF</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Education, Graduate &amp; Postdoctoral Studies, Western University, London, Ontario, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bird</LastName>                    <ForeName>Brian M</ForeName>                    <Initials>BM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, Simon Fraser University, British Columbia, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nelson</LastName>                    <ForeName>John</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Private Practice, North Bay, Ontario, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>McGuinty</LastName>                    <ForeName>Jazlyn L</ForeName>                    <Initials>JL</Initials>                    <AffiliationInfo>                        <Affiliation>Near North District School Board, North Bay, Ontario, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cashin</LastName>                    <ForeName>Andrew</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>School of Health and Human Sciences, Southern Cross University, Lismore, New South Wales, Australia.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>J Child Adolesc Psychiatr Nurs</MedlineTA>            <NlmUniqueID>9431738</NlmUniqueID>            <ISSNLinking>1073-6077</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">brief services</Keyword>            <Keyword MajorTopicYN="N">externalizing</Keyword>            <Keyword MajorTopicYN="N">high-functioning autism</Keyword>            <Keyword MajorTopicYN="N">metaphor</Keyword>            <Keyword MajorTopicYN="N">narrative therapy</Keyword>            <Keyword MajorTopicYN="N">process research</Keyword>            <Keyword MajorTopicYN="N">psychotherapy</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>21</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30317688</ArticleId>            <ArticleId IdType="doi">10.1111/jcap.12213</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30316998</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1559-2030</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>11</Day>                    </PubDate>                </JournalIssue>                <Title>Contemporary clinical trials</Title>                <ISOAbbreviation>Contemp Clin Trials</ISOAbbreviation>            </Journal>            <ArticleTitle>Peer support and mobile health technology targeting obesity-related cardiovascular risk in young adults with serious mental illness: Protocol for a randomized controlled trial.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">S1551-7144(18)30454-3</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cct.2018.10.005</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Individuals with serious mental illness (SMI) such as schizophrenia and bipolar disorder face a higher risk of early death due to cardiovascular disease and other preventable chronic illnesses. Young adulthood is a critical window of development for lifestyle interventions to improve the long-term health and quality of life in this population. Fit Forward is an NIH-funded randomized clinical trial examining the effectiveness of a group lifestyle intervention (PeerFIT) enhanced with mobile health technology compared to one-on-one mobile lifestyle coaching with Basic Education in fitness and nutrition supported by a wearable Activity Tracking device (BEAT) in achieving clinically significant weight loss and improved cardiorespiratory fitness in young adults with SMI.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Fit Forward targets 144 young adults (18 to 35 years) with SMI and a body mass index (BMI) of ≥25 receiving public mental health services. In a two-arm randomized clinical trial, participants will be randomly assigned with equal probability to PeerFIT or BEAT, stratified by birth sex and psychiatric diagnosis. Participants will be assessed at baseline, 6, and 12 months. The primary outcome is cardiovascular risk reduction indicated by either clinically significant weight loss (5% or greater) or increased fitness (&gt;50 m on the 6-Minute Walk Test). Secondary outcomes include change in BMI, lipids, and hemoglobin A1c. Perceived self-efficacy for exercise and peer support will be evaluated as mechanisms underlying intervention effects.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">If effective, PeerFIT will provide a potentially scalable approach to addressing health risks among young adults with SMI in mental health settings.</AbstractText>                <AbstractText Label="TRIALS REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov, NCT02815813.</AbstractText>                <CopyrightInformation>Copyright © 2018. Published by Elsevier Inc.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Aschbrenner</LastName>                    <ForeName>Kelly A</ForeName>                    <Initials>KA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH, United States; The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, United States. Electronic address: Kelly.A.Aschbrenner@Dartmouth.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Naslund</LastName>                    <ForeName>John A</ForeName>                    <Initials>JA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Global Health and Social Medicine, Harvard Medical School, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gorin</LastName>                    <ForeName>Amy A</ForeName>                    <Initials>AA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Connecticut, Storrs, CT, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mueser</LastName>                    <ForeName>Kim T</ForeName>                    <Initials>KT</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Occupational Therapy, Boston University, Boston, MA, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Scherer</LastName>                    <ForeName>Emily A</ForeName>                    <Initials>EA</Initials>                    <AffiliationInfo>                        <Affiliation>Biomedical Data Sciences, Geisel School of Medicine at Dartmouth, Lebanon, NH, United States; Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Viron</LastName>                    <ForeName>Mark</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Harvard Medical School, Boston, MA, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kinney</LastName>                    <ForeName>Allison</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bartels</LastName>                    <ForeName>Stephen J</ForeName>                    <Initials>SJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH, United States; The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, United States; Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, United States.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <DataBankList CompleteYN="Y">                <DataBank>                    <DataBankName>ClinicalTrials.gov</DataBankName>                    <AccessionNumberList>                        <AccessionNumber>NCT02815813</AccessionNumber>                    </AccessionNumberList>                </DataBank>            </DataBankList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Contemp Clin Trials</MedlineTA>            <NlmUniqueID>101242342</NlmUniqueID>            <ISSNLinking>1551-7144</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Lifestyle intervention</Keyword>            <Keyword MajorTopicYN="N">Mobile health technology</Keyword>            <Keyword MajorTopicYN="N">Peer support</Keyword>            <Keyword MajorTopicYN="N">Serious mental illness</Keyword>            <Keyword MajorTopicYN="N">Young adult</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>29</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30316998</ArticleId>            <ArticleId IdType="pii">S1551-7144(18)30454-3</ArticleId>            <ArticleId IdType="doi">10.1016/j.cct.2018.10.005</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30316721</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1873-7528</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>11</Day>                    </PubDate>                </JournalIssue>                <Title>Neuroscience and biobehavioral reviews</Title>                <ISOAbbreviation>Neurosci Biobehav Rev</ISOAbbreviation>            </Journal>            <ArticleTitle>Cortisol and alpha-amylase assessment in psychotherapeutic intervention studies: A systematic review.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">S0149-7634(18)30404-4</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neubiorev.2018.09.023</ELocationID>            <Abstract>                <AbstractText>Dysregulations of the hypothalamus-pituitary-adrenal (HPA) axis and the autonomic nervous system (ANS) as parts of the stress response system have been associated with development and maintenance of various mental disorders. It has been suggested that these alterations might normalize in the course of psychotherapy. We conducted a comprehensive review of psychotherapeutic intervention effects on HPA axis and ANS regulation in adult samples with mental disorders. We searched four databases for psychotherapeutic intervention studies with mentally ill patient samples, assessing cortisol and/or α-amylase before and after treatment. Study quality and confounder consideration within biomarker assessment were examined. Twenty-five studies were included. Psychotherapeutic interventions and biomarker assessment methodology varied substantially between studies. Accordingly, meta-analytical computations were deemed unfeasible. Study characteristics especially regarding cortisol and α-amylase assessment and analysis procedures were comprehensively reviewed. Study quality and biomarker confounder consideration ratings were mostly moderate to strong. Based on the results, we provide recommendations regarding intervention design and biomarker assessment methodology to increase comparability of psychotherapeutic treatment effects in future studies.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Laufer</LastName>                    <ForeName>Sebastian</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Clinical Psychological Intervention, Department of Education and Psychology, Freie Universität Berlin, Habelschwerdter Allee 45, 14195 Berlin, Germany. Electronic address: sebastian.laufer@fu-berlin.de.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Engel</LastName>                    <ForeName>Sinha</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Clinical Psychological Intervention, Department of Education and Psychology, Freie Universität Berlin, Habelschwerdter Allee 45, 14195 Berlin, Germany. Electronic address: s.engel@fu-berlin.de.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Knaevelsrud</LastName>                    <ForeName>Christine</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Clinical Psychological Intervention, Department of Education and Psychology, Freie Universität Berlin, Habelschwerdter Allee 45, 14195 Berlin, Germany. Electronic address: christine.knaevelsrud@fu-berlin.de.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Schumacher</LastName>                    <ForeName>Sarah</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Clinical Psychological Intervention, Department of Education and Psychology, Freie Universität Berlin, Habelschwerdter Allee 45, 14195 Berlin, Germany. Electronic address: sarah.schumacher@fu-berlin.de.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Neurosci Biobehav Rev</MedlineTA>            <NlmUniqueID>7806090</NlmUniqueID>            <ISSNLinking>0149-7634</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Cortisol</Keyword>            <Keyword MajorTopicYN="N">alpha-amylase</Keyword>            <Keyword MajorTopicYN="N">psychotherapy</Keyword>            <Keyword MajorTopicYN="N">stress response systems</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>25</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30316721</ArticleId>            <ArticleId IdType="pii">S0149-7634(18)30404-4</ArticleId>            <ArticleId IdType="doi">10.1016/j.neubiorev.2018.09.023</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30316630</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1876-2026</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>26</Day>                    </PubDate>                </JournalIssue>                <Title>Asian journal of psychiatry</Title>                <ISOAbbreviation>Asian J Psychiatr</ISOAbbreviation>            </Journal>            <ArticleTitle>Psychiatric comorbidity in persons with high-functioning autism spectrum disorders: Findings from a tertiary care neuropsychiatric hospital.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">S1876-2018(18)30328-9</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajp.2018.09.008</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The literature on co-morbid psychiatric illnesses in adults with high-functioning autism (HFA) spectrum disorder is sparse.</AbstractText>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To examine the nature of psychiatric comorbidity and treatment response in adults with HFA spectrum disorder.</AbstractText>                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Case records of subjects (age ≥17 years) who presented over a period of 16 years with primary psychiatric symptoms and further detected to have an HFA spectrum disorder, were analyzed. Autism spectrum disorders (ASD) along with near normal to normal verbal communication and general intelligence were considered as HFA spectrum disorders.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">33 subjects met the study criteria. Nine subjects (27%) were diagnosed to have an underlying Asperger's syndrome and the rest 24 (73%) had pervasive developmental disorders unspecified (PDD NOS). None of the subjects were diagnosed to be suffering from ASD prior to the visit to our hospital. Mean age at the time of psychiatric consultation was 22.7 (s.d=4.8) years and mean age at the onset of psychiatric comorbidity was 16.48 (s.d=4.4) years. Nearly half of the sample had more than one type of psychiatric illness. Most common lifetime psychiatric diagnosis was obsessive-compulsive disorder (OCD) (n=16, 48.4%). Bipolar disorder (BD) was the second most common type of psychiatric manifestation (n=13, 39.3%) followed by psychotic spectrum disorders (n=9, 27.2%). Overall response to treatment was minimal.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Individuals with HFA spectrum disorders suffer from multiple psychiatric comorbidities. OCD is the most common type of psychiatric comorbidity followed by BD and psychotic spectrum disorders. Comorbid psychiatric illnesses in individuals with HFA show poor response to treatment.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier B.V. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Nahar</LastName>                    <ForeName>Abhinav</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, 560029, India. Electronic address: abhinavnahar2002@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Thippeswamy</LastName>                    <ForeName>Harish</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, 560029, India. Electronic address: docharisht@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shanker Reddy</LastName>                    <ForeName>Mukku Shiva</ForeName>                    <Initials>MS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, 560029, India. Electronic address: shivakmc55@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kishore</LastName>                    <ForeName>M Thomas</ForeName>                    <Initials>MT</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Psychology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, 560029, India. Electronic address: mtkpsy@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chaturvedi</LastName>                    <ForeName>Santosh K</ForeName>                    <Initials>SK</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, 560029, India. Electronic address: skchatur@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>26</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Asian J Psychiatr</MedlineTA>            <NlmUniqueID>101517820</NlmUniqueID>            <ISSNLinking>1876-2018</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Asperger’s syndrome</Keyword>            <Keyword MajorTopicYN="N">High functioning autism</Keyword>            <Keyword MajorTopicYN="N">Obsessive-compulsive disorder</Keyword>            <Keyword MajorTopicYN="N">Schizophrenia</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>20</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30316630</ArticleId>            <ArticleId IdType="pii">S1876-2018(18)30328-9</ArticleId>            <ArticleId IdType="doi">10.1016/j.ajp.2018.09.008</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30316199</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>13</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1469-493X</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>10</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>13</Day>                    </PubDate>                </JournalIssue>                <Title>The Cochrane database of systematic reviews</Title>                <ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation>            </Journal>            <ArticleTitle>Information or education interventions for adult intensive care unit (ICU) patients and their carers.</ArticleTitle>            <Pagination>                <MedlinePgn>CD012471</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD012471.pub2</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">During intensive care unit (ICU) admission, patients and their carers experience physical and psychological stressors that may result in psychological conditions including anxiety, depression, and post-traumatic stress disorder (PTSD). Improving communication between healthcare professionals, patients, and their carers may alleviate these disorders. Communication may include information or educational interventions, in different formats, aiming to improve knowledge of the prognosis, treatment, or anticipated challenges after ICU discharge.</AbstractText>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the effects of information or education interventions for improving outcomes in adult ICU patients and their carers.</AbstractText>                <AbstractText Label="SEARCH METHODS" NlmCategory="METHODS">We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, CINAHL, and PsycINFO from database inception to 10 April 2017. We searched clinical trials registries and grey literature, and handsearched reference lists of included studies and related reviews.</AbstractText>                <AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">We included randomised controlled trials (RCTs), and planned to include quasi-RCTs, comparing information or education interventions presented to participants versus no information or education interventions, or comparing information or education interventions as part of a complex intervention versus a complex intervention without information or education. We included participants who were adult ICU patients, or their carers; these included relatives and non-relatives, including significant representatives of patients.</AbstractText>                <AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Two review authors independently assessed studies for inclusion, extracted data, assessed risk of bias, and applied GRADE criteria to assess certainty of the evidence.</AbstractText>                <AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">We included eight RCTs with 1157 patient participants and 943 carer participants. We found no quasi-RCTs. We identified seven studies that await classification, and three ongoing studies.Three studies designed an intervention targeted at patients, four at carers, and one at both patients and carers. Studies included varied information: standardised or tailored, presented once or several times, and that included verbal or written information, audio recordings, multimedia information, and interactive information packs. Five studies reported robust methods of randomisation and allocation concealment. We noted high attrition rates in five studies. It was not feasible to blind participants, and we rated all studies as at high risk of performance bias, and at unclear risk of detection bias because most outcomes required self reporting.We attempted to pool data statistically, however this was not always possible due to high levels of heterogeneity. We calculated mean differences (MDs) using data reported from individual study authors where possible, and narratively synthesised the results. We reported the following two comparisons.Information or education intervention versus no information or education intervention (4 studies)For patient anxiety, we did not pool data from three studies (332 participants) owing to unexplained substantial statistical heterogeneity and possible clinical or methodological differences between studies. One study reported less anxiety when an intervention was used (MD -3.20, 95% confidence interval (CI) -3.38 to -3.02), and two studies reported little or no difference between groups (MD -0.40, 95% CI -4.75 to 3.95; MD -1.00, 95% CI -2.94 to 0.94). Similarly, for patient depression, we did not pool data from two studies (160 patient participants). These studies reported less depression when an information or education intervention was used (MD -2.90, 95% CI -4.00 to -1.80; MD -1.27, 95% CI -1.47 to -1.07). However, it is uncertain whether information or education interventions reduce patient anxiety or depression due to very low-certainty evidence.It is uncertain whether information or education interventions improve health-related quality of life due to very low-certainty evidence from one study reporting little or no difference between intervention groups (MD -1.30, 95% CI -4.99 to 2.39; 143 patient participants). No study reported adverse effects, knowledge acquisition, PTSD severity, or patient or carer satisfaction.We used the GRADE approach and downgraded certainty of the evidence owing to study limitations, inconsistencies between results, and limited data from few small studies.Information or education intervention as part of a complex intervention versus a complex intervention without information or education (4 studies)One study (three comparison groups; 38 participants) reported little or no difference between groups in patient anxiety (tailored information pack versus control: MD 0.09, 95% CI -3.29 to 3.47; standardised general ICU information versus control: MD -0.25, 95% CI -4.34 to 3.84), and little or no difference in patient depression (tailored information pack versus control: MD -1.26, 95% CI -4.48 to 1.96; standardised general ICU information versus control: MD -1.47, 95% CI -6.37 to 3.43). It is uncertain whether information or education interventions as part of a complex intervention reduce patient anxiety and depression due to very low-certainty evidence.One study (175 carer participants) reported fewer carer participants with poor comprehension among those given information (risk ratio 0.28, 95% CI 0.15 to 0.53), but again this finding is uncertain due to very low-certainty evidence.Two studies (487 carer participants) reported little or no difference in carer satisfaction; it is uncertain whether information or education interventions as part of a complex intervention increase carer satisfaction due to very low-certainty evidence. Adverse effects were reported in only one study: one participant withdrew because of deterioration in mental health on completion of anxiety and depression questionnaires, but the study authors did not report whether this participant was from the intervention or comparison group.We downgraded certainty of the evidence owing to study limitations, and limited data from few small studies.No studies reported severity of PTSD, or health-related quality of life.</AbstractText>                <AbstractText Label="AUTHORS' CONCLUSIONS" NlmCategory="CONCLUSIONS">We are uncertain of the effects of information or education interventions given to adult ICU patients and their carers, as the evidence in all cases was of very low certainty, and our confidence in the evidence was limited. Ongoing studies may contribute more data and introduce more certainty when incorporated into future updates of the review.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Lewis</LastName>                    <ForeName>Sharon R</ForeName>                    <Initials>SR</Initials>                    <AffiliationInfo>                        <Affiliation>Lancaster Patient Safety Research Unit, Royal Lancaster Infirmary, Pointer Court 1, Ashton Road, Lancaster, UK, LA1 4RP.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pritchard</LastName>                    <ForeName>Michael W</ForeName>                    <Initials>MW</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Schofield-Robinson</LastName>                    <ForeName>Oliver J</ForeName>                    <Initials>OJ</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Evans</LastName>                    <ForeName>David Jw</ForeName>                    <Initials>DJ</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Alderson</LastName>                    <ForeName>Phil</ForeName>                    <Initials>P</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Smith</LastName>                    <ForeName>Andrew F</ForeName>                    <Initials>AF</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Cochrane Database Syst Rev</MedlineTA>            <NlmUniqueID>100909747</NlmUniqueID>            <ISSNLinking>1361-6137</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30316199</ArticleId>            <ArticleId IdType="doi">10.1002/14651858.CD012471.pub2</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30315433</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1535-1645</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>20</Volume>                    <Issue>12</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>13</Day>                    </PubDate>                </JournalIssue>                <Title>Current psychiatry reports</Title>                <ISOAbbreviation>Curr Psychiatry Rep</ISOAbbreviation>            </Journal>            <ArticleTitle>Update on Assisted Outpatient Treatment.</ArticleTitle>            <Pagination>                <MedlinePgn>112</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11920-018-0982-z</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Assisted outpatient treatment (AOT) is an outpatient court-ordered treatment for people with severe mental illness (SMI) whose care needs are often unmet in the community due, in part, to treatment non-adherence. AOT is controversial, and the goal of this review is to provide an update on recent research, the status of AOT in the United States, and future directions for research and implementation.</AbstractText>                <AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Several recent studies have demonstrated that it is not just a lack of access to appropriately intensive care that prevents some individuals with SMI from engaging in and benefiting from treatment and that AOT can improve engagement and patient outcomes over and above the provision of care. The future of AOT in the United States is still somewhat uncertain and will largely depend on the effectiveness and sustainability of the SAMHSA AOT grant programs. Future research efforts should investigate the conditions under which and for whom AOT can be most effective, to help avoid poor outcomes for this vulnerable population.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Cripps</LastName>                    <ForeName>Stephanie N</ForeName>                    <Initials>SN</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, 27710, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Swartz</LastName>                    <ForeName>Marvin S</ForeName>                    <Initials>MS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, 27710, USA. marvin.swartz@duke.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Curr Psychiatry Rep</MedlineTA>            <NlmUniqueID>100888960</NlmUniqueID>            <ISSNLinking>1523-3812</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Can J Psychiatry. 2017 Feb;62(2):102-108</RefSource>                <PMID Version="1">27777274</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adm Policy Ment Health. 2018 Jul;45(4):565-574</RefSource>                <PMID Version="1">29285729</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Ment Health Policy Econ. 2000 Jun 1;3(2):97-109</RefSource>                <PMID Version="1">11967443</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychiatr Serv. 2001 Mar;52(3):330-6</RefSource>                <PMID Version="1">11239100</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Soc Sci Med. 2017 Feb;175:152-160</RefSource>                <PMID Version="1">28092756</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychiatr Serv. 2016 Jun 1;67(6):630-5</RefSource>                <PMID Version="1">26828396</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychiatr Serv. 2014 Jun 1;65(6):808-11</RefSource>                <PMID Version="1">24881685</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2013 May 11;381(9878):1627-33</RefSource>                <PMID Version="1">23537605</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychiatr Serv. 2017 Feb 1;68(2):189-191</RefSource>                <PMID Version="1">27745539</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Can J Psychiatry. 2016 Jan;61(1):15-24</RefSource>                <PMID Version="1">27582449</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Soc Psychiatry Psychiatr Epidemiol. 2018 Jun;53(6):597-606</RefSource>                <PMID Version="1">29626237</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Psychiatry. 1999 Dec;156(12):1968-75</RefSource>                <PMID Version="1">10588412</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Assisted outpatient treatment</Keyword>            <Keyword MajorTopicYN="N">Community treatment orders</Keyword>            <Keyword MajorTopicYN="N">Involuntary outpatient commitment</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30315433</ArticleId>            <ArticleId IdType="doi">10.1007/s11920-018-0982-z</ArticleId>            <ArticleId IdType="pii">10.1007/s11920-018-0982-z</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30314604</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>13</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2162-5514</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>141</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>International review of neurobiology</Title>                <ISOAbbreviation>Int. Rev. Neurobiol.</ISOAbbreviation>            </Journal>            <ArticleTitle>Molecular Imaging of Addictive Behavior in Idiopathic Parkinson's Disease.</ArticleTitle>            <Pagination>                <MedlinePgn>365-404</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0074-7742(18)30059-X</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/bs.irn.2018.07.030</ELocationID>            <Abstract>                <AbstractText>Parkinson's disease (PD) is commonly associated with motor symptoms, however cognitive and neurobehavioral complications are increasingly recognized and contribute to long-term disability. Dopamine replacement therapy is effective for motor symptoms, but can also lead to motor side-effects and addictive behavior such as impulse control disorders. Molecular imaging is advancing our knowledge of the mechanisms involved in the development of behavioral addictions. This chapter will discuss potential risk factors and associations with the development of addictive behavior in PD including the role of dopaminergic medication and genetic predisposition. We further will describe the common neurobiology and similarities of addictive behavior in PD to addiction, particularly the neuroanatomy of reward processing and its alteration in substance and behavioral addictions. Finally, we will discuss molecular imaging approaches which are helping to delineate the structure as well as the dynamic interactions between different components involving neurotransmitters, transporters, and receptors.</AbstractText>                <CopyrightInformation>© 2018 Elsevier Inc. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Ghadery</LastName>                    <ForeName>Christine</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Morton and Gloria Shulman Movement Disorder Unit &amp; E.J. Safra Parkinson Disease Program, Neurology Division, Department of Medicine, Toronto Western Hospital, UHN, University of Toronto, Ontario, Canada; Division of Brain, Imaging and Behavior-Systems Neuroscience, Krembil Research Institute, UHN, University of Toronto, Ontario, Canada; Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada. Electronic address: christine.ghadery@camhpet.ca.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Valli</LastName>                    <ForeName>Mikaeel</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mihaescu</LastName>                    <ForeName>Alexander</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Strafella</LastName>                    <ForeName>Rebecca</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Navalpotro</LastName>                    <ForeName>Irene</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Morton and Gloria Shulman Movement Disorder Unit &amp; E.J. Safra Parkinson Disease Program, Neurology Division, Department of Medicine, Toronto Western Hospital, UHN, University of Toronto, Ontario, Canada; Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Jinhee</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Strafella</LastName>                    <ForeName>Antonio P</ForeName>                    <Initials>AP</Initials>                    <AffiliationInfo>                        <Affiliation>Morton and Gloria Shulman Movement Disorder Unit &amp; E.J. Safra Parkinson Disease Program, Neurology Division, Department of Medicine, Toronto Western Hospital, UHN, University of Toronto, Ontario, Canada; Division of Brain, Imaging and Behavior-Systems Neuroscience, Krembil Research Institute, UHN, University of Toronto, Ontario, Canada; Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada. Electronic address: antonio.strafella@uhn.ca.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>13</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Int Rev Neurobiol</MedlineTA>            <NlmUniqueID>0374740</NlmUniqueID>            <ISSNLinking>0074-7742</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Addictions</Keyword>            <Keyword MajorTopicYN="N">Addictive behavior</Keyword>            <Keyword MajorTopicYN="N">Dopamine dysregulation syndrome</Keyword>            <Keyword MajorTopicYN="N">Dopamine replacement therapy</Keyword>            <Keyword MajorTopicYN="N">Impulse control disorders</Keyword>            <Keyword MajorTopicYN="N">Molecular imaging</Keyword>            <Keyword MajorTopicYN="N">Parkinson's disease</Keyword>            <Keyword MajorTopicYN="N">The addiction circuitry</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30314604</ArticleId>            <ArticleId IdType="pii">S0074-7742(18)30059-X</ArticleId>            <ArticleId IdType="doi">10.1016/bs.irn.2018.07.030</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30314515</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>13</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1742-2094</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>15</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>12</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of neuroinflammation</Title>                <ISOAbbreviation>J Neuroinflammation</ISOAbbreviation>            </Journal>            <ArticleTitle>Adult neurogenic deficits in HIV-1 Tg26 transgenic mice.</ArticleTitle>            <Pagination>                <MedlinePgn>287</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12974-018-1322-2</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Even in the antiretroviral treatment (ART) era, HIV-1-infected patients suffer from milder forms of HIV-1-associated neurocognitive disorders (HAND). While the viral proteins Tat and gp120 have been shown to individually inhibit the proliferation and neural differentiation of neural stem cells (NSCs), no studies have characterized the effects of all the combined viral proteins on adult neurogenesis.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">The HIV-1 Tg26 transgenic mouse model was used due to its clinical relevance to ART-controlled HIV-1-infected patients who lack active viral replication but suffer from continuous stress from the viral proteins. Quantitative RT-PCR analysis was performed to validate the expression of viral genes in the neurogenic zones. In vitro stemness and lineage differentiation assays were performed in cultured NSCs from HIV-1 Tg26 transgenic mice and their wild-type littermates. Hippocampal neurogenic lineage analysis was performed to determine potential changes in initial and late differentiation of NSCs in the subgranular zone (SGZ). Finally, fluorescent retroviral labeling of mature dentate granule neurons was performed to assess dendritic complexity and dendritic spine densities.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Varying copy numbers of partial gag (p17), tat (unspliced and spliced variants), env (gp120), vpu, and nef transcripts were detected in the neurogenic zones of Tg26 mice. Significantly fewer primary neurospheres and a higher percentage of larger sized primary neurospheres were generated from Tg26 NSCs than from littermated wild-type mouse NSCs, implying that Tg26 mouse NSCs exhibit deficits in initial differentiation. In vitro differentiation assays revealed that Tg26 mouse NSCs have reduced neuronal differentiation and increased astrocytic differentiation. In the SGZs of Tg26 mice, significantly higher amounts of quiescent NSCs, as well as significantly lower levels of active NSCs, proliferating neural progenitor cells, and neuroblasts, were observed. Finally, newborn mature granule neurons in the dentate gyri of Tg26 mice had deficiencies in dendritic arborization, dendritic length, and dendritic spine density.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Both in vitro and in vivo studies demonstrate that HIV-1 Tg26 mice have early- and late-stage neurogenesis deficits, which could possibly contribute to the progression of HAND. Future therapies should be targeting this process to ameliorate, if not eliminate HAND-like symptoms in HIV-1-infected patients.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Putatunda</LastName>                    <ForeName>Raj</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, 3500 N Broad Street, Philadelphia, PA, 19140, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, 3500 N Broad Street, Philadelphia, PA, 19140, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Yonggang</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, 3500 N Broad Street, Philadelphia, PA, 19140, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, 3500 N Broad Street, Philadelphia, PA, 19140, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Fang</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, 3500 N Broad Street, Philadelphia, PA, 19140, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, 3500 N Broad Street, Philadelphia, PA, 19140, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Xiao-Feng</ForeName>                    <Initials>XF</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, 3500 N Broad Street, Philadelphia, PA, 19140, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology, Temple University Lewis Katz School of Medicine, 3500 N Broad Street, Philadelphia, PA, 19140, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Barbe</LastName>                    <ForeName>Mary F</ForeName>                    <Initials>MF</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Anatomy and Cell Biology, Temple University Lewis Katz School of Medicine, 3500 N Broad Street, Philadelphia, PA, 19140, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hu</LastName>                    <ForeName>Wenhui</ForeName>                    <Initials>W</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8152-6116</Identifier>                    <AffiliationInfo>                        <Affiliation>Center for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, 3500 N Broad Street, Philadelphia, PA, 19140, USA. whu@temple.edu.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, 3500 N Broad Street, Philadelphia, PA, 19140, USA. whu@temple.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>DK075964</GrantID>                    <Agency>National Institute of Diabetes and Digestive and Kidney Diseases</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>T32MH079785</GrantID>                    <Agency>National Institute of Mental Health</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>J Neuroinflammation</MedlineTA>            <NlmUniqueID>101222974</NlmUniqueID>            <ISSNLinking>1742-2094</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Dendritic spine density</Keyword>            <Keyword MajorTopicYN="N">Differentiation</Keyword>            <Keyword MajorTopicYN="N">HAND</Keyword>            <Keyword MajorTopicYN="N">HIV-1</Keyword>            <Keyword MajorTopicYN="N">Neural stem cells</Keyword>            <Keyword MajorTopicYN="N">Neurogenesis</Keyword>            <Keyword MajorTopicYN="N">Stemness</Keyword>            <Keyword MajorTopicYN="N">Tg26 mouse</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30314515</ArticleId>            <ArticleId IdType="doi">10.1186/s12974-018-1322-2</ArticleId>            <ArticleId IdType="pii">10.1186/s12974-018-1322-2</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30312914</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1879-1379</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>107</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>01</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of psychiatric research</Title>                <ISOAbbreviation>J Psychiatr Res</ISOAbbreviation>            </Journal>            <ArticleTitle>Prospective prediction of first lifetime onset of suicidal ideation in a national study of substance users.</ArticleTitle>            <Pagination>                <MedlinePgn>28-33</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0022-3956(18)30779-9</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2018.09.019</ELocationID>            <Abstract>                <AbstractText>Suicide rates have increased over the past several decades. Prior research has evaluated risk factors for suicidal behavior, but much of this work does not adequately differentiate between risk factors for suicidal ideation (SI) and suicide attempts, nor does it differentiate between first-onset SI and recurrent ideation. This study seeks to identify risk factors for first-onset SI among a high-risk group: individuals receiving treatment for substance use disorders. Data were drawn from the National Treatment Improvement Evaluation Study, a prospective study examining the impact of addiction treatment programs. Patients with no lifetime history of suicide attempts or ideation (n = 2560) were assessed at baseline and one year later for prospectively-occurring SI. Sociodemographic variables, mental health indices, interpersonal factors, and substance use severity indicators were evaluated as prospective predictors of first-onset SI in linear regression models. Current mental health problems (OR = 1.54, 95% CI = 1.19-2.01), current substance use problems (OR = 1.33, 95% CI = 1.04-1.70), and difficulty accessing treatment for substance use problems (OR = 1.90, 95% CI = 1.16-3.11) emerged as significant predictors of first-onset SI in a multivariate analysis, suggesting that individuals with current mental health or substance use related symptoms are among the most at risk for developing SI. Difficulty obtaining treatment remained significant, highlighting the importance of treatment accessibility. Future clinical work and research would benefit by addressing these issues, potentially by focusing on mental health treatment in substance abuse programs and evaluating barriers to treatment.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Walsh</LastName>                    <ForeName>Rachel F L</ForeName>                    <Initials>RFL</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Bradley Hospital, 1011 Veterans Memorial Parkway, East Providence, RI, 02915, United States. Electronic address: rachel_walsh@brown.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sheehan</LastName>                    <ForeName>Ana E</ForeName>                    <Initials>AE</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Bradley Hospital, 1011 Veterans Memorial Parkway, East Providence, RI, 02915, United States. Electronic address: ana_sheehan@brown.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Richard T</ForeName>                    <Initials>RT</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Bradley Hospital, 1011 Veterans Memorial Parkway, East Providence, RI, 02915, United States. Electronic address: rtliupsych@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>01</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>J Psychiatr Res</MedlineTA>            <NlmUniqueID>0376331</NlmUniqueID>            <ISSNLinking>0022-3956</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Longitudinal study</Keyword>            <Keyword MajorTopicYN="N">Substance use</Keyword>            <Keyword MajorTopicYN="N">Suicidal ideation</Keyword>            <Keyword MajorTopicYN="N">Suicide</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30312914</ArticleId>            <ArticleId IdType="pii">S0022-3956(18)30779-9</ArticleId>            <ArticleId IdType="doi">10.1016/j.jpsychires.2018.09.019</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30312634</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1878-4216</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>09</Day>                    </PubDate>                </JournalIssue>                <Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title>                <ISOAbbreviation>Prog. Neuropsychopharmacol. Biol. Psychiatry</ISOAbbreviation>            </Journal>            <ArticleTitle>The dynamic Duo: Combining noninvasive brain stimulation with cognitive interventions.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">S0278-5846(18)30251-3</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pnpbp.2018.10.006</ELocationID>            <Abstract>                <AbstractText>Pharmacotherapy, psychotherapy, and non-invasive brain stimulation (NIBS)<sup>1</sup> each show efficacy in the treatment of psychiatric disorders; however, more efficacious interventions are needed as reflected by an overall unmet need in mental health care. While each modality has typically been studied and developed as a monotherapy, in practice they are typically used in combination. Research has begun to emerge studying the potential synergistic actions of multi-modal, combination therapies. For example, NIBS combined with rehabilitation strategies have demonstrated some success for speech and motor rehabilitation in stroke patients. In this review we present evidence suggesting that combining NIBS with targeted, cognitive interventions offers a potentially powerful new approach to treating neuropsychiatric disorders. Here we focus on NIBS studies using transcranial direct current stimulation (tDCS)<sup>2</sup> and transcranial magnetic stimulation (TMS)<sup>3</sup> given that these modalities are relatively safe, noninvasive, and can be performed simultaneously with neurocognitive interventions. We review the concept of &quot;state dependent&quot; effects of NIBS and highlight how simultaneous or sequential cognitive interventions could help optimize NIBS therapy by providing further control of ongoing neural activity in targeted neural networks. This review spans a range of neuropsychiatric disorders including major depressive disorder, schizophrenia, generalized anxiety, and autism. For each disorder, we emphasize neuroanatomical circuitry that could be engaged with combination therapy and critically discuss the literature that has begun to emerge. Finally, we present possible underlying mechanisms and propose future research strategies that may further refine the potential of combination therapies.</AbstractText>                <CopyrightInformation>Copyright © 2018. Published by Elsevier Inc.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Sathappan</LastName>                    <ForeName>Aakash V</ForeName>                    <Initials>AV</Initials>                    <AffiliationInfo>                        <Affiliation>Noninvasive Neuromodulation Unit, Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Luber</LastName>                    <ForeName>Bruce M</ForeName>                    <Initials>BM</Initials>                    <AffiliationInfo>                        <Affiliation>Noninvasive Neuromodulation Unit, Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. Electronic address: Bruce.luber@nih.gov.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lisanby</LastName>                    <ForeName>Sarah H</ForeName>                    <Initials>SH</Initials>                    <AffiliationInfo>                        <Affiliation>Noninvasive Neuromodulation Unit, Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>09</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA>            <NlmUniqueID>8211617</NlmUniqueID>            <ISSNLinking>0278-5846</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Cognitive interventions</Keyword>            <Keyword MajorTopicYN="N">Non-invasive brain stimulation</Keyword>            <Keyword MajorTopicYN="N">Synergistic mechanisms</Keyword>            <Keyword MajorTopicYN="N">Transcranial direct current stimulation</Keyword>            <Keyword MajorTopicYN="N">Transcranial magnetic stimulation</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>10</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30312634</ArticleId>            <ArticleId IdType="pii">S0278-5846(18)30251-3</ArticleId>            <ArticleId IdType="doi">10.1016/j.pnpbp.2018.10.006</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30312490</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1098-108X</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>12</Day>                    </PubDate>                </JournalIssue>                <Title>The International journal of eating disorders</Title>                <ISOAbbreviation>Int J Eat Disord</ISOAbbreviation>            </Journal>            <ArticleTitle>The Athletes' relationships with training scale (ART): A self-report measure of unhealthy training behaviors associated with eating disorders.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/eat.22960</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Several studies indicate that eating-disorder (ED) psychopathology is elevated in athletes compared to non-athletes. The assessment of excessive exercise among athletes is a challenge because, compared to non-athletes, athletes are required to train at higher intensities and for longer periods of time. However, individuals participating in competitive sports are still susceptible to unhealthy physical-activity patterns. Most ED assessments were developed and normed in non-athlete samples and, therefore, do not capture the nuances of athletes' training experiences. The purpose of the current study was to develop and validate a clinically useful, self-report measure of unhealthy training behaviors and beliefs in athletes, the Athletes' Relationships with Training Scale (ART).</AbstractText>                <AbstractText Label="METHOD" NlmCategory="METHODS">The initial item pool was administered to N = 267 women collegiate athletes who were participating in an ED prevention program study and N = 65 women athletes who were in ED treatment.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Factor analyses indicated the ART had a four-factor structure. Factorial and construct validity of the ART were demonstrated. ART scores significantly predicted health care utilization and differed between athletes with an ED versus athletes without an ED. For athletes in ED treatment, ART scores significantly decreased from treatment admission to discharge.</AbstractText>                <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The ART showed evidence of strong psychometric properties and clinical utility. The ART could be helpful for clinicians and athletic trainers to help gauge whether athletes are engaging in unhealthy training practices that may warrant clinical attention and for tracking clinical outcomes in athletes with EDs who are receiving treatment.</AbstractText>                <CopyrightInformation>© 2018 The Authors. International Journal of Eating Disorders published by Wiley Periodicals, Inc.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Chapa</LastName>                    <ForeName>Danielle A N</ForeName>                    <Initials>DAN</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-6946-4194</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Kansas, Lawrence, Kansas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hagan</LastName>                    <ForeName>Kelsey E</ForeName>                    <Initials>KE</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5723-3591</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Kansas, Lawrence, Kansas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Forbush</LastName>                    <ForeName>Kelsie T</ForeName>                    <Initials>KT</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-5900-4204</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Kansas, Lawrence, Kansas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Perko</LastName>                    <ForeName>Victoria L</ForeName>                    <Initials>VL</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Kansas, Lawrence, Kansas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sorokina</LastName>                    <ForeName>Daria A</ForeName>                    <Initials>DA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Educational Psychology, University of Kansas, Lawrence, Kansas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Alasmar</LastName>                    <ForeName>Ahmed Y</ForeName>                    <Initials>AY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Kansas, Lawrence, Kansas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Becker</LastName>                    <ForeName>Carolyn B</ForeName>                    <Initials>CB</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-6369-2185</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, Trinity University, San Antonio, Texas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sherman</LastName>                    <ForeName>Roberta T</ForeName>                    <Initials>RT</Initials>                    <AffiliationInfo>                        <Affiliation>Bloomington, IN.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Thompson</LastName>                    <ForeName>Ron A</ForeName>                    <Initials>RA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Intercollegiate Athletics, Indiana University-Bloomington, Bloomington, Indiana.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Farrell</LastName>                    <ForeName>Jennifer G</ForeName>                    <Initials>JG</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Kinesiology, University of North Carolina, Greensboro, North Carolina.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Stewart</LastName>                    <ForeName>Tiffany M</ForeName>                    <Initials>TM</Initials>                    <AffiliationInfo>                        <Affiliation>Pennington Biomedical Research Center, Baton Rouge, Louisiana.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>1 RO1 MH094448-01</GrantID>                    <Agency>National Institutes of Mental Health (NIMH)</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Int J Eat Disord</MedlineTA>            <NlmUniqueID>8111226</NlmUniqueID>            <ISSNLinking>0276-3478</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">assessment</Keyword>            <Keyword MajorTopicYN="N">eating disorders</Keyword>            <Keyword MajorTopicYN="N">excessive exercise</Keyword>            <Keyword MajorTopicYN="N">scale development</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>29</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30312490</ArticleId>            <ArticleId IdType="doi">10.1002/eat.22960</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30312485</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1098-108X</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>12</Day>                    </PubDate>                </JournalIssue>                <Title>The International journal of eating disorders</Title>                <ISOAbbreviation>Int J Eat Disord</ISOAbbreviation>            </Journal>            <ArticleTitle>Development of the Pica, ARFID, and Rumination Disorder Interview, a multi-informant, semi-structured interview of feeding disorders across the lifespan: A pilot study for ages 10-22.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/eat.22958</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Avoidant/restrictive food intake disorder (ARFID), pica, and rumination disorder (RD) were added to the revised DSM-5 Feeding and Eating Disorders chapter in 2013. We developed a structured interview-the Pica, ARFID, and Rumination Disorder Interview (PARDI)-to assess the presence and severity of these diagnoses for evaluation and treatment planning in clinical and research settings. Here, we describe the development of the PARDI and provide a preliminary report on feasibility, acceptability, reliability, and validity in relation to ARFID.</AbstractText>                <AbstractText Label="METHOD" NlmCategory="METHODS">We created an initial item pool from existing measures of similar constructs and clinical experience. The PARDI includes items assessing the level of endorsement and overall severity of common ARFID features organized into profiles (i.e., sensory sensitivity, lack of interest in eating, and fear of aversive consequences) and algorithms for diagnosing ARFID, pica, and RD. We collected initial psychometric data from participants (10-22 years) with ARFID (n = 39), clinically significant avoidant/restrictive eating (n = 8), and healthy controls (n = 10).</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">On average, the PARDI took 39 min to complete and was acceptable to participants. All subscales achieved internal consistency greater ≥0.77, and inter-rater reliability for the ARFID diagnosis was moderate (κ = 0.75). Individuals with ARFID scored significantly higher than healthy controls on ARFID severity and ARFID profiles.</AbstractText>                <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The PARDI appears acceptable to respondents and preliminary evidence of reliability and validity has been demonstrated in an initial sample. Larger-scale validation studies are currently underway. The PARDI is freely available to clinicians and researchers.</AbstractText>                <CopyrightInformation>© 2018 Wiley Periodicals, Inc.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Bryant-Waugh</LastName>                    <ForeName>Rachel</ForeName>                    <Initials>R</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-7449-6059</Identifier>                    <AffiliationInfo>                        <Affiliation>Feeding Disorders Team, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Micali</LastName>                    <ForeName>Nadia</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Faculty of Medicine, University of Geneva, Geneva, Switzerland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cooke</LastName>                    <ForeName>Lucy</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Feeding Disorders Team, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lawson</LastName>                    <ForeName>Elizabeth A</ForeName>                    <Initials>EA</Initials>                    <AffiliationInfo>                        <Affiliation>Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medicine, Harvard Medical School, Boston, Massachusetts.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Eddy</LastName>                    <ForeName>Kamryn T</ForeName>                    <Initials>KT</Initials>                    <AffiliationInfo>                        <Affiliation>Eating Disorders Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Thomas</LastName>                    <ForeName>Jennifer J</ForeName>                    <Initials>JJ</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-2601-581X</Identifier>                    <AffiliationInfo>                        <Affiliation>Eating Disorders Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <Agency>American Psychological Foundation</Agency>                    <Country/>                </Grant>                <Grant>                    <Agency>Hilda and Preston Davis Foundation</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>1R01MH108595</GrantID>                    <Agency>National Institute of Mental Health</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Int J Eat Disord</MedlineTA>            <NlmUniqueID>8111226</NlmUniqueID>            <ISSNLinking>0276-3478</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">ARFID</Keyword>            <Keyword MajorTopicYN="N">assessment</Keyword>            <Keyword MajorTopicYN="N">avoidant/restrictive food intake disorder</Keyword>            <Keyword MajorTopicYN="N">clinical interview</Keyword>            <Keyword MajorTopicYN="N">pica</Keyword>            <Keyword MajorTopicYN="N">rumination disorder</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>15</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30312485</ArticleId>            <ArticleId IdType="doi">10.1002/eat.22958</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30312108</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1557-8992</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>12</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of child and adolescent psychopharmacology</Title>                <ISOAbbreviation>J Child Adolesc Psychopharmacol</ISOAbbreviation>            </Journal>            <ArticleTitle>A Focused Review on the Treatment of Pediatric Patients with Atypical Antipsychotics.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1089/cap.2018.0037</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The use of atypical antipsychotic medications in pediatric patients has become more prevalent in recent years. The purpose of this review is to provide a clinically relevant update of recent selected key publications regarding the use of atypical antipsychotics in this population.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Studies reviewed included randomized, double-blind, placebo-controlled medication trials conducted within the past 5 years. A PubMed search was conducted for each of the 11 second-generation antipsychotic medications currently approved by the Food and Drug Administration for use in the United States: clozapine, risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, paliperidone, asenapine, iloperidone, lurasidone, and cariprazine. Trials published in English with subjects 18 years of age and younger were included in this review. Additional studies, chosen for their significance to clinical practice, were also included at the discretion of the authors.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">This review demonstrates that more empiric data are available regarding both the acute efficacy and, to a lesser extent, the longer-term efficacy and tolerability for several of the considered antipsychotic medications. The clinical conditions for which these medications have been studied include schizophrenia, bipolar disorder, Tourette's disorder, and autism spectrum disorder. They have also been used as an adjunctive treatment for disruptive behavior disorders with aggression, which have not responded to treatment with stimulants.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Evidence regarding the efficacy and tolerability of antipsychotic medications for mental health disorders in children and adolescents has expanded exponentially in recent years. However, more information is needed so that evidence-based comparisons between medications can be made. In the future, data enabling the selection of medications based upon individual patient characteristics could potentially lead to greater efficacy and efficiency in treating what are frequently debilitating medical conditions. Maladaptive aggression in children, often treated with antipsychotics, is one such area in which there is a dearth of actual information available to the clinician. It is to be hoped that additional, longer-term studies of these medications will further inform evidence-based practice in clinical settings.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Lee</LastName>                    <ForeName>Esther S</ForeName>                    <Initials>ES</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins Hospital School of Medicine , Baltimore, Maryland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vidal</LastName>                    <ForeName>Carol</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins Hospital School of Medicine , Baltimore, Maryland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Findling</LastName>                    <ForeName>Robert L</ForeName>                    <Initials>RL</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins Hospital School of Medicine , Baltimore, Maryland.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Child Adolesc Psychopharmacol</MedlineTA>            <NlmUniqueID>9105358</NlmUniqueID>            <ISSNLinking>1044-5463</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">antipsychotics</Keyword>            <Keyword MajorTopicYN="N">attention-deficit/hyperactivity disorder</Keyword>            <Keyword MajorTopicYN="N">children and adolescents</Keyword>            <Keyword MajorTopicYN="N">mood disorders</Keyword>            <Keyword MajorTopicYN="N">psychopharmacology</Keyword>            <Keyword MajorTopicYN="N">psychotic disorders</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30312108</ArticleId>            <ArticleId IdType="doi">10.1089/cap.2018.0037</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30311416</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1751-7893</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>12</Day>                    </PubDate>                </JournalIssue>                <Title>Early intervention in psychiatry</Title>                <ISOAbbreviation>Early Interv Psychiatry</ISOAbbreviation>            </Journal>            <ArticleTitle>Understanding the direct and indirect costs of a first episode of psychosis program: Insights from PAFIP of Cantabria, Spain, during the first year of intervention.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/eip.12752</ELocationID>            <Abstract>                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">Early intervention psychiatric services for patients with psychosis aim to limit the most damaging outcomes and reduce the patient's risk of social drift, decreasing illness severity and thus containing healthcare costs. There is a scarcity of studies that focus on first-episode psychosis (FEP), and those few that have been published only looked at direct health costs, but not at indirect costs, which make up the bulk of the budget. Our study aims to explore the short-term (1-year follow-up) economic cost of a FEP Program, including both direct and indirect costs.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Data were collected retrospectively from the clinical records of 157 patients included in the Programa Atención Fases Iniciales de Psicosis, from Marqués de Valdecilla University Hospital, Santander. Our data collection sheet collated data from direct and indirect costs associated with the illness. Data were also extracted from the Cantabria Health Service Records. STATA 15.0 was used for statistical analysis.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">On average, the total costs during the first year were €48 353.51 per patient, with direct healthcare costs being €13 729.47 (28.39%), direct non-medical costs €108.6 (0.22%), and indirect costs €34 515.44 (71.39%). We found that hospitalization costs were higher in males (p = 0.081) and in cannabis users (p = 0.032). The number of relapses increased both, hospitalization and treatment costs (r = 0.40 p = 0.000; r = 0.24 p = 0.067, respectively).</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Intensive Early Intervention in Psychosis Services may result in cost savings by decreasing hospitalization, premature mortality, disability, unemployment, and legal problems; however, the first year after diagnosis would represent the one with the highest costs.</AbstractText>                <CopyrightInformation>© 2018 John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Mayoral-van Son</LastName>                    <ForeName>Jacqueline</ForeName>                    <Initials>J</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0033-7132</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Sierrallana Hospital, Torrelavega, Cantabria, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>School of Medicine, University of Cantabria, Santander, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Instituto de Investigación Sanitaria Valdecilla. IDIVAL, Santander, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Centro de Investigación Biomédica en Red en Salud Mental CIBERSAM, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Juncal-Ruiz</LastName>                    <ForeName>María</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Sierrallana Hospital, Torrelavega, Cantabria, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>School of Medicine, University of Cantabria, Santander, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Instituto de Investigación Sanitaria Valdecilla. IDIVAL, Santander, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Centro de Investigación Biomédica en Red en Salud Mental CIBERSAM, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ortiz-García de la Foz</LastName>                    <ForeName>Víctor</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Instituto de Investigación Sanitaria Valdecilla. IDIVAL, Santander, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cantarero-Prieto</LastName>                    <ForeName>David</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Economics, University of Cantabria, GIECONPSALUD, Santander, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Blázquez-Fenández</LastName>                    <ForeName>Carla</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Economics, University of Cantabria, GIECONPSALUD, Santander, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Paz-Zulueta</LastName>                    <ForeName>María</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Nursing School, University of Cantabria, IDIVAL, GI Derecho Sanitario y Bioética. GRIDES. Cantabria, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Paras</LastName>                    <ForeName>Paula</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Nursing School, University of Cantabria, IDIVAL, GI Derecho Sanitario y Bioética. GRIDES. Cantabria, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ayuso-Mateos</LastName>                    <ForeName>José L</ForeName>                    <Initials>JL</Initials>                    <AffiliationInfo>                        <Affiliation>Centro de Investigación Biomédica en Red en Salud Mental CIBERSAM, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department Psychiatry, University Hospital La Princesa, Autonomous University of Madrid, Madrid, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Crespo-Facorro</LastName>                    <ForeName>Benedicto</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>School of Medicine, University of Cantabria, Santander, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Instituto de Investigación Sanitaria Valdecilla. IDIVAL, Santander, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Centro de Investigación Biomédica en Red en Salud Mental CIBERSAM, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, University Hospital Marqués Valdecilla, Santander, Spain.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>API07/011</GrantID>                    <Agency>Fundación Marqués de Valdecilla</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>PI060507PI050427</GrantID>                    <Agency>Instituto de Salud Carlos III</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>NCT02916303</GrantID>                    <Agency>National Clinical Trial</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>sco/3246/2004</GrantID>                    <Agency>Plan Nacional de Drugs Research Grant 2005</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>CI 2005-0308007</GrantID>                    <Agency>SENY Fundació Research Grant</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Australia</Country>            <MedlineTA>Early Interv Psychiatry</MedlineTA>            <NlmUniqueID>101320027</NlmUniqueID>            <ISSNLinking>1751-7885</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">costs analysis</Keyword>            <Keyword MajorTopicYN="N">early intervention services</Keyword>            <Keyword MajorTopicYN="N">first episode psychosis</Keyword>            <Keyword MajorTopicYN="N">schizophrenia</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>15</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30311416</ArticleId>            <ArticleId IdType="doi">10.1111/eip.12752</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30311320</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1552-6569</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>11</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of neuroimaging : official journal of the American Society of Neuroimaging</Title>                <ISOAbbreviation>J Neuroimaging</ISOAbbreviation>            </Journal>            <ArticleTitle>Neuroimaging in Psychiatric Disorders: A Bibliometric Analysis of the 100 Most Highly Cited Articles.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jon.12570</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">Extensive research has been conducted to find neuroimaging biomarkers for psychiatric disorders. This study aimed at identifying trends of the 100 most highly cited articles on neuroimaging in primary psychiatric disorders.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">The most highly cited original research articles were identified and analyzed, following searches of MEDLINE and Web of Science All Databases.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The top 100 articles ranked by yearly citation (from 137.5 to 31.1) were published between 1989 and 2017. Depressive disorders (30 articles), schizophrenia spectrum and other psychotic disorders (27), autism spectrum disorder (17), substance-related and addictive disorders (7), and post-traumatic stress disorder (7) were among the most studied conditions. Functional magnetic resonance imaging (42), structural magnetic resonance imaging (30), and positron emission tomography (22) were the most utilized neuroimaging modalities. While 85 articles investigated the pathophysiology of psychiatric disorders (including 7 focusing on developmental changes and 1 on genetic susceptibility), 15 articles studied the impact of treatment, including antidepressants (6), deep brain stimulation (4), antipsychotics (3), behavior therapy (3), and exercise (1). The analysis also identified the most contributing authors, countries (the United States: 71 articles, the United Kingdom: 8, Canada: 5, and China: 5), and journals (JAMA Psychiatry: 20 articles and Biological Psychiatry: 17). Ninety-eight studies were prospective, and two were retrospective. The sample size ranged from 3 to 1,188 (median: 21).</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study identified intellectual milestones in the utility of neuroimaging in investigating primary psychiatric disorders. The historic trends could help guide future research in this field.</AbstractText>                <CopyrightInformation>© 2018 by the American Society of Neuroimaging.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Gong</LastName>                    <ForeName>Bo</ForeName>                    <Initials>B</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-6028-1818</Identifier>                    <AffiliationInfo>                        <Affiliation>MD Undergraduate Program, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Naveed</LastName>                    <ForeName>Sadiq</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Child and Adolescent Psychiatry, KVC Hospitals, Kansas City, KS.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hafeez</LastName>                    <ForeName>Dawood M</ForeName>                    <Initials>DM</Initials>                    <AffiliationInfo>                        <Affiliation>Capital Medical University, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Afzal</LastName>                    <ForeName>Khalid I</ForeName>                    <Initials>KI</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Majeed</LastName>                    <ForeName>Salman</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Penn State Hershey Medical Center, Hershey, PA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Abele</LastName>                    <ForeName>Jonathan</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nicolaou</LastName>                    <ForeName>Savvas</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiology, Vancouver General Hospital, Vancouver, British Columbia, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Khosa</LastName>                    <ForeName>Faisal</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiology, Vancouver General Hospital, Vancouver, British Columbia, Canada.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Neuroimaging</MedlineTA>            <NlmUniqueID>9102705</NlmUniqueID>            <ISSNLinking>1051-2284</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Neuroimaging</Keyword>            <Keyword MajorTopicYN="N">bibliometrics</Keyword>            <Keyword MajorTopicYN="N">mental disorders</Keyword>            <Keyword MajorTopicYN="N">psychiatry</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>25</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30311320</ArticleId>            <ArticleId IdType="doi">10.1111/jon.12570</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30311317</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1097-0193</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>11</Day>                    </PubDate>                </JournalIssue>                <Title>Human brain mapping</Title>                <ISOAbbreviation>Hum Brain Mapp</ISOAbbreviation>            </Journal>            <ArticleTitle>Quantifying the axonal pathways directly stimulated in therapeutic subcallosal cingulate deep brain stimulation.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hbm.24419</ELocationID>            <Abstract>                <AbstractText>Deep brain stimulation (DBS) of the subcallosal cingulate (SCC) is an emerging experimental therapy for treatment-resistant depression. New developments in SCC DBS surgical targeting are focused on identifying specific axonal pathways for stimulation that are estimated from patient-specific computational models. This connectomic-based biophysical modeling strategy has proven successful in improving the clinical response to SCC DBS therapy, but the DBS models used to date have been relatively simplistic, limiting the precision of the pathway activation estimates. Therefore, we used the most detailed patient-specific foundation for DBS modeling currently available (i.e., field-cable modeling) to evaluate SCC DBS in our most recent cohort of six subjects, all of which were responders to the therapy. We quantified activation of four major pathways in the SCC region: forceps minor (FM), cingulum bundle (CB), uncinate fasciculus (UF), and subcortical connections between the frontal pole and the thalamus or ventral striatum (FP). We then used the percentage of activated axons in each pathway as regressors in a linear model to predict the time it took patients to reach a stable response, or TSR. Our analysis suggests that stimulation of the left and right CBs, as well as FM are the most likely therapeutic targets for SCC DBS. In addition, the right CB alone predicted 84% of the variation in the TSR, and the correlation was positive, suggesting that activation of the right CB beyond a critical percentage may actually protract the recovery process.</AbstractText>                <CopyrightInformation>© 2018 Wiley Periodicals, Inc.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Howell</LastName>                    <ForeName>Bryan</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry and Behavioral Science, Emory University, Atlanta, Georgia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Choi</LastName>                    <ForeName>Ki Sueng</ForeName>                    <Initials>KS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry and Behavioral Science, Emory University, Atlanta, Georgia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Radiology, Mount Sinai School of Medicine, New York, New York.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Neurosurgery, Mount Sinai School of Medicine, New York, New York.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gunalan</LastName>                    <ForeName>Kabilar</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rajendra</LastName>                    <ForeName>Justin</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Scientific and Statistical Computational Core, National Institute of Mental Health, Bethesda, Maryland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mayberg</LastName>                    <ForeName>Helen S</ForeName>                    <Initials>HS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry and Behavioral Science, Emory University, Atlanta, Georgia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Neurosurgery, Mount Sinai School of Medicine, New York, New York.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, New York.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>McIntyre</LastName>                    <ForeName>Cameron C</ForeName>                    <Initials>CC</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0932-854X</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>R01 MH102238</GrantID>                    <Agency>National Institute of Mental Health</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>F32 NS096839</GrantID>                    <Agency>National Institute of Neurological Disorders and Stroke</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>GAANN P200A100112</GrantID>                    <Agency>U.S. Department of Education</Agency>                    <Country/>                </Grant>                <Grant>                    <Agency>Dana Foundation</Agency>                    <Country/>                </Grant>                <Grant>                    <Agency>Hope for Depression Research Foundation</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>T32 EB004314</GrantID>                    <Agency>National Institutes of Health</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>TL1 TR000441</GrantID>                    <Agency>National Institutes of Health</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>T32 GM007250</GrantID>                    <Agency>National Institutes of Health</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>UH3 NS103550</GrantID>                    <Agency>National Institutes of Health</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Hum Brain Mapp</MedlineTA>            <NlmUniqueID>9419065</NlmUniqueID>            <ISSNLinking>1065-9471</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">computational model</Keyword>            <Keyword MajorTopicYN="N">connectomic</Keyword>            <Keyword MajorTopicYN="N">pathway activation</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>21</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30311317</ArticleId>            <ArticleId IdType="doi">10.1002/hbm.24419</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30311279</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1365-2826</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>12</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of neuroendocrinology</Title>                <ISOAbbreviation>J. Neuroendocrinol.</ISOAbbreviation>            </Journal>            <ArticleTitle>Differential effects of chronic 17β-estradiol treatment on rat behaviours relevant to depression.</ArticleTitle>            <Pagination>                <MedlinePgn>e12652</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jne.12652</ELocationID>            <Abstract>                <AbstractText>Sex differences are a prominent feature of the pathophysiology of psychiatric disorders, such as major depressive disorder which affects women at a higher incidence than men. Research suggests that the most potent endogenous estrogen, 17β-estradiol, may have therapeutic potential in treating depression. However, preclinical studies have produced mixed results, likely due to various methodological factors such as treatment duration. This study aimed to investigate the effects of ovariectomy and chronic 17β-estradiol treatment via a subcutaneous silastic implant on behaviours relevant to depression in adult female Sprague-Dawley rats. Rats were assessed in the forced swim test, saccharin preference test, novel object recognition memory test and for possible confounding behaviours, including locomotion and anxiety (open field test) and motivation and anxiety (novelty supressed feeding test). Treatment effects were verified using body and uterus weight, as well as serum concentrations of 17β-estradiol, progesterone and testosterone. Compared to ovariectomised rats, chronic 17β-estradiol treatment enhanced saccharin preference and novel object recognition performance. There were no group differences in passive or active coping behaviour when assayed using the forced swim test. Taken together, these results support an antidepressant-like action of estrogens but highlight that the beneficial effects of chronic 17β-estradiol treatment may be related to specific depression-related symptoms, particularly anhedonia and memory. This article is protected by copyright. All rights reserved.</AbstractText>                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Gogos</LastName>                    <ForeName>Andrea</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>The Florey Institute of Neuroscience and Mental Health, Parkville, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>McCarthy</LastName>                    <ForeName>Madeleine</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>The Florey Institute of Neuroscience and Mental Health, Parkville, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Walker</LastName>                    <ForeName>Adam J</ForeName>                    <Initials>AJ</Initials>                    <AffiliationInfo>                        <Affiliation>The Florey Institute of Neuroscience and Mental Health, Parkville, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Udawela</LastName>                    <ForeName>Madhara</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>The Florey Institute of Neuroscience and Mental Health, Parkville, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gibbons</LastName>                    <ForeName>Andrew</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>The Florey Institute of Neuroscience and Mental Health, Parkville, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dean</LastName>                    <ForeName>Brian</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>The Florey Institute of Neuroscience and Mental Health, Parkville, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Centre for Mental Health, Faculty of Health, Arts and Design, Swinburne University, Hawthorn, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kusljic</LastName>                    <ForeName>Snezana</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>The Florey Institute of Neuroscience and Mental Health, Parkville, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Nursing, The University of Melbourne, Parkville, Australia.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Neuroendocrinol</MedlineTA>            <NlmUniqueID>8913461</NlmUniqueID>            <ISSNLinking>0953-8194</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Female rats</Keyword>            <Keyword MajorTopicYN="N">estrogen</Keyword>            <Keyword MajorTopicYN="N">forced swim test</Keyword>            <Keyword MajorTopicYN="N">locomotor</Keyword>            <Keyword MajorTopicYN="N">novel object recognition</Keyword>            <Keyword MajorTopicYN="N">novelty supressed feeding</Keyword>            <Keyword MajorTopicYN="N">ovariectomy</Keyword>            <Keyword MajorTopicYN="N">sucrose preference</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30311279</ArticleId>            <ArticleId IdType="doi">10.1111/jne.12652</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30310945</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1433-9285</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>11</Day>                    </PubDate>                </JournalIssue>                <Title>Social psychiatry and psychiatric epidemiology</Title>                <ISOAbbreviation>Soc Psychiatry Psychiatr Epidemiol</ISOAbbreviation>            </Journal>            <ArticleTitle>The prevalence of mental disorders in Taiwanese prisons: a nationwide population-based study.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00127-018-1614-y</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">In Taiwan, few studies explored the morbidity of mental disorders among prisoners. The purpose of this study is conducted to estimate the prevalence of mental disorders in Taiwanese prisoners.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Based on Nationwide population-based databank, 82,650 prisons were studied for mental disorders. Mental disorders were assessed with the International Classification of Diseases 9th revision Clinical Modification (ICD-9-CM).</AbstractText>                <AbstractText Label="RESULT" NlmCategory="RESULTS">The prevalence of mental disorders among prisoners was estimated 11.31%. Female prisons exhibited a higher prevalence than males (17.82% vs. 10.56%, p &lt; 0.01). Among all cases that were diagnosed with the contents of mental disorder, anxiety, dissociative and somatoform disorders was the most frequent disease (total: 49.48%, female: 59.42%, male: 47.55%) followed by special symptoms or syndromes (total: 38.24%, female: 33.20%, male: 39.22%), drug dependence (total: 15.41%, female: 9.22%, male: 16.61%), episodic mood disorders (total: 13.56%, female: 26.15%, male: 11.12%), nondependent abuse of drugs (total: 11.23%, female: 2.77%, male: 12.87%) and depressive disorder (total: 11.23%, female: 11.66%, male: 11.14%).</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A substantial proportion of prisoners reported having mental disorders. The results suggests the necessity of comprehensive assessment and more treatment programs that offer alternatives to incarceration of mental health for the criminal justice system in Taiwan.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Tung</LastName>                    <ForeName>Tao-Hsin</ForeName>                    <Initials>TH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Crime Prevention and Correction, Central Police University, Taoyuan, Taiwan, Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medical Research and Education, Cheng-Hsin General Hospital, Taipei, Taiwan, Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hsiao</LastName>                    <ForeName>Yi-Ying</ForeName>                    <Initials>YY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan, Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shen</LastName>                    <ForeName>Sheng-Ang</ForeName>                    <Initials>SA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Crime Prevention and Correction, Central Police University, Taoyuan, Taiwan, Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Psychology, School of Medicine, Fu-Jen Catholic University, Taipei, Taiwan, Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Huang</LastName>                    <ForeName>Chien</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Crime Prevention and Correction, Central Police University, Taoyuan, Taiwan, Republic of China. hj9605@gmail.com.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Psychology, School of Medicine, Fu-Jen Catholic University, Taipei, Taiwan, Republic of China. hj9605@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Soc Psychiatry Psychiatr Epidemiol</MedlineTA>            <NlmUniqueID>8804358</NlmUniqueID>            <ISSNLinking>0933-7954</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Mental disorders</Keyword>            <Keyword MajorTopicYN="N">Population-based study</Keyword>            <Keyword MajorTopicYN="N">Prevalence</Keyword>            <Keyword MajorTopicYN="N">Prisons</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>09</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30310945</ArticleId>            <ArticleId IdType="doi">10.1007/s00127-018-1614-y</ArticleId>            <ArticleId IdType="pii">10.1007/s00127-018-1614-y</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30310285</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1176-6328</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>14</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Neuropsychiatric disease and treatment</Title>                <ISOAbbreviation>Neuropsychiatr Dis Treat</ISOAbbreviation>            </Journal>            <ArticleTitle>Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline.</ArticleTitle>            <Pagination>                <MedlinePgn>2473-2484</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.2147/NDT.S159800</ELocationID>            <Abstract>                <AbstractText Label="Purpose" NlmCategory="UNASSIGNED">To compare treatment outcomes in patients with major depressive disorder treated with duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline for up to 6 months.</AbstractText>                <AbstractText Label="Patients and methods" NlmCategory="UNASSIGNED">Data were taken from a 6-month prospective, observational study that included 1,549 major depressive disorder patients without sexual dysfunction in 12 countries. We report the overall results and those from Asian countries. Depression severity was measured using the Clinical Global Impression and the 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR<sub>16</sub>). Clinical and functional remissions were defined as having a QIDS-SR<sub>16</sub> &lt;6, and as having a rating of &lt;3 on all three Sheehan Disability Scale items and no reduced productivity, respectively. Mixed effects modeling with repeated measures analysis and generalized estimating equation models were used. Propensity scores were included in the models.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">The mixed effects modeling with repeated measures regression models showed that the Clinical Global Impression rating during follow-up was significantly lower in those patients treated with duloxetine compared with escitalopram (0.40, 95% CI 0.25 to 0.56); fluoxetine (0.22, 95% CI 0.05 to 0.38); paroxetine (0.38, 95% CI 0.23 to 0.54); and sertraline (0.32, 95% CI 0.16 to 0.49). The QIDS-SR<sub>16</sub> of duloxetine-treated patients was significantly lower than those treated with escitalopram (1.58, 95% CI 1.03 to 2.12); fluoxetine (1.48, 95% CI 0.90 to 2.06); paroxetine (1.53, 95% CI 1.00 to 2.07); and sertraline (1.19, 95% CI 0.61 to 1.78). The probability of clinical remission of the patients treated with escitalopram, fluoxetine, paroxetine, and sertraline was lower than those treated with duloxetine (OR 0.46, 95% CI 0.33 to 0.64; OR 0.42, 95% CI 0.29 to 0.61; OR 0.40, 95% CI 0.29 to 0.56; OR 0.50, 95% CI 0.35 to 0.71; respectively). The regression analysis of functional remission also showed more favorable results for duloxetine, with OR ranging from 0.43, 95% CI 0.31 to 0.60 for paroxetine to 0.49, 95% CI 0.35 to 0.70 for sertraline. The results for the Asian countries were generally consistent.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Duloxetine-treated patients had better 6-month outcomes in terms of depression severity and clinical and functional remission, compared with selective serotonin reuptake inhibitor-treated patients.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Huang</LastName>                    <ForeName>Jia</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China, yirufang@aliyun.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Yun</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China, yirufang@aliyun.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Jun</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China, yirufang@aliyun.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Yanlei</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Department, Eli Lilly and Company, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yuan</LastName>                    <ForeName>Zheng</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Department, Eli Lilly and Company, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yue</LastName>                    <ForeName>Li</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Department, Eli Lilly and Company, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Haro</LastName>                    <ForeName>Josep Maria</ForeName>                    <Initials>JM</Initials>                    <AffiliationInfo>                        <Affiliation>Research, Teaching and Innovation Unit, Parc Sanitari Sant Joan De Déu, CIBERSAM, Universitat de Barcelona, Sant Boi De Llobregat, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Moneta</LastName>                    <ForeName>Maria Victoria</ForeName>                    <Initials>MV</Initials>                    <AffiliationInfo>                        <Affiliation>Research, Teaching and Innovation Unit, Parc Sanitari Sant Joan De Déu, CIBERSAM, Universitat de Barcelona, Sant Boi De Llobregat, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Novick</LastName>                    <ForeName>Diego</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Health Outcomes, Eli Lilly and Company, Windlesham, Surrey, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fang</LastName>                    <ForeName>Yiru</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China, yirufang@aliyun.com.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>State Key Laboratory of Neuroscience, Shanghai Institutes for Biological Sciences, CAS, Shanghai, China, yirufang@aliyun.com.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China, yirufang@aliyun.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>26</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>New Zealand</Country>            <MedlineTA>Neuropsychiatr Dis Treat</MedlineTA>            <NlmUniqueID>101240304</NlmUniqueID>            <ISSNLinking>1176-6328</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Int Clin Psychopharmacol. 2012 Nov;27(6):298-309</RefSource>                <PMID Version="1">22954893</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Pract Epidemiol Ment Health. 2015 Mar 31;11:130-9</RefSource>                <PMID Version="1">25870649</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2003 Jun 18;289(23):3095-105</RefSource>                <PMID Version="1">12813115</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychiatr Dis Treat. 2017 Aug 04;13:2105-2114</RefSource>                <PMID Version="1">28831259</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Pharm Des. 2005;11(12):1475-93</RefSource>                <PMID Version="1">15892657</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 1997 May 24;349(9064):1498-504</RefSource>                <PMID Version="1">9167458</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hum Psychopharmacol. 2011 Apr;26(3):242-51</RefSource>                <PMID Version="1">21681815</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int Clin Psychopharmacol. 2012 Jan;27(1):17-26</RefSource>                <PMID Version="1">22027844</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pain. 2016 Mar;157(3):577-84</RefSource>                <PMID Version="1">26882344</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 2009 Oct;117 Suppl 1:S26-43</RefSource>                <PMID Version="1">19674794</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Med. 1998 May;28(3):551-8</RefSource>                <PMID Version="1">9626712</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Acad Med Singapore. 2009 Nov;38(11):974-9</RefSource>                <PMID Version="1">19956820</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cochrane Database Syst Rev. 2012 Oct 17;10:CD006533</RefSource>                <PMID Version="1">23076926</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Psychol Rev. 2009 Apr;29(3):243-59</RefSource>                <PMID Version="1">19269076</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Asia Pac Psychiatry. 2016 Mar;8(1):51-9</RefSource>                <PMID Version="1">25808275</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2018 Apr 7;391(10128):1357-1366</RefSource>                <PMID Version="1">29477251</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Chin J Physiol. 2014 Oct 31;57(5):265-70</RefSource>                <PMID Version="1">25241986</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Fam Med. 1994 Sep;3(9):774-9</RefSource>                <PMID Version="1">7987511</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Sex Marital Ther. 2000 Jan-Mar;26(1):25-40</RefSource>                <PMID Version="1">10693114</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Psychiatry. 2006 Jan;163(1):148-50</RefSource>                <PMID Version="1">16390903</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2012 Dec 15;380(9859):2197-223</RefSource>                <PMID Version="1">23245608</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Drug Investig. 2016 Jul;36(7):539-43</RefSource>                <PMID Version="1">27071759</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Gen Intern Med. 1997 Jun;12(6):384-9</RefSource>                <PMID Version="1">9192257</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Annu Rev Public Health. 2013;34:119-38</RefSource>                <PMID Version="1">23514317</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int Clin Psychopharmacol. 2011 Mar;26(2):75-83</RefSource>                <PMID Version="1">21102344</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Med Res Opin. 2013 Jul;29(7):827-33</RefSource>                <PMID Version="1">23581532</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Psychiatry. 2004 Apr;65(4):521-30</RefSource>                <PMID Version="1">15119915</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int Clin Psychopharmacol. 1998 Jul;13 Suppl 6:S1-4</RefSource>                <PMID Version="1">9728667</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Prim Care Companion J Clin Psychiatry. 2010;12(2):null</RefSource>                <PMID Version="1">20694113</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Psychiatry. 2001 Mar;178:234-41</RefSource>                <PMID Version="1">11230034</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2003 Sep 1;54(5):573-83</RefSource>                <PMID Version="1">12946886</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA Psychiatry. 2017 Apr 1;74(4):370-378</RefSource>                <PMID Version="1">28241180</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2006 Mar 15;59(6):493-501</RefSource>                <PMID Version="1">16199008</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Psychopharmacol. 2015 May;29(5):459-525</RefSource>                <PMID Version="1">25969470</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2007 Dec 1;62(11):1217-27</RefSource>                <PMID Version="1">17588546</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 2009 Jan;112(1-3):135-43</RefSource>                <PMID Version="1">18539337</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Psychiatry Clin Pract. 2011 Jun;15(2):80-90</RefSource>                <PMID Version="1">22121855</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Psychiatry Clin Pract. 2011 Nov;15(4):242-54</RefSource>                <PMID Version="1">22121997</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Psychopharmacol. 2007 Dec;27(6):672-6</RefSource>                <PMID Version="1">18004135</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Stat Med. 2012 Mar 30;31(7):681-97</RefSource>                <PMID Version="1">21351291</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acta Psychiatr Scand. 2015 Jan;131(1):51-60</RefSource>                <PMID Version="1">24954156</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychiatr Dis Treat. 2016 Feb 23;12:383-92</RefSource>                <PMID Version="1">26966361</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Compr Psychiatry. 2004 Nov-Dec;45(6):423-30</RefSource>                <PMID Version="1">15526252</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 2010 Nov;126(3):420-9</RefSource>                <PMID Version="1">20510459</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychiatr Dis Treat. 2015 Jan 22;11:197-205</RefSource>                <PMID Version="1">25653529</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hum Psychopharmacol. 2012 Jan;27(1):47-56</RefSource>                <PMID Version="1">22241678</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">functioning</Keyword>            <Keyword MajorTopicYN="N">health outcomes</Keyword>            <Keyword MajorTopicYN="N">observational study</Keyword>            <Keyword MajorTopicYN="N">treatment</Keyword>        </KeywordList>        <CoiStatement>Disclosure Yanlei Zhang, Zheng Yuan, Li Yue, and Diego Novick are Eli Lilly and Co employees. Maria Victoria Moneta conducted the statistical analysis under a contract of CIBER with Eli Lilly and Co. Josep Maria Haro has received economic compensation for his participation in educational lectures or advisory boards of Eli Lilly and Co., Otsuka, and Lundbeck. The authors report no other conflicts of interest in this work.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30310285</ArticleId>            <ArticleId IdType="doi">10.2147/NDT.S159800</ArticleId>            <ArticleId IdType="pii">ndt-14-2473</ArticleId>            <ArticleId IdType="pmc">PMC6165742</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30310078</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">2158-3188</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>8</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>11</Day>                    </PubDate>                </JournalIssue>                <Title>Translational psychiatry</Title>                <ISOAbbreviation>Transl Psychiatry</ISOAbbreviation>            </Journal>            <ArticleTitle>GSK3β: a plausible mechanism of cognitive and hippocampal changes induced by erythropoietin treatment in mood disorders?</ArticleTitle>            <Pagination>                <MedlinePgn>216</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41398-018-0270-z</ELocationID>            <Abstract>                <AbstractText>Mood disorders are associated with significant psychosocial and occupational disability. It is estimated that major depressive disorder (MDD) will become the second leading cause of disability worldwide by 2020. Existing pharmacological and psychological treatments are limited for targeting cognitive dysfunctions in mood disorders. However, growing evidence from human and animal studies has shown that treatment with erythropoietin (EPO) can improve cognitive function. A recent study involving EPO-treated patients with mood disorders showed that the neural basis for their cognitive improvements appeared to involve an increase in hippocampal volume. Molecular mechanisms underlying hippocampal changes have been proposed, including the activation of anti-apoptotic, antioxidant, pro-survival and anti-inflammatory signalling pathways. The aim of this review is to describe the potential importance of glycogen synthase kinase 3-beta (GSK3β) as a multi-potent molecular mechanism of EPO-induced hippocampal volume change in mood disorder patients. We first examine published associations between EPO administration, mood disorders, cognition and hippocampal volume. We then highlight evidence suggesting that GSK3β influences hippocampal volume in MDD patients, and how this could assist with targeting more precise treatments particularly for cognitive deficits in patients with mood disorders. We conclude by suggesting how this developing area of research can be further advanced, such as using pharmacogenetic studies of EPO treatment in patients with mood disorders.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Inkster</LastName>                    <ForeName>Becky</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Wolfson College, University of Cambridge, Cambridge, UK. becky.inkster@gmail.com.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, University of Cambridge, Cambridge, UK. becky.inkster@gmail.com.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Cambridgeshire &amp; Peterborough NHS Foundation Trust, Cambridge, UK. becky.inkster@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zai</LastName>                    <ForeName>Gwyneth</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, University of Cambridge, Cambridge, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Neurogenetics Section, Molecular Brain Science Department, Campbell Family Mental Health Research Institute, and Mood &amp; Anxiety Division, Centre for Addiction and Mental Health, Toronto, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, University of Toronto, Toronto, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lewis</LastName>                    <ForeName>Gemma</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Psychiatric Epidemiology at the Division of Psychiatry, University College London, London, UK. gemma.lewis@ucl.ac.uk.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Miskowiak</LastName>                    <ForeName>Kamilla W</ForeName>                    <Initials>KW</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-2572-1384</Identifier>                    <AffiliationInfo>                        <Affiliation>Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, København, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Transl Psychiatry</MedlineTA>            <NlmUniqueID>101562664</NlmUniqueID>            <ISSNLinking>2158-3188</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurochem. 2002 Jul;82(1):75-83</RefSource>                <PMID Version="1">12091467</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genome. 1998 Oct;41(5):720-7</RefSource>                <PMID Version="1">9809441</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neurosci Lett. 2005 Mar 7;376(1):51-5</RefSource>                <PMID Version="1">15694273</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2006 Jun 15;59(12):1116-27</RefSource>                <PMID Version="1">16631126</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Neurobiol. 2018 Apr;55(4):3290-3299</RefSource>                <PMID Version="1">28488208</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Mol Neurosci. 2012 Feb 20;5:14</RefSource>                <PMID Version="1">22363263</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 2015 Oct 1;185:149-55</RefSource>                <PMID Version="1">26186530</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Rev Med Liege. 2014 Jul-Aug;69(7-8):434-40</RefSource>                <PMID Version="1">25158385</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychiatr Serv. 2014 Aug 1;65(8):977-87</RefSource>                <PMID Version="1">24789696</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Bipolar Disord. 2013 Mar;15(2):167-76</RefSource>                <PMID Version="1">23317454</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychiatry Res. 2008 Mar 15;158(2):132-40</RefSource>                <PMID Version="1">17976739</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Gen Psychiatry. 2005 Jun;62(6):593-602</RefSource>                <PMID Version="1">15939837</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Sci. 2003 Apr 1;116(Pt 7):1175-86</RefSource>                <PMID Version="1">12615961</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Brain Res. 2010 Oct 8;1355:1-6</RefSource>                <PMID Version="1">20682308</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Med. 2013 Oct;43(10):2017-26</RefSource>                <PMID Version="1">23098294</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H748-55</RefSource>                <PMID Version="1">16565311</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2013 Jul 1;74(1):62-8</RefSource>                <PMID Version="1">23419546</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CNS Drugs. 2008;22(5):389-406</RefSource>                <PMID Version="1">18399708</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2005 Oct 27;437(7063):1370-5</RefSource>                <PMID Version="1">16251967</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Epilepsia. 2007 Jan;48(1):175-81</RefSource>                <PMID Version="1">17241225</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Med. 2016 Jun;46(8):1679-91</RefSource>                <PMID Version="1">26996196</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochemistry (Mosc). 2017 May;82(5):606-612</RefSource>                <PMID Version="1">28601070</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Neurol. 2005 Dec;58(6):829-39</RefSource>                <PMID Version="1">16315267</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Med. 2013 Jun;43(6):1187-96</RefSource>                <PMID Version="1">22935452</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Neuropharmacol. 2012 Sep;10(3):239-53</RefSource>                <PMID Version="1">23449817</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 2007 Aug;101(1-3):201-9</RefSource>                <PMID Version="1">17224185</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CNS Drugs. 2016 Oct;30(10):931-49</RefSource>                <PMID Version="1">27638546</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurosci. 2007 Mar 14;27(11):2788-92</RefSource>                <PMID Version="1">17360900</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>NeuroRx. 2006 Jan;3(1):22-41</RefSource>                <PMID Version="1">16490411</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Psychiatry. 2008 Jul;69(7):1122-30</RefSource>                <PMID Version="1">18572982</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Mol Pharmacol. 2010 Jan;3(1):12-29</RefSource>                <PMID Version="1">20030625</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Sci. 2014 Apr 1;127(Pt 7):1369-78</RefSource>                <PMID Version="1">24687186</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Brain Res. 2015 Aug 27;1618:159-67</RefSource>                <PMID Version="1">26049128</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Psychiatry. 2002;7 Suppl 1:S29-34</RefSource>                <PMID Version="1">11986993</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Neuropsychopharmacol. 2016 Aug 24;:null</RefSource>                <PMID Version="1">27312740</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Toxicol Lett. 2010 Mar 15;193(2):189-93</RefSource>                <PMID Version="1">20093173</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Mol Sci. 2016 May 06;17(5):</RefSource>                <PMID Version="1">27164096</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Aging (Albany NY). 2015 Dec;7(12):1094-111</RefSource>                <PMID Version="1">26647069</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 1996 Nov 1;274(5288):740-3</RefSource>                <PMID Version="1">8966556</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nucleic Acids Res. 2008 Jan;36(Database issue):D695-9</RefSource>                <PMID Version="1">17981841</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Psychiatry. 2013 Feb;18(2):154-65</RefSource>                <PMID Version="1">23183489</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Neurosci. 1996 Apr;8(4):666-76</RefSource>                <PMID Version="1">9081618</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurosci. 2016 Jul 6;36(27):7253-67</RefSource>                <PMID Version="1">27383599</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Crit Rev Oncol Hematol. 2007 Nov;64(2):159-71</RefSource>                <PMID Version="1">17482474</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cell Biol. 2007 May;27(9):3253-65</RefSource>                <PMID Version="1">17325032</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pharmacogenomics J. 2008 Dec;8(6):384-90</RefSource>                <PMID Version="1">18195729</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Psychiatry. 2011 Nov;16(11):1068-70</RefSource>                <PMID Version="1">21502951</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anesth Analg. 2010 Oct;111(4):1051-8</RefSource>                <PMID Version="1">20705789</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychopharmacology. 2008 Feb;33(3):611-8</RefSource>                <PMID Version="1">17473836</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Psychiatry. 2011 Jan;16(1):26-36, 1</RefSource>                <PMID Version="1">20479759</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Blood. 2001 Sep 1;98(5):1374-81</RefSource>                <PMID Version="1">11520785</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2015 Aug 15;78(4):270-7</RefSource>                <PMID Version="1">25641635</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hum Brain Mapp. 2014 Sep;35(9):4293-302</RefSource>                <PMID Version="1">24639328</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>AJNR Am J Neuroradiol. 2011 Apr;32(4):671-6</RefSource>                <PMID Version="1">21372170</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Behav Pharmacol. 2008 Feb;19(1):41-9</RefSource>                <PMID Version="1">18195593</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 2008 Apr 18;283(16):10385-95</RefSource>                <PMID Version="1">18276585</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Soc Psychiatry Psychiatr Epidemiol. 1995 Aug;30(5):213-9</RefSource>                <PMID Version="1">7482006</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur Neuropsychopharmacol. 2016 Oct;26(10):1541-61</RefSource>                <PMID Version="1">27593623</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychiatry Res. 2014 Sep 30;223(3):210-7</RefSource>                <PMID Version="1">24994693</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Neurovasc Res. 2011 May;8(2):103-20</RefSource>                <PMID Version="1">21443457</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA Psychiatry. 2017 Apr 1;74(4):399-405</RefSource>                <PMID Version="1">28249076</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Prog Neuropsychopharmacol Biol Psychiatry. 2003 Jun;27(4):687-700</RefSource>                <PMID Version="1">12787858</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Neurosci. 2005 Jun;6(6):484-94</RefSource>                <PMID Version="1">15928718</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuroscientist. 2002 Dec;8(6):524-31</RefSource>                <PMID Version="1">12467374</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurosci. 2011 Sep 28;31(39):13921-35</RefSource>                <PMID Version="1">21957254</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur Neuropsychopharmacol. 2016 Dec;26(12):1845-1867</RefSource>                <PMID Version="1">27745932</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Mol Sci. 2012;13(9):11102-29</RefSource>                <PMID Version="1">23109841</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 2009 Jan 30;284(5):3323-33</RefSource>                <PMID Version="1">19047045</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Dialogues Clin Neurosci. 2013 Dec;15(4):419-29</RefSource>                <PMID Version="1">24459409</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acta Psychiatr Scand. 2012 Nov;126(5):315-31</RefSource>                <PMID Version="1">22881296</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychopharmacology. 2014 May;39(6):1399-408</RefSource>                <PMID Version="1">24322509</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Mar;2(2):115-122</RefSource>                <PMID Version="1">28299368</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2007 Dec 1;62(11):1244-50</RefSource>                <PMID Version="1">17553466</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acta Psychiatr Scand. 2016 Sep;134(3):249-59</RefSource>                <PMID Version="1">27259062</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropharmacology. 2013 Jan;64:337-46</RefSource>                <PMID Version="1">22992331</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Best Pract Res Clin Anaesthesiol. 2010 Dec;24(4):573-94</RefSource>                <PMID Version="1">21619868</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropharmacology. 2009 May-Jun;56(6-7):1027-34</RefSource>                <PMID Version="1">19268480</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Anaesth. 2013 Jun;110 Suppl 1:i3-9</RefSource>                <PMID Version="1">23533250</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem Biophys Res Commun. 2001 Jan 26;280(3):720-5</RefSource>                <PMID Version="1">11162580</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acta Psychiatr Scand. 2013 Sep;128(3):149-62</RefSource>                <PMID Version="1">23617548</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2014 Aug 1;76(3):239-48</RefSource>                <PMID Version="1">24199669</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acta Neurobiol Exp (Wars). 2016;76(1):1-19</RefSource>                <PMID Version="1">27102914</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Psychiatry. 2016 Dec;21(12):1752-1767</RefSource>                <PMID Version="1">26809838</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2013 Apr 1;73(7):646-51</RefSource>                <PMID Version="1">23219367</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neural Transm (Vienna). 2010 Mar;117(3):393-401</RefSource>                <PMID Version="1">20033742</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genes Brain Behav. 2010 Oct;9(7):799-807</RefSource>                <PMID Version="1">20618448</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 1999 Nov 1;46(9):1181-91</RefSource>                <PMID Version="1">10560024</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Pharmacol. 2009 Mar;156(6):885-98</RefSource>                <PMID Version="1">19366350</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 2003 Aug 8;301(5634):805-9</RefSource>                <PMID Version="1">12907793</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychopharmacology. 2007 Mar;32(3):719-27</RefSource>                <PMID Version="1">16525415</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Psychiatry. 2014 Dec;75(12):1347-55</RefSource>                <PMID Version="1">25099079</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurosci Res. 2011 Sep;89(9):1400-8</RefSource>                <PMID Version="1">21671255</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Psychiatry. 2015 Apr;76(4):418-25</RefSource>                <PMID Version="1">25919832</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Can J Psychiatry. 2014 Mar;59(3):120-30</RefSource>                <PMID Version="1">24881160</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neurobiol Learn Mem. 2011 Nov;96(4):553-63</RefSource>                <PMID Version="1">21704176</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Exp Transl Stroke Med. 2009 Oct 21;1:4</RefSource>                <PMID Version="1">20142991</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Commun Integr Biol. 2009;2(1):46-9</RefSource>                <PMID Version="1">19513264</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Zhonghua Yi Xue Za Zhi. 2008 Apr 1;88(13):876-9</RefSource>                <PMID Version="1">18756950</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 2014 Dec;169 Suppl 1:S3-11</RefSource>                <PMID Version="1">25533912</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Trauma. 2011 Jun;70(6):1471-9</RefSource>                <PMID Version="1">21817985</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Psychiatr Res. 2010 Jul;44(10):655-62</RefSource>                <PMID Version="1">20096419</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Rep. 2015 Dec 08;5:17878</RefSource>                <PMID Version="1">26643367</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2009 Aug 1;66(3):267-74</RefSource>                <PMID Version="1">19185286</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Psychiatry. 2013 Aug;74(8):e747-53</RefSource>                <PMID Version="1">24021515</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Encephale. 2016 Apr;42(2):156-64</RefSource>                <PMID Version="1">26995153</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neurosci Lett. 1999 Apr 2;264(1-3):125-8</RefSource>                <PMID Version="1">10320030</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychopharmacology. 2017 Mar;42(4):864-875</RefSource>                <PMID Version="1">27577603</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trials. 2010 Oct 13;11:97</RefSource>                <PMID Version="1">20942940</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Prog Neuropsychopharmacol Biol Psychiatry. 2010 Mar 17;34(2):331-4</RefSource>                <PMID Version="1">20015462</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trans Assoc Am Physicians. 1957;70:305-17</RefSource>                <PMID Version="1">13496139</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Histol Histopathol. 2010 Feb;25(2):237-58</RefSource>                <PMID Version="1">20017110</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychiatry Res. 2006 Nov 29;145(1):39-48</RefSource>                <PMID Version="1">17045658</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 1995 Dec 21-28;378(6559):785-9</RefSource>                <PMID Version="1">8524413</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Psychiatry. 2017 May;4(5):419-426</RefSource>                <PMID Version="1">28395988</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Appl Physiol (1985). 2010 Aug;109(2):476-83</RefSource>                <PMID Version="1">20522733</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neurosci Lett. 2004 Jan 23;355(1-2):37-40</RefSource>                <PMID Version="1">14729229</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Neurosci. 2010 Aug;11(8):539-51</RefSource>                <PMID Version="1">20648061</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neurol Sci. 2012 Dec;33(6):1249-56</RefSource>                <PMID Version="1">22294054</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychiatr Genet. 2018 Oct;28(5):77-84</RefSource>                <PMID Version="1">30080747</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ups J Med Sci. 2015;120(4):241-8</RefSource>                <PMID Version="1">26220286</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Psychiatry Neurosci. 2009 Jan;34(1):41-54</RefSource>                <PMID Version="1">19125212</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Bipolar Disord. 2012 May;14(3):217-26</RefSource>                <PMID Version="1">22548895</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pharmacol Biochem Behav. 2004 Feb;77(2):381-90</RefSource>                <PMID Version="1">14751468</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Pharmacol. 2002 Feb 22;437(3):147-50</RefSource>                <PMID Version="1">11890902</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2015 Jun 12;10(6):e0127955</RefSource>                <PMID Version="1">26070195</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Psychiatry. 2016 Apr;21(4):523-30</RefSource>                <PMID Version="1">25917369</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Pharmacol. 2017 Mar 20;8:139</RefSource>                <PMID Version="1">28373844</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 1990 Oct;87(20):8060-4</RefSource>                <PMID Version="1">2236018</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychopharmacology. 2004 Aug;29(8):1426-31</RefSource>                <PMID Version="1">15039769</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Psychiatry. 2016 Jun;21(6):806-12</RefSource>                <PMID Version="1">26122586</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem J. 2001 Oct 1;359(Pt 1):1-16</RefSource>                <PMID Version="1">11563964</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2014 May 30;5(10):2881-911</RefSource>                <PMID Version="1">24931005</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trends Biochem Sci. 2004 Feb;29(2):95-102</RefSource>                <PMID Version="1">15102436</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Aust N Z J Psychiatry. 2013 Dec;47(12):1165-75</RefSource>                <PMID Version="1">23956342</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>ACS Chem Neurosci. 2012 Nov 21;3(11):963-71</RefSource>                <PMID Version="1">23173075</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Med Sci. 2017 Jan;353(1):76-81</RefSource>                <PMID Version="1">28104107</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1333-8</RefSource>                <PMID Version="1">18212115</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:168-84</RefSource>                <PMID Version="1">23268191</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann N Y Acad Sci. 2004 Jun;1018:323-7</RefSource>                <PMID Version="1">15240385</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Mol Med (Berl). 2012 Mar;90(3):217-31</RefSource>                <PMID Version="1">22349396</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CNS Drugs. 2015 Jan;29(1):1-15</RefSource>                <PMID Version="1">25380674</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Microbes Infect. 2012 Mar;14(3):238-46</RefSource>                <PMID Version="1">22094132</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2009 May 1;65(9):732-41</RefSource>                <PMID Version="1">19150053</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Gen Psychiatry. 2009 Jul;66(7):721-8</RefSource>                <PMID Version="1">19581563</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropharmacology. 2011 Feb-Mar;60(2-3):354-64</RefSource>                <PMID Version="1">20932982</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Psychiatry. 2017 Mar;4(3):208-217</RefSource>                <PMID Version="1">28185899</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurochem. 2011 Aug;118(3):429-39</RefSource>                <PMID Version="1">21605119</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 2016 Jan 15;190:842-845</RefSource>                <PMID Version="1">25487682</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuroimage. 2010 Nov 15;53(3):908-17</RefSource>                <PMID Version="1">20219685</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Depress Anxiety. 2006;23(8):482-4</RefSource>                <PMID Version="1">16845648</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurochem. 2010 Sep;114(6):1840-51</RefSource>                <PMID Version="1">20626564</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Psychiatry. 2015 Oct;172(10):950-66</RefSource>                <PMID Version="1">26423481</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Bipolar Disord. 2012 Dec;14(8):822-30</RefSource>                <PMID Version="1">23167932</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Brain. 2007 Oct;130(Pt 10):2577-88</RefSource>                <PMID Version="1">17728357</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem Biophys Res Commun. 2016 Jan 29;470(1):220-225</RefSource>                <PMID Version="1">26777998</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Med. 2010 May;40(5):761-70</RefSource>                <PMID Version="1">19732478</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Psychiatry. 2007 Feb;12(2):206-20</RefSource>                <PMID Version="1">17033631</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CNS Neurol Disord Drug Targets. 2014;13(10):1819-35</RefSource>                <PMID Version="1">25470397</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Med. 2012 Sep 07;18:1029-40</RefSource>                <PMID Version="1">22669473</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychiatry Investig. 2010 Sep;7(3):202-7</RefSource>                <PMID Version="1">20927309</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neurotherapeutics. 2009 Jan;6(1):108-27</RefSource>                <PMID Version="1">19110203</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H2079-86</RefSource>                <PMID Version="1">18805899</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Rep. 2016 May 25;6:26781</RefSource>                <PMID Version="1">27221778</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Obstet Gynecol Reprod Biol. 2012 Sep;164(1):79-84</RefSource>                <PMID Version="1">22656329</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ther Adv Chronic Dis. 2015 May;6(3):97-114</RefSource>                <PMID Version="1">25954495</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Brain. 2006 Feb;129(Pt 2):480-9</RefSource>                <PMID Version="1">16339796</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychother Psychosom. 2009;78(5):285-97</RefSource>                <PMID Version="1">19602917</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Cell Neurosci. 2013 Nov 20;7:218</RefSource>                <PMID Version="1">24312008</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2005 May 10;102(19):6990-5</RefSource>                <PMID Version="1">15867159</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Neurol. 2012 Jan;19(1):155-62</RefSource>                <PMID Version="1">22175760</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10526-31</RefSource>                <PMID Version="1">10984541</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Sci. 2005 Jan 1;118(Pt 1):89-99</RefSource>                <PMID Version="1">15585578</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Biosci (Elite Ed). 2014 Jan 01;6:89-103</RefSource>                <PMID Version="1">24389145</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genet Test Mol Biomarkers. 2012 Dec;16(12):1382-9</RefSource>                <PMID Version="1">23030648</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Med Genet B Neuropsychiatr Genet. 2014 Apr;165B(3):217-22</RefSource>                <PMID Version="1">24677591</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2007 Dec 1;62(11):1295-302</RefSource>                <PMID Version="1">17628506</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>11</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>06</Month>                <Day>11</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30310078</ArticleId>            <ArticleId IdType="doi">10.1038/s41398-018-0270-z</ArticleId>            <ArticleId IdType="pii">10.1038/s41398-018-0270-z</ArticleId>            <ArticleId IdType="pmc">PMC6181907</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30309992</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">2044-6055</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>8</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>BMJ open</Title>                <ISOAbbreviation>BMJ Open</ISOAbbreviation>            </Journal>            <ArticleTitle>Detection and treatment initiation for depression and alcohol use disorders: facility-based cross-sectional studies in five low-income and middle-income country districts.</ArticleTitle>            <Pagination>                <MedlinePgn>e023421</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2018-023421</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To estimate the proportion of adult primary care outpatients who are clinically detected and initiate treatment for depression and alcohol use disorder (AUD) in low-income and middle-income country (LMIC) settings.</AbstractText>                <AbstractText Label="DESIGN" NlmCategory="METHODS">Five cross-sectional studies.</AbstractText>                <AbstractText Label="SETTING" NlmCategory="METHODS">Adult outpatient services in 36 primary healthcare facilities in Sodo District, Ethiopia (9 facilities); Sehore District, India (3); Chitwan District, Nepal (8); Dr Kenneth Kaunda District, South Africa (3); and Kamuli District, Uganda (13).</AbstractText>                <AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Between 760 and 1893 adults were screened in each district. Across five districts, between 4.2% and 20.1% screened positive for depression and between 1.2% and 16.4% screened positive for AUD. 96% of screen-positive participants provided details about their clinical consultations that day.</AbstractText>                <AbstractText Label="PRIMARY OUTCOMES" NlmCategory="UNASSIGNED">Detection of depression, treatment initiation for depression, detection of AUD and treatment initiation for AUD.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among depression screen-positive participants, clinical detection of depression ranged from 0% in India to 11.7% in Nepal. Small proportions of screen-positive participants received treatment (0% in Ethiopia, India and South Africa to 4.2% in Uganda). Among AUD screen-positive participants, clinical detection of AUD ranged from 0% in Ethiopia and India to 7.8% in Nepal. Treatment was 0% in all countries aside Nepal, where it was 2.2%.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The findings of this study suggest large detection and treatment gaps for adult primary care patients, which are likely contributors to the population-level mental health treatment gap in LMIC. Primary care facilities remain unfulfilled intervention points for reducing the population-level burden of disease in LMIC.</AbstractText>                <CopyrightInformation>© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Rathod</LastName>                    <ForeName>Sujit D</ForeName>                    <Initials>SD</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8783-7724</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Population Health, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Roberts</LastName>                    <ForeName>Tessa</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Centre for Global Mental Health, Department of Population Health, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Health Services and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Medhin</LastName>                    <ForeName>Girmay</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Aklilu Lemma Institute of Pathology, Addis Ababa University, Addis Ababa, Ethiopia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Murhar</LastName>                    <ForeName>Vaibhav</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Sangath, Bhopal, Madhya Pradesh, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Samudre</LastName>                    <ForeName>Sandesh</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Health Services and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Centre for Chronic Conditions and Injuries, Public Health foundation of India, New Delhi, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Luitel</LastName>                    <ForeName>Nagendra P</ForeName>                    <Initials>NP</Initials>                    <AffiliationInfo>                        <Affiliation>Transcultural Psychosocial Organization (TPO), Kathmandu, Nepal.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Selohilwe</LastName>                    <ForeName>One</ForeName>                    <Initials>O</Initials>                    <AffiliationInfo>                        <Affiliation>Centre for Rural Health, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ssebunnya</LastName>                    <ForeName>Joshua</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Makerere University/Butabika National Referral and Teaching Mental Hospital, Kampala, Uganda.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jordans</LastName>                    <ForeName>Mark J D</ForeName>                    <Initials>MJD</Initials>                    <AffiliationInfo>                        <Affiliation>Centre for Global Mental Health, Institute of Psychiatry, Psychology and Neurosciences, King's College London, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bhana</LastName>                    <ForeName>Arvin</ForeName>                    <Initials>A</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4235-0108</Identifier>                    <AffiliationInfo>                        <Affiliation>Centre for Rural Health, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Petersen</LastName>                    <ForeName>Inge</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Centre for Rural Health, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kigozi</LastName>                    <ForeName>Fred</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Makerere University/Butabika National Referral and Teaching Mental Hospital, Kampala, Uganda.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nakku</LastName>                    <ForeName>Juliet</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Makerere University/Butabika National Referral and Teaching Mental Hospital, Kampala, Uganda.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lund</LastName>                    <ForeName>Crick</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Centre for Global Mental Health, Institute of Psychiatry, Psychology and Neurosciences, King's College London, London, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry and Mental Health, Alan J Flisher Centre for Public Mental Health, University of Cape Town, Cape Town, South Africa.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="Y">                    <LastName>Fekadu</LastName>                    <ForeName>Abebaw</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Global Health &amp; Infection Department, Brighton and Sussex Medical School, Brighton, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="Y">                    <LastName>Shidhaye</LastName>                    <ForeName>Rahul</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Centre for Mental Health, Public health foundation of India, New Delhi, India.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>CAPHRI (Care and Public Health Research Institute), Maastricht University, Maastricht, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>BMJ Open</MedlineTA>            <NlmUniqueID>101552874</NlmUniqueID>            <ISSNLinking>2044-6055</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">alcohol use disorder</Keyword>            <Keyword MajorTopicYN="N">clinical detection</Keyword>            <Keyword MajorTopicYN="N">low- and middle-income countries</Keyword>            <Keyword MajorTopicYN="N">primary care</Keyword>        </KeywordList>        <CoiStatement>Competing interests: None declared.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30309992</ArticleId>            <ArticleId IdType="pii">bmjopen-2018-023421</ArticleId>            <ArticleId IdType="doi">10.1136/bmjopen-2018-023421</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30309804</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1532-2653</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>08</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia</Title>                <ISOAbbreviation>J Clin Neurosci</ISOAbbreviation>            </Journal>            <ArticleTitle>Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob disease.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">S0967-5868(18)31450-4</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jocn.2018.09.031</ELocationID>            <Abstract>                <AbstractText>Sporadic Creutzfeldt-Jakob disease (sCJD) is the most common form of human prion disease. It is invariably fatal and displays a short clinical disease stage. The key event in sCJD is the propagation of a beta-sheet rich conformer of the physiological PrP<sup>C</sup> protein, known as PrP<sup>Sc</sup>. Neuropathological disease characteristics include gliosis, neuronal loss and spongiform degeneration; disease clinical manifestations refer to mental and visual disabilities, cognitive impairment, gait or limb ataxia, myoclonus and mutism. Definite sCJD diagnosis requires post-mortem brain material histopathological examination. However, highly certain pre-mortem differential diagnosis is desired to exclude other treatable disorders and to reduce disease transmission risks. Detection and/or quantification of cerebrospinal fluid (CSF) biomarkers reflecting neuronal damage and PrP<sup>C</sup> misfolding in the diseased brain significantly enhance pre-mortem diagnosis. Previously established and newly identified biomarkers are used towards this direction. Increased CSF Neurofilament light chain (NFL) concentrations have been reported in several neurological disorders, including prion diseases. In the present study, we analyzed CSF NFL levels in two independent patient cohorts, consisting of highly suspected sCJD cases that were further classified as sCJD or non-CJD according to established diagnostic criteria. CSF NFL concentrations were increased in sCJD compared to non-CJD cases in both cohorts (area under the curve (with 95% confidence interval) equal to 0.89 (0.82 to 0.97) and 0.86 (0.77 to 0.96), respectively. CSF NFL was associated neither to age nor to sex but correlated with total-tau concentrations in both cohorts. Overall, our data provide independent validation of CSF NFL utility in sCJD differential diagnosis.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kanata</LastName>                    <ForeName>Eirini</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Pharmacology, School of Health Sciences, Department of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece. Electronic address: ekanata@bio.auth.gr.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Golanska</LastName>                    <ForeName>Ewa</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Pathology and Neuropathology, Medical University of Lodz, Lodz, Poland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Villar-Piqué</LastName>                    <ForeName>Anna</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, University Medical School, Göttingen, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Karsanidou</LastName>                    <ForeName>Aikaterini</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Pharmacology, School of Health Sciences, Department of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dafou</LastName>                    <ForeName>Dimitra</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Genetics, Development, and Molecular Biology, School of Biology, Aristotle University, Thessaloniki, Greece.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xanthopoulos</LastName>                    <ForeName>Konstantinos</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Pharmacology, School of Health Sciences, Department of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Schmitz</LastName>                    <ForeName>Matthias</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, University Medical School, Göttingen, Germany; German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ferrer</LastName>                    <ForeName>Isidro</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Ministry of Health, L'Hospitalet de Llobregat, Spain; Bellvitge University Hospital-IDIBELL, Department of Pathology and Experimental Therapeutics, University of Barcelona, Hospitalet de Llobregat, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Karch</LastName>                    <ForeName>André</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sikorska</LastName>                    <ForeName>Beata</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Pathology and Neuropathology, Medical University of Lodz, Lodz, Poland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liberski</LastName>                    <ForeName>Pawel P</ForeName>                    <Initials>PP</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Pathology and Neuropathology, Medical University of Lodz, Lodz, Poland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sklaviadis</LastName>                    <ForeName>Theodoros</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Pharmacology, School of Health Sciences, Department of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zerr</LastName>                    <ForeName>Inga</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, University Medical School, Göttingen, Germany; German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Llorens</LastName>                    <ForeName>Franc</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, University Medical School, Göttingen, Germany; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Ministry of Health, L'Hospitalet de Llobregat, Spain; Bellvitge Biomedical Research Institute (IDBELL), L'Hospitalet de Llobregat, Spain. Electronic address: franc.llorens@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Scotland</Country>            <MedlineTA>J Clin Neurosci</MedlineTA>            <NlmUniqueID>9433352</NlmUniqueID>            <ISSNLinking>0967-5868</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Cerebrospinal fluid</Keyword>            <Keyword MajorTopicYN="N">Neurodegenerative dementias</Keyword>            <Keyword MajorTopicYN="N">Neurofilament light</Keyword>            <Keyword MajorTopicYN="N">Prion diseases</Keyword>            <Keyword MajorTopicYN="N">Sporadic Creutzfeldt-Jakob disease</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30309804</ArticleId>            <ArticleId IdType="pii">S0967-5868(18)31450-4</ArticleId>            <ArticleId IdType="doi">10.1016/j.jocn.2018.09.031</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30309389</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1758-9193</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>10</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>12</Day>                    </PubDate>                </JournalIssue>                <Title>Alzheimer's research &amp; therapy</Title>                <ISOAbbreviation>Alzheimers Res Ther</ISOAbbreviation>            </Journal>            <ArticleTitle>Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.</ArticleTitle>            <Pagination>                <MedlinePgn>107</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13195-018-0431-6</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">PQ912 is an inhibitor of the glutaminyl cyclase enzyme that plays a central role in the formation of synaptotoxic pyroglutamate-A-beta oligomers. We report on the first clinical study with PQ912 in subjects with biomarker-proven Alzheimer's disease (AD). The aim was to determine the maximal tolerated dose, target occupancy and treatment-related pharmacodynamic effects. The exploratory efficacy readouts selected were tailored to the patient population with early AD. The therapeutic approach focuses on synaptic dysfunction as captured by various measures such as electroencephalography (EEG), synaptic biomarkers and sensitive cognitive tests.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">This was a randomized, double-blind, placebo-controlled trial evaluating the safety, tolerability and efficacy of PQ912 800 mg twice daily (bid) for 12 weeks in subjects with mild cognitive impairment or mild dementia due to AD. The 120 enrolled subjects were treatment-naïve at the start of the study, had confirmed AD biomarkers in their cerebrospinal fluid at screening and had a Mini Mental State Examination score between 21 and 30. After 1 week of treatment with 400 mg bid, patients were up-titrated to 800 mg bid for 11 weeks. Patients were randomized 1:1 to either PQ912 or placebo. The primary composite endpoints were to assess safety and tolerability based on the number of patients who discontinued due to (serious) adverse events (safety), and based on dose adjustment during the treatment period and/or nonadherence to randomized treatment (tolerability). All randomized subjects who took at least one dose of the study treatment or placebo were used for safety analyses.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">There was no significant difference between treatments in the number of subjects with (serious) adverse events, although there were slightly more patients with a serious adverse event in the PQ912 group compared to placebo. More subjects treated with PQ912 discontinued treatment due to adverse events, mostly related to gastrointestinal and skin/subcutaneous tissue disorders. PQ912 treatment resulted in a significant reduction in glutaminyl cyclase activity, which resulted in an average target occupancy of &gt; 90%. A significant reduction of theta power in the EEG frequency analysis and a significant improvement in the One Back test of our Neuropsychological Test Battery was observed. The exploratory biomarker readouts, neurogranin for synaptic toxicity and YKL-40 as a marker of inflammation, appear to be sensitive enough to serve as efficacy markers in the next phase 2b study.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The maximal tolerated dose of PQ912 has been identified and the results support future studies at still lower doses reaching &gt; 50% target occupancy, a longer up-titration phase to potentially induce adaptation and longer treatment periods to confirm the early signals of efficacy as seen in this study.</AbstractText>                <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Clinicaltrials.gov, NCT 02389413 . Registered on 17 March 2015.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Scheltens</LastName>                    <ForeName>Philip</ForeName>                    <Initials>P</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-1046-6408</Identifier>                    <AffiliationInfo>                        <Affiliation>Alzheimer Center and Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands. p.scheltens@vumc.nl.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hallikainen</LastName>                    <ForeName>Merja</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>University of Eastern Finland, Institute of Clinical Medicine, Kuopio, Finland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Grimmer</LastName>                    <ForeName>Timo</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Duning</LastName>                    <ForeName>Thomas</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, University of Münster, Münster, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gouw</LastName>                    <ForeName>Alida A</ForeName>                    <Initials>AA</Initials>                    <AffiliationInfo>                        <Affiliation>Alzheimer Center and Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Neurophysiology and MEG Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Teunissen</LastName>                    <ForeName>Charlotte E</ForeName>                    <Initials>CE</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Chemistry, Neurochemistry Laboratory and Biobank, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wink</LastName>                    <ForeName>Alle Meije</ForeName>                    <Initials>AM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiology, Nuclear Medicine and PET Research, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Maruff</LastName>                    <ForeName>Paul</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Cogstate Ltd, Melbourne, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Harrison</LastName>                    <ForeName>John</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Alzheimer Center and Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>van Baal</LastName>                    <ForeName>Caroline M</ForeName>                    <Initials>CM</Initials>                    <AffiliationInfo>                        <Affiliation>Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bruins</LastName>                    <ForeName>Suzanne</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Probiodrug AG, Halle, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lues</LastName>                    <ForeName>Inge</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Probiodrug AG, Halle, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Prins</LastName>                    <ForeName>Niels D</ForeName>                    <Initials>ND</Initials>                    <AffiliationInfo>                        <Affiliation>Alzheimer Center and Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Brain Research Center, Amsterdam, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <DataBankList CompleteYN="Y">                <DataBank>                    <DataBankName>ClinicalTrials.gov</DataBankName>                    <AccessionNumberList>                        <AccessionNumber>NCT02389413</AccessionNumber>                    </AccessionNumberList>                </DataBank>            </DataBankList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Alzheimers Res Ther</MedlineTA>            <NlmUniqueID>101511643</NlmUniqueID>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword>            <Keyword MajorTopicYN="N">Glutaminyl cyclase inhibitor</Keyword>            <Keyword MajorTopicYN="N">PQ912</Keyword>            <Keyword MajorTopicYN="N">Phase 2a</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>15</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30309389</ArticleId>            <ArticleId IdType="doi">10.1186/s13195-018-0431-6</ArticleId>            <ArticleId IdType="pii">10.1186/s13195-018-0431-6</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30309245</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1440-1614</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>12</Day>                    </PubDate>                </JournalIssue>                <Title>The Australian and New Zealand journal of psychiatry</Title>                <ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation>            </Journal>            <ArticleTitle>Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan.</ArticleTitle>            <Pagination>                <MedlinePgn>4867418805559</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1177/0004867418805559</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although antipsychotic monotherapy is recommended as the main treatment for schizophrenia, antipsychotic polypharmacy is not rare in practice. However, longitudinal data on antipsychotic polypharmacy in schizophrenia treatment are limited.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">This longitudinal database study described antipsychotic polypharmacy in the treatment of schizophrenia in real-world settings in China and Japan. We retrieved information about antipsychotic treatment for schizophrenia from January 2010 to December 2014 from two hospital Electronic Medical Records databases in China and one claims database, Japan Medical Data Centre in Japan. Eligible patients had a diagnosis of schizophrenia (International Classification of Diseases, Tenth Revision F20.x) and at least one prescription for first or second generation antipsychotics. Antipsychotic polypharmacy was defined as having more than one antipsychotic medication overlapping for ⩾60 days. The Japan Medical Data Centre study cohort was further stratified by employees (insurance beneficiaries) and their dependents.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The study cohorts comprised 11,961 patients from China and 25,034 (10,661 employee sub-cohort and 14,373 dependent sub-cohort) from 14 days Japan Medical Data Centre in Japan. Most patients were prescribed monotherapy (87.3% in China and 80.1% in Japan), of which oral second-generation antipsychotics were the majority (78.9% in China and 65.8% in Japan). The prevalence rate of antipsychotic polypharmacy was 12.7% in China and 19.9% in Japan (13.7% in employees vs 24.5% in dependents). The most common combinations were two oral antipsychotics. Combinations of more than two drugs were uncommon in China (0.3%) but were prescribed for 5.3% of patients in Japan. Among patients treated with monotherapy, 12.6/100 person-years (11.8%) in China and 9.6/100 person-years (11.0%) in Japan switched to antipsychotic polypharmacy during follow-up. Younger patients were more likely to switch to antipsychotic polypharmacy than older patents in all study cohorts.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The observed rates of antipsychotic polypharmacy ranged from 12.7% in China to 19.9% in Japan. Switching from monotherapy to antipsychotic polypharmacy was most likely to occur in younger patients with schizophrenia.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Qiu</LastName>                    <ForeName>Hong</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>1 Epidemiology, Janssen Research and Development, Titusville, NJ, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>He</LastName>                    <ForeName>Yong</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>2 Peking University Sixth Hospital (Institute of Mental Health), Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Yongjing</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>3 Epidemiology, Janssen Research &amp; Development, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>He</LastName>                    <ForeName>Minfu</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>3 Epidemiology, Janssen Research &amp; Development, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Jin</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>2 Peking University Sixth Hospital (Institute of Mental Health), Beijing, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>4 National Clinical Research Center for Mental Disorders &amp; Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chi</LastName>                    <ForeName>Rui</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>2 Peking University Sixth Hospital (Institute of Mental Health), Beijing, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>4 National Clinical Research Center for Mental Disorders &amp; Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Si</LastName>                    <ForeName>Tianmei</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>2 Peking University Sixth Hospital (Institute of Mental Health), Beijing, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>4 National Clinical Research Center for Mental Disorders &amp; Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Huaning</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>5 Department of Psychiatry, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dong</LastName>                    <ForeName>Wentian</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>2 Peking University Sixth Hospital (Institute of Mental Health), Beijing, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>4 National Clinical Research Center for Mental Disorders &amp; Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Aust N Z J Psychiatry</MedlineTA>            <NlmUniqueID>0111052</NlmUniqueID>            <ISSNLinking>0004-8674</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Schizophrenia</Keyword>            <Keyword MajorTopicYN="N">antipsychotic polypharmacy</Keyword>            <Keyword MajorTopicYN="N">database research</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30309245</ArticleId>            <ArticleId IdType="doi">10.1177/0004867418805559</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30309019</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Print">2077-0383</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>7</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of clinical medicine</Title>                <ISOAbbreviation>J Clin Med</ISOAbbreviation>            </Journal>            <ArticleTitle>Cellular and Molecular Mechanisms of Recessive Hereditary Methaemoglobinaemia Type II.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">E341</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm7100341</ELocationID>            <Abstract>                <AbstractText>Cytochrome b5 reductase 3 (CYB5R3) is a membrane-bound NADH-dependent redox enzyme anchored to the mitochondrial outer membrane, endoplasmic reticulum, and plasma membrane. Recessive hereditary methaemoglobinaemia (RHM) type II is caused by CYB5R3 deficiency and is an incurable disease characterized by severe encephalopathy with mental retardation, microcephaly, generalized dystonia, and movement disorders. Currently, the etiology of type II RHM is poorly understood and there is no treatment for encephalopathy associated with this disease. Defective CYB5R3 leads to defects in the elongation and desaturation of fatty acids and cholesterol biosynthesis, which are conventionally linked with neurological disorders of type II RHM. Nevertheless, this abnormal lipid metabolism cannot explain all manifestations observed in patients. Current molecular and cellular studies indicate that CYB5R3 deficiency has pleiotropic tissue effects. Its localization in lipid rafts of neurons indicates its role in interneuronal contacts and its presence in caveolae of the vascular endothelial membrane suggests a role in the modulation of nitric oxide diffusion. Its role in aerobic metabolism and oxidative stress in fibroblasts, neurons, and cardiomyocytes has been reported to be due to its ability to modulate the intracellular ratio of NAD⁺/NADH. Based on the new molecular and cellular functions discovered for CYB5R3 linked to the plasma membrane and mitochondria, the conventional conception that the cause of type II RHM is a lipid metabolism disorder should be revised. We hypothesized that neurological symptoms of the disease could be caused by disorders in the synapse, aerobic metabolism, and/or vascular homeostasis rather than in disturbances of lipid metabolism.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Siendones</LastName>                    <ForeName>Emilio</ForeName>                    <Initials>E</Initials>                    <Identifier Source="ORCID">0000-0001-6006-563X</Identifier>                    <AffiliationInfo>                        <Affiliation>Centro Andaluz de Biología del Desarrollo, Departamento de Anatomía, Fisiología y Biología Celular, Universidad Pablo de Olavide-CSIC, 41013 Sevilla, Spain. esiecas@upo.es.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ballesteros</LastName>                    <ForeName>Manuel</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Centro Andaluz de Biología del Desarrollo, Departamento de Anatomía, Fisiología y Biología Celular, Universidad Pablo de Olavide-CSIC, 41013 Sevilla, Spain. mbalsim@upo.es.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Centro de Investigación Biomédica en Red (CIBERER), Instituto de Salud Carlos III, 41013 Sevilla, Spain. mbalsim@upo.es.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Navas</LastName>                    <ForeName>Plácido</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Centro Andaluz de Biología del Desarrollo, Departamento de Anatomía, Fisiología y Biología Celular, Universidad Pablo de Olavide-CSIC, 41013 Sevilla, Spain. pnavas@upo.es.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Centro de Investigación Biomédica en Red (CIBERER), Instituto de Salud Carlos III, 41013 Sevilla, Spain. pnavas@upo.es.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>PI14-01962</GrantID>                    <Agency>Instituto de Salud Carlos III</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>J Clin Med</MedlineTA>            <NlmUniqueID>101606588</NlmUniqueID>            <ISSNLinking>2077-0383</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">CYB5R3</Keyword>            <Keyword MajorTopicYN="N">NAD(P)H oxidase</Keyword>            <Keyword MajorTopicYN="N">NAD+ depletion</Keyword>            <Keyword MajorTopicYN="N">diaphorase</Keyword>            <Keyword MajorTopicYN="N">methaemoglobinaemia etiology</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>29</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>10</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30309019</ArticleId>            <ArticleId IdType="pii">jcm7100341</ArticleId>            <ArticleId IdType="doi">10.3390/jcm7100341</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30308952</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Print">2077-0383</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>7</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of clinical medicine</Title>                <ISOAbbreviation>J Clin Med</ISOAbbreviation>            </Journal>            <ArticleTitle>Use of Psychotropic Drugs among Children and Adolescents with Autism Spectrum Disorders in Denmark: A Nationwide Drug Utilization Study.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">E339</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm7100339</ELocationID>            <Abstract>                <AbstractText>Children with autism spectrum disorder (ASD) have a considerable use of psychotropics. Leveraging nationwide registry data, we aimed to describe the use of psychotropics among children and adolescents with ASD in Denmark. Use of melatonin and attention-deficit/hyperactivity disorder (ADHD) medication increased from 2010 to 2017, while there were limited changes in use of antidepressants and antipsychotics. Thirty percent of the identified children used psychotropics in 2017 most commonly ADHD medication (17%) and melatonin (13%). Methylphenidate, sertraline and risperidone were most often prescribed. Most children filled more than one prescription and, across drug classes, at least 38% received treatment two years after treatment initiation. Use of psychotropics followed psychiatric comorbidities. Comorbidities did not affect age at treatment initiation. Use of psychotropics varied according to age and sex with limited use in the youngest children. In summary, psychotropic drug use has increased in children with ASD mainly due to an increase in the use of ADHD medication and melatonin. In accordance with previous studies, use seems to follow comorbidities. The long treatment duration underlines the need to investigate long-term effects of psychotropic drug use in children with ASD.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Rasmussen</LastName>                    <ForeName>Lotte</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, 5000 Odense C, Denmark. lorasmussen@health.sdu.dk.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bilenberg</LastName>                    <ForeName>Niels</ForeName>                    <Initials>N</Initials>                    <Identifier Source="ORCID">0000-0002-5838-556X</Identifier>                    <AffiliationInfo>                        <Affiliation>Child and Adolescent Psychiatric Department, Mental Health Hospital and University Clinic, Region of Southern Denmark, 5000 Odense C, Denmark. Niels.Bilenberg@rsyd.dk.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Thomsen Ernst</LastName>                    <ForeName>Martin</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, 5000 Odense C, Denmark. mternst@health.sdu.dk.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Odense Patient Data Explorative Network (OPEN), Odense University Hospital, 5000 Odense C, Denmark. mternst@health.sdu.dk.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Abitz Boysen</LastName>                    <ForeName>Sidsel</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, 5000 Odense C, Denmark. Sidsel.abitz@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pottegård</LastName>                    <ForeName>Anton</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, 5000 Odense C, Denmark. apottegaard@health.sdu.dk.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>6210</GrantID>                    <Agency>Jascha Fonden</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>J Clin Med</MedlineTA>            <NlmUniqueID>101606588</NlmUniqueID>            <ISSNLinking>2077-0383</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Denmark</Keyword>            <Keyword MajorTopicYN="N">adolescent</Keyword>            <Keyword MajorTopicYN="N">autism spectrum disorder</Keyword>            <Keyword MajorTopicYN="N">central nervous system stimulants</Keyword>            <Keyword MajorTopicYN="N">child</Keyword>            <Keyword MajorTopicYN="N">drug utilization</Keyword>            <Keyword MajorTopicYN="N">prevalence</Keyword>            <Keyword MajorTopicYN="N">psychotropic drugs</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>21</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>10</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30308952</ArticleId>            <ArticleId IdType="pii">jcm7100339</ArticleId>            <ArticleId IdType="doi">10.3390/jcm7100339</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30308695</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>11</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1099-1611</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>11</Day>                    </PubDate>                </JournalIssue>                <Title>Psycho-oncology</Title>                <ISOAbbreviation>Psychooncology</ISOAbbreviation>            </Journal>            <ArticleTitle>Contribution of Psychiatric Diagnoses to Extent of Opioid Prescription in the First Year Post-Head and Neck Cancer Diagnosis: A Longitudinal Study.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/pon.4917</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The purpose of this study was to determine, within the first-year post-head and neck cancer (HNC) diagnosis, the contribution of past and upon HNC psychiatric diagnoses (i.e., substance use disorder (SUD), major depressive disorder (MDD), and anxiety disorder (AD)) to the extent (i.e., cumulated dose) of opioid prescription.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Prospective longitudinal study of 223 consecutive adults (on 313 approached; 72% participation) newly diagnosed (&lt;2 weeks) with a first occurrence of primary HNC, including Structured Clinical Interviews for DSM-IV disorders, validated psychometric measures, and medical chart reviews. Opioid doses were translated into standardized morphine milligram equivalents (MME) using CDC guidelines. A model of variables was tested using multiple linear regression.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty-five percent (123/223) of patients received opioids at some point during the first 12 months post-HNC diagnosis, 37.7% (84/223) upon HNC diagnosis (pre-treatment), 40.8% (91/223) during treatments, and 31.4% (70/223) post-treatment. The multiple linear regression indicated that an AD (p=0.04) upon HNC diagnosis in early stage contributes to cumulated MME dose in the first year post-HNC diagnosis.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study underlines how anxiety has important repercussions on the management of pain and illustrates the importance of screening for AD upon HNC diagnosis to allow for early prophylactic treatment and support.</AbstractText>                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Henry</LastName>                    <ForeName>Melissa</ForeName>                    <Initials>M</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-0642-0888</Identifier>                    <AffiliationInfo>                        <Affiliation>McGill University.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Jewish General Hospital.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Alias</LastName>                    <ForeName>Ali</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>McGill University.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Frenkiel</LastName>                    <ForeName>Saul</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>McGill University.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Jewish General Hospital.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>McGill University Health Centre.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Richardson</LastName>                    <ForeName>Keith</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>McGill University.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>McGill University Health Centre.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hier</LastName>                    <ForeName>Michael</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>McGill University.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Jewish General Hospital.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zeitouni</LastName>                    <ForeName>Anthony</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>McGill University.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>McGill University Health Centre.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kost</LastName>                    <ForeName>Karen</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>McGill University.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>McGill University Health Centre.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mlynarek</LastName>                    <ForeName>Alex</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>McGill University.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Jewish General Hospital.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>McGill University Health Centre.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Black</LastName>                    <ForeName>Martin</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>McGill University.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Jewish General Hospital.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>MacDonald</LastName>                    <ForeName>Christina</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Jewish General Hospital.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chartier</LastName>                    <ForeName>Gabrielle</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Jewish General Hospital.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rosberger</LastName>                    <ForeName>Zeev</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>McGill University.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Jewish General Hospital.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Psychooncology</MedlineTA>            <NlmUniqueID>9214524</NlmUniqueID>            <ISSNLinking>1057-9249</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Cancer</Keyword>            <Keyword MajorTopicYN="N">anxiety disorder</Keyword>            <Keyword MajorTopicYN="N">head and neck cancer</Keyword>            <Keyword MajorTopicYN="N">major depressive disorder</Keyword>            <Keyword MajorTopicYN="N">mental health</Keyword>            <Keyword MajorTopicYN="N">oncology</Keyword>            <Keyword MajorTopicYN="N">opioid</Keyword>            <Keyword MajorTopicYN="N">pain management</Keyword>            <Keyword MajorTopicYN="N">substance use disorder</Keyword>            <Keyword MajorTopicYN="N">total pain</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>31</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30308695</ArticleId>            <ArticleId IdType="doi">10.1002/pon.4917</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30308474</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1873-7897</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>59</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>03</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of anxiety disorders</Title>                <ISOAbbreviation>J Anxiety Disord</ISOAbbreviation>            </Journal>            <ArticleTitle>The effects of psychosocial interventions on death anxiety: A meta-analysis and systematic review of randomised controlled trials.</ArticleTitle>            <Pagination>                <MedlinePgn>64-73</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0887-6185(18)30251-2</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.janxdis.2018.09.004</ELocationID>            <Abstract>                <AbstractText>Death anxiety has been proposed as a transdiagnostic construct, underlying numerous mental disorders. Although it has been argued that treatments, which reduce death anxiety, are needed, research investigating the impact of interventions on death fears has produced mixed results. As such, the current meta-analysis aimed to examine the effect of psychosocial interventions on death anxiety. Overall, results from 15 randomised controlled trials suggested that psychosocial treatments produced significant reductions in death anxiety, with a small to medium effect size (g = .45). Intervention type (death education vs. therapy) did not significantly moderate the effect of intervention on death anxiety (g = -.47). However, therapy type was a significant moderator of treatment efficacy (g = -1.39). Cognitive Behaviour Therapy was found to be particularly efficacious, producing significant reductions in death anxiety relative to control (g = 1.7), whereas other therapies did not (g = .20). The number of treatment sessions and baseline death anxiety significantly moderated intervention efficacy, whereas the duration of the intervention, training of the interventionist, and clinical nature of the sample did not. Given the small number and generally low quality of the included studies, future research using more rigorous methodology, as well as clinical samples, is needed.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Menzies</LastName>                    <ForeName>Rachel E</ForeName>                    <Initials>RE</Initials>                    <AffiliationInfo>                        <Affiliation>The University of Sydney, Australia. Electronic address: rmen9233@uni.sydney.edu.au.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zuccala</LastName>                    <ForeName>Matteo</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>The University of Sydney, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sharpe</LastName>                    <ForeName>Louise</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>The University of Sydney, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dar-Nimrod</LastName>                    <ForeName>Ilan</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>The University of Sydney, Australia.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>03</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>J Anxiety Disord</MedlineTA>            <NlmUniqueID>8710131</NlmUniqueID>            <ISSNLinking>0887-6185</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Death anxiety</Keyword>            <Keyword MajorTopicYN="N">Fear of death</Keyword>            <Keyword MajorTopicYN="N">Meta-analysis</Keyword>            <Keyword MajorTopicYN="N">Systematic review</Keyword>            <Keyword MajorTopicYN="N">Transdiagnostic</Keyword>            <Keyword MajorTopicYN="N">Treatment outcome</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>21</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30308474</ArticleId>            <ArticleId IdType="pii">S0887-6185(18)30251-2</ArticleId>            <ArticleId IdType="doi">10.1016/j.janxdis.2018.09.004</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30307783</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>11</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1096-4673</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>11</Day>                    </PubDate>                </JournalIssue>                <Title>Issues in mental health nursing</Title>                <ISOAbbreviation>Issues Ment Health Nurs</ISOAbbreviation>            </Journal>            <ArticleTitle>&quot;It's the Symptom of the Problem, Not the Problem itself&quot;: A Qualitative Exploration of the Role of Pro-anorexia Websites in User's Disordered Eating.</ArticleTitle>            <Pagination>                <MedlinePgn>1-11</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1080/01612840.2018.1493625</ELocationID>            <Abstract>                <AbstractText>The growing trend in the use of the Internet and social media as a method of self-managing illness presents a critical opportunity to better understand the role of pro-anorexia (pro-ana) websites for eating disorders. Therefore, 155 pro-ana website messages regarding criticism that the site was responsible for developing anorexia were inductively thematically analysed. The analysis revealed five main themes: eating disorders are mental illnesses and websites do not cause mental illness, pro-ana websites and eating disorders are more than wanting to be thin (with sub-theme residents and visitors), eating disorders develop regardless of pro-ana websites, pro-ana sites do not cause eating disorders but they may trigger or encourage them (with sub-theme the problem is the user, not the site) and pro-ana sites provide support. Pro-ana websites and online communities present clinicians with complex treatment challenges. Collaborative, therapeutic consultations about pro-ana website use may help to establish how and when accessing them may hinder the treatment process.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Emma Hilton</LastName>                    <ForeName>Charlotte</ForeName>                    <Initials>C</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-6034-118X</Identifier>                    <AffiliationInfo>                        <Affiliation>a Department of Health and Life Sciences, School of Psychological, Social and Behavioural Sciences , Coventry University , Coventry , UK.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Issues Ment Health Nurs</MedlineTA>            <NlmUniqueID>7907126</NlmUniqueID>            <ISSNLinking>0161-2840</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30307783</ArticleId>            <ArticleId IdType="doi">10.1080/01612840.2018.1493625</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30307266</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>11</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1939-134X</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>11</Day>                    </PubDate>                </JournalIssue>                <Title>Psychological assessment</Title>                <ISOAbbreviation>Psychol Assess</ISOAbbreviation>            </Journal>            <ArticleTitle>Cross-validation of the demoralization construct in the Revised NEO Personality Inventory.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1037/pas0000655</ELocationID>            <Abstract>                <AbstractText>Demoralization is defined as a pervasive, generalized negative emotional construct present in psychiatric disorders and a variety of medical conditions. Demoralization is also conceptualized as a ubiquitous affective-laden factor common to most forms of psychopathology that increases the magnitude of intercorrelations among putatively distinct psychiatric symptom scales (Tellegen, 1985). Using exploratory structural equation modeling to identify common variance across the revised NEO Personality Inventory (NEO PI-R), a measure of the five-factor model of personality, Noordhof, Sellbom, Eigenhuis, and Kamphuis (2015) constructed an 18-item Demoralization subscale in a Dutch-speaking sample of patients attending a clinic for personality disorders in the Netherlands. In the current study we sought to cross-validate these findings in an English-speaking and diagnostically heterogeneous sample of psychiatric patients (N = 1930) receiving consultation or treatment at a large mental health and addiction center in Canada. Our results support the construct validity of the Demoralization subscale and its capacity to account for demoralization-related variance in the NEO PI-R. We believe these findings support the general tenets of demoralization and the presence of this construct in the NEO PI-R item pool. (PsycINFO Database Record (c) 2018 APA, all rights reserved).</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Uliaszek</LastName>                    <ForeName>Amanda A</ForeName>                    <Initials>AA</Initials>                    <Identifier Source="ORCID">0000-0003-4500-0795</Identifier>                    <AffiliationInfo>                        <Affiliation>Departments of Psychology, University of Toronto Scarborough.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Al-Dajani</LastName>                    <ForeName>Nadia</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Psychology, University of Toronto Scarborough.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sellbom</LastName>                    <ForeName>Martin</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Otago.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bagby</LastName>                    <ForeName>R Michael</ForeName>                    <Initials>RM</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Psychology, University of Toronto.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <Agency>University of Minnesota Press</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Psychol Assess</MedlineTA>            <NlmUniqueID>8915253</NlmUniqueID>            <ISSNLinking>1040-3590</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30307266</ArticleId>            <ArticleId IdType="pii">2018-50881-001</ArticleId>            <ArticleId IdType="doi">10.1037/pas0000655</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30306671</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>11</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1099-1077</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>33</Volume>                    <Issue>5</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Human psychopharmacology</Title>                <ISOAbbreviation>Hum Psychopharmacol</ISOAbbreviation>            </Journal>            <ArticleTitle>A proof-of-principle study of the effect of combined haloperidol and levodopa administration on working memory-related brain activation in humans.</ArticleTitle>            <Pagination>                <MedlinePgn>e2675</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hup.2675</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Cognitive deficits including impaired working memory are a hallmark feature of schizophrenia. Dopamine D1 receptor modulated changes in prefrontal cortex function play a potentially important role in the pathology underlying such deficits. However, pharmacological interventions that selectively engage the D1 receptor are severely restricted for research in humans. The present study is a proof-of-principle for enhancing cognitive performance and associated brain activation via indirect D1 stimulation, operationalised by combining the nonselective dopamine agonist L-dopa with the D2-antagonist haloperidol.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Fourteen healthy volunteers received placebo or combined carbidopa (25 mg)/L-dopa (100 mg) plus haloperidol (2 mg) orally on two separate occasions according to a within-subjects crossover design. Drug-induced differences in brain activity were assessed during an N-back working memory task in a 3T magnetic resonance imaging environment.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Drug treatment was associated with greater functional connectivity between the dorsolateral prefrontal cortex and areas within the salience network during all N-back trials. Drug treatment was also associated with reduced activation, most prominently in the occipital/temporal brain areas during 2-back performance.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This preliminary study provides initial evidence for combined L-dopa/haloperidol modulation in cognition-related brain areas and networks, which is relevant for the treatment of cognitive impairments in mental illness.</AbstractText>                <CopyrightInformation>© 2018 John Wiley &amp; Sons, Ltd.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>van Ruitenbeek</LastName>                    <ForeName>Peter</ForeName>                    <Initials>P</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-3802-6551</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hernaus</LastName>                    <ForeName>Dennis</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry; Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mehta</LastName>                    <ForeName>Mitul Ashok</ForeName>                    <Initials>MA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Hum Psychopharmacol</MedlineTA>            <NlmUniqueID>8702539</NlmUniqueID>            <ISSNLinking>0885-6222</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">D1 receptor</Keyword>            <Keyword MajorTopicYN="N">dopamine</Keyword>            <Keyword MajorTopicYN="N">haloperidol</Keyword>            <Keyword MajorTopicYN="N">levodopa</Keyword>            <Keyword MajorTopicYN="N">schizophrenia</Keyword>            <Keyword MajorTopicYN="N">working memory</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>01</Month>                <Day>29</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>29</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30306671</ArticleId>            <ArticleId IdType="doi">10.1002/hup.2675</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30306618</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>11</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1531-8257</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>Movement disorders : official journal of the Movement Disorder Society</Title>                <ISOAbbreviation>Mov. Disord.</ISOAbbreviation>            </Journal>            <ArticleTitle>Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.27487</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Outcome measures that capture functional abilities related to cognition offer the potential to demonstrate real-world effectiveness of cognitive-enhancing treatments. However, distinguishing functional disability related to cognition from that attributed to motor symptoms can be difficult in PD. A performance-based functional assessment allows for direct observation of activity of daily living skills and separation of cognitive from motoric disabilities.</AbstractText>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Validate the University of California San Diego Performance-Based Skills Assessment in PD.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">One hundred PD participants, ranging from normal cognition to dementia, completed the University of California San Diego Performance-Based Skills Assessment, a performance-based measure of cognitively demanding activities of daily living, as well as a neuropsychological battery and motor examination. Cognitive classification was determined by consensus conference, blinded to University of California San Diego Performance-Based Skills Assessment scores. Psychometric properties of the University of California San Diego Performance-Based Skills Assessment, including internal consistency, test-retest and inter-rater reliability, and discriminant validity for dementia, were examined.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The University of California San Diego Performance-Based Skills Assessment demonstrated strong internal consistency (Cronbach's α = 0.82) and test-retest reliability (r = 0.89) and correlated strongly with global cognition (Mattis Dementia Rating Scale: r = 0.80; P &lt; 0.001). University of California San Diego Performance-Based Skills Assessment regression models indicated greater contribution from cognitive explanatory variables (marginal partial: R<sup>2</sup>  = 0.33) than motor variables (marginal partial: R<sup>2</sup>  = 0.05), controlling for age, education, disease duration, and l-dopa equivalent dose. Additionally, the University of California San Diego Performance-Based Skills Assessment exhibited strong discriminant validity for dementia (area under the curve = 0.91).</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The University of California San Diego Performance-Based Skills Assessment is a valid measure of functional abilities related to cognition rather than motor symptoms in PD. Furthermore, it reliably distinguishes demented from nondemented participants. The University of California San Diego Performance-Based Skills Assessment may be considered as an outcome measure that combines cognitive and functional abilities in treatment trials for cognitive impairment in PD.</AbstractText>                <CopyrightInformation>© 2018 International Parkinson and Movement Disorder Society.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Holden</LastName>                    <ForeName>Samantha K</ForeName>                    <Initials>SK</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-6494-0606</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Medina</LastName>                    <ForeName>Luis D</ForeName>                    <Initials>LD</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Houston, Houston, Texas, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hoyt</LastName>                    <ForeName>Brian</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurosurgery, University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sillau</LastName>                    <ForeName>Stefan H</ForeName>                    <Initials>SH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Berman</LastName>                    <ForeName>Brian D</ForeName>                    <Initials>BD</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-0602-9942</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Neurology Section, Denver VA Medical Center, Denver, Colorado, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Goldman</LastName>                    <ForeName>Jennifer G</ForeName>                    <Initials>JG</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurological Sciences, Section of Parkinson's Disease and Movement Disorders, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Weintraub</LastName>                    <ForeName>Daniel</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Parkinson's Disease and Mental Illness Research Education, Clinical and Education Centers, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Departments of Psychiatry and Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kluger</LastName>                    <ForeName>Benzi M</ForeName>                    <Initials>BM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>10879</GrantID>                    <Agency>Michael J. Fox Foundation for Parkinson's Research</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>UL1TR002535</GrantID>                    <Agency>NCATS (National Center for Advancing Translational Sciences)</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>L30 NS103315</GrantID>                    <Agency>NINDS (National Institute of Neurological Disorders and Stroke)</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Mov Disord</MedlineTA>            <NlmUniqueID>8610688</NlmUniqueID>            <ISSNLinking>0885-3185</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Parkinson's disease</Keyword>            <Keyword MajorTopicYN="N">dementia</Keyword>            <Keyword MajorTopicYN="N">functional assessment</Keyword>            <Keyword MajorTopicYN="N">mild cognitive impairment</Keyword>            <Keyword MajorTopicYN="N">outcome measures</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>16</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30306618</ArticleId>            <ArticleId IdType="doi">10.1002/mds.27487</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30306495</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>11</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1557-1904</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology</Title>                <ISOAbbreviation>J Neuroimmune Pharmacol</ISOAbbreviation>            </Journal>            <ArticleTitle>Sigma-1 Receptor Antagonist (BD1047) Decreases Cathepsin B Secretion in HIV-Infected Macrophages Exposed to Cocaine.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11481-018-9807-4</ELocationID>            <Abstract>                <AbstractText>Pathogenesis of HIV-associated neurocognitive disorders (HAND) is mediated through the infiltration of perivascular macrophages into the brain with the secretion of viral, neurotoxic and inflammatory proteins. One of these proteins is cathepsin B (CATB), a lysosomal cysteine protease that induces neuronal apoptosis, and increases in plasma and cerebrospinal fluid from HIV-1 infected patients (Cantres-Rosario et al. AIDS 27(3):347-356, 2013). Cocaine further potentiates CATB neurotoxicity in vitro and in vivo (Zenón et al. J NeuroImmune Pharmacol 9(5):703-715, 2014). Modulation of sigma-1 (Sig1R) by cocaine increases oxidative species, cytokines and other factors that promote lysosomal disruption. However, the role of Sig1R in CATB secretion and HIV-1 replication in macrophages exposed to cocaine is unknown. We hypothesized that pharmacological modulation of Sig1R would alter CATB secretion from HIV-1 infected macrophages in vitro and in vivo. To test our hypothesis, monocyte derived-macrophages (MDM) from HIV-1 seronegative donors were isolated, infected with HIV-1<sub>ADA,</sub> and pretreated with Sig1R antagonist (BD1047) or Sig1R agonist (PRE-084) prior to cocaine exposure and followed for 3,6,9 and 11 days post-infection (dpi). Experiments in vivo were conducted using the HIV encephalitis mouse model (HIVE) with BD1047 treatments prior to cocaine for 14 days. Results demonstrate that in presence of cocaine, BD1047 decreases CATB secretion at 11 dpi, while PRE-084 did not have an effect. In the mouse model, BD1047 treatment prior to cocaine decreased CATB expression, cleaved caspase-3 an p24 antigen levels, reduced astrocytosis, but did not increase MAP-2 or synaptophysin. Results demonstrate that Sig1R plays a role in the modulation of CATB levels in HIV-1 infected MDM exposed to cocaine in vitro and in vivo. Graphical Abstract ᅟ.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>López</LastName>                    <ForeName>Omar Vélez</ForeName>                    <Initials>OV</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Microbiology and Medical Zoology, School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, 00936-5067, Puerto Rico.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gorantla</LastName>                    <ForeName>Santhi</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>University of Nebraska Medical Center, Omaha, NE, 68198-5880, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Segarra</LastName>                    <ForeName>Annabell C</ForeName>                    <Initials>AC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Physiology, University of Puerto Rico Medical Sciences Campus, San Juan, 00921, Puerto Rico.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Andino Norat</LastName>                    <ForeName>María C</ForeName>                    <Initials>MC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biology, University of Puerto Rico Bayamón Campus, Bayamón, 00959, Puerto Rico.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Álvarez</LastName>                    <ForeName>Manuel</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biology, University of Puerto Rico, Río Piedras Campus, San Juan, 00921, Puerto Rico.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Skolasky</LastName>                    <ForeName>Richard L</ForeName>                    <Initials>RL</Initials>                    <AffiliationInfo>                        <Affiliation>Orthopaedic Surgery and Physical Medicine &amp; Rehabilitation Director, Spine Outcomes Research Center, Johns Hopkins University, Baltimore, MD, 21287, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Meléndez</LastName>                    <ForeName>Loyda M</ForeName>                    <Initials>LM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Microbiology and Medical Zoology, School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, 00936-5067, Puerto Rico. loyda.melendez@upr.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>SC1GM113691</GrantID>                    <Agency>National Institute of General Medical Sciences</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>R25GM061838</GrantID>                    <Agency>National Institute of General Medical Sciences</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>U54MD007600</GrantID>                    <Agency>National Institute of Minority Health and Health Disparities</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>1R21DA041018-01</GrantID>                    <Agency>National Institute on Drug Abuse (US)</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>R13 DA023184</GrantID>                    <Agency>National Institute of Mental Health (US)</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>U01MH083501</GrantID>                    <Acronym>NS</Acronym>                    <Agency>NINDS NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R24MH59724</GrantID>                    <Acronym>MH</Acronym>                    <Agency>NIMH NIH HHS</Agency>                    <Country>United States</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Neuroimmune Pharmacol</MedlineTA>            <NlmUniqueID>101256586</NlmUniqueID>            <ISSNLinking>1557-1890</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Cathepsin B</Keyword>            <Keyword MajorTopicYN="N">Cocaine</Keyword>            <Keyword MajorTopicYN="N">HAND</Keyword>            <Keyword MajorTopicYN="N">HIV-1</Keyword>            <Keyword MajorTopicYN="N">Sigma-1 receptor</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2016</Year>                <Month>11</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30306495</ArticleId>            <ArticleId IdType="doi">10.1007/s11481-018-9807-4</ArticleId>            <ArticleId IdType="pii">10.1007/s11481-018-9807-4</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30306259</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>11</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1435-1269</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>Zeitschrift fur Gerontologie und Geriatrie</Title>                <ISOAbbreviation>Z Gerontol Geriatr</ISOAbbreviation>            </Journal>            <ArticleTitle>[Somatic risks in elderly people with severe psychiatric illnesses].</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00391-018-1458-9</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Aged patients with severe mental illness (SMI) suffer from a high risk for functional impairment and a high load of somatic comorbidities. Until now, there has been a lack of systematic studies on this patient population in later life. This review summarizes the most significant somatic comorbidities and discusses the consequences for the medical care of this elderly group of patients.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">A selective narrative review based on PubMed research and observations in clinical practice.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Life expectancy is shortened by approximately 10 years in patients with SMI. The main reasons are somatic comorbidities, particularly lung and respiratory tract disorders, metabolic syndrome with its subsequent cardiovascular complications, in addition to osteoporosis and fractures with a complicated clinical course. Although life expectancy is shortened, the number of geriatric patients with SMI is increasing and requires special attention to be given to out-patient psychosocial care, self-management of somatic diseases, and to age-appropriate continuation of psychiatric treatment.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The life expectancy of patients with SMI is reduced because of their typically somatic comorbidity, but they are reaching increasingly advanced ages as a consequence of improved treatment possibilities. They often require special attention in their diagnostic work-up and support in the management of their treatment. Collaborative care linking medical geriatric and geronto-psychiatric treatment facilities is helpful in the the interdisciplinary therapy required.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kopf</LastName>                    <ForeName>Daniel</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Geriatrische Klinik, Zentrum für klinische Psychologie und Psychotherapie, Kath. Marienkrankenhaus gGmbH, Alfredstraße 9, 22087, Hamburg, Deutschland. kopf.geriatrie@marienkrankenhaus.org.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hewer</LastName>                    <ForeName>Walter</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Klinik für Gerontopsychiatrie, Klinikum Christophsbad, Göppingen, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>ger</Language>            <PublicationTypeList>                <PublicationType UI="D004740">English Abstract</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <VernacularTitle>Somatische Risiken bei alt gewordenen Menschen mit schweren psychiatrischen Erkrankungen.</VernacularTitle>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Z Gerontol Geriatr</MedlineTA>            <NlmUniqueID>9506215</NlmUniqueID>            <ISSNLinking>0948-6704</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Comorbidity</Keyword>            <Keyword MajorTopicYN="N">Geriatric patients</Keyword>            <Keyword MajorTopicYN="N">Life expectancy</Keyword>            <Keyword MajorTopicYN="N">Psychosocial nursing</Keyword>            <Keyword MajorTopicYN="N">Severe mental illness</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>09</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>20</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30306259</ArticleId>            <ArticleId IdType="doi">10.1007/s00391-018-1458-9</ArticleId>            <ArticleId IdType="pii">10.1007/s00391-018-1458-9</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30305450</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>11</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1526-632X</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>Neurology</Title>                <ISOAbbreviation>Neurology</ISOAbbreviation>            </Journal>            <ArticleTitle>Gray matter differences in patients with functional movement disorders.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">10.1212/WNL.0000000000006514</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000006514</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To explore alterations in gray matter volume in patients with functional movement disorders.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We obtained T1-weighted MRI on 48 patients with clinically definite functional movement disorders, a subset of functional neurologic symptom disorder characterized by abnormal involuntary movements, and on 55 age- and sex-matched healthy controls. We compared between-group differences in gray matter volume using voxel-based morphometry across the whole brain. All participants in addition underwent a thorough neuropsychological battery, including the Hamilton Anxiety and Depression Scales and the Childhood Trauma Questionnaire. To determine whether confounding factors such as comorbid depression, anxiety, or childhood trauma exposure contributed to the observed structural changes, nonparametric correlation analysis was performed.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with functional movement disorders exhibited increased volume of the left amygdala, left striatum, left cerebellum, left fusiform gyrus, and bilateral thalamus, and decreased volume of the left sensorimotor cortex (whole-brain corrected <i>p</i> ≤ 0.05). Volumetric differences did not correlate with measures of disease duration or patient-rated disease severity.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study demonstrates that patients with functional movement disorders exhibit structural gray matter abnormalities in critical components of the limbic and sensorimotor circuitry. These abnormalities may represent a premorbid trait rendering patients more susceptible to disease, the disease itself, or a compensatory response to disease.</AbstractText>                <CopyrightInformation>© 2018 American Academy of Neurology.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Maurer</LastName>                    <ForeName>Carine W</ForeName>                    <Initials>CW</Initials>                    <AffiliationInfo>                        <Affiliation>From the Human Motor Control Section, Medical Neurology Branch (C.W.M., K.L., G.S.L., G.C., M.H., S.G.H.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; Department of Neurology (C.W.M.), Stony Brook University School of Medicine, NY; Department of Neurology (K.L.), University of Louisville, KY; Experimental Therapeutics and Pathophysiology Branch (R.A.) and Office of the Clinical Director (S.S.), National Institute of Mental Health, NIH, Bethesda, MD; and Department of Psychiatry (S.A.E.), Georgetown University, Washington, DC. carine.maurer@stonybrookmedicine.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>LaFaver</LastName>                    <ForeName>Kathrin</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>From the Human Motor Control Section, Medical Neurology Branch (C.W.M., K.L., G.S.L., G.C., M.H., S.G.H.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; Department of Neurology (C.W.M.), Stony Brook University School of Medicine, NY; Department of Neurology (K.L.), University of Louisville, KY; Experimental Therapeutics and Pathophysiology Branch (R.A.) and Office of the Clinical Director (S.S.), National Institute of Mental Health, NIH, Bethesda, MD; and Department of Psychiatry (S.A.E.), Georgetown University, Washington, DC.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Limachia</LastName>                    <ForeName>Gaurang S</ForeName>                    <Initials>GS</Initials>                    <AffiliationInfo>                        <Affiliation>From the Human Motor Control Section, Medical Neurology Branch (C.W.M., K.L., G.S.L., G.C., M.H., S.G.H.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; Department of Neurology (C.W.M.), Stony Brook University School of Medicine, NY; Department of Neurology (K.L.), University of Louisville, KY; Experimental Therapeutics and Pathophysiology Branch (R.A.) and Office of the Clinical Director (S.S.), National Institute of Mental Health, NIH, Bethesda, MD; and Department of Psychiatry (S.A.E.), Georgetown University, Washington, DC.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Capitan</LastName>                    <ForeName>Geanna</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>From the Human Motor Control Section, Medical Neurology Branch (C.W.M., K.L., G.S.L., G.C., M.H., S.G.H.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; Department of Neurology (C.W.M.), Stony Brook University School of Medicine, NY; Department of Neurology (K.L.), University of Louisville, KY; Experimental Therapeutics and Pathophysiology Branch (R.A.) and Office of the Clinical Director (S.S.), National Institute of Mental Health, NIH, Bethesda, MD; and Department of Psychiatry (S.A.E.), Georgetown University, Washington, DC.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ameli</LastName>                    <ForeName>Rezvan</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>From the Human Motor Control Section, Medical Neurology Branch (C.W.M., K.L., G.S.L., G.C., M.H., S.G.H.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; Department of Neurology (C.W.M.), Stony Brook University School of Medicine, NY; Department of Neurology (K.L.), University of Louisville, KY; Experimental Therapeutics and Pathophysiology Branch (R.A.) and Office of the Clinical Director (S.S.), National Institute of Mental Health, NIH, Bethesda, MD; and Department of Psychiatry (S.A.E.), Georgetown University, Washington, DC.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sinclair</LastName>                    <ForeName>Stephen</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>From the Human Motor Control Section, Medical Neurology Branch (C.W.M., K.L., G.S.L., G.C., M.H., S.G.H.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; Department of Neurology (C.W.M.), Stony Brook University School of Medicine, NY; Department of Neurology (K.L.), University of Louisville, KY; Experimental Therapeutics and Pathophysiology Branch (R.A.) and Office of the Clinical Director (S.S.), National Institute of Mental Health, NIH, Bethesda, MD; and Department of Psychiatry (S.A.E.), Georgetown University, Washington, DC.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Epstein</LastName>                    <ForeName>Steven A</ForeName>                    <Initials>SA</Initials>                    <AffiliationInfo>                        <Affiliation>From the Human Motor Control Section, Medical Neurology Branch (C.W.M., K.L., G.S.L., G.C., M.H., S.G.H.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; Department of Neurology (C.W.M.), Stony Brook University School of Medicine, NY; Department of Neurology (K.L.), University of Louisville, KY; Experimental Therapeutics and Pathophysiology Branch (R.A.) and Office of the Clinical Director (S.S.), National Institute of Mental Health, NIH, Bethesda, MD; and Department of Psychiatry (S.A.E.), Georgetown University, Washington, DC.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hallett</LastName>                    <ForeName>Mark</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>From the Human Motor Control Section, Medical Neurology Branch (C.W.M., K.L., G.S.L., G.C., M.H., S.G.H.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; Department of Neurology (C.W.M.), Stony Brook University School of Medicine, NY; Department of Neurology (K.L.), University of Louisville, KY; Experimental Therapeutics and Pathophysiology Branch (R.A.) and Office of the Clinical Director (S.S.), National Institute of Mental Health, NIH, Bethesda, MD; and Department of Psychiatry (S.A.E.), Georgetown University, Washington, DC.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Horovitz</LastName>                    <ForeName>Silvina G</ForeName>                    <Initials>SG</Initials>                    <AffiliationInfo>                        <Affiliation>From the Human Motor Control Section, Medical Neurology Branch (C.W.M., K.L., G.S.L., G.C., M.H., S.G.H.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; Department of Neurology (C.W.M.), Stony Brook University School of Medicine, NY; Department of Neurology (K.L.), University of Louisville, KY; Experimental Therapeutics and Pathophysiology Branch (R.A.) and Office of the Clinical Director (S.S.), National Institute of Mental Health, NIH, Bethesda, MD; and Department of Psychiatry (S.A.E.), Georgetown University, Washington, DC.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Neurology</MedlineTA>            <NlmUniqueID>0401060</NlmUniqueID>            <ISSNLinking>0028-3878</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30305450</ArticleId>            <ArticleId IdType="pii">WNL.0000000000006514</ArticleId>            <ArticleId IdType="doi">10.1212/WNL.0000000000006514</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30305443</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>11</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1526-632X</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>Neurology</Title>                <ISOAbbreviation>Neurology</ISOAbbreviation>            </Journal>            <ArticleTitle>Atrial fibrillation, antithrombotic treatment, and cognitive aging: A population-based study.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">10.1212/WNL.0000000000006456</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000006456</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the association of atrial fibrillation (AF) with cognitive decline and dementia in old age, and to explore the cognitive benefit of antithrombotic treatment in patients with AF.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">This population-based cohort study included 2,685 dementia-free participants from the Swedish National Study on Aging and Care in Kungsholmen, who were regularly examined from 2001-2004 to 2010-2013. AF was ascertained from clinical examination, ECG, and patient registry. Global cognitive function was assessed using the Mini-Mental State Examination. We followed the DSM-IV criteria for the diagnosis of dementia, the NINDS-AIREN (National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l'Enseignement en Neurosciences) criteria for vascular dementia, and the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) criteria for Alzheimer disease. Data were analyzed using multiple linear mixed-effects and Cox regression models.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 243 participants (9.1%) with AF at baseline. During the 9-year follow-up period, 279 participants (11.4%) developed AF and 399 (14.9%) developed dementia. As a time-varying variable, AF was significantly associated with a faster annual Mini-Mental State Examination decline (β coefficient = -0.24, 95% confidence interval [CI]: -0.31 to -0.16) and an increased hazard ratio (HR) of all-cause dementia (HR = 1.40, 95% CI: 1.11-1.77) and vascular and mixed dementia (HR = 1.88, 95% CI: 1.09-3.23), but not Alzheimer disease (HR = 1.33, 95% CI: 0.92-1.94). Among people with either prevalent or incident AF, use of anticoagulant drugs, but not antiplatelet treatment, was associated with a 60% decreased risk of dementia (HR = 0.40, 95% CI: 0.18-0.92).</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">AF is associated with a faster global cognitive decline and an increased risk of dementia in older people. Use of anticoagulant drugs may reduce dementia risk in patients with AF.</AbstractText>                <CopyrightInformation>Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Ding</LastName>                    <ForeName>Mozhu</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>From the Aging Research Center (M.D., L.F., K.J., G.S., J.F., A.M., C.Q.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University; Stockholm Gerontology Research Center (L.F.), Stockholm; Institute of Environmental Medicine (P.L.), Karolinska Institutet, Stockholm; Department of Cardiology (P.L.), Danderyd Hospital, Stockholm, Sweden; and Department of Clinical and Experimental Sciences (A.M.), University of Brescia, Italy. mozhu.ding@ki.se.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fratiglioni</LastName>                    <ForeName>Laura</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>From the Aging Research Center (M.D., L.F., K.J., G.S., J.F., A.M., C.Q.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University; Stockholm Gerontology Research Center (L.F.), Stockholm; Institute of Environmental Medicine (P.L.), Karolinska Institutet, Stockholm; Department of Cardiology (P.L.), Danderyd Hospital, Stockholm, Sweden; and Department of Clinical and Experimental Sciences (A.M.), University of Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Johnell</LastName>                    <ForeName>Kristina</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>From the Aging Research Center (M.D., L.F., K.J., G.S., J.F., A.M., C.Q.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University; Stockholm Gerontology Research Center (L.F.), Stockholm; Institute of Environmental Medicine (P.L.), Karolinska Institutet, Stockholm; Department of Cardiology (P.L.), Danderyd Hospital, Stockholm, Sweden; and Department of Clinical and Experimental Sciences (A.M.), University of Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Santoni</LastName>                    <ForeName>Giola</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>From the Aging Research Center (M.D., L.F., K.J., G.S., J.F., A.M., C.Q.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University; Stockholm Gerontology Research Center (L.F.), Stockholm; Institute of Environmental Medicine (P.L.), Karolinska Institutet, Stockholm; Department of Cardiology (P.L.), Danderyd Hospital, Stockholm, Sweden; and Department of Clinical and Experimental Sciences (A.M.), University of Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fastbom</LastName>                    <ForeName>Johan</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>From the Aging Research Center (M.D., L.F., K.J., G.S., J.F., A.M., C.Q.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University; Stockholm Gerontology Research Center (L.F.), Stockholm; Institute of Environmental Medicine (P.L.), Karolinska Institutet, Stockholm; Department of Cardiology (P.L.), Danderyd Hospital, Stockholm, Sweden; and Department of Clinical and Experimental Sciences (A.M.), University of Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ljungman</LastName>                    <ForeName>Petter</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>From the Aging Research Center (M.D., L.F., K.J., G.S., J.F., A.M., C.Q.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University; Stockholm Gerontology Research Center (L.F.), Stockholm; Institute of Environmental Medicine (P.L.), Karolinska Institutet, Stockholm; Department of Cardiology (P.L.), Danderyd Hospital, Stockholm, Sweden; and Department of Clinical and Experimental Sciences (A.M.), University of Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Marengoni</LastName>                    <ForeName>Alessandra</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>From the Aging Research Center (M.D., L.F., K.J., G.S., J.F., A.M., C.Q.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University; Stockholm Gerontology Research Center (L.F.), Stockholm; Institute of Environmental Medicine (P.L.), Karolinska Institutet, Stockholm; Department of Cardiology (P.L.), Danderyd Hospital, Stockholm, Sweden; and Department of Clinical and Experimental Sciences (A.M.), University of Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Qiu</LastName>                    <ForeName>Chengxuan</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>From the Aging Research Center (M.D., L.F., K.J., G.S., J.F., A.M., C.Q.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University; Stockholm Gerontology Research Center (L.F.), Stockholm; Institute of Environmental Medicine (P.L.), Karolinska Institutet, Stockholm; Department of Cardiology (P.L.), Danderyd Hospital, Stockholm, Sweden; and Department of Clinical and Experimental Sciences (A.M.), University of Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Neurology</MedlineTA>            <NlmUniqueID>0401060</NlmUniqueID>            <ISSNLinking>0028-3878</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>01</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30305443</ArticleId>            <ArticleId IdType="pii">WNL.0000000000006456</ArticleId>            <ArticleId IdType="doi">10.1212/WNL.0000000000006456</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30305148</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>11</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1745-6215</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>19</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>Trials</Title>                <ISOAbbreviation>Trials</ISOAbbreviation>            </Journal>            <ArticleTitle>Psychological Support for Personality (PSP) versus treatment as usual: study protocol for a feasibility randomized controlled trial of a low intensity intervention for people with personality disorder.</ArticleTitle>            <Pagination>                <MedlinePgn>547</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-018-2920-0</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous research has demonstrated the clinical effectiveness of long-term psychological treatment for people with some types of personality disorder. However, the high intensity and cost of these interventions limit their availability. Lower-intensity interventions are increasingly being offered to people with personality disorder, but their clinical and cost effectiveness have not been properly tested in experimental studies. We therefore set out to develop a low intensity intervention for people with personality disorder and to test the feasibility of conducting a randomized controlled trial to compare the clinical effectiveness of this intervention with that of treatment as usual (TAU).</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">A two-arm, parallel-group, single-blind, randomized controlled trial of Psychological Support for Personality (PSP) versus TAU for people aged over 18 years, who are using secondary care mental health services and have personality disorder. We will exclude people with co-existing organic or psychotic mental disorders (dementia, bipolar affective disorder, delusional disorder, schizophrenia, schizoaffective disorder, or schizotypal disorder), those with cognitive or language difficulties that would preclude them from providing informed consent or compromise participation in study procedures, and those who are already receiving psychological treatment for personality disorder. Participants will be randomized via a remote system in a ratio of PSP to TAU of 1:1. Randomization will be stratified according to the referring team and gender of the participant. A single follow-up assessment will be conducted by masked researchers 24 weeks after randomization to assess mental health (using the Warwick and Edinburgh Well-Being Schedule), social functioning (using the Work and Social Adjustment Scale), health-related quality of life (EQ-5D-5 L), incidence of suicidal behavior, satisfaction with care (Client Satisfaction Questionnaire), and resource use and costs using a modified version of the Adult Service Use Schedule. In addition to this, each participant will be asked to complete the patient version of the Clinical Global Impression Scale. Feasibility and acceptability will primarily be judged by study recruitment rate and engagement and retention in treatment. The analysis will focus principally on descriptive data on the rate of recruitment, characteristics of participants, attrition, adherence to therapy, and follow-up. We will explore the distribution of study outcomes to investigate assumptions of normality in order to plan the analysis and sample size of a future definitive trial.</AbstractText>                <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Most people with personality disorder do not currently receive evidence-based interventions. While a number of high intensity psychological treatments have been shown to be effective, there is an urgent need to develop effective low intensity approaches to help people unable to use existing treatments. PSP is a low intensity intervention for individuals, which was developed following extensive consultation with users and providers of services for people with personality disorder. This study aims to examine the feasibility of a randomized trial of PSP compared to TAU for people with personality disorder.</AbstractText>                <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ISRCTN Registry, ISRCTN14994755 . Registered on 18 July 2017.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Crawford</LastName>                    <ForeName>Mike J</ForeName>                    <Initials>MJ</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-3137-5772</Identifier>                    <AffiliationInfo>                        <Affiliation>Personality Disorder Research Unit, Centre for Psychiatry, Imperial College London, London, UK. m.crawford@imperial.ac.uk.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medicine, Division of Brain Sciences, Centre for Psychiatry, 7th Floor Commonwealth Building, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK. m.crawford@imperial.ac.uk.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Thana</LastName>                    <ForeName>Lavanya</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Personality Disorder Research Unit, Centre for Psychiatry, Imperial College London, London, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medicine, Division of Brain Sciences, Centre for Psychiatry, 7th Floor Commonwealth Building, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Parker</LastName>                    <ForeName>Jennie</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Research and Development Department, Central and North West London NHS Foundation Trust, Stephenson House, 75 Hampstead Road, London, NW1 2PL, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Turner</LastName>                    <ForeName>Oliver</ForeName>                    <Initials>O</Initials>                    <AffiliationInfo>                        <Affiliation>Barnet, Enfield and Haringey NHS Foundation Trust, St Ann's Hospital, St Ann's Road, Haringey, London, N15 3TH, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xing</LastName>                    <ForeName>Kwek Pei</ForeName>                    <Initials>KP</Initials>                    <AffiliationInfo>                        <Affiliation>Personality Disorder Research Unit, Centre for Psychiatry, Imperial College London, London, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medicine, Division of Brain Sciences, Centre for Psychiatry, 7th Floor Commonwealth Building, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>McMurran</LastName>                    <ForeName>Mary</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Section of Forensic Mental Health, University of Nottingham, Nottingham, NG7 2UH, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Moran</LastName>                    <ForeName>Paul</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>School of Social and Community Medicine, Bristol University, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Weaver</LastName>                    <ForeName>Timothy</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Mental Health Social Work &amp; Integrative Medicine, Middlesex University, The Burroughs, Hendon, London, NW4 4BT, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Barrett</LastName>                    <ForeName>Barbara</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Centre for the Economics of Mental and Physical Health, King's College London, David Goldberg Centre, De Crespigny Park, London, SE5 8AF, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Claringbold</LastName>                    <ForeName>Amy</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Personality Disorder Research Unit, Centre for Psychiatry, Imperial College London, London, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medicine, Division of Brain Sciences, Centre for Psychiatry, 7th Floor Commonwealth Building, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bassett</LastName>                    <ForeName>Paul</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Statsconsultancy Limited, 40 Longwood Lane, Amersham, Buckinghamshire, HP7 9EN, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sanatinia</LastName>                    <ForeName>Rahil</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Personality Disorder Research Unit, Centre for Psychiatry, Imperial College London, London, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medicine, Division of Brain Sciences, Centre for Psychiatry, 7th Floor Commonwealth Building, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>PB-PG-0215-36065</GrantID>                    <Agency>Research for Patient Benefit Programme</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Trials</MedlineTA>            <NlmUniqueID>101263253</NlmUniqueID>            <ISSNLinking>1745-6215</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Brief intervention</Keyword>            <Keyword MajorTopicYN="N">Low intensity</Keyword>            <Keyword MajorTopicYN="N">Personality disorder</Keyword>            <Keyword MajorTopicYN="N">Psychological treatment</Keyword>            <Keyword MajorTopicYN="N">Randomized trial</Keyword>            <Keyword MajorTopicYN="N">Suicidal behavior</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30305148</ArticleId>            <ArticleId IdType="doi">10.1186/s13063-018-2920-0</ArticleId>            <ArticleId IdType="pii">10.1186/s13063-018-2920-0</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30304442</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2168-6238</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>08</Day>                    </PubDate>                </JournalIssue>                <Title>JAMA psychiatry</Title>                <ISOAbbreviation>JAMA Psychiatry</ISOAbbreviation>            </Journal>            <ArticleTitle>Association of Pre-onset Subthreshold Psychotic Symptoms With Longitudinal Outcomes During Treatment of a First Episode of Psychosis.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapsychiatry.2018.2552</ELocationID>            <Abstract>                <AbstractText Label="Importance" NlmCategory="UNASSIGNED">The clinical high-risk state in psychosis is most often characterized by subthreshold psychotic symptoms (STPS) and represents a target for psychosis prevention. However, evidence suggests that between 30% and 50% of patients with a first episode of psychosis (FEP) report no prior history of STPS, indicating that not all patients with FEP experience a previous clinical high-risk phase. As with other early characteristics of illness onset, this diversity in the early course of symptoms may offer prognostic value for subsequent clinical trajectories.</AbstractText>                <AbstractText Label="Objective" NlmCategory="UNASSIGNED">To determine whether a history of pre-onset STPS is associated with differential 1-year treatment outcomes in an early intervention service for FEP.</AbstractText>                <AbstractText Label="Design, Setting, and Participants" NlmCategory="UNASSIGNED">Data on 195 patients 15 to 35 years of age who were recruited between January 17, 2003, and October 17, 2013, were collected from a catchment-based specialized early intervention service for FEP. Patients who reported experiencing at least 1 STPS prior to the onset of FEP were identified as STPS present (STPSp; n = 135); those who reported no such history were identified as STPS absent (STPSa; n = 60). Statistical analysis was conducted from December 15, 2016, to February 15, 2018.</AbstractText>                <AbstractText Label="Main Outcomes and Measures" NlmCategory="UNASSIGNED">Summary scores on the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Negative Symptoms, Calgary Depression Scale for Schizophrenia, Hamilton Anxiety Rating Scale, Global Assessment of Functioning scores, and Social and Occupational Functioning Assessment Scale scores at baseline and after 1 year of treatment were analyzed to evaluate 1-year outcomes.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Individuals in the STPSp group (39 female and 96 male participants; mean [SD] age, 23.4 [4.2] years) and the STPSa group (20 female and 40 male participants; mean [SD] age, 23.9 [5.1] years) did not differ in symptom severity or functioning at baseline. Although both groups improved by 1 year of treatment, mixed analyses of covariance (controlling for duration of untreated psychosis) revealed group-by-time interactions for scores on the Scale for the Assessment of Negative Symptoms (F1,192 = 6.17; P = .01), the Global Assessment of Functioning (F1,188 = 7.54; P = .006), and the Social and Occupational Functioning Assessment Scale (F1,192 = 3.79; P = .05). Mixed analyses of covariance also revealed a group effect for scores on the Scale for the Assessment of Positive Symptoms (F1,192 = 5.31; P = .02). After controlling for multiple comparisons, all significant results indicate poorer 1-year outcomes for patients with STPSp compared with patients with STPSa.</AbstractText>                <AbstractText Label="Conclusions and Relevance" NlmCategory="UNASSIGNED">A history of pre-onset STPS consistent with a prior clinical high-risk state is associated with poorer outcomes in psychotic symptoms and global functioning for patients after 1 year of treatment for FEP. The presence or absence of pre-onset STPS therefore has prognostic value for treatment outcomes, even during a later stage of psychotic illness.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Rosengard</LastName>                    <ForeName>Rachel J</ForeName>                    <Initials>RJ</Initials>                    <AffiliationInfo>                        <Affiliation>Prevention and Early Intervention Program for Psychosis (PEPP-Montreal), Douglas Mental Health University Institute, Montreal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Integrated Program in Neuroscience, McGill University, Montreal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Malla</LastName>                    <ForeName>Ashok</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Prevention and Early Intervention Program for Psychosis (PEPP-Montreal), Douglas Mental Health University Institute, Montreal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, McGill University, Montreal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mustafa</LastName>                    <ForeName>Sally</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Prevention and Early Intervention Program for Psychosis (PEPP-Montreal), Douglas Mental Health University Institute, Montreal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, McGill University, Montreal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Iyer</LastName>                    <ForeName>Srividya N</ForeName>                    <Initials>SN</Initials>                    <AffiliationInfo>                        <Affiliation>Prevention and Early Intervention Program for Psychosis (PEPP-Montreal), Douglas Mental Health University Institute, Montreal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, McGill University, Montreal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Joober</LastName>                    <ForeName>Ridha</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Prevention and Early Intervention Program for Psychosis (PEPP-Montreal), Douglas Mental Health University Institute, Montreal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, McGill University, Montreal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bodnar</LastName>                    <ForeName>Michael</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, McGill University, Montreal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lepage</LastName>                    <ForeName>Martin</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Prevention and Early Intervention Program for Psychosis (PEPP-Montreal), Douglas Mental Health University Institute, Montreal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Integrated Program in Neuroscience, McGill University, Montreal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, McGill University, Montreal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shah</LastName>                    <ForeName>Jai L</ForeName>                    <Initials>JL</Initials>                    <AffiliationInfo>                        <Affiliation>Prevention and Early Intervention Program for Psychosis (PEPP-Montreal), Douglas Mental Health University Institute, Montreal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Integrated Program in Neuroscience, McGill University, Montreal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, McGill University, Montreal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>JAMA Psychiatry</MedlineTA>            <NlmUniqueID>101589550</NlmUniqueID>            <ISSNLinking>2168-622X</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30304442</ArticleId>            <ArticleId IdType="pii">2706434</ArticleId>            <ArticleId IdType="doi">10.1001/jamapsychiatry.2018.2552</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30304337</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2168-6238</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>JAMA psychiatry</Title>                <ISOAbbreviation>JAMA Psychiatry</ISOAbbreviation>            </Journal>            <ArticleTitle>Mapping the Heterogeneous Phenotype of Schizophrenia and Bipolar Disorder Using Normative Models.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapsychiatry.2018.2467</ELocationID>            <Abstract>                <AbstractText Label="Importance" NlmCategory="UNASSIGNED">Schizophrenia and bipolar disorder are severe and complex brain disorders characterized by substantial clinical and biological heterogeneity. However, case-control studies often ignore such heterogeneity through their focus on the average patient, which may be the core reason for a lack of robust biomarkers indicative of an individual's treatment response and outcome.</AbstractText>                <AbstractText Label="Objectives" NlmCategory="UNASSIGNED">To investigate the degree to which case-control analyses disguise interindividual differences in brain structure among patients with schizophrenia and bipolar disorder and to map the brain alterations linked to these disorders at the level of individual patients.</AbstractText>                <AbstractText Label="Design, Setting, and Participants" NlmCategory="UNASSIGNED">This study used cross-sectional, T1-weighted magnetic resonance imaging data from participants recruited for the Thematically Organized Psychosis study from October 27, 2004, to October 17, 2012. Data were reanalyzed in 2017 and 2018. Patients were recruited from inpatient and outpatient clinics in the Oslo area of Norway, and healthy individuals from the same catchment area were drawn from the national population registry.</AbstractText>                <AbstractText Label="Main Outcomes and Measures" NlmCategory="UNASSIGNED">Interindividual differences in brain structure among patients with schizophrenia and bipolar disorder. Voxel-based morphometry maps were computed, which were used for normative modeling to map the range of interindividual differences in brain structure.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">This study included 218 patients with schizophrenia spectrum disorders (mean [SD] age, 30 [9.3] years; 126 [57.8%] male), of whom 163 had schizophrenia (mean [SD] age, 31 [8.7] years; 105 [64.4%] male) and 190 had bipolar disorder (mean [SD] age, 34 [11.3] years; 79 [41.6%] male), and 256 healthy individuals (mean [SD] age, 34 [9.5] years; 140 [54.7%] male). At the level of the individual, deviations from the normative model were frequent in both disorders but highly heterogeneous. Overlap of more than 2% among patients was observed in only a few loci, primarily in frontal, temporal, and cerebellar regions. The proportion of alterations was associated with diagnosis and cognitive and clinical characteristics within clinical groups. Patients with schizophrenia, on average, had significantly reduced gray matter in frontal regions, cerebellum, and temporal cortex. In patients with bipolar disorder, mean deviations were primarily present in cerebellar regions.</AbstractText>                <AbstractText Label="Conclusions and Relevance" NlmCategory="UNASSIGNED">This study found that group-level differences disguised biological heterogeneity and interindividual differences among patients with the same diagnosis. This finding suggests that the idea of the average patient is a noninformative construct in psychiatry that falls apart when mapping abnormalities at the level of the individual patient. This study presents a workable route toward precision medicine in psychiatry.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Wolfers</LastName>                    <ForeName>Thomas</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Donders Centre for Cognitive Neuroimaging, Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, the Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Doan</LastName>                    <ForeName>Nhat Trung</ForeName>                    <Initials>NT</Initials>                    <AffiliationInfo>                        <Affiliation>Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kaufmann</LastName>                    <ForeName>Tobias</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Alnæs</LastName>                    <ForeName>Dag</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Moberget</LastName>                    <ForeName>Torgeir</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Agartz</LastName>                    <ForeName>Ingrid</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Buitelaar</LastName>                    <ForeName>Jan K</ForeName>                    <Initials>JK</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Karakter Child and Adolescent Psychiatry University Centre, Radboud University Medical Centre, Nijmegen, the Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ueland</LastName>                    <ForeName>Torill</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Oslo, Oslo, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Melle</LastName>                    <ForeName>Ingrid</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Franke</LastName>                    <ForeName>Barbara</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Andreassen</LastName>                    <ForeName>Ole A</ForeName>                    <Initials>OA</Initials>                    <AffiliationInfo>                        <Affiliation>Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Beckmann</LastName>                    <ForeName>Christian F</ForeName>                    <Initials>CF</Initials>                    <AffiliationInfo>                        <Affiliation>Donders Centre for Cognitive Neuroimaging, Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, the Netherlands.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Centre for Functional MRI of the Brain, University of Oxford, Oxford, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Westlye</LastName>                    <ForeName>Lars T</ForeName>                    <Initials>LT</Initials>                    <AffiliationInfo>                        <Affiliation>Norwegian Centre for Mental Disorders Research, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Oslo, Oslo, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Marquand</LastName>                    <ForeName>Andre F</ForeName>                    <Initials>AF</Initials>                    <AffiliationInfo>                        <Affiliation>Donders Centre for Cognitive Neuroimaging, Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, the Netherlands.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Neuroimaging, Institute of Psychiatry, King's College London, London, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>JAMA Psychiatry</MedlineTA>            <NlmUniqueID>101589550</NlmUniqueID>            <ISSNLinking>2168-622X</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30304337</ArticleId>            <ArticleId IdType="pii">2705762</ArticleId>            <ArticleId IdType="doi">10.1001/jamapsychiatry.2018.2467</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30304241</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1678-2690</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>90</Volume>                    <Issue>3</Issue>                    <PubDate>                        <MedlineDate>2018 Jul-Sep</MedlineDate>                    </PubDate>                </JournalIssue>                <Title>Anais da Academia Brasileira de Ciencias</Title>                <ISOAbbreviation>An. Acad. Bras. Cienc.</ISOAbbreviation>            </Journal>            <ArticleTitle>Dextran Sulphate of Sodium-induced colitis in mice: antihyperalgesic effects of ethanolic extract of Citrus reticulata and potential damage to the central nervous system.</ArticleTitle>            <Pagination>                <MedlinePgn>3139-3145</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0001-37652018000603139</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1590/0001-3765201820170946</ELocationID>            <Abstract>                <AbstractText>Citrus species are widely related to antihyperalgesic and anti-inflammatory effects. The aim of this study was to investigate if treatment with ethanolic extract from peels of mature Citrus reticulata Blanco causes antihyperalgesic effects on the referred mechanical hyperalgesia in a model of dextran sulphate of sodium (DSS)-induced colitis in mice, as well as the possible oxidative damage in different regions of the brain induced by its inflammatory reaction. Antihyperalgesia (30 to 300 mg/kg) was investigated by behavioral response (frequency of response to von Frey filament stimulation) in Swiss mice, while damage to central nervous system was investigated through techniques that evaluated oxidative stress using male black C57 BL6 mice (n=8). Treatment of the animals with the extract (100 mg/kg) from days 3 to 5 after colitis induction reduced referred the mechanical hyperalgesia (32.6 ± 5.1) in relation to the control group (57.4 ± 2.0). Levels of lipid peroxidation or carbonyl proteins were augmented in colitis-induced animals in relation to the disease group. These results indicated an antihyperalgesic effect of the studied extract and a potential impairment of the central nervous system functioning caused by inflammation during colitis, which could be related to mental disorders observed in patients suffering of this pathology.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Hilel</LastName>                    <ForeName>Alexandre S</ForeName>                    <Initials>AS</Initials>                    <AffiliationInfo>                        <Affiliation>Programa de Pós-Graduação em Ciências da Saúde, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Laboratório de Neurociência Experimental/LaNex, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gysemans</LastName>                    <ForeName>Bruna</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratório de Neurociência Experimental/LaNex, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Curso de Graduação em Medicina, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lisbôa</LastName>                    <ForeName>Maria E M</ForeName>                    <Initials>MEM</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratório de Neurociência Experimental/LaNex, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Curso de Graduação em Medicina, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Heymanns</LastName>                    <ForeName>Ana C</ForeName>                    <Initials>AC</Initials>                    <AffiliationInfo>                        <Affiliation>Programa de Pós-Graduação em Ciências da Saúde, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Laboratório de Neurociência Experimental/LaNex, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Freiberger</LastName>                    <ForeName>Viviane</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Programa de Pós-Graduação em Ciências da Saúde, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Laboratório de Neurociência Experimental/LaNex, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ventura</LastName>                    <ForeName>Letícia</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Programa de Pós-Graduação em Ciências da Saúde, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Laboratório de Neurociência Experimental/LaNex, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Magnago</LastName>                    <ForeName>Rachel F</ForeName>                    <Initials>RF</Initials>                    <AffiliationInfo>                        <Affiliation>Programa de Pós-Graduação em Ciências Ambientais/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Comim</LastName>                    <ForeName>Clarissa M</ForeName>                    <Initials>CM</Initials>                    <AffiliationInfo>                        <Affiliation>Programa de Pós-Graduação em Ciências da Saúde, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Laboratório de Neurociência Experimental/LaNex, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Horewics</LastName>                    <ForeName>Verônica</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Programa de Pós-Graduação em Ciências da Saúde, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Laboratório de Neurociência Experimental/LaNex, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Martins</LastName>                    <ForeName>Daniel F</ForeName>                    <Initials>DF</Initials>                    <AffiliationInfo>                        <Affiliation>Programa de Pós-Graduação em Ciências da Saúde, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Laboratório de Neurociência Experimental/LaNex, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bobinski</LastName>                    <ForeName>Franciane</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Programa de Pós-Graduação em Ciências da Saúde, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Laboratório de Neurociência Experimental/LaNex, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Piovezan</LastName>                    <ForeName>Anna P</ForeName>                    <Initials>AP</Initials>                    <AffiliationInfo>                        <Affiliation>Programa de Pós-Graduação em Ciências da Saúde, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Laboratório de Neurociência Experimental/LaNex, Universidade do Sul de Santa Catarina/UNISUL, Avenida Pedra Branca, 25, 88137-270 Palhoça, SC, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Brazil</Country>            <MedlineTA>An Acad Bras Cienc</MedlineTA>            <NlmUniqueID>7503280</NlmUniqueID>            <ISSNLinking>0001-3765</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>11</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>03</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30304241</ArticleId>            <ArticleId IdType="pii">S0001-37652018000603139</ArticleId>            <ArticleId IdType="doi">10.1590/0001-3765201820170946</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30303888</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1935-3227</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>09</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of addiction medicine</Title>                <ISOAbbreviation>J Addict Med</ISOAbbreviation>            </Journal>            <ArticleTitle>Evaluating the Validity of the DSM-5 Alcohol Use Disorder Diagnostic Criteria in a Sample of Treatment-seeking Native Americans.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/ADM.0000000000000452</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Despite high rates of alcohol use disorder (AUD) and alcohol-induced deaths among Native Americans, there has been limited study of the construct validity of the AUD diagnostic criteria. The purpose of the current study was to examine the validity of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) AUD criteria in a treatment-seeking group of Native Americans.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">As part of a larger study, 79 Native Americans concerned about their alcohol or drug use were recruited from a substance use treatment agency located on a reservation in the southwestern United States. Participants were administered the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (SCID for DSM-IV-TR) reworded to assess 11 DSM-5 criteria for AUD. Confirmatory factor analysis (CFA) was used to test the validity of the AUD diagnostic criteria, and item response theory (IRT) was used to examine the item characteristics of the AUD diagnostic criteria in this Native American sample.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">CFA indicated that a 1-factor model of the 11 items provided a good fit of the data. IRT parameter estimates suggested that &quot;withdrawal,&quot; &quot;social/interpersonal problems,&quot; and &quot;activities given up to use&quot; had the highest magnitude of discrimination. &quot;Much time spent using&quot; and &quot;activities given up to use&quot; were associated with the greatest severity.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The current study provided support for the validity of the AUD DSM-5 criteria and a unidimensional latent construct of AUD in this sample of treatment-seeking Native Americans. IRT analyses replicate findings from previous studies. To our knowledge, this is the first study to examine the validity of the DSM-5 AUD criteria in a treatment-seeking sample of Native Americans. Continued research in other Native American samples is needed.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Serier</LastName>                    <ForeName>Kelsey N</ForeName>                    <Initials>KN</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of New Mexico, Albuquerque, NM (KNS); Center on Alcoholism, Substance Abuse, &amp; Addictions, Department of Psychology, University of New Mexico, Albuquerque, NM (KLV); and Department of Psychology, University of New Mexico, Albuquerque, NM (RES).</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Venner</LastName>                    <ForeName>Kamilla L</ForeName>                    <Initials>KL</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Sarafin</LastName>                    <ForeName>Ruth E</ForeName>                    <Initials>RE</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>09</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Addict Med</MedlineTA>            <NlmUniqueID>101306759</NlmUniqueID>            <ISSNLinking>1932-0620</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30303888</ArticleId>            <ArticleId IdType="doi">10.1097/ADM.0000000000000452</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30303861</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1533-712X</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>09</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of clinical psychopharmacology</Title>                <ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation>            </Journal>            <ArticleTitle>Methylenedioxymethamphetamine (MDMA) in Psychiatry: Pros, Cons, and Suggestions.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/JCP.0000000000000962</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">For a number of mental health disorders, including posttraumatic stress disorders (PTSD), there are not many available treatment options. Recently, there has been renewed interest in the potential of methylenedioxymethamphetamine (MDMA) to restore function for patients with these disorders. The primary hypothesis is that MDMA, via prosocial effects, increases the ability of patients to address the underlying psychopathology of the disorder. However, the use of MDMA poses potential problems of neurotoxicity, in addition to its own potential for misuse.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">In this article, the proposed potential of MDMA as an adjunct to psychotherapy for PTSD is evaluated. The rationale for the use of MDMA and the positive results of studies that have administered MDMA in the treatment of PTSD are provided (pros). A description of potential adverse effects of treatment is also presented (cons). An overview of MDMA pharmacology and pharmacokinetics and a description of potential adverse effects of treatments are also presented. Methylenedioxymethamphetamine-produced oxytocin release and decreased expression of fear conditioning as well as one of the MDMA enantiomers (the n R- entaniomer) are suggested as potential mechanisms for the beneficial effects of MDMA in PTSD (suggestions).</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">There is some evidence that MDMA facilitates recovery of PTSD. However, the significant adverse effects of MDMA raise concern for its adoption as a pharmacotherapy. Alternative potential treatments with less adverse effects and that are based on the ubiquitous pharmacology of MDMA are presented.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We suggest that additional research investigating the basis for the putative beneficial effects of MDMA might reveal an effective treatment with fewer adverse effects. Suggestions of alternative treatments based on the behavioral pharmacology and toxicology of MDMA and its enantiomers are presented.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Schenk</LastName>                    <ForeName>Susan</ForeName>                    <Initials>S</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Newcombe</LastName>                    <ForeName>David</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Centre for Addiction Research, School of Population Health, University of Auckland, Auckland, New Zealand.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>09</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Clin Psychopharmacol</MedlineTA>            <NlmUniqueID>8109496</NlmUniqueID>            <ISSNLinking>0271-0749</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30303861</ArticleId>            <ArticleId IdType="doi">10.1097/JCP.0000000000000962</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30303308</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1751-7893</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>Early intervention in psychiatry</Title>                <ISOAbbreviation>Early Interv Psychiatry</ISOAbbreviation>            </Journal>            <ArticleTitle>Does rTMS reduce depressive symptoms in young people who have not responded to antidepressants?</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/eip.12743</ELocationID>            <Abstract>                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">Depression is common in young people, and there is a need for safe, effective treatments. This study examined the efficacy of repetitive transcranial magnetic stimulation in a sample of young people aged 17 to 25 years.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective study included 15 people aged 17 to 25 years referred by their private psychiatrists affiliated with Ramsay Health Care, South Australia Mental Health Services. All patients met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for treatment-resistant Major Depressive Disorder. Eleven patients received right unilateral treatment and four patients received bilateral treatment. Patients were assessed at baseline and after treatment.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">There was a significant improvement on the Hamilton Rating Scale for Depression (t(14) = 4.71, P &lt; 0.0001); Montgomery-Åsperg Depression Rating Scale (t(14) = 3.96, P &lt; 0.01) and the Zung Self-Rating Depression Scale (t(14) = 4.13, P &lt; 0.01). There was no difference in response by gender or age. The response rates in these young people did not differ significantly from those of adults aged 25 to 82 years.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This open label, naturalistic study suggests that repetitive transcranial magnetic stimulation is an effective treatment in young adults who have treatment-resistant depression. Randomized sham-controlled studies are needed to further investigate the efficacy of this treatment in this age group.</AbstractText>                <CopyrightInformation>© 2018 John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Rosenich</LastName>                    <ForeName>Emily</ForeName>                    <Initials>E</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-7600-9277</Identifier>                    <AffiliationInfo>                        <Affiliation>International Centre for Allied Health Evidence, Sansom Institute for Health Research, University of South Australia, Adelaide, South Australia, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gill</LastName>                    <ForeName>Shane</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Discipline of Psychiatry, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>The Adelaide Clinic, Ramsay Health Care (SA) Mental Health Services, Adelaide, South Australia, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>South Australian Psychiatry Training Committee, Central Adelaide Local Health Network-Mental Health Directorate, Adelaide, South Australia, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Clarke</LastName>                    <ForeName>Patrick</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Discipline of Psychiatry, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>The Adelaide Clinic, Ramsay Health Care (SA) Mental Health Services, Adelaide, South Australia, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Paterson</LastName>                    <ForeName>Tom</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Discipline of Psychiatry, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>The Adelaide Clinic, Ramsay Health Care (SA) Mental Health Services, Adelaide, South Australia, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hahn</LastName>                    <ForeName>Lisa</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Discipline of Psychiatry, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>The Adelaide Clinic, Ramsay Health Care (SA) Mental Health Services, Adelaide, South Australia, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Galletly</LastName>                    <ForeName>Cherrie</ForeName>                    <Initials>C</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-6185-9677</Identifier>                    <AffiliationInfo>                        <Affiliation>Discipline of Psychiatry, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>The Adelaide Clinic, Ramsay Health Care (SA) Mental Health Services, Adelaide, South Australia, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Northern Adelaide Local Health Network, Adelaide, South Australia, Australia.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Australia</Country>            <MedlineTA>Early Interv Psychiatry</MedlineTA>            <NlmUniqueID>101320027</NlmUniqueID>            <ISSNLinking>1751-7885</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">left unilateral rTMS</Keyword>            <Keyword MajorTopicYN="N">major depressive disorder</Keyword>            <Keyword MajorTopicYN="N">rTMS</Keyword>            <Keyword MajorTopicYN="N">treatment resistant</Keyword>            <Keyword MajorTopicYN="N">youth</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30303308</ArticleId>            <ArticleId IdType="doi">10.1111/eip.12743</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30303187</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">2038-1840</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>109</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Recenti progressi in medicina</Title>                <ISOAbbreviation>Recenti Prog Med</ISOAbbreviation>            </Journal>            <ArticleTitle>[Depression in pregnancy: focus on the safety of antidepressant drugs.]</ArticleTitle>            <Pagination>                <MedlinePgn>432-442</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1701/2990.29929</ELocationID>            <Abstract>                <AbstractText>Antepartum depression, frequently in comorbidity with anxiety disorders, is a severe psychopathological condition frequently reported in pregnancy and in many cases associated with obstetric and neonatal complications and potential negative consequences on child neurodevelopment. However, the pharmacological treatment of depression, during pregnancy generates a lot of concerns about the risks of such treatment for the fetus development and the neonatal health. The aim of this review is to present a selection of the latest international literature including recent original studies, systematic reviews, meta-analyses and recommendations from the guidelines, both on the risks of an untreated depressive disorders and on the risk of antidepressant therapy during gestation with drugs belonging to the SSRI and SNRI (SRI) class. An updated information of the recent risk-benefit data of these drug treatments in women with affective disorders in pregnancy may actually enable better and more conscious management of these disorders, not only for those working in the mental health field but also for general practitioners and those of other medical specialties.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Vivenzio</LastName>                    <ForeName>Viviana</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Clinica Psichiatrica, Dipartimento di Neuroscienze, Università Politecnica delle Marche, Ancona.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nardi</LastName>                    <ForeName>Bernardo</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Clinica Psichiatrica, Dipartimento di Neuroscienze, Università Politecnica delle Marche, Ancona.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bellantuono</LastName>                    <ForeName>Cesario</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Ambulatorio di Psichiatria e Psicofarmacologia Perinatale &quot;DeGra&quot;, Ancona, Rimini, Verona.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>ita</Language>            <PublicationTypeList>                <PublicationType UI="D004740">English Abstract</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <VernacularTitle>Depressione in gravidanza: focus sulla sicurezza dei farmaci antidepressivi.</VernacularTitle>        </Article>        <MedlineJournalInfo>            <Country>Italy</Country>            <MedlineTA>Recenti Prog Med</MedlineTA>            <NlmUniqueID>0401271</NlmUniqueID>            <ISSNLinking>0034-1193</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30303187</ArticleId>            <ArticleId IdType="doi">10.1701/2990.29929</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30302925</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1751-7893</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>Early intervention in psychiatry</Title>                <ISOAbbreviation>Early Interv Psychiatry</ISOAbbreviation>            </Journal>            <ArticleTitle>Physical activity and exercise as a universal depression prevention in young people: A narrative review.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/eip.12737</ELocationID>            <Abstract>                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim of this narrative summary was to examine the efficacy of physical activity and exercise as a universal prevention for depression in young people.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a search of the literature in the open-access evidence database of controlled trials and systematic reviews in youth mental health, an initiative between Orygen, The National Centre of Excellence in Youth Mental Health and headspace, National Youth Mental Health Foundation. In April 2018, we searched for all papers published between 1980 and 2017 relating to &quot;Depressive Disorder&quot; under the &quot;Universal Prevention&quot; illness stage and classified as &quot;Physical activity/Exercise&quot; under the treatment/intervention classification. Systematic reviews, randomized control trials (RCTs) and controlled clinical trials were all included.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 11 papers were returned. Three of these studies were observational and eight studies were controlled trials. The reviewed studies indicate that exercise and physical activity might be an effective universal depression prevention intervention for young people. Three of the controlled studies had a passive control group or no control group and only one study had longer-term follow-up. No trial used a longitudinal design to determine if interventions prevent the onset of new cases of depression.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The studies reviewed in the current review demonstrate a bidirectional relationship between physical activity, exercise and adolescent mental health. The results of the current review suggest that physical activity and exercise programs designed to increase the level of activity in young people should be implemented to be attractive and achievable to young people that may have poor psychological health.</AbstractText>                <CopyrightInformation>© 2018 John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Pascoe</LastName>                    <ForeName>Michaela C</ForeName>                    <Initials>MC</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-3831-5660</Identifier>                    <AffiliationInfo>                        <Affiliation>Institute for Health and Sport, Victoria University, Melbourne, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Parker</LastName>                    <ForeName>Alexandra G</ForeName>                    <Initials>AG</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2398-6306</Identifier>                    <AffiliationInfo>                        <Affiliation>Institute for Health and Sport, Victoria University, Melbourne, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Orygen, the National Centre of Excellence in Youth Mental Health (Centre for Youth Mental Health), University of Melbourne, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Australia</Country>            <MedlineTA>Early Interv Psychiatry</MedlineTA>            <NlmUniqueID>101320027</NlmUniqueID>            <ISSNLinking>1751-7885</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">adolescent</Keyword>            <Keyword MajorTopicYN="N">depression</Keyword>            <Keyword MajorTopicYN="N">mood</Keyword>            <Keyword MajorTopicYN="N">physical activity</Keyword>            <Keyword MajorTopicYN="N">well-being</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30302925</ArticleId>            <ArticleId IdType="doi">10.1111/eip.12737</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30302537</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1435-1269</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>09</Day>                    </PubDate>                </JournalIssue>                <Title>Zeitschrift fur Gerontologie und Geriatrie</Title>                <ISOAbbreviation>Z Gerontol Geriatr</ISOAbbreviation>            </Journal>            <ArticleTitle>[Psychiatric pharmacotherapy of older individuals with severe mental illness].</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00391-018-1455-z</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Chronic schizophrenia, depression, and bipolar disorders, among other chronic psychiatric disorders with onset at youth or early adulthood are often referred to as severe mental illness (SMI). Aging with SMI is associated with various psychosocial, physiological, and medical problems with potential impact on psychiatric pharmacotherapy.</AbstractText>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Determination and discussion of problems and special features of the psychopharmacological treatment of older persons with SMI and presentation of treatment recommendations for the distinct diagnoses.</AbstractText>                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">International literature and guidelines were searched. In addition, the basic literature and expert opinions are discussed.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">General problems that influence the psychiatric pharmacotherapy of older persons with SMI include nonadherence, nonresponse, polypharmacy, and distinct pharmacokinetic changes with aging and somatic comorbidity. Psychotropic drugs may exhibit cardiovascular, metabolic, and neuropsychiatric risks, among others. The literature regarding effectiveness of psychotropic drugs, drug groups, or combination of drugs in older patients with SMI is scarce to nonexistent.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Drug treatment of older persons with SMI should be part of an overall treatment plan that also has to include social and psychotherapeutic components that address the specific problems of this population. Most importantly, psychiatric pharmacotherapy should consider these risks and the treatment should be tailored to a patient's individual risk profile. Due to a general lack of evidence in this special population, treatment strategies of standard guidelines should be adjusted with special consideration to physiological changes of age.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Lange-Asschenfeldt</LastName>                    <ForeName>Christian</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Abteilung Gerontopsychiatrie, Klinik und Poliklinik für Psychiatrie und Psychotherapie, LVR-Klinikum, Medizinische Fakultät, Heinrich-Heine-Universität Düsseldorf, Bergische Landstr. 2, 40629, Düsseldorf, Deutschland. christian.lange-asschenfeldt@lvr.de.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>ger</Language>            <PublicationTypeList>                <PublicationType UI="D004740">English Abstract</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <VernacularTitle>Psychopharmakotherapie bei älteren Menschen mit schweren psychischen Erkrankungen.</VernacularTitle>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>09</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Z Gerontol Geriatr</MedlineTA>            <NlmUniqueID>9506215</NlmUniqueID>            <ISSNLinking>0948-6704</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Bipolar disorder</Keyword>            <Keyword MajorTopicYN="N">Chronic depression</Keyword>            <Keyword MajorTopicYN="N">Pharmacotherapy</Keyword>            <Keyword MajorTopicYN="N">Schizophrenia</Keyword>            <Keyword MajorTopicYN="N">Severe mental illness</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30302537</ArticleId>            <ArticleId IdType="doi">10.1007/s00391-018-1455-z</ArticleId>            <ArticleId IdType="pii">10.1007/s00391-018-1455-z</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30302516</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1433-0407</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>09</Day>                    </PubDate>                </JournalIssue>                <Title>Der Nervenarzt</Title>                <ISOAbbreviation>Nervenarzt</ISOAbbreviation>            </Journal>            <ArticleTitle>[Patho- and therapyepigenetics of mental disorders].</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00115-018-0625-y</ELocationID>            <Abstract>                <AbstractText>Epigenetic mechanisms, such as DNA methylation and histone modifications are biochemical alterations of the DNA or its spatial structure. They regulate gene function, can be modified by environmental influences and are temporally dynamic. In this review, the current state of knowledge regarding the role of epigenetics in the pathogenesis of mental disorders is summarized exemplarily for schizophrenia, depression, anxiety disorders and posttraumatic stress disorder. Additionally, findings on epigenetic alterations in the course of pharmacotherapeutic and psychotherapeutic interventions are presented. Epigenetic mechanisms have a central function at the crossroads between genes and environment and consequently in the vulnerability-stress model of mental disorders. Prospectively, in line with a precision medicine approach epigenetic profiles may represent useful markers of disease risk and therapy response or even constitute new druggable targets.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Ziegler</LastName>                    <ForeName>Christiane</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Freiburg, Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg, Hauptstraße 5, 79104, Freiburg, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Schiele</LastName>                    <ForeName>Miriam A</ForeName>                    <Initials>MA</Initials>                    <AffiliationInfo>                        <Affiliation>Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Freiburg, Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg, Hauptstraße 5, 79104, Freiburg, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Domschke</LastName>                    <ForeName>Katharina</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Freiburg, Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg, Hauptstraße 5, 79104, Freiburg, Deutschland. katharina.domschke@uniklinik-freiburg.de.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>ger</Language>            <PublicationTypeList>                <PublicationType UI="D004740">English Abstract</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <VernacularTitle>Patho- und Therapieepigenetik psychischer Erkrankungen.</VernacularTitle>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>09</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Nervenarzt</MedlineTA>            <NlmUniqueID>0400773</NlmUniqueID>            <ISSNLinking>0028-2804</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">DNA methylation</Keyword>            <Keyword MajorTopicYN="N">Epigenetic markers</Keyword>            <Keyword MajorTopicYN="N">Gene-environment interaction</Keyword>            <Keyword MajorTopicYN="N">Histone modifications</Keyword>            <Keyword MajorTopicYN="N">Resilience</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30302516</ArticleId>            <ArticleId IdType="doi">10.1007/s00115-018-0625-y</ArticleId>            <ArticleId IdType="pii">10.1007/s00115-018-0625-y</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30302317</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">2215-0013</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>15</Volume>                    <PubDate>                        <Year>2019</Year>                        <Month>Mar</Month>                    </PubDate>                </JournalIssue>                <Title>Schizophrenia research. Cognition</Title>                <ISOAbbreviation>Schizophr Res Cogn</ISOAbbreviation>            </Journal>            <ArticleTitle>The impact of schizophrenia and intelligence on the relationship between age and brain volume.</ArticleTitle>            <Pagination>                <MedlinePgn>1-6</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.scog.2018.09.002</ELocationID>            <Abstract>                <AbstractText>Age has been shown to have an impact on both grey (GM) and white matter (WM) volume, with a steeper slope of age-related decline in schizophrenia compared to healthy controls. In schizophrenia, the relation between age and brain volume is further complicated by factors such as lower intelligence, antipsychotic medication, and cannabis use, all of which have been shown to have independent effects on brain volume. In a study of first-episode, antipsychotic-naïve schizophrenia patients (N = 54) and healthy controls (N = 56), we examined the effects of age on whole brain measures of GM and WM volume, and whether these relationships were moderated by schizophrenia and intelligence (IQ). Secondarily, we examined lifetime cannabis use as a moderator of the relationship between age and brain volume. Schizophrenia patients had lower GM volumes than healthy controls but did not differ on WM volume. We found an age effect on GM indicating that increasing age was associated with lower GM volumes, which did not differ between groups. IQ did not have a direct effect on GM, but showed a trend-level interaction with age, suggesting a greater impact of age with lower IQ. There were no age effects on WM volume, but a direct effect of IQ, with higher IQ showing an association with larger WM volume. Lifetime cannabis use did not alter these findings significantly. This study points to effects of schizophrenia on GM early in the illness, before antipsychotic treatment is initiated, suggesting that WM changes may occur later in the disease process.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Jensen</LastName>                    <ForeName>Maria H</ForeName>                    <Initials>MH</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Neuropsychiatric Schizophrenia Research (CNSR), Mental Health Center Glostrup, Glostrup, Denmark.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>University of Copenhagen, Faculty of Health and Medical Sciences, Denmark.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Center Glostrup, Glostrup, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bak</LastName>                    <ForeName>Nikolaj</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Neuropsychiatric Schizophrenia Research (CNSR), Mental Health Center Glostrup, Glostrup, Denmark.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Center Glostrup, Glostrup, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rostrup</LastName>                    <ForeName>Egill</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Neuropsychiatric Schizophrenia Research (CNSR), Mental Health Center Glostrup, Glostrup, Denmark.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Functional Imaging Unit, Department of Diagnostics, Glostrup Hospital, Denmark.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Center Glostrup, Glostrup, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nielsen</LastName>                    <ForeName>Mette Ø</ForeName>                    <Initials>MØ</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Neuropsychiatric Schizophrenia Research (CNSR), Mental Health Center Glostrup, Glostrup, Denmark.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Center Glostrup, Glostrup, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pantelis</LastName>                    <ForeName>Christos</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Neuropsychiatric Schizophrenia Research (CNSR), Mental Health Center Glostrup, Glostrup, Denmark.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Carlton South, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Center Glostrup, Glostrup, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Glenthøj</LastName>                    <ForeName>Birte Y</ForeName>                    <Initials>BY</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Neuropsychiatric Schizophrenia Research (CNSR), Mental Health Center Glostrup, Glostrup, Denmark.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>University of Copenhagen, Faculty of Health and Medical Sciences, Denmark.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Center Glostrup, Glostrup, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ebdrup</LastName>                    <ForeName>Bjørn H</ForeName>                    <Initials>BH</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Neuropsychiatric Schizophrenia Research (CNSR), Mental Health Center Glostrup, Glostrup, Denmark.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>University of Copenhagen, Faculty of Health and Medical Sciences, Denmark.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Center Glostrup, Glostrup, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fagerlund</LastName>                    <ForeName>Birgitte</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Neuropsychiatric Schizophrenia Research (CNSR), Mental Health Center Glostrup, Glostrup, Denmark.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Copenhagen, Denmark.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Center Glostrup, Glostrup, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>05</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Schizophr Res Cogn</MedlineTA>            <NlmUniqueID>101632223</NlmUniqueID>            <ISSNLinking>2215-0013</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Neuroimage. 2014 Oct 15;100:676-83</RefSource>                <PMID Version="1">24816534</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Psychiatry Neurosci. 2016 Mar;41(2):133-41</RefSource>                <PMID Version="1">26599135</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Intelligence. 2015 Jul-Aug;51:47-56</RefSource>                <PMID Version="1">26240470</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Transl Psychiatry. 2012 Nov 20;2:e190</RefSource>                <PMID Version="1">23168990</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur Psychiatry. 2008 Jun;23(4):245-54</RefSource>                <PMID Version="1">18513927</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Transl Psychiatry. 2017 Apr 11;7(4):e1087</RefSource>                <PMID Version="1">28398342</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2011 Oct 1;70(7):672-9</RefSource>                <PMID Version="1">21784414</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Schizophr Res. 2013 Jan;143(1):179-84</RefSource>                <PMID Version="1">23201308</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Schizophr Res. 2005 Nov 15;79(2-3):231-8</RefSource>                <PMID Version="1">15982856</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Psychiatry. 2002 Feb;159(2):244-50</RefSource>                <PMID Version="1">11823266</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Assessment. 2002 Mar;9(1):17-23</RefSource>                <PMID Version="1">11911230</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Psychiatry. 2017 Mar 1;174(3):286-295</RefSource>                <PMID Version="1">27919183</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hum Brain Mapp. 2012 Aug;33(8):1987-2002</RefSource>                <PMID Version="1">21915942</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Brain. 2012 Jul;135(Pt 7):2245-55</RefSource>                <PMID Version="1">22669080</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Schizophr Bull. 2013 Sep;39(5):1129-38</RefSource>                <PMID Version="1">23042112</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2006 Mar 30;440(7084):676-9</RefSource>                <PMID Version="1">16572172</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 1):2418-23</RefSource>                <PMID Version="1">23000300</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Psychiatry. 2009 Oct;14(10):976-86</RefSource>                <PMID Version="1">18607377</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychology. 2009 May;23(3):315-36</RefSource>                <PMID Version="1">19413446</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neurosci Biobehav Rev. 2015 Oct;57:411-32</RefSource>                <PMID Version="1">26449760</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Med. 2018 May 8;:1-10</RefSource>                <PMID Version="1">29734953</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Gen Psychiatry. 2004 Jan;61(1):17-22</RefSource>                <PMID Version="1">14706940</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2003 Mar 1;53(5):412-21</RefSource>                <PMID Version="1">12614994</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Psychiatry Neurosci. 2010 Mar;35(2):95-104</RefSource>                <PMID Version="1">20184807</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Med. 2012 Sep;42(9):1847-56</RefSource>                <PMID Version="1">22357376</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurosci. 2010 Apr 21;30(16):5519-24</RefSource>                <PMID Version="1">20410105</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ageing Res Rev. 2014 Jan;13:1-9</RefSource>                <PMID Version="1">24211464</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Gen Psychiatry. 2008 Jun;65(6):694-701</RefSource>                <PMID Version="1">18519827</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2012 May 15;71(10):898-905</RefSource>                <PMID Version="1">22418013</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA Psychiatry. 2015 Aug;72(8):803-12</RefSource>                <PMID Version="1">26083394</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Schizophr Bull. 2011 May;37(3):504-13</RefSource>                <PMID Version="1">21505117</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuroimage. 2012 Mar;60(1):340-52</RefSource>                <PMID Version="1">22178809</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Gen Psychiatry. 1994 Jun;51(6):477-84</RefSource>                <PMID Version="1">8192550</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2011 Jul 1;70(1):88-96</RefSource>                <PMID Version="1">21457946</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Gen Psychiatry. 1990 Jun;47(6):589-93</RefSource>                <PMID Version="1">2190539</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Schizophr Bull. 1987;13(2):261-76</RefSource>                <PMID Version="1">3616518</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Med. 2015 Feb;45(3):515-27</RefSource>                <PMID Version="1">25077698</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Age</Keyword>            <Keyword MajorTopicYN="N">Cannabis</Keyword>            <Keyword MajorTopicYN="N">Grey matter volume</Keyword>            <Keyword MajorTopicYN="N">Intelligence</Keyword>            <Keyword MajorTopicYN="N">Schizophrenia</Keyword>            <Keyword MajorTopicYN="N">White matter volume</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>29</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>20</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30302317</ArticleId>            <ArticleId IdType="doi">10.1016/j.scog.2018.09.002</ArticleId>            <ArticleId IdType="pii">S2215-0013(18)30016-7</ArticleId>            <ArticleId IdType="pmc">PMC6176038</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30302053</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1178-2226</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>10</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Biomedical informatics insights</Title>                <ISOAbbreviation>Biomed Inform Insights</ISOAbbreviation>            </Journal>            <ArticleTitle>Monte Carlo Simulations Demonstrate Algorithmic Interventions Over Time Reduce Hospitalisation in Patients With Schizophrenia and Bipolar Disorder.</ArticleTitle>            <Pagination>                <MedlinePgn>1178222618803076</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1177/1178222618803076</ELocationID>            <Abstract>                <AbstractText>Non-adherence with pharmacologic treatment is associated with increased rates of relapse and rehospitalisation among patients with schizophrenia and bipolar disorder. To improve treatment response, remission, and recovery, research efforts are still needed to elucidate how to effectively map patient's response to medication treatment including both therapeutic and adverse effects, compliance, and satisfaction in the prodromal phase of illness (ie, the time period in between direct clinical consultation and relapse). The Actionable Intime Insights (AI<sup>2</sup>) application draws information from Australian Medicare administrative claims records in real time when compliance with treatment does not meet best practice guidelines for managing chronic severe mental illness. Subsequently, the AI<sup>2</sup> application alerts clinicians and patients when patients do not adhere to guidelines for treatment. The aim of this study was to evaluate the impact of the AI<sup>2</sup> application on the risk of hospitalisation among simulated patients with schizophrenia and bipolar disorder. Monte Carlo simulation methodology was used to estimate the impact of the AI<sup>2</sup> intervention on the probability of hospitalisation over a 2-year period. Results indicated that when the AI<sup>2</sup> algorithmic intervention had an efficacy level of (&gt;0.6), over 80% of actioned alerts were contributing to reduced hospitalisation risk among the simulated patients. Such findings indicate the potential utility of the AI<sup>2</sup> application should replication studies validate its methodologic and ecological rigour in real-world settings.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Knight</LastName>                    <ForeName>Alissa</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Personal Health Informatics, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jarrad</LastName>                    <ForeName>Geoff A</ForeName>                    <Initials>GA</Initials>                    <AffiliationInfo>                        <Affiliation>Data to Decisions Cooperative Research Centre, Adelaide, SA, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Schrader</LastName>                    <ForeName>Geoff D</ForeName>                    <Initials>GD</Initials>                    <AffiliationInfo>                        <Affiliation>Personal Health Informatics, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Country Mental Health Services, SA Health, Adelaide, SA, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Strobel</LastName>                    <ForeName>Jorg</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Personal Health Informatics, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Country Mental Health Services, SA Health, Adelaide, SA, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Horton</LastName>                    <ForeName>Dennis</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Data to Decisions Cooperative Research Centre, Adelaide, SA, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bidargaddi</LastName>                    <ForeName>Niranjan</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Personal Health Informatics, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>South Australian Health and Medical Research Institute, Adelaide, SA, Australia.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>02</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Biomed Inform Insights</MedlineTA>            <NlmUniqueID>101512875</NlmUniqueID>            <ISSNLinking>1178-2226</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Med Care. 2005 Jun;43(6):521-30</RefSource>                <PMID Version="1">15908846</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2016 Jul 29;11(7):e0159621</RefSource>                <PMID Version="1">27472449</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JMIR Med Inform. 2018 Apr 24;6(2):e28</RefSource>                <PMID Version="1">29691211</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biomed Inform. 2014 Aug;50:4-19</RefSource>                <PMID Version="1">24936746</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Med (Lausanne). 2015 Oct 08;2:73</RefSource>                <PMID Version="1">26501062</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Perspect Health Inf Manag. 2015 Nov 01;12:1b</RefSource>                <PMID Version="1">26604871</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Gen Psychiatry. 1999 Mar;56(3):241-7</RefSource>                <PMID Version="1">10078501</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Patient Prefer Adherence. 2017 Apr 20;11:801-810</RefSource>                <PMID Version="1">28461742</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Schizophr Res. 2016 Oct;176(2-3):272-280</RefSource>                <PMID Version="1">27237598</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Schizophr Res. 2003 Sep 1;63(1-2):49-58</RefSource>                <PMID Version="1">12892857</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur Neuropsychopharmacol. 2015 Oct;25(10):1501-12</RefSource>                <PMID Version="1">26238969</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Card Fail. 2014 Jul;20(7):459-64</RefSource>                <PMID Version="1">24709663</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Addict Behav. 1999 Mar-Apr;24(2):287-91</RefSource>                <PMID Version="1">10336110</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Radiology. 2015 Oct;277(1):81-7</RefSource>                <PMID Version="1">25961634</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Psychiatry. 2005 Jan;10(1):79-104</RefSource>                <PMID Version="1">15289815</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Med Care. 2002 Sep;40(9):794-811</RefSource>                <PMID Version="1">12218770</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2016 Aug 23;11(8):e0161381</RefSource>                <PMID Version="1">27551748</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2012 Jun 2;379(9831):2063-71</RefSource>                <PMID Version="1">22560607</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Soc Work. 2012 Jul;57(3):235-46</RefSource>                <PMID Version="1">23252315</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2013 May 11;381(9878):1672-82</RefSource>                <PMID Version="1">23663953</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Med Inform Decis Mak. 2017 Dec 4;17(1):157</RefSource>                <PMID Version="1">29202795</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Patient Relat Outcome Meas. 2014 Jun 23;5:43-62</RefSource>                <PMID Version="1">25061342</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Non-compliance</Keyword>            <Keyword MajorTopicYN="N">algorithms</Keyword>            <Keyword MajorTopicYN="N">bipolar disorder</Keyword>            <Keyword MajorTopicYN="N">rehospitalisation</Keyword>            <Keyword MajorTopicYN="N">schizophrenia</Keyword>            <Keyword MajorTopicYN="N">simulation models</Keyword>        </KeywordList>        <CoiStatement>Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>15</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30302053</ArticleId>            <ArticleId IdType="doi">10.1177/1178222618803076</ArticleId>            <ArticleId IdType="pii">10.1177_1178222618803076</ArticleId>            <ArticleId IdType="pmc">PMC6170953</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30301955</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">2158-3188</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>8</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>09</Day>                    </PubDate>                </JournalIssue>                <Title>Translational psychiatry</Title>                <ISOAbbreviation>Transl Psychiatry</ISOAbbreviation>            </Journal>            <ArticleTitle>Fasting enhances extinction retention and prevents the return of fear in humans.</ArticleTitle>            <Pagination>                <MedlinePgn>214</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41398-018-0260-1</ELocationID>            <Abstract>                <AbstractText>Fear is prone to return following extinction that is the basis of exposure therapy for fear-related disorders. Manipulations that enhance the extinction process can be beneficial for treatment. Animal studies have shown that fasting or caloric restriction can enhance extinction and inhibit the return of fear. The present study examined the effects of fasting on fear acquisition, extinction, and the return of fear in humans. One hundred and twenty-five male participants were randomized into a fasting group and food group and exposed to a Pavlovian fear conditioning paradigm. Changes in plasma cortisol and ghrelin levels were examined using enzyme-linked immunosorbent assays. One-night fasting had no effect on fear acquisition but enhanced fear extinction retention and prevented the return of fear, and this effect persisted for at least 6 months. This procedure was also effective for remote fear memory. Plasma ghrelin levels were elevated after fasting and had a negative relationship with the fear response in spontaneous recovery test. However, overnight fasting did not affect cortisol levels. These findings indicate that fasting enhances extinction retention and prevents the return of fear, without influencing fear memory formation. We propose that this novel procedure may open new avenues for promoting extinction-based therapies for fear-related disorders.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Shi</LastName>                    <ForeName>Le</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmacology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>National Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, 100191, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Peking University Sixth Hospital, Peking University Institute of Mental Health Key Laboratory of Mental Health, Ministry of Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Deng</LastName>                    <ForeName>Jiahui</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University Sixth Hospital, Peking University Institute of Mental Health Key Laboratory of Mental Health, Ministry of Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Sijing</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University Sixth Hospital, Peking University Institute of Mental Health Key Laboratory of Mental Health, Ministry of Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Que</LastName>                    <ForeName>Jianyu</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University Sixth Hospital, Peking University Institute of Mental Health Key Laboratory of Mental Health, Ministry of Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sun</LastName>                    <ForeName>Yekun</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Psychology, North China University of Science and Technology, Tangshan, 063009, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Zhong</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University Sixth Hospital, Peking University Institute of Mental Health Key Laboratory of Mental Health, Ministry of Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medical Psychology, Anhui Medical University, Hefei, 230032, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Guo</LastName>                    <ForeName>Xiaojie</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University Sixth Hospital, Peking University Institute of Mental Health Key Laboratory of Mental Health, Ministry of Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Han</LastName>                    <ForeName>Ying</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>National Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, 100191, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhou</LastName>                    <ForeName>Yuxin</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neuroscience, Allegheny College, Meadville, 16335, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Xiujun</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Psychology, North China University of Science and Technology, Tangshan, 063009, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xie</LastName>                    <ForeName>Wen</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Mental Health Center of Anhui Province, Hefei, 230032, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lin</LastName>                    <ForeName>Xiao</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Peking-Tsinghua Center for Life Sciences and PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, 100191, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shi</LastName>                    <ForeName>Jie</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>National Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, 100191, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lu</LastName>                    <ForeName>Lin</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>National Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, 100191, China. linlu@bjmu.edu.cn.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Peking University Sixth Hospital, Peking University Institute of Mental Health Key Laboratory of Mental Health, Ministry of Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China. linlu@bjmu.edu.cn.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Peking-Tsinghua Center for Life Sciences and PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, 100191, China. linlu@bjmu.edu.cn.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>31230033</GrantID>                    <Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>09</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Transl Psychiatry</MedlineTA>            <NlmUniqueID>101562664</NlmUniqueID>            <ISSNLinking>2158-3188</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2014 Dec 1;76(11):895-901</RefSource>                <PMID Version="1">24813334</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neurology. 2013 Nov 12;81(20):1746-52</RefSource>                <PMID Version="1">24153444</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurosci. 2002 Mar 15;22(6):2343-51</RefSource>                <PMID Version="1">11896173</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychopharmacology (Berl). 2015 May;232(10):1843-57</RefSource>                <PMID Version="1">25466701</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trends Neurosci. 2012 Jan;35(1):24-35</RefSource>                <PMID Version="1">21798604</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 2013 Jan 25;339(6118):443-6</RefSource>                <PMID Version="1">23349290</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 1999 Dec 9;402(6762):656-60</RefSource>                <PMID Version="1">10604470</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Clin Nutr. 2014 Jun;99(6):1319-30</RefSource>                <PMID Version="1">24760977</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurosci. 2001 Jul 15;21(14):5304-10</RefSource>                <PMID Version="1">11438606</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):E2428-36</RefSource>                <PMID Version="1">23754384</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2010 Jan 7;463(7277):49-53</RefSource>                <PMID Version="1">20010606</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Neurosci. 2006 Jan;7(1):54-64</RefSource>                <PMID Version="1">16371950</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropharmacology. 2016 Feb;101:36-45</RefSource>                <PMID Version="1">26384653</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Psychiatr Res. 1995 May-Jun;29(3):245-53</RefSource>                <PMID Version="1">7473300</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Appetite. 2014 Jun;77:52-61</RefSource>                <PMID Version="1">24583414</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 1998 Feb 20;92(4):573-85</RefSource>                <PMID Version="1">9491897</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychopharmacology. 2016 Jan;41(2):431-9</RefSource>                <PMID Version="1">26062787</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Behav Brain Res. 2018 Feb 15;338:166-172</RefSource>                <PMID Version="1">29097329</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genes Brain Behav. 2012 Jul;11(5):503-12</RefSource>                <PMID Version="1">22530815</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2011 Sep 16;146(6):992-1003</RefSource>                <PMID Version="1">21925320</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Neurosci. 2007 Sep 19;27(38):10185-95</RefSource>                <PMID Version="1">17881524</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Brain Imaging Behav. 2018 Aug;12(4):1150-1159</RefSource>                <PMID Version="1">29071464</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Brain Stimul. 2017 Mar - Apr;10(2):291-297</RefSource>                <PMID Version="1">27931887</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Endocrinol. 2005 Jun;152(6):845-50</RefSource>                <PMID Version="1">15941923</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Brain Stimul. 2016 Jul-Aug;9(4):529-36</RefSource>                <PMID Version="1">27037186</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychologia. 1989;27(9):1129-38</RefSource>                <PMID Version="1">2812297</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nutr Rev. 2013 Aug;71(8):541-61</RefSource>                <PMID Version="1">23865799</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Med. 2003 Sep;9(9):1173-9</RefSource>                <PMID Version="1">12925848</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Exp Psychol Anim Behav Process. 1975 Jan;1(1):88-96</RefSource>                <PMID Version="1">1151290</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropeptides. 2016 Feb;55:111-26</RefSource>                <PMID Version="1">26444585</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trends Neurosci. 2015 Sep;38(9):550-9</RefSource>                <PMID Version="1">26216377</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Exp Psychol Anim Behav Process. 1983 Jul;9(3):248-65</RefSource>                <PMID Version="1">6886630</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Neurosci. 2010 Jul;17(3):136-41</RefSource>                <PMID Version="1">25205891</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neurobiol Learn Mem. 2015 Sep;123:159-67</RefSource>                <PMID Version="1">26071676</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuroscience. 2008 Sep 22;156(1):11-29</RefSource>                <PMID Version="1">18672030</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Learn Mem. 2002 Nov-Dec;9(6):402-7</RefSource>                <PMID Version="1">12464700</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychopharmacology. 2006 May;31(5):912-24</RefSource>                <PMID Version="1">16205786</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2015 Apr 1;77(7):642-52</RefSource>                <PMID Version="1">25481622</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Appetite. 2016 Jun 1;101:1-7</RefSource>                <PMID Version="1">26921488</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2013 Jun 03;8(6):e66069</RefSource>                <PMID Version="1">23755298</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 2010 Jun 4;328(5983):1288-90</RefSource>                <PMID Version="1">20522777</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Behav Brain Res. 2008 Feb 11;187(1):123-32</RefSource>                <PMID Version="1">17949826</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Behav Brain Res. 1998 Jun;93(1-2):71-6</RefSource>                <PMID Version="1">9659988</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Rep. 2017 Aug 10;7(1):7857</RefSource>                <PMID Version="1">28798340</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Endocrinol Metab. 2011 Feb;96(2):486-93</RefSource>                <PMID Version="1">21106712</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Psychiatry. 2007 Feb;12(2):120-50</RefSource>                <PMID Version="1">17160066</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychopharmacology (Berl). 2012 Apr;220(3):577-89</RefSource>                <PMID Version="1">21979440</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 2009 May 15;324(5929):951-5</RefSource>                <PMID Version="1">19342552</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Neurosci. 2018 May 03;12:295</RefSource>                <PMID Version="1">29773974</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocr J. 2013;60(6):781-9</RefSource>                <PMID Version="1">23411585</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hum Brain Mapp. 2015 Mar;36(3):839-51</RefSource>                <PMID Version="1">25393934</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2008 Jun 15;63(12):1118-26</RefSource>                <PMID Version="1">18313643</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Behav Processes. 2013 Nov;100:54-7</RefSource>                <PMID Version="1">23941975</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Med. 1998 Apr;4(4):385-6</RefSource>                <PMID Version="1">9546775</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Prog Neuropsychopharmacol Biol Psychiatry. 2014 Apr 3;50:125-36</RefSource>                <PMID Version="1">24361378</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Neurosci. 2006 Mar;9(3):381-8</RefSource>                <PMID Version="1">16491079</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sleep. 2015 Mar 01;38(3):423-31</RefSource>                <PMID Version="1">25348121</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychopharmacology. 2018 Jan;43(2):384-392</RefSource>                <PMID Version="1">28948980</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuropsychopharmacology. 2014 Nov;39(12):2732-41</RefSource>                <PMID Version="1">24930888</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Learn Mem. 2004 Sep-Oct;11(5):485-94</RefSource>                <PMID Version="1">15466298</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biol Psychiatry. 2013 Jun 1;73(11):1071-7</RefSource>                <PMID Version="1">23245749</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Physiol Rev. 2010 Apr;90(2):419-63</RefSource>                <PMID Version="1">20393190</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychopharmacology (Berl). 2010 Aug;211(3):337-46</RefSource>                <PMID Version="1">20559821</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>12</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30301955</ArticleId>            <ArticleId IdType="doi">10.1038/s41398-018-0260-1</ArticleId>            <ArticleId IdType="pii">10.1038/s41398-018-0260-1</ArticleId>            <ArticleId IdType="pmc">PMC6177454</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30301823</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1468-960X</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>09</Day>                    </PubDate>                </JournalIssue>                <Title>Evidence-based mental health</Title>                <ISOAbbreviation>Evid Based Ment Health</ISOAbbreviation>            </Journal>            <ArticleTitle>Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">ebmental-2018-300050</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1136/ebmental-2018-300050</ELocationID>            <Abstract>                <AbstractText>In this clinical review we summarise what in our view have been some the most important advances in the past two decades, in terms of diagnostic definition, epidemiology, genetics and environmental causes, neuroimaging/cognition and treatment of attention-deficit/hyperactivity disorder (ADHD), including: (1) the most recent changes to the diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders and International Classification of Diseases; (2) meta-analytic evidence showing that, after accounting for diagnostic methods, the rates of ADHD are fairly consistent across Western countries; (3) the recent finding of the first genome-wide significant risk loci for ADHD; (4) the paradigm shift in the pathophysiological conceptualisation of ADHD from alterations in individual brain regions to a complex dysfunction in brain networks; (5) evidence supporting the short-term efficacy of ADHD pharmacological treatments, with a different profile of efficacy and tolerability in children/adolescents versus adults; (6) a series of meta-analyses showing that, while non-pharmacological treatment may not be effective to target ADHD core symptoms, some of them effectively address ADHD-related impairments (such as oppositional behaviours for parent training and working memory deficits for cognitive training). We also discuss key priorities for future research in each of these areas of investigation. Overall, while many research questions have been answered, many others need to be addressed. Strengthening multidisciplinary collaborations, relying on large data sets in the spirit of Open Science and supporting research in less advantaged countries will be key to face the challenges ahead.</AbstractText>                <CopyrightInformation>© Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Cortese</LastName>                    <ForeName>Samuele</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Academic Unit of Psychology, Center for Innovation in Mental Health, University of Southampton, Southampton, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Solent NHS Trust, Southampton, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>New York University Child Study Center, New York City, New York, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Coghill</LastName>                    <ForeName>David</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Paediatrics and Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Murdoch Children's Research Institute, Melbourne, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Royal Children's Hospital, Melbourne, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>09</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Evid Based Ment Health</MedlineTA>            <NlmUniqueID>100883413</NlmUniqueID>            <ISSNLinking>1362-0347</ISSNLinking>        </MedlineJournalInfo>        <CoiStatement>Competing interests: SC declares reimbursement for travel and accommodation expenses from the Association for Child and Adolescent Central Health (ACAMH) in relation to lectures delivered for ACAMH, and from Healthcare Convention for educational activity on ADHD. DC declares grants and personal fees from Shire and Servier; personal fees from Eli Lilly, Novartis and Oxford University Press; and grants from Vifor.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30301823</ArticleId>            <ArticleId IdType="pii">ebmental-2018-300050</ArticleId>            <ArticleId IdType="doi">10.1136/ebmental-2018-300050</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30301704</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2050-0521</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>06</Day>                    </PubDate>                </JournalIssue>                <Title>Sexual medicine reviews</Title>                <ISOAbbreviation>Sex Med Rev</ISOAbbreviation>            </Journal>            <ArticleTitle>Exo-Clinical Trials of Nutritional Supplements for Sexual Dysfunction: Precedents, Principles, and Protocols.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">S2050-0521(18)30086-6</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sxmr.2018.07.002</ELocationID>            <Abstract>                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Care-seeking for sexual dysfunction is limited by embarrassment, efficacy/safety concerns, and cost. Nutritional supplements (NSs) are low-cost but unproven.</AbstractText>                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To provide hypotheses on whether effective NS combinations for sexual dysfunction can be created following known pharmacology principles and tested with sufficient rigor in Internet-based &quot;exo-clinical&quot; trials (XCTs).</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">PubMed and Google searches were conducted to review the feasibility of XCTs of NS combinations for sexual dysfunction. Findings were synthesized into recommendations for XCTs to treat the most common sexual problems.</AbstractText>                <AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">The hierarchy of references used for making recommendations was controlled clinical trials over uncontrolled trials. The frequency of sexual dysfunction was determined in population-representative national surveys.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">XCTs of cognitive behavioral therapy show conclusive efficacy for anxiety and depression. 5 small XCTs showed efficacy for female sexual dysfunction and erectile dysfunction (ED), and 2 XCTs of NS for other medical problems substantiated feasibility. To test the feasibility of XCTs for the most common forms of sexual dysfunction-ED, hypoactive sexual desire disorder (HSDD), and sexual performance anxiety-protocol outlines were generated for frugal XCTs; the total estimated subject time burden is ≤1 hour.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">An XCT is a cost-effective method of evaluating new treatments, including sexual dysfunction and common mental disorders, if compliance is maintained by regular outreach while minimizing the time burden on subjects and handling consent and privacy issues appropriately. NS combinations might expand the opportunities for relief of sexual dysfunction if formulated with pharmacologically active doses of NS with already supported efficacy and safety. The feasibility of XCTs of NS combinations for sexual dysfunction might be tested most productively in men with ED, in women with HSDD, and in men and women with sexual performance anxiety. Pyke RE. Exo-Clinical Trials of Nutritional Supplements for Sexual Dysfunction: Precedents, Principles, and Protocols. Sex Med Rev 2018;XX:XX-XX.</AbstractText>                <CopyrightInformation>Copyright © 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Pyke</LastName>                    <ForeName>Robert E</ForeName>                    <Initials>RE</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>06</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Sex Med Rev</MedlineTA>            <NlmUniqueID>101614773</NlmUniqueID>            <ISSNLinking>2050-0521</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Erectile Dysfunction</Keyword>            <Keyword MajorTopicYN="N">Exo-Clinical Trials</Keyword>            <Keyword MajorTopicYN="N">Hypoactive Sexual Desire Disorder</Keyword>            <Keyword MajorTopicYN="N">Internet Medical Research</Keyword>            <Keyword MajorTopicYN="N">Nutritional Supplements</Keyword>            <Keyword MajorTopicYN="N">Sexual Performance Anxiety</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30301704</ArticleId>            <ArticleId IdType="pii">S2050-0521(18)30086-6</ArticleId>            <ArticleId IdType="doi">10.1016/j.sxmr.2018.07.002</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30301448</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1557-9700</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>Psychiatric services (Washington, D.C.)</Title>                <ISOAbbreviation>Psychiatr Serv</ISOAbbreviation>            </Journal>            <ArticleTitle>Integrating Predictive Modeling Into Mental Health Care: An Example in Suicide Prevention.</ArticleTitle>            <Pagination>                <MedlinePgn>appips201800242</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ps.201800242</ELocationID>            <Abstract>                <AbstractText>Recent advances in statistical methods and computing power have improved the ability to predict risks associated with mental illness with more efficiency and accuracy. However, integrating statistical prediction into a clinical setting poses new challenges that need creative solutions. A case example explores the challenges and innovations that emerged at a Department of Veterans Affairs hospital while implementing REACH VET (Recovery Engagement and Coordination for Health-Veterans Enhanced Treatment), a suicide prevention program that is based on a predictive model that identifies veterans at statistical risk for suicide.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Reger</LastName>                    <ForeName>Greg M</ForeName>                    <Initials>GM</Initials>                    <AffiliationInfo>                        <Affiliation>Mental Health Service, Veterans Affairs Puget Sound Health Care System, Seattle/Takoma, Washington (all authors); Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (G. Reger, Ruskin, M. Reger).</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>McClure</LastName>                    <ForeName>Mary Lou</ForeName>                    <Initials>ML</Initials>                    <AffiliationInfo>                        <Affiliation>Mental Health Service, Veterans Affairs Puget Sound Health Care System, Seattle/Takoma, Washington (all authors); Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (G. Reger, Ruskin, M. Reger).</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ruskin</LastName>                    <ForeName>David</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Mental Health Service, Veterans Affairs Puget Sound Health Care System, Seattle/Takoma, Washington (all authors); Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (G. Reger, Ruskin, M. Reger).</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Carter</LastName>                    <ForeName>Sarah P</ForeName>                    <Initials>SP</Initials>                    <AffiliationInfo>                        <Affiliation>Mental Health Service, Veterans Affairs Puget Sound Health Care System, Seattle/Takoma, Washington (all authors); Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (G. Reger, Ruskin, M. Reger).</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Reger</LastName>                    <ForeName>Mark A</ForeName>                    <Initials>MA</Initials>                    <AffiliationInfo>                        <Affiliation>Mental Health Service, Veterans Affairs Puget Sound Health Care System, Seattle/Takoma, Washington (all authors); Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle (G. Reger, Ruskin, M. Reger).</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Psychiatr Serv</MedlineTA>            <NlmUniqueID>9502838</NlmUniqueID>            <ISSNLinking>1075-2730</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Computer technology</Keyword>            <Keyword MajorTopicYN="N">Self-destructive behavior</Keyword>            <Keyword MajorTopicYN="N">Suicide</Keyword>            <Keyword MajorTopicYN="N">predictive models</Keyword>            <Keyword MajorTopicYN="N">veterans</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30301448</ArticleId>            <ArticleId IdType="doi">10.1176/appi.ps.201800242</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30301428</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2369-5293</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of palliative care</Title>                <ISOAbbreviation>J Palliat Care</ISOAbbreviation>            </Journal>            <ArticleTitle>On the Margins of Death: A Scoping Review on Palliative Care and Schizophrenia.</ArticleTitle>            <Pagination>                <MedlinePgn>825859718804108</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1177/0825859718804108</ELocationID>            <Abstract>                <AbstractText>Schizophrenia is a serious chronic mental illness that results in marginalization and stigma for sufferers. It is the seventh leading cause for disability worldwide. The symptoms of the illness, including hallucinations, delusions, and extremely disordered thinking and behavior, may also introduce barriers to accessing treatment, education, housing, and employment. Little is known about end-of-life care for individuals with schizophrenia. To address this gap, a scoping review was conducted to enhance understanding of hospice and palliative care for patients with schizophrenia. From this scoping review, 342 unique titles and abstracts were identified through a search of 20 databases, including 11 social science databases, 6 medical databases, and 3 gray literature databases. A total of 32 articles met the inclusion criteria and the following 4 themes were identified: Stigma affecting quality of care and access to care; Issues related to consent and capacity for the patient's end-of-life care decisions and to appoint substitute decision makers; Best practices for psychosocial interventions, pharmacology, family and health-care collaborations, goals of care, setting, and smoking; and Barriers to care, including setting, communication, provider education, and access to care. The review suggests the importance of mandatory interdisciplinary training practices and policy standards outlining cooperative communication across health-care providers. It highlights gaps in evidence-based research on psychosocial interventions and collaborative frameworks to enable the provision of quality end-of-life care for individuals with schizophrenia.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Relyea</LastName>                    <ForeName>Erin</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>1 Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, ON, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>MacDonald</LastName>                    <ForeName>Brooke</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>1 Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, ON, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cattaruzza</LastName>                    <ForeName>Christina</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>1 Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, ON, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Marshall</LastName>                    <ForeName>Denise</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>1 Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, ON, Canada.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Palliat Care</MedlineTA>            <NlmUniqueID>8610345</NlmUniqueID>            <ISSNLinking>0825-8597</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">capacity</Keyword>            <Keyword MajorTopicYN="N">collaborative health care</Keyword>            <Keyword MajorTopicYN="N">end-of-life care</Keyword>            <Keyword MajorTopicYN="N">mental health</Keyword>            <Keyword MajorTopicYN="N">psychiatry</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30301428</ArticleId>            <ArticleId IdType="doi">10.1177/0825859718804108</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30300818</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1532-8384</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>87</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>08</Day>                    </PubDate>                </JournalIssue>                <Title>Comprehensive psychiatry</Title>                <ISOAbbreviation>Compr Psychiatry</ISOAbbreviation>            </Journal>            <ArticleTitle>Women with compulsive buying or gambling disorder: Similar profiles for different behavioural addictions.</ArticleTitle>            <Pagination>                <MedlinePgn>95-99</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0010-440X(18)30156-1</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.comppsych.2018.09.002</ELocationID>            <Abstract>                <AbstractText>The aim of the present study was to examine the differences in sociodemographic and clinical characteristics of 104 women diagnosed with compulsive buying behaviour (CBB = 55) or gambling disorder (GD = 49) treated at three public hospitals unit specialized in behavioural addictions from January 2004 to December 2015. Significant between-group differences in sociodemographic variables were observed for cohabitation status (living with a partner or not) and educational level, with a higher percentage of women in the GD group cohabiting (х<sup>2</sup> (<sub>1</sub>), p = .029). By contrast, the CBB group had a significantly higher educational level (х<sup>2</sup> (<sub>1</sub>) = 7.4, p = .007). There were no significant differences between the groups in age of onset, age at treatment initiation, age at the onset of behavioural problems, or in the years elapsed until presenting addiction problems. However, there were significant between-group differences in the amount of money spent weekly (F <sub>(1.100)</sub> = 4.9, p = .028), with women in the CBB group spending on average €289.4/week (SD, 412.4) versus €151/week (SD, 141.23) in the GD group. The CBB group had significantly more depressive disorders compared to the GD group (х<sup>2</sup><sub>(1)</sub> = 5.4, p = .020). In contrast, the GD group presented significantly more tobacco use than the CBB group (х<sup>2</sup><sub>(1)</sub> = 1.19, p = .000). This study suggests that women with CBB or GD share more characteristics than differences and the treatment approaches must take into account gender related factors.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Inc. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Díez</LastName>                    <ForeName>Dominica</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Departament de Psiquiatria i Medicina Legal, Universitat Autònoma de Barcelona, Spain; Grup de Recerca en Salut Mental i Innovació Social (SaMIS), Divisió de Salut Mental, Fundació Althaia, Xarxa Assistencial Universitària de Manresa, Spain. Electronic address: ddiez@althaia.cat.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Aragay</LastName>                    <ForeName>Núria</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Consorci Sanitari de Terrassa, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Soms</LastName>                    <ForeName>Mercè</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>XSM-Institut d'Assistència Sanitària de Girona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Prat</LastName>                    <ForeName>Gemma</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Grup de Recerca en Salut Mental i Innovació Social (SaMIS), Divisió de Salut Mental, Fundació Althaia, Xarxa Assistencial Universitària de Manresa, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bonet</LastName>                    <ForeName>Pere</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Grup de Recerca en Salut Mental i Innovació Social (SaMIS), Divisió de Salut Mental, Fundació Althaia, Xarxa Assistencial Universitària de Manresa, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Casas</LastName>                    <ForeName>Miquel</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Departament de Psiquiatria, Hospital Universitari Vall d'Hebron, Barcelona, Spain; CIBER Salud Mental (CIBERSAM), Instituto Salud Carlos III, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Compr Psychiatry</MedlineTA>            <NlmUniqueID>0372612</NlmUniqueID>            <ISSNLinking>0010-440X</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Behavioural addictions</Keyword>            <Keyword MajorTopicYN="N">Compulsive buying</Keyword>            <Keyword MajorTopicYN="N">Gambling disorder</Keyword>            <Keyword MajorTopicYN="N">Psychiatric comorbidity</Keyword>            <Keyword MajorTopicYN="N">Women</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30300818</ArticleId>            <ArticleId IdType="pii">S0010-440X(18)30156-1</ArticleId>            <ArticleId IdType="doi">10.1016/j.comppsych.2018.09.002</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30300732</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1879-1379</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>107</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>29</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of psychiatric research</Title>                <ISOAbbreviation>J Psychiatr Res</ISOAbbreviation>            </Journal>            <ArticleTitle>Interventions for common mental health problems among university and college students: A systematic review and meta-analysis of randomized controlled trials.</ArticleTitle>            <Pagination>                <MedlinePgn>1-10</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0022-3956(17)31362-6</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2018.09.018</ELocationID>            <Abstract>                <AbstractText>Common mental health problems (CMHPs), such as depression, anxiety disorder, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD) are internalizing disorders with high comorbidity. University and college students are under many stressors and transitional events, and students fall within the age range when CMHPs are at their developmental peak. Compared to the expanded effort to explore and treat CMHPs, there has been no a meta-analysis that comprehensively reviewed the interventions for CMHPs and examined the effects of interventions for CMHPs in college students. The objective of this review is to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) examining interventions for CMHPs among university and college students and to estimate their post-intervention effect size (ES), as well as follow-up ES, for depression, anxiety disorder, OCD and PTSD separately. Meta-analytic procedures were conducted in accordance with PRISMA guidelines. We reviewed 7768 abstracts from which 331 full-text articles were reviewed and 51 RCTs were included in the analysis. We found moderate effect sizes for both depression (Hedges' g = -0.60) and anxiety disorder (Hedges' g = -0.48). There was no evidence that existing interventions for OCD or PTSD were effective in this population. For interventions with high number of papers, we performed subgroup analysis and found that cognitive behavioral therapy (CBT) and mindfulness-based interventions were effective for both depression and generalized anxiety disorder (GAD), and attention/perception modification was effective for GAD; other interventions (i.e. art, exercise and peer support) had the highest ES for both depression and GAD among university and college students.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Huang</LastName>                    <ForeName>Junping</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Child and Adolescent Health, School of Public Health, Tianjin Medical University, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nigatu</LastName>                    <ForeName>Yeshambel T</ForeName>                    <Initials>YT</Initials>                    <AffiliationInfo>                        <Affiliation>Work &amp; Mental Health Research Unit, The Royal's Institute of Mental Health Research, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Smail-Crevier</LastName>                    <ForeName>Rachel</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Work &amp; Mental Health Research Unit, The Royal's Institute of Mental Health Research, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Xin</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Child and Adolescent Health, School of Public Health, Tianjin Medical University, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Jianli</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Work &amp; Mental Health Research Unit, The Royal's Institute of Mental Health Research, Canada; School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Canada; School of Psychology, Faculty of Social Sciences, University of Ottawa, Canada; Department of Psychiatry, Faculty of Medicine, University of Ottawa, Canada. Electronic address: Jianli.Wang@theroyal.ca.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>29</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>J Psychiatr Res</MedlineTA>            <NlmUniqueID>0376331</NlmUniqueID>            <ISSNLinking>0022-3956</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Anxiety disorder</Keyword>            <Keyword MajorTopicYN="N">Depression</Keyword>            <Keyword MajorTopicYN="N">Intervention</Keyword>            <Keyword MajorTopicYN="N">Meta-analysis</Keyword>            <Keyword MajorTopicYN="N">OCD</Keyword>            <Keyword MajorTopicYN="N">Obsessive-compulsive disorder</Keyword>            <Keyword MajorTopicYN="N">PTSD</Keyword>            <Keyword MajorTopicYN="N">Post-traumatic stress disorder</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>12</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30300732</ArticleId>            <ArticleId IdType="pii">S0022-3956(17)31362-6</ArticleId>            <ArticleId IdType="doi">10.1016/j.jpsychires.2018.09.018</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30300463</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1468-1331</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>09</Day>                    </PubDate>                </JournalIssue>                <Title>European journal of neurology</Title>                <ISOAbbreviation>Eur. J. Neurol.</ISOAbbreviation>            </Journal>            <ArticleTitle>Management of psychogenic nonepileptic seizures (PNES): a multidisciplinary approach.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.13818</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The International League Against Epilepsy (ILAE) proposed a diagnostic scheme for psychogenic nonepileptic seizures (PNES). The debate on ethical aspects of the diagnostic procedures is ongoing, the treatment is not standardized, and management might differ according to the age groups.</AbstractText>                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To reach an expert and stakeholder consensus on PNES management.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">A board comprising adult and child neurologists, neuropsychologists, psychiatrists, pharmacologists, experts in forensic medicine and bioethics as well as patients' representatives was formed. The board chose five main topics regarding PNES: &quot;diagnosis&quot;; &quot;ethical issues&quot;; &quot;psychiatric comorbidities&quot;; &quot;psychological treatment&quot;; &quot;pharmacological treatment&quot;. After a systematic review of the literature, the board met in a Consensus Conference in Catanzaro (Italy). Further consultations using the model of Delphi panel were held.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The global level of evidence for all topics was low. Even though most questions were formulated separately for children/adolescents and adults, no major age-related differences emerged. The board established that the approach to PNES diagnosis should comply with ILAE recommendations. Seizures' induction was considered ethical, preferring the least invasive techniques. The board recommended: to carefully look for mood disturbances, personality disorders and psychic trauma in persons with PNES; to consider cognitive-behavioural therapy as first line psychological approach and pharmacological treatment to manage comorbid conditions, namely anxiety and depression.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">PNES management should be multidisciplinary. High-quality, long-term studies are needed to standardize PNES management. This article is protected by copyright. All rights reserved.</AbstractText>                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Gasparini</LastName>                    <ForeName>Sara</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical and Surgical Sciences, Magna Greacia University of Catanzaro, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Regional Epilepsy Centre, Great Metropolitan Hospital of Reggio Calabria, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Beghi</LastName>                    <ForeName>Ettore</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurosciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ferlazzo</LastName>                    <ForeName>Edoardo</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical and Surgical Sciences, Magna Greacia University of Catanzaro, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Regional Epilepsy Centre, Great Metropolitan Hospital of Reggio Calabria, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Beghi</LastName>                    <ForeName>Massimiliano</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Mental Health, AUSL Romagna, Ravenna, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Belcastro</LastName>                    <ForeName>Vincenzo</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Neurology Unit, Department of Medicine, S. Anna Hospital, Como, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Biermann</LastName>                    <ForeName>Klaus P</ForeName>                    <Initials>KP</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Trial Office, Meyer Children's Hospital, Florence, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bottini</LastName>                    <ForeName>Gabriella</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Capovilla</LastName>                    <ForeName>Giuseppe</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>President of the Italian League Against Epilepsy, Child Neuropsychiatry Unit, Azienda Ospedaliera Carlo Poma, Mantova, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cervellione</LastName>                    <ForeName>Rosa A</ForeName>                    <Initials>RA</Initials>                    <AffiliationInfo>                        <Affiliation>President of the Italian Federation against Epilepsies.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cianci</LastName>                    <ForeName>Vittoria</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Regional Epilepsy Centre, Great Metropolitan Hospital of Reggio Calabria, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Coppola</LastName>                    <ForeName>Giangennaro</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Child Neuropsychiatry Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cornaggia</LastName>                    <ForeName>Cesare M</ForeName>                    <Initials>CM</Initials>                    <AffiliationInfo>                        <Affiliation>Delegate of the Italian Society for Disorder of Neurological Development, School of Medicine and Surgery, University of Milano Bicocca, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>De Fazio</LastName>                    <ForeName>Pasquale</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Delegate of the Italian Society of Psychiatry, Psychiatric Unit, Department of Health Sciences, University &quot;Magna Graecia&quot;, Catanzaro, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>De Masi</LastName>                    <ForeName>Salvatore</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Trial Office, Meyer Children's Hospital, Florence, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>De Sarro</LastName>                    <ForeName>Giovambattista</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Pharmacology Unit, Department of Health Sciences, Magna Graecia University, Catanzaro, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Elia</LastName>                    <ForeName>Maurizio</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Unit of Neurology and Clinical Neurophysiopathology, Oasi Research Institute - IRCCS, Troina, EN, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Erba</LastName>                    <ForeName>Giuseppe</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, SEC, University of Rochester, Rochester, NY, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fusco</LastName>                    <ForeName>Lucia</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Neurophysiology Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, Rome, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gambardella</LastName>                    <ForeName>Antonio</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical and Surgical Sciences, Magna Greacia University of Catanzaro, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gentile</LastName>                    <ForeName>Valentina</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Delegate of the Italian Association Against Epilepsies.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Giallonardo</LastName>                    <ForeName>Anna T</ForeName>                    <Initials>AT</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neuroscience, Neurology Unit, &quot;Sapienza&quot; University, Rome, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Guerrini</LastName>                    <ForeName>Renzo</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Delegate of the Italian Society of Neurology and Psychiatry of Infancy and Adolescence.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Neurosciences, Psychology, Drug Research, and Child Health, University of Florence, Florence, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ingravallo</LastName>                    <ForeName>Francesca</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Iudice</LastName>                    <ForeName>Alfonso</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Neurology, University of Pisa, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Labate</LastName>                    <ForeName>Angelo</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical and Surgical Sciences, Magna Greacia University of Catanzaro, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lucenteforte</LastName>                    <ForeName>Ersilia</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurosciences, Psychology, Drug Research, and Child Health, University of Florence, Florence, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Magaudda</LastName>                    <ForeName>Adriana</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Epilepsy Centre, University of Messina, Messina, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mumoli</LastName>                    <ForeName>Laura</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical and Surgical Sciences, Magna Greacia University of Catanzaro, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Papagno</LastName>                    <ForeName>Costanza</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>President of the Italian Society of Neuropsychology, CIMeC and CeRiN, University of Trento, and Department of Psychology, University of Milano-Bicocca, Milano, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pesce</LastName>                    <ForeName>Giovanni B</ForeName>                    <Initials>GB</Initials>                    <AffiliationInfo>                        <Affiliation>President of the Italian Association Against Epilepsies.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pucci</LastName>                    <ForeName>Eugenio</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Coordinator of the Bioethics Study Group of Italian Neurology Society, Neurology Unit, ASUR Marche AV3, Macerata, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ricci</LastName>                    <ForeName>Pietrantonio</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Chair of Legal Medicine, University &quot;Magna Graecia&quot; of Catanzaro, Catanzaro, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Romeo</LastName>                    <ForeName>Antonino</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Pediatric Neurology Unit and Epilepsy Center, &quot;Fatebenefratelli e Oftalmico&quot; Hospital, Milano, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Quintas</LastName>                    <ForeName>Rui</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical and Experimental Epileptology Unit, Neurological Institute Carlo Besta - I.R.C.C.S. Foundation, Milan, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sueri</LastName>                    <ForeName>Chiara</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Regional Epilepsy Centre, Great Metropolitan Hospital of Reggio Calabria, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vitaliti</LastName>                    <ForeName>Giovanna</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Delegate of the Italian Society of Pediatric Neurology, University Hospital Policlinico-Vittorio Emanuele, Catania, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zoia</LastName>                    <ForeName>Riccardo</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Health and Biomedical Sciences, Section of Legal Medicine, University of Milan, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Aguglia</LastName>                    <ForeName>Umberto</ForeName>                    <Initials>U</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical and Surgical Sciences, Magna Greacia University of Catanzaro, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Regional Epilepsy Centre, Great Metropolitan Hospital of Reggio Calabria, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Coordinator of the Epilepsy Study Group of Italian Neurology Society.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>09</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Eur J Neurol</MedlineTA>            <NlmUniqueID>9506311</NlmUniqueID>            <ISSNLinking>1351-5101</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">EEG</Keyword>            <Keyword MajorTopicYN="N">conversion disorder</Keyword>            <Keyword MajorTopicYN="N">epilepsy</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30300463</ArticleId>            <ArticleId IdType="doi">10.1111/ene.13818</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30300379</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1932-6203</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>13</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>PloS one</Title>                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>            </Journal>            <ArticleTitle>Child sexual abuse in India: A systematic review.</ArticleTitle>            <Pagination>                <MedlinePgn>e0205086</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0205086</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Child Sexual Abuse (CSA) is a pressing human right issue and public health concern. We conducted a systematic review of quantitative and qualitative studies published in the past decade on CSA in India to examine the distribution of the prevalence estimates for both genders, to improve understanding of the determinants and consequences of CSA and identify gaps in the current state of research.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">For this systematic review, we searched electronic literature databases (PubMed, POPLINE, and PsycINFO) for articles published in English on Child Sexual Abuse in India between January 1, 2006 and January 1, 2016 using 55 search terms. Data were extracted from published articles only.</AbstractText>                <AbstractText Label="FINDINGS" NlmCategory="RESULTS">Fifty-one studies met inclusion criteria for the review. The review indicates that prevalence rates of CSA is high among both boys and girls in India. Due to heterogeneity of study designs and lack of standardised assessments, reported prevalence estimates varied greatly among both genders in different studies. There is a need to conduct representative studies using a validated instrument to obtain valid epidemiological estimates. Commercial sex workers, men who have sex with men, and women with psychiatric disorders were at higher risks for sexual abuse during childhood. In addition, the synthesis of qualitative data across studies included in the review suggests that exposure and perpetration of CSA is a multifaceted phenomenon grounded in the interplay between individual, family, community, and societal factors. The review indicates poor physical, behavioural, social, and mental health outcomes of CSA in India. We conclude with a research agenda calling for quantitative and qualitative studies to explore the determinants and perpetration of child sexual abuse in India from an ecological lens. This research agenda may be necessary to inform the development of a culturally tailored primary prevention and treatment strategy for CSA victims in India.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Choudhry</LastName>                    <ForeName>Vikas</ForeName>                    <Initials>V</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-3439-7846</Identifier>                    <AffiliationInfo>                        <Affiliation>Public Health Foundation of India, Institutional Area, Gurugram, Haryana, India.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Sambodhi Research and Communications Pvt. Ltd., Noida, Uttar Pradesh, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dayal</LastName>                    <ForeName>Radhika</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Public Health Foundation of India, Institutional Area, Gurugram, Haryana, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pillai</LastName>                    <ForeName>Divya</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Public Health Foundation of India, Institutional Area, Gurugram, Haryana, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kalokhe</LastName>                    <ForeName>Ameeta S</ForeName>                    <Initials>AS</Initials>                    <AffiliationInfo>                        <Affiliation>Emory University School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, Georgia, United States of America.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Emory University Rollins School of Public Health, Department of Global Health, Atlanta, Georgia, United States of America.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Beier</LastName>                    <ForeName>Klaus</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Sexology and Sexual Medicine, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Luisenstraße, Berlin, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Patel</LastName>                    <ForeName>Vikram</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Public Health Foundation of India, Institutional Area, Gurugram, Haryana, India.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, United States of America.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>09</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>PLoS One</MedlineTA>            <NlmUniqueID>101285081</NlmUniqueID>            <ISSNLinking>1932-6203</ISSNLinking>        </MedlineJournalInfo>        <CoiStatement>The authors declare that there is no conflict of interest financial or non-financial with regard to the study. The interpretation and presentation of the facts and figures given in the paper is not influenced by any personal or financial relationship with any individual or organisation. The funding agency or commercial affiliation (Sambodhi Research and Communications Pvt. Ltd.) of the lead author does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products to declare.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>11</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30300379</ArticleId>            <ArticleId IdType="doi">10.1371/journal.pone.0205086</ArticleId>            <ArticleId IdType="pii">PONE-D-17-37081</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30299334</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1538-9782</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>32</Volume>                    <Issue>6</Issue>                    <PubDate>                        <MedlineDate>2018 Nov/Dec</MedlineDate>                    </PubDate>                </JournalIssue>                <Title>Clinical nurse specialist CNS</Title>                <ISOAbbreviation>Clin Nurse Spec</ISOAbbreviation>            </Journal>            <ArticleTitle>Clinical Nurse Specialists' Perceptions of a Mental Health Patient Portal.</ArticleTitle>            <Pagination>                <MedlinePgn>313-322</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/NUR.0000000000000406</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The purposes of this study were to explore clinical nurse specialists' views of the potential influence of a mental health portal on nursing practice and to identify portal implementation strategies.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">A qualitative descriptive approach was used. Semistructured interviews were conducted with 5 clinical nurse specialists. Two independent coders conducted an inductive content analysis of the transcribed interviews to generate codes describing patterns in the data to identify originating themes.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The content analysis uncovered the following 4 themes: (1) implementation strategies, (2) nurse likelihood to recommend, (3) impact on nursing practice, and (4) perceived influence on patients.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Direct care nurses may benefit from education and coaching on how to document in the record using patient-centered language that is understandable to patients who may be reading it. In addition, the use of patient portals should be designed to fit into nurses' existing clinical workflows. Finally, more research is needed to identify the benefits and unintended consequences of patient portals within a mental health context.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Mayhew</LastName>                    <ForeName>Cari</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Author Affiliations: Master of Nursing Student (Ms Mayhew) and Associate Professor (Dr Waddell), Daphne Cockwell School of Nursing, Ryerson University; and Project Scientist (Dr Strudwick), Centre for Addiction Mental Health, Toronto, Ontario, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Strudwick</LastName>                    <ForeName>Gillian</ForeName>                    <Initials>G</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Waddell</LastName>                    <ForeName>Janice</ForeName>                    <Initials>J</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Clin Nurse Spec</MedlineTA>            <NlmUniqueID>8709115</NlmUniqueID>            <ISSNLinking>0887-6274</ISSNLinking>        </MedlineJournalInfo>        <CitationSubset>N</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D001291" MajorTopicYN="Y">Attitude of Health Personnel</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName>                <QualifierName UI="Q000451" MajorTopicYN="Y">nursing</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009720" MajorTopicYN="N">Nurse Clinicians</DescriptorName>                <QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000072638" MajorTopicYN="Y">Patient Portals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D036301" MajorTopicYN="N">Qualitative Research</DescriptorName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30299334</ArticleId>            <ArticleId IdType="doi">10.1097/NUR.0000000000000406</ArticleId>            <ArticleId IdType="pii">00002800-201811000-00008</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30299333</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1538-9782</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>32</Volume>                    <Issue>6</Issue>                    <PubDate>                        <MedlineDate>2018 Nov/Dec</MedlineDate>                    </PubDate>                </JournalIssue>                <Title>Clinical nurse specialist CNS</Title>                <ISOAbbreviation>Clin Nurse Spec</ISOAbbreviation>            </Journal>            <ArticleTitle>Alcohol Withdrawal Assessment Tool: Validity and Reliability Testing in Acute Care.</ArticleTitle>            <Pagination>                <MedlinePgn>307-312</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/NUR.0000000000000408</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE/AIMS" NlmCategory="UNASSIGNED">The purpose of this study was to validate a tool to assess alcohol withdrawal in acute care patients. Study aims included (1) establish content validity, (2) examine criterion-related validity, (3) test interrater reliability, and (4) assess nurse usability.</AbstractText>                <AbstractText Label="DESIGN" NlmCategory="METHODS">A psychometric research study was designed to evaluate the Alcohol Withdrawal Assessment Tool.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Validation was conducted using an expert panel to determine content validity. The Clinical Institute Withdrawal Assessment for Alcohol-Revised was used as comparison for the criterion related validity. Interrater reliability was determined by having 2 investigators simultaneously complete the assessment on the same patients. Usability was determined using a Likert scale survey.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The average age of participants was 53 years, with a range of 27 to 81 years. Interrater reliability was supported by a κ statistic range of 0.61 to 0.6957, and content validity was supported by a content validity index of 1.0. Criterion-related validity was supported with a Pearson r correlation of 0.665 (P &lt; .000). Of nurses surveyed, all answered agree or strongly agree to the usability survey.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The assessment tool may be an effective alternative to utilize in the acute care setting. It is easy to use and drives frequency of assessment and appropriate pharmacologic treatment.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Davis</LastName>                    <ForeName>Carmen R</ForeName>                    <Initials>CR</Initials>                    <AffiliationInfo>                        <Affiliation>Author Affiliations: Clinical Nurse Specialists (Mss Davis and Keen), Indiana University Health, University Hospital, Indianapolis; Clinical Nurse Specialist (Mr Holly), Indiana University Health, Bloomington Hospital; Clinical Nurse Specialist (Ms Balaguras), Indiana University Health, Bloomington Hospital; and Assistant Professor (Dr Miller), Indiana University School of Nursing, Indianapolis.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Keen</LastName>                    <ForeName>Alyson</ForeName>                    <Initials>A</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Holly</LastName>                    <ForeName>Vince</ForeName>                    <Initials>V</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Balaguras</LastName>                    <ForeName>Jean</ForeName>                    <Initials>J</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Miller</LastName>                    <ForeName>Wendy R</ForeName>                    <Initials>WR</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Clin Nurse Spec</MedlineTA>            <NlmUniqueID>8709115</NlmUniqueID>            <ISSNLinking>0887-6274</ISSNLinking>        </MedlineJournalInfo>        <CitationSubset>N</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000430" MajorTopicYN="N">Alcohol Withdrawal Delirium</DescriptorName>                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D003422" MajorTopicYN="Y">Critical Care</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D064648" MajorTopicYN="N">Critical Care Nursing</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30299333</ArticleId>            <ArticleId IdType="doi">10.1097/NUR.0000000000000408</ArticleId>            <ArticleId IdType="pii">00002800-201811000-00007</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30298927</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1440-1630</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>09</Day>                    </PubDate>                </JournalIssue>                <Title>Australian occupational therapy journal</Title>                <ISOAbbreviation>Aust Occup Ther J</ISOAbbreviation>            </Journal>            <ArticleTitle>The capacity of the BATCH as a predictive tool for discharge planning for people with neuropsychiatric disorders.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/1440-1630.12533</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Assessment of cognitive function in people with neurosychiatric disorders can be challenging, due to behavioural and psychiatric symptomatology. The Behavioural Assesment Tool for Cognition and Higher Functioning (BATCH) is a validated observational tool that complements formal cognitive testing in this patient population. This study aimed to determine the capacity of the BATCH as a predictive tool for discharge planning.</AbstractText>                <AbstractText Label="METHOD" NlmCategory="METHODS">BATCH scores for 330 consecutive admissions for assessment to a specialist neuropsychiatry unit between 2007 and 2015 were analysed. The variables of interest included discharge destination, diagnosis, length of stay, age at discharge and BATCH scores (both subdomain and total). Significant predictors of discharge destination were identified using logistic regression analysis.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">After adjusting for age at discharge, three variables were found to be significant predictors of discharge destination - length of stay, diagnosis, and BATCH total score. The odds of being discharged to a destination other than home decreased by 3% for each additional BATCH total score unit. The length of stay remained a significant predictor of discharge destination when adjusting for BATCH total score, age at admission and diagnosis.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">BATCH total scores, but not subdomain scores, were predictive of discharge destination, along with the patients' length of stay and diagnosis. Knowledge of this relationship may guide clinical discharge planning, when working with the complex needs of this group of patients. A larger study is indicated to determine the range and cut-off scores for discharge destinations other than home.</AbstractText>                <CopyrightInformation>© 2018 Occupational Therapy Australia.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Miller</LastName>                    <ForeName>Kathryn</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Occupational Therapy, North Western Mental Health, Melbourne, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mancuso</LastName>                    <ForeName>Serafino</ForeName>                    <Initials>S</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-1039-3277</Identifier>                    <AffiliationInfo>                        <Affiliation>EpiCentre, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tacey</LastName>                    <ForeName>Mark</ForeName>                    <Initials>M</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-6318-3911</Identifier>                    <AffiliationInfo>                        <Affiliation>EpiCentre, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Walterfang</LastName>                    <ForeName>Mark</ForeName>                    <Initials>M</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-1389-3691</Identifier>                    <AffiliationInfo>                        <Affiliation>Melbourne Neuropsychiatry Centre, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Velakoulis</LastName>                    <ForeName>Dennis</ForeName>                    <Initials>D</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8842-8479</Identifier>                    <AffiliationInfo>                        <Affiliation>Melbourne Neuropsychiatry Centre, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hitch</LastName>                    <ForeName>Danielle</ForeName>                    <Initials>D</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-2798-2246</Identifier>                    <AffiliationInfo>                        <Affiliation>Occupational Therapy, North Western Mental Health, Melbourne, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Occupational Therapy, Deakin University, Geelong, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <Agency>North Western Mental Health 2014 Seeding Grant</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>09</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Australia</Country>            <MedlineTA>Aust Occup Ther J</MedlineTA>            <NlmUniqueID>15420200R</NlmUniqueID>            <ISSNLinking>0045-0766</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Behavioural Assessment Tool for Cognition and Higher Functioning (BATCH)</Keyword>            <Keyword MajorTopicYN="N">discharge planning</Keyword>            <Keyword MajorTopicYN="N">neuropsychiatry</Keyword>            <Keyword MajorTopicYN="N">occupational therapy</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30298927</ArticleId>            <ArticleId IdType="doi">10.1111/1440-1630.12533</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30298793</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1552-8448</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>09</Day>                    </PubDate>                </JournalIssue>                <Title>Violence against women</Title>                <ISOAbbreviation>Violence Against Women</ISOAbbreviation>            </Journal>            <ArticleTitle>&quot;If He's Abusing You . . . the Baby Is Going to Be Affected&quot;: HIV-Positive Pregnant Women's Experiences of Intimate Partner Violence.</ArticleTitle>            <Pagination>                <MedlinePgn>1077801218802640</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1177/1077801218802640</ELocationID>            <Abstract>                <AbstractText>Pregnancy represents a time of increased risk for intimate partner violence (IPV), and an HIV diagnosis further increases the vulnerability of this at-risk group. This study explores experiences of recent IPV using qualitative interviews with N = 12 HIV-positive pregnant women recruited from a clinical setting in South Africa, a location with a high global prevalence of IPV and HIV. Partner dynamics around IPV resulted in HIV shame and stigma and adversely affected engagement in HIV care and HIV treatment behaviors. The results highlight the challenges women face in navigating disclosure of both IPV and HIV, accessing necessary support, and engaging in both HIV-related and pregnancy-related care in the context of an abusive relationship.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Marais</LastName>                    <ForeName>Adele</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>1 Department of Psychiatry and Mental Health, University of Cape Town, South Africa.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kuo</LastName>                    <ForeName>Caroline C</ForeName>                    <Initials>CC</Initials>                    <AffiliationInfo>                        <Affiliation>1 Department of Psychiatry and Mental Health, University of Cape Town, South Africa.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>2 Brown University, Providence, RI, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Julies</LastName>                    <ForeName>Robin</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>1 Department of Psychiatry and Mental Health, University of Cape Town, South Africa.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Stein</LastName>                    <ForeName>Dan J</ForeName>                    <Initials>DJ</Initials>                    <AffiliationInfo>                        <Affiliation>1 Department of Psychiatry and Mental Health, University of Cape Town, South Africa.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>3 SA MRC Unit on Risk and Resilience in Mental Disorders.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Joska</LastName>                    <ForeName>John A</ForeName>                    <Initials>JA</Initials>                    <AffiliationInfo>                        <Affiliation>1 Department of Psychiatry and Mental Health, University of Cape Town, South Africa.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zlotnick</LastName>                    <ForeName>Caron</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>1 Department of Psychiatry and Mental Health, University of Cape Town, South Africa.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>4 The Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>5 Women &amp; Infants Hospital, Providence, RI, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>6 Butler Hospital, Providence, RI, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>09</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Violence Against Women</MedlineTA>            <NlmUniqueID>9506308</NlmUniqueID>            <ISSNLinking>1077-8012</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">HIV</Keyword>            <Keyword MajorTopicYN="N">South Africa</Keyword>            <Keyword MajorTopicYN="N">intimate partner violence</Keyword>            <Keyword MajorTopicYN="N">pregnancy</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30298793</ArticleId>            <ArticleId IdType="doi">10.1177/1077801218802640</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30298566</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1475-6773</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>08</Day>                    </PubDate>                </JournalIssue>                <Title>Health services research</Title>                <ISOAbbreviation>Health Serv Res</ISOAbbreviation>            </Journal>            <ArticleTitle>The Impact of Medicaid Enrollment on Veterans Health Administration Enrollees' Behavioral Health Services Use.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/1475-6773.13062</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine Veterans Health Administration (VA) enrollees' use of VA services for treatment of behavioral health conditions (BHCs) after gaining Medicaid, and if VA reliance varies by complexity of BHCs.</AbstractText>                <AbstractText Label="DATA SOURCES/STUDY SETTING" NlmCategory="METHODS">VA and Medicaid Analytic eXtract utilization data from 31 states, 2006-2010.</AbstractText>                <AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">A retrospective, longitudinal study of Veterans enrolled in VA care in the year before and year after enrollment in Medicaid among 7,249 nonelderly Veterans with serious mental illness (SMI), substance use disorder (SUD), posttraumatic stress disorder (PTSD), depression, or other BHCs.</AbstractText>                <AbstractText Label="DATA COLLECTION/EXTRACTION METHODS" NlmCategory="METHODS">Utilization and VA reliance (proportion of care received at VA) for BH outpatient and inpatient services in unadjusted and adjusted analyses.</AbstractText>                <AbstractText Label="PRINCIPAL FINDINGS" NlmCategory="RESULTS">In adjusted analyses, we found that overall Veterans did not significantly change their use of VA outpatient BH services after Medicaid enrollment. In beta-binomial models predicting VA BH outpatient reliance, veterans with SMI (IRR = 1.38, p &lt; .05), PTSD (IRR = 1.62, p &lt; .01), and depression (IRR = 1.36, p &lt; .05) had higher reliance than veterans with other BHCs after Medicaid enrollment.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">While veterans did not change the amount of VA outpatient BH services they used after enrolling in Medicaid, the proportion of care they received through VA or Medicaid varied by BHC.</AbstractText>                <CopyrightInformation>© Health Research and Educational Trust.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Vanneman</LastName>                    <ForeName>Megan E</ForeName>                    <Initials>ME</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-3013-1362</Identifier>                    <AffiliationInfo>                        <Affiliation>Informatics, Decision-Enhancement and Analytic Sciences Center, VA Salt Lake City Health Care System, Salt Lake City, UT.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, UT.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Population Health Sciences, Division of Health System Innovation and Research, University of Utah School of Medicine, Salt Lake City, UT.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>University of Utah Health, Williams Building, 295 Chipeta Way, Salt Lake City, UT.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Phibbs</LastName>                    <ForeName>Ciaran S</ForeName>                    <Initials>CS</Initials>                    <AffiliationInfo>                        <Affiliation>Health Economics Resource Center, VA Palo Alto Health Care System, Menlo Park, CA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Center for Innovation to Implementation, VA Palo Alto Health Care System, Menlo Park, CA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pediatrics, Stanford University School of Medicine, Stanford, CA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dally</LastName>                    <ForeName>Sharon K</ForeName>                    <Initials>SK</Initials>                    <AffiliationInfo>                        <Affiliation>Health Economics Resource Center, VA Palo Alto Health Care System, Menlo Park, CA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Trivedi</LastName>                    <ForeName>Amal N</ForeName>                    <Initials>AN</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-9695-4727</Identifier>                    <AffiliationInfo>                        <Affiliation>Providence VA Medical Center, Providence, RI.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Brown University School of Public Health, Providence, RI.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yoon</LastName>                    <ForeName>Jean</ForeName>                    <Initials>J</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8565-2881</Identifier>                    <AffiliationInfo>                        <Affiliation>Health Economics Resource Center, VA Palo Alto Health Care System, Menlo Park, CA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of General Internal Medicine, UCSF School of Medicine, San Francisco, CA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>IIR 13-313</GrantID>                    <Agency>Health Services Research and Development</Agency>                    <Country/>                </Grant>                <Grant>                    <Agency>VA Office of Academic Affiliations</Agency>                    <Country/>                </Grant>                <Grant>                    <Agency>University of Utah Health Enhancing Development-Generating Excellence (EDGE) Scholar and Vice President's Clinical and Translational Scholars (VPCAT) programs</Agency>                    <Country/>                </Grant>                <Grant>                    <Agency>Department of Veterans Affairs, VA Health Services Research and Development Service</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>SDR 02-237</GrantID>                    <Agency>VA Information Resource Center</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>98-004</GrantID>                    <Agency>VA Information Resource Center</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Health Serv Res</MedlineTA>            <NlmUniqueID>0053006</NlmUniqueID>            <ISSNLinking>0017-9124</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Medicaid</Keyword>            <Keyword MajorTopicYN="N">Veterans</Keyword>            <Keyword MajorTopicYN="N">behavioral health</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30298566</ArticleId>            <ArticleId IdType="doi">10.1111/1475-6773.13062</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30296954</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1471-6348</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>09</Day>                    </PubDate>                </JournalIssue>                <Title>International journal of technology assessment in health care</Title>                <ISOAbbreviation>Int J Technol Assess Health Care</ISOAbbreviation>            </Journal>            <ArticleTitle>COST-EFFECTIVENESS OF INTERVENTIONS BASED ON PHYSICAL ACTIVITY IN THE TREATMENT OF CHRONIC CONDITIONS: A SYSTEMATIC LITERATURE REVIEW.</ArticleTitle>            <Pagination>                <MedlinePgn>1-17</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1017/S0266462318000533</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study is to review evidence on the cost-effectiveness of exercise-based interventions in the treatment of chronic conditions a decade after the publication of Roine et al. in 2009 (Roine E, Roine RP, Räsänen P, et al. Int J Technol Assess Health Care. 2009;25:427-454).</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We carried out a review of published articles in PUBMED and JSTOR between January 1, 2008, and December 31, 2016. Full economic evaluations of exercise programs targeting patients with a chronic condition were eligible for inclusion. Data on program, design, and economic characteristics were extracted using a predefined extraction form. The quality of the economic evaluations was appraised using the adjusted Consensus Health Economic Criteria List.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 426 articles were identified and thirty-seven studies were selected. Eleven studies dealt with musculoskeletal and rheumatologic disorders, ten with cardiovascular diseases, six with neurological disorders, three with mental illnesses, three with cancers, and four with diabetes, respiratory diseases, or pelvic organ prolapse. In total, 60 percent of exercise programs were dominant or cost-effective. For musculoskeletal and rheumatologic disorders, 72 percent of programs were dominant or cost-effective while this was the case for 57 percent of programs for cardiovascular diseases using a nonsurgical comparator.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There is clear evidence in favor of exercise-based programs for the treatment of musculoskeletal and rheumatologic disorders and, to a lesser extent, for the treatment of cardiovascular diseases. More research is needed to evaluate the cost-effectiveness of physical activity in the treatment of neurological disorders, mental illnesses, cancers, respiratory diseases, and diabetes/obesity.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Guillon</LastName>                    <ForeName>Marlène</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Université Clermont Auvergne,CNRS,CERDI and Hospinnomics - PSE - École d'économie de Paris,Assistance publique Hôpitaux de Parismarlene.guillon@uca.fr.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rochaix</LastName>                    <ForeName>Lise</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Université Paris 1 and Hospinnomics - PSE - École d'économie de Paris,Assistance publique Hôpitaux de Paris.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dupont</LastName>                    <ForeName>Jean-Claude K</ForeName>                    <Initials>JK</Initials>                    <AffiliationInfo>                        <Affiliation>Hospinnomics - PSE - École d'économie de Paris,Assistance publique Hôpitaux de Paris.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>09</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Int J Technol Assess Health Care</MedlineTA>            <NlmUniqueID>8508113</NlmUniqueID>            <ISSNLinking>0266-4623</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Chronic disease</Keyword>            <Keyword MajorTopicYN="N">Cost-benefit analysis</Keyword>            <Keyword MajorTopicYN="N">Exercise</Keyword>            <Keyword MajorTopicYN="N">Review</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30296954</ArticleId>            <ArticleId IdType="pii">S0266462318000533</ArticleId>            <ArticleId IdType="doi">10.1017/S0266462318000533</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30296883</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1557-1246</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>08</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of attention disorders</Title>                <ISOAbbreviation>J Atten Disord</ISOAbbreviation>            </Journal>            <ArticleTitle>The Relationship Between Executive Function Deficits and DSM-5-Defined ADHD Symptoms.</ArticleTitle>            <Pagination>                <MedlinePgn>1087054718804347</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1177/1087054718804347</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To identify the relationship between the core Diagnostic and Statistical Manual of Mental Disorders (5th ed.) ADHD symptoms and executive function deficits (EFDs), to evaluate ADHD characteristics of those with executive dysfunction (ED), and to examine the predictive utility of the Adult ADHD Investigator Symptom Rating Scale (AISRS) in identifying those with adult ADHD and ED.</AbstractText>                <AbstractText Label="METHOD" NlmCategory="METHODS">Two samples (referred and primary care practice) were pooled together for present analysis.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Final analysis included 297 respondents, 171 with adult ADHD. Spearman correlation coefficients and binary logistic regressions demonstrated that ADHD inattentive (IA) and hyperactive-impulsive (H-I) symptoms were moderately to strongly correlated with and highly predictive of EFDs. Receiver operating characteristic curve analysis showed that an AISRS DSM 18-item score of ⩾ 28 was most predictive of clinical ED.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">ADHD symptoms were strongly correlated with and predictive of EFDs, clinicians should screen adults with ADHD for EFDs and ADHD treatment providers should track EFD improvement in addition to DSM-5 ADHD symptoms.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Silverstein</LastName>                    <ForeName>Michael J</ForeName>                    <Initials>MJ</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0002-8697-6631</Identifier>                    <AffiliationInfo>                        <Affiliation>1 Drexel University, Philadelphia, PA, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>2 New York University School of Medicine, New York City, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Faraone</LastName>                    <ForeName>Stephen V</ForeName>                    <Initials>SV</Initials>                    <AffiliationInfo>                        <Affiliation>3 SUNY Upstate Medical University, Syracuse, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Leon</LastName>                    <ForeName>Terry L</ForeName>                    <Initials>TL</Initials>                    <AffiliationInfo>                        <Affiliation>2 New York University School of Medicine, New York City, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Biederman</LastName>                    <ForeName>Joseph</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>4 Massachusetts General Hospital, Boston, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Spencer</LastName>                    <ForeName>Thomas J</ForeName>                    <Initials>TJ</Initials>                    <AffiliationInfo>                        <Affiliation>4 Massachusetts General Hospital, Boston, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Adler</LastName>                    <ForeName>Lenard A</ForeName>                    <Initials>LA</Initials>                    <AffiliationInfo>                        <Affiliation>2 New York University School of Medicine, New York City, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Atten Disord</MedlineTA>            <NlmUniqueID>9615686</NlmUniqueID>            <ISSNLinking>1087-0547</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">ADHD</Keyword>            <Keyword MajorTopicYN="N">etiology</Keyword>            <Keyword MajorTopicYN="N">executive function</Keyword>            <Keyword MajorTopicYN="N">scale psychometrics</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30296883</ArticleId>            <ArticleId IdType="doi">10.1177/1087054718804347</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30296504</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1095-8304</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>Appetite</Title>                <ISOAbbreviation>Appetite</ISOAbbreviation>            </Journal>            <ArticleTitle>Dopamine genetic risk is related to food addiction and body mass through reduced reward-related ventral striatum activity.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">S0195-6663(17)31900-1</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.appet.2018.09.010</ELocationID>            <Abstract>                <AbstractText>The prevalence rate of obesity continues to rise in the U.S., but effective treatment options remain elusive resulting in increased emphasis on prevention. One such area of prevention research capitalizes on the relatively novel behavioral construct of food addiction, which has been implicated in obesity. Food addiction reflects an individual's propensity for compulsive eating despite negative consequences, and shares not only symptoms with both eating and substance use disorders but also genetic and neural correlates within neural reward-circuitry modulated by dopamine. Here, we examined associations between food addiction scores, body mass index (BMI), reward-related ventral striatum activity, and a polygenic score approximating dopamine signaling in 115 non-Hispanic Caucasian young adult university students. As predicted, polygenic dopamine scores were related to ventral striatum activity, which in turn was associated with higher food addiction scores. In addition, food addiction was related to BMI. An exploratory post-hoc path analysis further indicated that polygenic scores were indirectly related to both food addiction and BMI, in part, through ventral striatum activity. Collectively, our results provide evidence supporting the utility of food addiction in weight gain prevention research by establishing links with known risk-related neural and genetic biomarkers.</AbstractText>                <CopyrightInformation>Copyright © 2018. Published by Elsevier Ltd.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Romer</LastName>                    <ForeName>Adrienne L</ForeName>                    <Initials>AL</Initials>                    <AffiliationInfo>                        <Affiliation>Duke University, Durham, NC, USA. Electronic address: adrienne.romer@duke.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Su Kang</LastName>                    <ForeName>Min</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>McLean Hospital, Belmont, MA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nikolova</LastName>                    <ForeName>Yuliya S</ForeName>                    <Initials>YS</Initials>                    <AffiliationInfo>                        <Affiliation>Centre for Addiction and Mental Health, Toronto, Ontario, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gearhardt</LastName>                    <ForeName>Ashley N</ForeName>                    <Initials>AN</Initials>                    <AffiliationInfo>                        <Affiliation>University of Michigan, Ann Arbor, MI, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hariri</LastName>                    <ForeName>Ahmad R</ForeName>                    <Initials>AR</Initials>                    <AffiliationInfo>                        <Affiliation>Duke University, Durham, NC, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>05</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Appetite</MedlineTA>            <NlmUniqueID>8006808</NlmUniqueID>            <ISSNLinking>0195-6663</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">BMI</Keyword>            <Keyword MajorTopicYN="N">Dopamine</Keyword>            <Keyword MajorTopicYN="N">Food addiction</Keyword>            <Keyword MajorTopicYN="N">Obesity</Keyword>            <Keyword MajorTopicYN="N">Ventral striatum</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>12</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30296504</ArticleId>            <ArticleId IdType="pii">S0195-6663(17)31900-1</ArticleId>            <ArticleId IdType="doi">10.1016/j.appet.2018.09.010</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="HSR">        <PMID Version="1">30296038</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Print">1068-2716</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>26</Volume>                    <Issue>39</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>NCSL legisbrief</Title>                <ISOAbbreviation>NCSL Legisbrief</ISOAbbreviation>            </Journal>            <ArticleTitle>Addressing Children’s Mental Health.</ArticleTitle>            <Pagination>                <MedlinePgn>1-2</MedlinePgn>            </Pagination>            <Abstract>                <AbstractText>(1) Untreated mental disorders and mental illness in children can lead to costly outcomes such as school dropout, substance use and suicide. (2) Half of lifetime cases of mental illness begin by age 14 and 75 percent of all lifetime cases present by age 24. (3) Early intervention and access to treatment may decrease the financial and health burdens associated with mental illness.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Takkunen</LastName>                    <ForeName>Alison</ForeName>                    <Initials>A</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Zlevor</LastName>                    <ForeName>Annie</ForeName>                    <Initials>A</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>NCSL Legisbrief</MedlineTA>            <NlmUniqueID>101092658</NlmUniqueID>            <ISSNLinking>1068-2716</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30296038</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30295645</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1558-8238</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>08</Day>                    </PubDate>                </JournalIssue>                <Title>The Journal of clinical investigation</Title>                <ISOAbbreviation>J. Clin. Invest.</ISOAbbreviation>            </Journal>            <ArticleTitle>Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI93090</ELocationID>            <ELocationID EIdType="pii" ValidYN="Y">93090</ELocationID>            <Abstract>                <AbstractText>Atypical antipsychotics are highly effective antischizophrenic medications but their clinical utility is limited by adverse metabolic sequelae. We investigated whether upregulation of macrophage migration inhibitory factor (MIF) underlies the insulin resistance that develops during treatment with the most commonly prescribed atypical antipsychotic, olanzapine. Olanzapine monotherapy increased BMI and circulating insulin, triglyceride, and MIF concentrations in drug-naive schizophrenic patients with normal MIF expression, but not in genotypic low MIF expressers. Olanzapine administration to mice increased their food intake and hypothalamic MIF expression, which led to activation of the appetite-related AMP-activated protein kinase and Agouti-related protein pathway. Olanzapine also upregulated MIF expression in adipose tissue, which reduced lipolysis and increased lipogenic pathways. Increased plasma lipid concentrations were associated with abnormal fat deposition in liver and skeletal muscle, which are important determinants of insulin resistance. Global MIF-gene deletion protected mice from olanzapine-induced insulin resistance, as did intracerebroventricular injection of neutralizing anti-MIF antibody, supporting the role of increased hypothalamic MIF expression in metabolic dysfunction. These findings uphold the potential pharmacogenomic value of MIF genotype determination and suggest that MIF may be a tractable target for reducing the metabolic side effects of atypical antipsychotic therapy.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Cui</LastName>                    <ForeName>Donghong</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Brain Science and Technology Research Center, Shanghai Jiao Tong University, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Peng</LastName>                    <ForeName>Yanmin</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Chengfang</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Shanghai Pudong New Area Mental Health Center, Tongji University School of Medicine, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Zezhi</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Su</LastName>                    <ForeName>Yousong</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Qi</LastName>                    <ForeName>Yadan</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xing</LastName>                    <ForeName>Mengjuan</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Jia</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Grace E</ForeName>                    <Initials>GE</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Su</LastName>                    <ForeName>Kevin N</ForeName>                    <Initials>KN</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xu</LastName>                    <ForeName>Jinjie</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Meiti</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ding</LastName>                    <ForeName>Wenhua</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Piecychna</LastName>                    <ForeName>Marta</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Leng</LastName>                    <ForeName>Lin</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hirasawa</LastName>                    <ForeName>Michiru</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Biomedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jiang</LastName>                    <ForeName>Kaida</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Young</LastName>                    <ForeName>Lawrence</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xu</LastName>                    <ForeName>Yifeng</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Qi</LastName>                    <ForeName>Dake</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Division of Biomedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bucala</LastName>                    <ForeName>Richard</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Clin Invest</MedlineTA>            <NlmUniqueID>7802877</NlmUniqueID>            <ISSNLinking>0021-9738</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Metabolism</Keyword>            <Keyword MajorTopicYN="N">Schizophrenia</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>01</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30295645</ArticleId>            <ArticleId IdType="pii">93090</ArticleId>            <ArticleId IdType="doi">10.1172/JCI93090</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30295108</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1741-2811</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>08</Day>                    </PubDate>                </JournalIssue>                <Title>Health informatics journal</Title>                <ISOAbbreviation>Health Informatics J</ISOAbbreviation>            </Journal>            <ArticleTitle>Sweet care against sugar bitterness, designing health-based electronic game.</ArticleTitle>            <Pagination>                <MedlinePgn>1460458218799444</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1177/1460458218799444</ELocationID>            <Abstract>                <AbstractText>Health-based electronic games present an innovative tool to deal with mental and behavioral disorders as well as physical. An appropriately designed game can optimize health care. The aim of this study was to establish a design for health-based electronic games model and to develop a sample game in diabetes. This study was carried out in two phases: first, the design of a health-based electronic game framework and second, the design and production of sweet care game. There were two intended information prerequisites: determination of effective components in models of behavior change and validation of these components on health topics and structural formation of a game. The game framework design was presented. In the second phase, a sample of the game was developed in the field of diabetes. Important components to empower people were ranked using the Friedman test in the following order: self-learning, treatment, mental empowerment, condition management, healthy eating and physical activity. The axis of self-learning received the highest rating from the perspective of the subjects with an average of 3.93 percent. Another part was the game framework with components as follows: application areas, educational content for change behavior, resources, game structure and game production. Finally, the sweet care game was designed on diabetes with educational, technological and clinical content. The health-based electronic game designed on a systematic framework could be applied as a tool to expanding the knowledge base on how to create effective health-based digital games that entertain while promoting behavior change.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Safdari</LastName>                    <ForeName>Reza</ForeName>                    <Initials>R</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Ghazisaeidi</LastName>                    <ForeName>Marjan</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>University of Medical Sciences, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Goodini</LastName>                    <ForeName>Azadeh</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>University of Medical Sciences, Iran; Tehran University of Medical Sciences, Iran.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Health Informatics J</MedlineTA>            <NlmUniqueID>100883604</NlmUniqueID>            <ISSNLinking>1460-4582</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">design</Keyword>            <Keyword MajorTopicYN="N">electronic game</Keyword>            <Keyword MajorTopicYN="N">health</Keyword>            <Keyword MajorTopicYN="N">sweet care</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30295108</ArticleId>            <ArticleId IdType="doi">10.1177/1460458218799444</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30295107</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1532-5725</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>08</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of the American Psychiatric Nurses Association</Title>                <ISOAbbreviation>J Am Psychiatr Nurses Assoc</ISOAbbreviation>            </Journal>            <ArticleTitle>Two Different Buprenorphine Treatment Settings With Similar Retention Rates: Implications for Expanding Access to Treatment for Opioid Use Disorder.</ArticleTitle>            <Pagination>                <MedlinePgn>1078390318805562</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1177/1078390318805562</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is considerable need for effective and accessible treatment for opioid use disorder.</AbstractText>                <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Our study explored differences in buprenorphine treatment retention and duration, with a focus on selected sociodemographic factors and treatment indicators, in two different settings: an office-based buprenorphine induction and stabilization clinic (OBIC) and a community-based primary care clinic (CPC).</AbstractText>                <AbstractText Label="METHOD" NlmCategory="METHODS">This nonexperimental retrospective chart review compared demographic information and buprenorphine treatment details, including treatment retention and duration.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no statistically significant differences in buprenorphine treatment indicators between the OBIC and CPC groups, with two exceptions: the number of written buprenorphine prescriptions was significantly greater for the OBIC group, as was the number of filled buprenorphine prescriptions.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Given similar treatment retention and duration in two different buprenorphine treatment settings, our findings suggest that access to buprenorphine treatment in standard integrated care settings can be supplemented by novel treatment structures such as the OBIC in order to increase access to care during the current opioid epidemic.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Tierney</LastName>                    <ForeName>Matthew</ForeName>                    <Initials>M</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0003-4531-9317</Identifier>                    <AffiliationInfo>                        <Affiliation>1 Matthew Tierney, RN, MS, ANP-BC, PMHNP-BC, University of California, San Francisco, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Melino</LastName>                    <ForeName>Katerina</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>2 Katerina Melino, RN, MS, PMHNP-BC, University of California, San Francisco, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Adeniji</LastName>                    <ForeName>Adebowale</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>3 Adebowale Adeniji, RN, PMHNP, MSPH, Community Mental Health Nurse, San Mateo County, Daly City, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shumway</LastName>                    <ForeName>Martha</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>4 Martha Shumway, PhD, University of California, San Francisco, CA, USA; Zuckerberg San Francisco General Hospital, San Francisco, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Allen</LastName>                    <ForeName>Isabel E</ForeName>                    <Initials>IE</Initials>                    <AffiliationInfo>                        <Affiliation>5 Isabel E. Allen, PhD, University of California, San Francisco, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Waters</LastName>                    <ForeName>Catherine M</ForeName>                    <Initials>CM</Initials>                    <AffiliationInfo>                        <Affiliation>6 Catherine M. Waters, RN, PhD, FAAN, University of California, San Francisco, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Am Psychiatr Nurses Assoc</MedlineTA>            <NlmUniqueID>9507418</NlmUniqueID>            <ISSNLinking>1078-3903</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">buprenorphine</Keyword>            <Keyword MajorTopicYN="N">health services accessibility</Keyword>            <Keyword MajorTopicYN="N">opioid-related disorders</Keyword>            <Keyword MajorTopicYN="N">public health</Keyword>            <Keyword MajorTopicYN="N">retrospective studies</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30295107</ArticleId>            <ArticleId IdType="doi">10.1177/1078390318805562</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30294986</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1440-1754</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>54</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Journal of paediatrics and child health</Title>                <ISOAbbreviation>J Paediatr Child Health</ISOAbbreviation>            </Journal>            <ArticleTitle>Anxiety-related disorders: An overview.</ArticleTitle>            <Pagination>                <MedlinePgn>1104-1109</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jpc.14167</ELocationID>            <Abstract>                <AbstractText>Anxiety-related disorders are common in the child and adolescent population. They cause significant distress, which can affect social, emotional, family and academic functioning. They frequently present in general paediatric and primary care settings. Comprehensive assessment should include the child as well as parent and family functioning because anxiety-related disorders in other family members are common and, if untreated, can affect outcomes for the child. There are good evidence-based psychological interventions available, which should be the first line of treatment offered; accessing appropriate therapies for an adequate duration of treatment can, however, be challenging. Medication, particularly selective serotonin reuptake inhibitors, may have a role to play but should be used in the context of psychologically based therapies. Prevention of anxiety-related disorders in childhood is a major public health issue. Prevention programmes are available and should commence in the antenatal period through infancy, early childhood and adolescence, promoting positive attachments and resilience.</AbstractText>                <CopyrightInformation>© 2018 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Riordan</LastName>                    <ForeName>Denise M</ForeName>                    <Initials>DM</Initials>                    <AffiliationInfo>                        <Affiliation>Northern Territory Department of Health, Darwin, Northern Territory, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Singhal</LastName>                    <ForeName>Deepa</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>ACT Health, Mental Health Justice Health Alcohol and Drug Services, Canberra, Australian Capital Territory, Australia.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Australia</Country>            <MedlineTA>J Paediatr Child Health</MedlineTA>            <NlmUniqueID>9005421</NlmUniqueID>            <ISSNLinking>1034-4810</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30294986</ArticleId>            <ArticleId IdType="doi">10.1111/jpc.14167</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30294979</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1440-1754</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>54</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Journal of paediatrics and child health</Title>                <ISOAbbreviation>J Paediatr Child Health</ISOAbbreviation>            </Journal>            <ArticleTitle>The aggressive child.</ArticleTitle>            <Pagination>                <MedlinePgn>1165-1169</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jpc.14182</ELocationID>            <Abstract>                <AbstractText>Aggression in children is a common transdiagnostic symptom associated with a wide range of developmental and mental health problems. It emerges early and without intervention, may increase in severity as the child grows stronger. Aggressive children are more likely to experience physical and mental illness, unemployment, poverty and forensic problems as adults. Strategies to prevent aggression must address risk factors: low maternal education, adolescent pregnancy, in utero exposure to tobacco and alcohol, poverty, coercive parenting, childhood maltreatment and bullying victimisation. The aggressive child requires a comprehensive assessment to identify and manage underlying or comorbid problems, to understand the reasons for the aggressive behaviour and to detect modifiable factors that exacerbate or perpetuate the aggression. Psychosocial interventions include parenting skills training and child-directed cognitive behavioural therapy, whereas pharmacotherapy may be used to treat underlying developmental or mental health problems or to manage the aggression.</AbstractText>                <CopyrightInformation>© 2018 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Scott</LastName>                    <ForeName>James G</ForeName>                    <Initials>JG</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-0744-0688</Identifier>                    <AffiliationInfo>                        <Affiliation>Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Child and Youth Mental Health Research, Queensland Centre for Mental Health Research, Brisbane, Queensland, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Metro North Mental Health, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tunbridge</LastName>                    <ForeName>Michael</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Child and Youth Mental Health Service, Children's Hospital and Health Service District, Brisbane, Queensland, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Stathis</LastName>                    <ForeName>Stephen</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Child and Youth Mental Health Service, Children's Hospital and Health Service District, Brisbane, Queensland, Australia.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>APP1105807</GrantID>                    <Agency>National Health and Medical Research Council</Agency>                    <Country/>                </Grant>                <Grant>                    <Agency>Queensland Health</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Australia</Country>            <MedlineTA>J Paediatr Child Health</MedlineTA>            <NlmUniqueID>9005421</NlmUniqueID>            <ISSNLinking>1034-4810</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">adolescent</Keyword>            <Keyword MajorTopicYN="N">aggression</Keyword>            <Keyword MajorTopicYN="N">assessment</Keyword>            <Keyword MajorTopicYN="N">children</Keyword>            <Keyword MajorTopicYN="N">management</Keyword>            <Keyword MajorTopicYN="N">prevention</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30294979</ArticleId>            <ArticleId IdType="doi">10.1111/jpc.14182</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30294906</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1531-8249</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>07</Day>                    </PubDate>                </JournalIssue>                <Title>Annals of neurology</Title>                <ISOAbbreviation>Ann. Neurol.</ISOAbbreviation>            </Journal>            <ArticleTitle>N-acetylcysteine targets 5 lipoxygenase-derived, toxic lipids and can synergize with PGE<sub>2</sub> to inhibit ferroptosis and improve outcomes following hemorrhagic stroke in mice.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.25356</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">N-acetylcysteine (NAC) is a clinically approved thiol-containing redox modulatory compound currently in trials for many neurological and psychiatric disorders. Although generically labeled as an &quot;antioxidant&quot;, poor understanding of its site(s) of action is a barrier to its use in neurological practice. Here, we examined the efficacy and mechanism of action of NAC in rodent models of hemorrhagic stroke.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Hemin was used to model ferroptosis and hemorrhagic stroke in cultured neurons. Striatal infusion of collagenase was used to model intracerebral hemorrhage (ICH) in mice and rats. Chemical biology, targeted lipidomics, 5-lipoxygenase (ALOX5) knockout mice and viral-gene transfer were used to gain insight into the pharmacological targets and mechanism of action of NAC.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">NAC prevented hemin-induced ferroptosis by neutralizing toxic lipids generated via arachidonate dependent ALOX5 activity. NAC efficacy required increases in glutathione and is correlated with suppression of reactive lipids by glutathione dependent enzymes such as glutathione-S-transferase. Accordingly, its protective effects were mimicked by chemical or molecular lipid peroxidation inhibitors. NAC delivered post-injury reduced neuronal death and improved functional recovery at least 7 days following ICH in mice, and can synergize with clinically-approved prostaglandin E<sub>2</sub> (PGE<sub>2</sub> ).</AbstractText>                <AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">NAC is a promising, protective therapy for ICH, which acted to inhibit toxic arachidonic acid (AA) products of nuclear ALOX5 that synergized with exogenously delivered protective PGE<sub>2</sub> in vitro and in vivo. The findings provide novel insight into a target for NAC, beyond the generic characterization as an antioxidant, resulting in neuroprotection and offer a feasible combinatorial strategy to optimize efficacy and safety in dosing of NAC for treatment of neurological disorders involving ferroptosis such as ICH. This article is protected by copyright. All rights reserved.</AbstractText>                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Karuppagounder</LastName>                    <ForeName>Saravanan S</ForeName>                    <Initials>SS</Initials>                    <AffiliationInfo>                        <Affiliation>Sperling Center for Hemorrhagic Stroke Recovery, Burke Neurological Institute, White Plains, NY.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, NY.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Alin</LastName>                    <ForeName>Lauren</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Sperling Center for Hemorrhagic Stroke Recovery, Burke Neurological Institute, White Plains, NY.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, NY.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Yingxin</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Sperling Center for Hemorrhagic Stroke Recovery, Burke Neurological Institute, White Plains, NY.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, NY.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Brand</LastName>                    <ForeName>David</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Sperling Center for Hemorrhagic Stroke Recovery, Burke Neurological Institute, White Plains, NY.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, NY.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bourassa</LastName>                    <ForeName>Megan W</ForeName>                    <Initials>MW</Initials>                    <AffiliationInfo>                        <Affiliation>Sperling Center for Hemorrhagic Stroke Recovery, Burke Neurological Institute, White Plains, NY.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, NY.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dietrich</LastName>                    <ForeName>Kristen</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Neuroscience and Mental Health Institute.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wilkinson</LastName>                    <ForeName>Cassandra M</ForeName>                    <Initials>CM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Alberta, Edmonton, Alberta, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nadeau</LastName>                    <ForeName>Colby A</ForeName>                    <Initials>CA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Alberta, Edmonton, Alberta, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kumar</LastName>                    <ForeName>Amit</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Sperling Center for Hemorrhagic Stroke Recovery, Burke Neurological Institute, White Plains, NY.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, NY.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Perry</LastName>                    <ForeName>Steve</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemistry and Biochemistry, University of California at Santa Cruz, Santa Cruz, CA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pinto</LastName>                    <ForeName>John T</ForeName>                    <Initials>JT</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Darley-Usmar</LastName>                    <ForeName>Victor</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, University of Alabama at Birmingham, Birmingham, AL.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sanchez</LastName>                    <ForeName>Stephanie</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Pharmacology, Vanderbilt University, Nashville, TN.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Milne</LastName>                    <ForeName>Ginger L</ForeName>                    <Initials>GL</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Pharmacology, Vanderbilt University, Nashville, TN.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pratico</LastName>                    <ForeName>Domenico</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Alzheimer's Center at Temple University, Lewis Katz School of Medicine, Philadelphia, PA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Holman</LastName>                    <ForeName>Theodore R</ForeName>                    <Initials>TR</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemistry and Biochemistry, University of California at Santa Cruz, Santa Cruz, CA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Carmichael</LastName>                    <ForeName>S Thomas</ForeName>                    <Initials>ST</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Coppola</LastName>                    <ForeName>Giovanni</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Colbourne</LastName>                    <ForeName>Frederick</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Neuroscience and Mental Health Institute.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Psychology, University of Alberta, Edmonton, Alberta, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ratan</LastName>                    <ForeName>Rajiv R</ForeName>                    <Initials>RR</Initials>                    <AffiliationInfo>                        <Affiliation>Sperling Center for Hemorrhagic Stroke Recovery, Burke Neurological Institute, White Plains, NY.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, NY.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>07</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Ann Neurol</MedlineTA>            <NlmUniqueID>7707449</NlmUniqueID>            <ISSNLinking>0364-5134</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Ferroptosis, Intracerebral hemorrhage, N-acetylcysteine</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>01</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>10</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30294906</ArticleId>            <ArticleId IdType="doi">10.1002/ana.25356</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30294765</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Print">0171-2004</ISSN>                <JournalIssue CitedMedium="Print">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>08</Day>                    </PubDate>                </JournalIssue>                <Title>Handbook of experimental pharmacology</Title>                <ISOAbbreviation>Handb Exp Pharmacol</ISOAbbreviation>            </Journal>            <ArticleTitle>Neurostimulation Therapies.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/164_2018_157</ELocationID>            <Abstract>                <AbstractText>Depression is one of the most disabling conditions in the world. In many cases patients continue to suffer with depressive disorders despite a series of adequate trials of medication and psychotherapy. Neuromodulation treatments offer a qualitatively different modality of treatment that can frequently prove efficacious in these treatment-refractory patients. The field of neuromodulation focuses on the use of electrical/electromagnetic energy, both invasively and noninvasively, to interface with and ultimately alter activity within the human brain for therapeutic purposes. These treatments provide another set of options to offer patients when clinically indicated, and knowledge of their safety, risks and benefits, and appropriate clinical application is essential for modern psychiatrists and other mental health professionals. Although neuromodulation techniques hold tremendous promise, only three such treatments are currently approved by the United States Food and Drug Administration (FDA) for the treatment of major depressive disorder: electroconvulsive therapy (ECT), vagus nerve stimulation (VNS), and repetitive transcranial magnetic stimulation (rTMS). Additionally, numerous other neurostimulation modalities (deep brain stimulation [DBS], magnetic seizure therapy [MST], transcranial electric stimulation [tES], and trigeminal nerve stimulation [TNS]), though currently experimental, show considerable therapeutic promise. Researchers are actively looking for ways to optimize outcomes and clinical benefits by making neuromodulation treatments safer, more efficacious, and more durable.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Trapp</LastName>                    <ForeName>Nicholas T</ForeName>                    <Initials>NT</Initials>                    <AffiliationInfo>                        <Affiliation>University of Iowa Hospitals and Clinics, Iowa City, IA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xiong</LastName>                    <ForeName>Willa</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Conway</LastName>                    <ForeName>Charles R</ForeName>                    <Initials>CR</Initials>                    <AffiliationInfo>                        <Affiliation>Washington University School of Medicine, St. Louis, MO, USA. conwaycr@wustl.edu.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>John Cochran Division, VA St. Louis Health Care System, St. Louis, MO, USA. conwaycr@wustl.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Handb Exp Pharmacol</MedlineTA>            <NlmUniqueID>7902231</NlmUniqueID>            <ISSNLinking>0171-2004</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Brain stimulation</Keyword>            <Keyword MajorTopicYN="N">Electroconvulsive therapy</Keyword>            <Keyword MajorTopicYN="N">Neuromodulation</Keyword>            <Keyword MajorTopicYN="N">Neurostimulation</Keyword>            <Keyword MajorTopicYN="N">Repetitive transcranial magnetic stimulation</Keyword>            <Keyword MajorTopicYN="N">Treatment-resistant depression</Keyword>            <Keyword MajorTopicYN="N">Treatment-resistant mood disorders</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30294765</ArticleId>            <ArticleId IdType="doi">10.1007/164_2018_157</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30294451</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">2056-4724</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>4</Volume>                    <Issue>5</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>BJPsych open</Title>                <ISOAbbreviation>BJPsych Open</ISOAbbreviation>            </Journal>            <ArticleTitle>Demographic and clinical predictors of response to internet-enabled cognitive-behavioural therapy for depression and anxiety.</ArticleTitle>            <Pagination>                <MedlinePgn>411-418</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1192/bjo.2018.57</ELocationID>            <Abstract>                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Common mental health problems affect a quarter of the population. Online cognitive-behavioural therapy (CBT) is increasingly used, but the factors modulating response to this treatment modality remain unclear.</AbstractText>                <AbstractText Label="Aims" NlmCategory="UNASSIGNED">This study aims to explore the demographic and clinical predictors of response to one-to-one CBT delivered via the internet.</AbstractText>                <AbstractText Label="Method" NlmCategory="UNASSIGNED">Real-world clinical outcomes data were collected from 2211 NHS England patients completing a course of CBT delivered by a trained clinician via the internet. Logistic regression analyses were performed using patient and service variables to identify significant predictors of response to treatment.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Multiple patient variables were significantly associated with positive response to treatment including older age, absence of long-term physical comorbidities and lower symptom severity at start of treatment. Service variables associated with positive response to treatment included shorter waiting times for initial assessment and longer treatment durations in terms of the number of sessions.</AbstractText>                <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Knowledge of which patient and service variables are associated with good clinical outcomes can be used to develop personalised treatment programmes, as part of a quality improvement cycle aiming to drive up standards in mental healthcare. This study exemplifies translational research put into practice and deployed at scale in the National Health Service, demonstrating the value of technology-enabled treatment delivery not only in facilitating access to care, but in enabling accelerated data capture for clinical research purposes.</AbstractText>                <AbstractText Label="Declaration of interest" NlmCategory="UNASSIGNED">A.C., S.B., V.T., K.I., S.F., A.R., A.H. and A.D.B. are employees or board members of the sponsor. S.R.C. consults for Cambridge Cognition and Shire. Keywords: Anxiety disorders; cognitive behavioural therapies; depressive disorders; individual psychotherapy.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Catarino</LastName>                    <ForeName>Ana</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Senior Scientist, Clinical Science Laboratory at Ieso, Ieso Digital Health, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bateup</LastName>                    <ForeName>Sarah</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Chief Clinical Officer, Clinical Science Laboratory at Ieso, Ieso Digital Health, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tablan</LastName>                    <ForeName>Valentin</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Senior Vice President for Artifical intelligence, Clinical Science Laboratory at Ieso, Ieso Digital Health, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Innes</LastName>                    <ForeName>Katherine</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Informatics &amp; Visualisation Specialist, Clinical Science Laboratory at Ieso, Ieso Digital Health, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Freer</LastName>                    <ForeName>Stephen</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>UK Clinical Lead, Clinical Science Laboratory at Ieso, Ieso Digital Health, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Richards</LastName>                    <ForeName>Andy</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Director, Ieso Digital Health, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Stott</LastName>                    <ForeName>Richard</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Visiting Associate, Department of Psychology, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hollon</LastName>                    <ForeName>Steven D</ForeName>                    <Initials>SD</Initials>                    <AffiliationInfo>                        <Affiliation>Professor of Psychology, Department of Psychology, Vanderbilt University, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chamberlain</LastName>                    <ForeName>Samuel Robin</ForeName>                    <Initials>SR</Initials>                    <Identifier Source="ORCID">0000-0001-7014-8121</Identifier>                    <AffiliationInfo>                        <Affiliation>Wellcome Trust Clinical Fellow and Honorary Consultant, Department of Psychiatry, University of Cambridge and Cambridge and Peterborough NHS Foundation Trust, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hayes</LastName>                    <ForeName>Ann</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Independent Pharmaceutical and Digital Health Consultant, Ieso Digital Health, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Blackwell</LastName>                    <ForeName>Andrew D</ForeName>                    <Initials>AD</Initials>                    <AffiliationInfo>                        <Affiliation>Chief Scientific Officer, Clinical Science Laboratory at Ieso, Ieso Digital Health, UK.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>02</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>BJPsych Open</MedlineTA>            <NlmUniqueID>101667931</NlmUniqueID>            <ISSNLinking>2056-4724</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Gen Intern Med. 2001 Sep;16(9):606-13</RefSource>                <PMID Version="1">11556941</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Psychiatry. 2008 Oct;193(4):270-1</RefSource>                <PMID Version="1">18827286</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychother Res. 2012;22(1):1-11</RefSource>                <PMID Version="1">21943215</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Intern Med. 2007 Mar 6;146(5):317-25</RefSource>                <PMID Version="1">17339617</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2009 Aug 22;374(9690):628-34</RefSource>                <PMID Version="1">19700005</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2015 Apr 20;10(4):e0124258</RefSource>                <PMID Version="1">25893687</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Geriatr Soc. 2012 Feb;60(2):218-29</RefSource>                <PMID Version="1">22283717</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Health Psychol Behav Med. 2014 Jan 1;2(1):841-881</RefSource>                <PMID Version="1">25750823</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Med. 2007 Mar;37(3):319-28</RefSource>                <PMID Version="1">17112400</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cochrane Database Syst Rev. 2015 Mar 05;(3):CD011565</RefSource>                <PMID Version="1">25742186</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2018 Feb 17;391(10121):679-686</RefSource>                <PMID Version="1">29224931</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Opin Psychiatry. 2006 Jul;19(4):421-7</RefSource>                <PMID Version="1">16721175</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Consult Clin Psychol. 2017 Oct;85(10):988-999</RefSource>                <PMID Version="1">28650193</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Intern Med. 2006 May 22;166(10):1092-7</RefSource>                <PMID Version="1">16717171</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Behav Res Ther. 2013 Sep;51(9):597-606</RefSource>                <PMID Version="1">23872702</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Health Aff (Millwood). 2017 Jan 1;36(1):124-132</RefSource>                <PMID Version="1">28069855</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2016 Sep 12;11(9):e0161191</RefSource>                <PMID Version="1">27618548</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS Med. 2013 Nov;10(11):e1001547</RefSource>                <PMID Version="1">24223526</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int Rev Psychiatry. 2011 Aug;23(4):318-27</RefSource>                <PMID Version="1">22026487</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Methods. 2008 Sep;13(3):272-7</RefSource>                <PMID Version="1">18778155</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Psychol. 2004 Feb;60(2):147-57</RefSource>                <PMID Version="1">14724922</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Health Expect. 2009 Mar;12(1):45-59</RefSource>                <PMID Version="1">19250152</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30294451</ArticleId>            <ArticleId IdType="doi">10.1192/bjo.2018.57</ArticleId>            <ArticleId IdType="pii">00057</ArticleId>            <ArticleId IdType="pmc">PMC6171334</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30294448</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">2056-4724</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>4</Volume>                    <Issue>5</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>BJPsych open</Title>                <ISOAbbreviation>BJPsych Open</ISOAbbreviation>            </Journal>            <ArticleTitle>Metacognitive therapy versus cognitive-behavioural therapy in adults with generalised anxiety disorder.</ArticleTitle>            <Pagination>                <MedlinePgn>393-400</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1192/bjo.2018.54</ELocationID>            <Abstract>                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Cognitive-behavioural therapy (CBT) is the treatment of choice for generalised anxiety disorder (GAD), yielding significant improvements in approximately 50% of patients. There is significant room for improvement in the outcomes of treatment, especially in recovery.</AbstractText>                <AbstractText Label="Aims" NlmCategory="UNASSIGNED">We aimed to compare metacognitive therapy (MCT) with the gold standard treatment, CBT, in patients with GAD (clinicaltrials.gov identifier: NCT00426426).</AbstractText>                <AbstractText Label="Method" NlmCategory="UNASSIGNED">A total of 246 patients with long-term GAD were assessed and 81 were randomised into three conditions: CBT (<i>n</i> = 28), MCT (<i>n</i> = 32) and a wait-list control (<i>n</i> = 21). Assessments were made at pre-treatment, post-treatment and at 2 year follow-up.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Both CBT and MCT were effective treatments, but MCT was more effective (mean difference 9.762, 95% CI 2.679-16.845, <i>P</i> = 0.004) and led to significantly higher recovery rates (65% <i>v</i>. 38%). These differences were maintained at 2 year follow-up.</AbstractText>                <AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">MCT seems to produce recovery rates that exceed those of CBT. These results demonstrate that the effects of treatment cannot be attributed to non-specific therapy factors.</AbstractText>                <AbstractText Label="Declaration of interest" NlmCategory="UNASSIGNED">A.W. wrote the treatment protocol in MCT and several books on CBT and MCT, and receives royalties from these. T.D.B. wrote the protocol in CBT and has published several articles and chapters on CBT and receives royalties from these. All other authors declare no competing interests.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Nordahl</LastName>                    <ForeName>Hans M</ForeName>                    <Initials>HM</Initials>                    <Identifier Source="ORCID">0000-0001-9275-646X</Identifier>                    <AffiliationInfo>                        <Affiliation>Professor, Department of Mental Health, Norwegian University of Science and Technology and Research Director, St Olavs Hospital, Nidaros DPS, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Borkovec</LastName>                    <ForeName>Thomas D</ForeName>                    <Initials>TD</Initials>                    <AffiliationInfo>                        <Affiliation>Professor, Department of Psychology, Penn State University, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hagen</LastName>                    <ForeName>Roger</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Professor, Department of Psychology, Norwegian University of Science and Technology, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kennair</LastName>                    <ForeName>Leif E O</ForeName>                    <Initials>LEO</Initials>                    <AffiliationInfo>                        <Affiliation>Professor, Department of Psychology, Norwegian University of Science and Technology, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hjemdal</LastName>                    <ForeName>Odin</ForeName>                    <Initials>O</Initials>                    <AffiliationInfo>                        <Affiliation>Professor, Department of Psychology, Norwegian University of Science and Technology, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Solem</LastName>                    <ForeName>Stian</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Associate Professor, Department of Psychology, Norwegian University of Science and Technology, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hansen</LastName>                    <ForeName>Bjarne</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Associate Professor, Department of Psychology, University of Bergen, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Haseth</LastName>                    <ForeName>Svein</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Consultant, St. Olavs Hospital, Nidaros DPS, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wells</LastName>                    <ForeName>Adrian</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Professor, School of Psychological Sciences, University of Manchester and Greater Manchester Mental Health NHS Foundation Trust, UK.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <DataBankList CompleteYN="Y">                <DataBank>                    <DataBankName>ClinicalTrials.gov</DataBankName>                    <AccessionNumberList>                        <AccessionNumber>NCT00426426</AccessionNumber>                    </AccessionNumberList>                </DataBank>            </DataBankList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>BJPsych Open</MedlineTA>            <NlmUniqueID>101667931</NlmUniqueID>            <ISSNLinking>2056-4724</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Psychol Rev. 2014 Mar;34(2):130-40</RefSource>                <PMID Version="1">24487344</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Behav Res Ther. 2010 May;48(5):429-34</RefSource>                <PMID Version="1">20060517</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Psychiatry. 2001;62 Suppl 11:37-42; discussion 43-5</RefSource>                <PMID Version="1">11414549</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Bull. 2005 Sep;131(5):785-95</RefSource>                <PMID Version="1">16187860</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Consult Clin Psychol. 1993 Aug;61(4):611-9</RefSource>                <PMID Version="1">8370856</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2006 Dec 16;368(9553):2156-66</RefSource>                <PMID Version="1">17174708</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur Neuropsychopharmacol. 2005 Aug;15(4):445-52</RefSource>                <PMID Version="1">15951160</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Consult Clin Psychol. 1988 Dec;56(6):893-7</RefSource>                <PMID Version="1">3204199</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Behav Res Ther. 1990;28(6):487-95</RefSource>                <PMID Version="1">2076086</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Psychol Rev. 2013 Feb;33(1):120-32</RefSource>                <PMID Version="1">23168445</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Consult Clin Psychol. 1988 Dec;56(6):885-92</RefSource>                <PMID Version="1">3204198</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001848</RefSource>                <PMID Version="1">17253466</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Behav Res Ther. 1992 Jan;30(1):33-7</RefSource>                <PMID Version="1">1540110</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Psychol Rev. 2017 Mar;52:124-136</RefSource>                <PMID Version="1">28119196</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Behav Ther Exp Psychiatry. 2000 Jun;31(2):73-86</RefSource>                <PMID Version="1">11132119</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Depress Anxiety. 2002;16(4):162-71</RefSource>                <PMID Version="1">12497648</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Behav Res Ther. 2012 Feb;50(2):100-9</RefSource>                <PMID Version="1">22222208</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Anxiety Disord. 2008;22(1):108-16</RefSource>                <PMID Version="1">17321717</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Consult Clin Psychol. 1991 Feb;59(1):12-9</RefSource>                <PMID Version="1">2002127</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Consult Clin Psychol. 2007 Aug;75(4):513-22</RefSource>                <PMID Version="1">17663606</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Aust N Z J Psychiatry. 2006 Jan;40(1):9-19</RefSource>                <PMID Version="1">16403033</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Consult Clin Psychol. 1998 Feb;66(1):136-42</RefSource>                <PMID Version="1">9489267</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Anxiety Disord. 2012 Jan;26(1):1-11</RefSource>                <PMID Version="1">21907538</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Generalised anxiety disorder</Keyword>            <Keyword MajorTopicYN="N">anxiety disorders</Keyword>            <Keyword MajorTopicYN="N">cognitive–behavioural therapy</Keyword>            <Keyword MajorTopicYN="N">metacognitive therapy</Keyword>            <Keyword MajorTopicYN="N">randomised controlled trial</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30294448</ArticleId>            <ArticleId IdType="doi">10.1192/bjo.2018.54</ArticleId>            <ArticleId IdType="pii">00054</ArticleId>            <ArticleId IdType="pmc">PMC6171331</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>